Paclitaxel (Synonyms: 紫杉醇)

目录号: HY-B0015 纯度: 99.97%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Paclitaxel 是一种天然抗肿瘤药，可稳定微管蛋白 (tubulin) 的聚合。Paclitaxel 可导致有丝分裂停滞和诱导细胞凋亡 (apoptosis)，最终导致细胞死亡。Paclitaxel 还可诱导细胞自噬 (autophagy)。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CAS No. : 33069-62-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥572	In-stock
5 mg	￥325	In-stock
10 mg	￥520	In-stock
50 mg	￥900	In-stock
100 mg	￥1500	In-stock
500 mg	￥3500	In-stock
1 g	￥5300	In-stock
5 g		询价
10 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Paclitaxel:

MCE 顾客使用本产品发表的 307 篇科研文献

Proliferation Assay

Cell Viability Assay

RT-PCR

: Paclitaxel purchased from MCE. Usage Cited in: Nat Med. 2024 Mar;30(3):749-761. [Abstract]; The relative cell viability of shCtl-, shNDUFB8-, and shCEMIP2-transfected cells was detected by XTT assay after paclitaxel (50 nM) plus gemcitabine treatment (A+G), single-agent 5-Fu (5-FU), and the FOLFIRINOX chemotherapy cocktail [FU+IRI+OXA: 5-FU+Irinotecan (SN-38) +Oxaliplatin] for 48h.

: Paclitaxel purchased from MCE. Usage Cited in: Bioact Mater. 2024 May 11:38:384-398. [Abstract]; Paclitaxel （10 μM；3-5 天）可降低肺癌类器官-3（LCO-3）的活性，对LCO-1和LCO-2的活性影响不显著。

: Paclitaxel purchased from MCE. Usage Cited in: ACS Nano. 2024 Jun 18;18(24):15864-15877. [Abstract]; Paclitaxel (PTX, 0.1–1 μM, 24 h) increases COX-2 mRNA expression in 4T1 cells in a dose-dependent manner and induces elevated PGE2 release in the culture medium.

: Paclitaxel purchased from MCE. Usage Cited in: Mar Drugs. 2023 Apr 23;21(5):259.; Paclitaxel (PTX; 50 nM; 48 h) increases the expression of Cleaved-caspase-9 and Cleaved-caspase-3 in Hela cells.

: Paclitaxel purchased from MCE. Usage Cited in: Mar Drugs. 2023 Apr 23;21(5):259.; Paclitaxel (PTX; 3.125, 6.25, 12.5, 25, 50, 100 nM; 48 h) reduces the viability of Hela, SiHa, and C33A cells in a dose-dependent manner.(3.125 nM for Hela cells, 100 nM for SiHa and C33A cells)

: Paclitaxel purchased from MCE. Usage Cited in: Oncol Lett. 2023 Feb 15;25(4):134.; Paclitaxel (PTX; 0‑100 nM; 72 h) inhibits the viability of MDA‑MB‑231cells.

: Paclitaxel purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2023 Aug 20:669:61-67.; Paclitaxel (25, 50 μM; 24 h) significantly increases the expression of caspase-3 in PK-15 cells.

: Paclitaxel purchased from MCE. Usage Cited in: Arch Cancer Res. 2023 Jan 30.; Paclitaxel (CPT; 10^-6 -12^-10 M; 72 h) demonstrates a strong antitumor activity and an inhibitory of proliferation (IC₅₀ = 6.28 nM) in U937 cells.

: Paclitaxel purchased from MCE. Usage Cited in: Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]; Bar graphs show the GI50 of 5-fluoruracil (48 h), irinotecan (48 h), gemcitabine (48 h), paclitaxel (48 h), and oxaliplatin (48 h) in PDAC cells in combination with bioactive hexapeptides (NTAIYY and PTTIYY) or controls (saline and NTAIYA).

: Paclitaxel purchased from MCE. Usage Cited in: J Agric Food Chem. 2019 Feb 13;67(6):1656-1665. [Abstract]; Western blot image and statistical analysis of phosphorylated γH2AX levels in HT-29 cells with different treatments after 48 h. Myricetin and PTX used are 32 μM and 100 nM, respectively.

: Paclitaxel purchased from MCE. Usage Cited in: Biochim Biophys Acta. 2018 May;1862(5):1134-1147. [Abstract]; The effects of CS1 on polymerized microtubules are also investigated using a cellular tubulin polymer assay. Nocodazole (1 μM) and Paclitaxel (1.5 μM) are used as depolymerization and polymerization controls, respectively.

: Paclitaxel purchased from MCE. Usage Cited in: Am J Cancer Res. 2017 Apr 1;7(4):903-912. [Abstract]; Synergistic inhibition of colony formation of ATC cells by E7080 and Paclitaxel. Representative images of colony formation in C643 cells treated with vehicle control (DMSO) or E7080 and Paclitaxel at the indicated concentrations, individually or in combination, are shown in left panel. Quantitative analysis of colony numbers is shown in right panel.

Paclitaxel 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 ADC Payload 亚型特异性产品:

查看所有亚型

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

生物活性
纯度 & 产品资料
参考文献

生物活性

Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy^[1]^[2].

IC₅₀ & Target^[1]

Traditional Cytotoxic Agents

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
143B	IC₅₀	5.56 μM Compound: Paclitaxel	Antiproliferative activity against human 143B cells after 48 hrs by MTT assay Antiproliferative activity against human 143B cells after 48 hrs by MTT assay	[PMID: 29223717]
184B5	IC₅₀	2.32 μM Compound: Paclitaxel	Antiproliferative activity against human 184B5 cells after 72 hrs by SRB assay Antiproliferative activity against human 184B5 cells after 72 hrs by SRB assay	[PMID: 26602827]
1A9	ED₅₀	0.001 μg/mL Compound: 1	Cytotoxicity against human 1A9 cells by sulforhodamine B assay Cytotoxicity against human 1A9 cells by sulforhodamine B assay	[PMID: 17643301]
1A9	ED₅₀	0.002 μg/mL Compound: Paclitaxel	Effective dose required for inhibitory activity against 1A9 human tumor cell line. Effective dose required for inhibitory activity against 1A9 human tumor cell line.	[PMID: 12852747]
1A9	ED₅₀	0.002 μg/mL Compound: paclitaxel	Cytotoxicity against human 1A9 cells after 3 days by SRB assay Cytotoxicity against human 1A9 cells after 3 days by SRB assay	[PMID: 14640511]
1A9	ED₅₀	0.041 μg/mL Compound: paclitaxel	Cytotoxicity against human 1A9 cells after 6 days by SRB assay Cytotoxicity against human 1A9 cells after 6 days by SRB assay	[PMID: 14640511]
1A9	ED₅₀	1 nM Compound: 1	Cytotoxicity against human 1A9 cells by sulforhodamine B assay Cytotoxicity against human 1A9 cells by sulforhodamine B assay	[PMID: 17350834]
1A9	ED₅₀	2.09 nM Compound: Paclitaxel	Antiproliferative activity against human 1A9 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human 1A9 cells after 3 days by sulforhodamine B assay	[PMID: 21296579]
1A9	GI₅₀	0.71 nM Compound: paclitaxel	Growth inhibition of human 1A9 cells after 72 hrs Growth inhibition of human 1A9 cells after 72 hrs	[PMID: 17542572]
1A9	GI₅₀	5.2 nM Compound: Taxol	Induction of microtubule stabilization in human 1A9 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter reagent-based assay Induction of microtubule stabilization in human 1A9 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter reagent-based assay	[PMID: 31191870]
1A9	IC₅₀	0.002 μM Compound: Paclitaxel	Cytotoxicity against human 1A9 cells after 3 days by SRB assay Cytotoxicity against human 1A9 cells after 3 days by SRB assay	[PMID: 16038545]
1A9	IC₅₀	21.5 nM Compound: 1a, PTX	Inhibition of growth in epothilone A resistant 1A9-A8 T-beta-274I mutant cell line after 72 hrs by SRB assay Inhibition of growth in epothilone A resistant 1A9-A8 T-beta-274I mutant cell line after 72 hrs by SRB assay	[PMID: 17263521]
1A9	IC₅₀	3.71 nM Compound: 7	Cytotoxicity against human 1A9 cells Cytotoxicity against human 1A9 cells	[PMID: 28850227]
1A9	IC₅₀	3.9 nM Compound: Paclitaxel, Taxol	Cytotoxicity against human 1A9 cells by MTT assay Cytotoxicity against human 1A9 cells by MTT assay	[PMID: 25047938]
1A9	IC₅₀	4.8 nM Compound: 1a, PTX	Inhibition of growth in 1A9 cell line after 72 hrs Inhibition of growth in 1A9 cell line after 72 hrs	[PMID: 17263521]
1A9/ptx-10	ED₅₀	0.041 μg/mL Compound: Paclitaxel	Effective dose required for inhibitory activity against PTX10 human tumor cell line Effective dose required for inhibitory activity against PTX10 human tumor cell line	[PMID: 12852747]
1A9/ptx-10	GI₅₀	64 nM Compound: paclitaxel	Growth inhibition of beta tubulin Phe270Val mutant expressing human 1A9/Ptx10 cells after 72 hrs Growth inhibition of beta tubulin Phe270Val mutant expressing human 1A9/Ptx10 cells after 72 hrs	[PMID: 17542572]
1A9/ptx-10	IC₅₀	157 nM Compound: 1a, PTX	Inhibition of growth in paclitaxel resistant 1A9-PTX10 F-beta-270V mutant cell line after 72 hrs by SRB assay Inhibition of growth in paclitaxel resistant 1A9-PTX10 F-beta-270V mutant cell line after 72 hrs by SRB assay	[PMID: 17263521]
1A9/ptx-10	IC₅₀	30 nM Compound: 6	Cytotoxicity against human 1A9PTX10 cells Cytotoxicity against human 1A9PTX10 cells	[PMID: 17206139]
1A9/ptx-10	IC₅₀	532.95 nM Compound: Taxol	Cytotoxicity against paclitaxel-resistant human 1A9PTX10 cells Cytotoxicity against paclitaxel-resistant human 1A9PTX10 cells	[PMID: 24680057]
1A9/ptx-10	IC₅₀	532.95 nM Compound: paclitaxel	Cytotoxicity against paclitaxel resistant human 1A9PTX10 cells expressing class 1 beta-tubulin mutant after 72 hrs Cytotoxicity against paclitaxel resistant human 1A9PTX10 cells expressing class 1 beta-tubulin mutant after 72 hrs	[PMID: 18465846]
1A9/ptx-10	IC₅₀	532.95 nM Compound: paclitaxel	Cytotoxicity against paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin after 72 hrs Cytotoxicity against paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin after 72 hrs	[PMID: 19239240]
1A9/ptx-10	IC₅₀	81.4 nM Compound: Paclitaxel, Taxol	Cytotoxicity against human 1A9PTX10 cells by MTT assay Cytotoxicity against human 1A9PTX10 cells by MTT assay	[PMID: 25047938]
1A9/ptx-22	GI₅₀	51 nM Compound: paclitaxel	Growth inhibition of beta tubulin A364T mutant expressing human 1A9/Ptx22 cells after 72 hrs Growth inhibition of beta tubulin A364T mutant expressing human 1A9/Ptx22 cells after 72 hrs	[PMID: 17542572]
1A9/ptx-22	IC₅₀	160.7 nM Compound: Taxol	Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells	[PMID: 24680057]
1A9/ptx-22	IC₅₀	160.7 nM Compound: paclitaxel	Cytotoxicity against paclitaxel resistant human 1A9PTX22 cells expressing class 1 beta-tubulin mutant after 72 hrs Cytotoxicity against paclitaxel resistant human 1A9PTX22 cells expressing class 1 beta-tubulin mutant after 72 hrs	[PMID: 18465846]
1A9/ptx-22	IC₅₀	160.7 nM Compound: paclitaxel	Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells harboring point mutation in beta-tubulin after 72 hrs Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells harboring point mutation in beta-tubulin after 72 hrs	[PMID: 19239240]
1A9/ptx-22	IC₅₀	19 nM Compound: 6	Cytotoxicity against human 1A9PTX22 cells Cytotoxicity against human 1A9PTX22 cells	[PMID: 17206139]
1A9/ptx-22	IC₅₀	32.8 nM Compound: Paclitaxel, Taxol	Cytotoxicity against human 1A9PTX22 cells by MTT assay Cytotoxicity against human 1A9PTX22 cells by MTT assay	[PMID: 25047938]
2008	GI₅₀	0.0092 nM Compound: Paclitaxel	Inhibitory concentration against 2008 (ovarian) cells Inhibitory concentration against 2008 (ovarian) cells	[PMID: 12825928]
2008	GI₅₀	3 nM Compound: PTX, Taxol	Growth inhibition of human 2008 cells Growth inhibition of human 2008 cells	[PMID: 23750455]
4T1	IC₅₀	0.001 mM Compound: Taxol	Antiproliferative activity against mouse 4T1 cells incubated for 24 hrs by MTT assay Antiproliferative activity against mouse 4T1 cells incubated for 24 hrs by MTT assay	[PMID: 31857837]
4T1	IC₅₀	0.094 μM Compound: Paclitaxel	Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
4T1	IC₅₀	0.094 μM Compound: Taxol	Cytotoxicity against mouse 4T1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34704758]
4T1	IC₅₀	0.2 μM Compound: Taxol	Cytotoxicity against mouse 4T1 cells by MTT assay Cytotoxicity against mouse 4T1 cells by MTT assay	[PMID: 16539377]
4T1	IC₅₀	0.8 μM Compound: Paclitaxel	Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34018743]
4T1	IC₅₀	3.84 μM Compound: Taxol	Antiproliferative activity against mouse 4T1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against mouse 4T1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 39044437]
5637	IC₅₀	0.002 μM Compound: PTX	Cytotoxicity against human 5637 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human 5637 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
769-P	IC₅₀	7.1 μM Compound: Paclitaxel	Cytotoxicity against human 769-P cells by MTT assay Cytotoxicity against human 769-P cells by MTT assay	[PMID: 20122764]
769-P	IC₅₀	7.1 μM Compound: Paclitaxel	Cytotoxicity against human 769-P cells by MTT assay Cytotoxicity against human 769-P cells by MTT assay	[PMID: 20627721]
769-P	IC₅₀	7.1 μM Compound: Paclitaxel	Cytotoxicity against human 769-P cells by MTT assay Cytotoxicity against human 769-P cells by MTT assay	[PMID: 20716468]
769-P	IC₅₀	7.1 μM Compound: Paclitaxel	Cytotoxicity against human 769-P cells by MTT assay Cytotoxicity against human 769-P cells by MTT assay	[PMID: 21875764]
786-0	GI₅₀	0.02 μM Compound: PCT	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 24727464]
786-0	GI₅₀	39 nM Compound: Paclitaxel	Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
786-0	GI₅₀	39 nM Compound: Paclitaxel	Cytotoxicity against human 786-0 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human 786-0 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
786-0	IC₅₀	2.55 nM Compound: PTX	Antiproliferative activity against human 786-O cells incubated for 72 hrs by MTT assay Antiproliferative activity against human 786-O cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
786-0	IC₅₀	31 nM Compound: Paclitaxel	Antiproliferative activity against MDR-1 overexpressing human 786-0 cells Antiproliferative activity against MDR-1 overexpressing human 786-0 cells	[PMID: 21774499]
786-0	IC₅₀	4 nM Compound: Paclitaxel	Antiproliferative activity against MDR-1 overexpressing human 786-0 cells in presence of MDR1 inhibitor verapamil Antiproliferative activity against MDR-1 overexpressing human 786-0 cells in presence of MDR1 inhibitor verapamil	[PMID: 21774499]
786-0	IC₅₀	< 0.01 μM Compound: Taxol	Anticancer activity against human 786-0 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human 786-0 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
786-0	IC₅₀	< 0.08 μM Compound: Paclitaxel	Cytotoxicity against human 786-0 cells by MTT assay Cytotoxicity against human 786-0 cells by MTT assay	[PMID: 20122764]
786-0	IC₅₀	< 0.08 μM Compound: Paclitaxel	Cytotoxicity against human 786-0 cells by MTT assay Cytotoxicity against human 786-0 cells by MTT assay	[PMID: 20627721]
786-0	IC₅₀	< 0.08 μM Compound: Paclitaxel	Cytotoxicity against human 786-0 cells by MTT assay Cytotoxicity against human 786-0 cells by MTT assay	[PMID: 20716468]
786-0	IC₅₀	< 0.08 μM Compound: Paclitaxel	Cytotoxicity against human 786-0 cells by MTT assay Cytotoxicity against human 786-0 cells by MTT assay	[PMID: 21875764]
A 172	GI₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human A-172 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human A-172 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31945642]
A 172	GI₅₀	0.01 μM Compound: Taxol	Cytotoxicity against human A172 cells after 72 hrs by MTT assay Cytotoxicity against human A172 cells after 72 hrs by MTT assay	[PMID: 20538462]
A 172	GI₅₀	0.01 μM Compound: taxol	Cytotoxicity against human A172 cells after 72 hrs by MTT colorimetric assay Cytotoxicity against human A172 cells after 72 hrs by MTT colorimetric assay	[PMID: 19081249]
A-375	EC₅₀	0.002 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human A-375 cells incubated for 48 to 72 hrs by MTT assay Cytotoxicity against human A-375 cells incubated for 48 to 72 hrs by MTT assay	[PMID: 39038808]
A-375	GI₅₀	0.01 μM Compound: Taxol	Antiproliferative activity against human A375 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay Antiproliferative activity against human A375 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay	[PMID: 32199690]
A-375	IC₅₀	0.002 μM Compound: PTX	Cytotoxicity against human A375 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human A375 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 30633861]
A-375	IC₅₀	0.01 μM Compound: Paclitaxel	Antiproliferative activity against human A375 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human A375 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
A-375	IC₅₀	0.013 μM Compound: Paclitaxel	Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39163776]
A-375	IC₅₀	0.059 μM Compound: Taxol	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
A-375	IC₅₀	0.1 μM Compound: Paclitaxel	Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A-375	IC₅₀	0.1 μM Compound: Taxol	Cytotoxicity against human A-375 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34704758]
A-375	IC₅₀	0.68 μM Compound: Paclitaxel	Antiproliferative activity against human A375 cells after 48 hrs by MTT assay Antiproliferative activity against human A375 cells after 48 hrs by MTT assay	10.1039/C6MD00256K
A-375	IC₅₀	0.7 μM Compound: Paclitaxel	Antiproliferative activity against human A375 cells after 48 hrs by MTT assay Antiproliferative activity against human A375 cells after 48 hrs by MTT assay	[PMID: 28667872]
A-375	IC₅₀	0.81 μM Compound: Paclitaxel	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 20122764]
A-375	IC₅₀	0.81 μM Compound: Paclitaxel	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 20627721]
A-375	IC₅₀	0.81 μM Compound: Paclitaxel	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 20716468]
A-375	IC₅₀	0.81 μM Compound: Paclitaxel	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 21875764]
A-375	IC₅₀	1.6 nM Compound: Paclitaxel	Cytotoxicity against human A-375 cells measured after 72 hrs by western blot Cytotoxicity against human A-375 cells measured after 72 hrs by western blot	[PMID: 34378386]
A-375	IC₅₀	1.7 nM Compound: Paclitaxel	Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A-375	IC₅₀	11.26 μM Compound: Paclitaxel	Cytotoxicity against human A375 cells measured after 24 hrs by MTT assay Cytotoxicity against human A375 cells measured after 24 hrs by MTT assay	[PMID: 27769031]
A-375	IC₅₀	15.8 μM Compound: Paclitaxel	Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay	[PMID: 30433783]
A-375	IC₅₀	2.2 x 10^-2 μM Compound: Paclitaxel	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 27441892]
A-375	IC₅₀	4.6 nM Compound: Taxol	Antiproliferative activity against human A375 cells after 96 hrs by MTT assay Antiproliferative activity against human A375 cells after 96 hrs by MTT assay	[PMID: 21296467]
A-375	IC₅₀	4.9 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 21928797]
A-375	IC₅₀	47.8 nM Compound: Paclitaxel	Antiproliferative activity against human A375 cells after 72 hrs by MTS assay Antiproliferative activity against human A375 cells after 72 hrs by MTS assay	[PMID: 30099258]
A-375	IC₅₀	5.1 nM Compound: PT	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
A-375	IC₅₀	8 μM Compound: Pacli	Cytotoxicity against human A375 cells after 48 hrs by MTT assay Cytotoxicity against human A375 cells after 48 hrs by MTT assay	[PMID: 25563891]
A-375	IC₅₀	8.9 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human A375 cells after 72 hrs by MTS assay Cytotoxicity against human A375 cells after 72 hrs by MTS assay	[PMID: 21812410]
A-375	IC₅₀	8.9 x 10^-3 μM Compound: paclitaxel	Cytotoxicity against human A375 cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human A375 cells assessed as reduction in cell viability by MTS assay	[PMID: 25760674]
A-375	IC₅₀	9.2 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
A-431	EC₅₀	0.009 μM Compound: Taxol	Cell cycle arrest in A431 cells by accumulation at G2/M phase Cell cycle arrest in A431 cells by accumulation at G2/M phase	[PMID: 16377187]
A-431	ED₅₀	0.01 μg/mL Compound: 1	Cytotoxicity against human A431 cells Cytotoxicity against human A431 cells	[PMID: 17643301]
A-431	GI₅₀	0.0023 μg/mL Compound: Paclitaxel	Cytotoxicity against human A431 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A431 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26642768]
A-431	GI₅₀	2.355 nM Compound: 1, Taxol	Growth inhibition of human A431 cells by MTT assay Growth inhibition of human A431 cells by MTT assay	[PMID: 24405702]
A-431	GI₅₀	< 0.00001 μM Compound: Paclitaxel	Antiproliferative activity against human A431 cells by SRB assay Antiproliferative activity against human A431 cells by SRB assay	[PMID: 19394218]
A-431	IC₅₀	0.001 μM Compound: Taxol	Anticancer activity against human A431 cells by MTT assay Anticancer activity against human A431 cells by MTT assay	[PMID: 33316408]
A-431	IC₅₀	0.002 μM Compound: Taxol	Antiproliferative activity against human A431 wild type cells measured after 72 hrs by Sulforhodamine B assay Antiproliferative activity against human A431 wild type cells measured after 72 hrs by Sulforhodamine B assay	[PMID: 31889606]
A-431	IC₅₀	0.007 μM Compound: Taxol	Cytotoxicity against human A431 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human A431 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25091926]
A-431	IC₅₀	25.1 nM Compound: Paclitaxel	Cytotoxicity against human A431 cells after 72 hrs by SRB method Cytotoxicity against human A431 cells after 72 hrs by SRB method	[PMID: 18990574]
A-431	IC₅₀	9.2 nM Compound: Paclitaxel	Antiproliferative activity against human A431 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A431 cells after 72 hrs by sulforhodamine B assay	[PMID: 21480626]
A10	IC₅₀	38 nM Compound: Paclitaxel	Growth inhibition of rat A10 cells Growth inhibition of rat A10 cells	[PMID: 19601594]
A121	IC₅₀	6.1 nM Compound: Paclitaxel	Cytotoxicity against human A121 ovarian cells Cytotoxicity against human A121 ovarian cells	10.1016/S0960-894X(01)80298-5
A121	IC₅₀	6.1 nM Compound: Paclitaxel	Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines	10.1016/S0960-894X(01)80568-0
A121	IC₅₀	6.1 nM Compound: Paclitaxel	Growth inhibition of human ovarian carcinoma (A121) cell line Growth inhibition of human ovarian carcinoma (A121) cell line	[PMID: 9022793]
A121	IC₅₀	6.1 nM Compound: Paclitaxel	Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure	[PMID: 9022794]
A121	IC₅₀	6.1 nM Compound: paclitaxel	In vitro cytotoxicity against human ovarian carcinoma A21 In vitro cytotoxicity against human ovarian carcinoma A21	[PMID: 8182698]
A121	IC₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line	10.1016/S0960-894X(96)00595-1
A121	IC₅₀	6.3 nM Compound: paclitaxel	Concentration required to inhibit growth of human tumor A121 (ovarian) cell line. Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.	[PMID: 8831755]
A2058	IC₅₀	0.0047 μM Compound: Taxol	Cytotoxicity against human A2058 cells after 96 hrs by CellTire-Glo luminescent assay Cytotoxicity against human A2058 cells after 96 hrs by CellTire-Glo luminescent assay	[PMID: 23623678]
A2780	EC₅₀	2.4 nM Compound: Paclitaxel	Antiproliferative activity against D4-9-31 resistance human A2780 cells incubated for 72 hrs by ATPlite reagent based assay Antiproliferative activity against D4-9-31 resistance human A2780 cells incubated for 72 hrs by ATPlite reagent based assay	[PMID: 31047749]
A2780	EC₅₀	2.5 nM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells incubated for 72 hrs by ATPlite reagent based assay Antiproliferative activity against human A2780 cells incubated for 72 hrs by ATPlite reagent based assay	[PMID: 31047749]
A2780	EC₅₀	> 10 μM Compound: paclitaxel	Induction of mitotic arrest in human A2780 cells expressing MDR1 after 16 hrs Induction of mitotic arrest in human A2780 cells expressing MDR1 after 16 hrs	[PMID: 18578472]
A2780	GI₅₀	0.27 nM Compound: Paclitaxel	Growth inhibition of human A2780 cells Growth inhibition of human A2780 cells	[PMID: 21986585]
A2780	IC₅₀	0.00082 μM Compound: Taxol	Cytotoxicity against compound-sensitive human A2780 cells after 24 hrs by MTT assay Cytotoxicity against compound-sensitive human A2780 cells after 24 hrs by MTT assay	[PMID: 21396747]
A2780	IC₅₀	0.001 μM Compound: PTX	Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay	[PMID: 29306206]
A2780	IC₅₀	0.0015 μM Compound: PTX	Growth inhibition human A2780 cells after 72 hrs by MTS assay Growth inhibition human A2780 cells after 72 hrs by MTS assay	[PMID: 30633861]
A2780	IC₅₀	0.0016 μM Compound: 1	Cytotoxicity against A2780 cells by MTT assay Cytotoxicity against A2780 cells by MTT assay	[PMID: 17395465]
A2780	IC₅₀	0.002 μM Compound: PTX	Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay	[PMID: 35065411]
A2780	IC₅₀	0.005 μM Compound: TAX	Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27149641]
A2780	IC₅₀	0.006 μM Compound: 6	Antiproliferative activity against human A2780 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A2780 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25682561]
A2780	IC₅₀	0.006 μM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36621138]
A2780	IC₅₀	0.0063 μM Compound: paclitaxel	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 18001087]
A2780	IC₅₀	0.00676 μg/mL Compound: Paclitaxel	Inhibitory concentration against A2780 proliferation after 72 hr Inhibitory concentration against A2780 proliferation after 72 hr	[PMID: 15664868]
A2780	IC₅₀	0.008 μM Compound: PTX	Cytotoxicity against human A2780 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A2780 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
A2780	IC₅₀	0.009 μM Compound: Paclitaxel	Growth inhibition of human A2780 cells after 72 hrs by SRB assay Growth inhibition of human A2780 cells after 72 hrs by SRB assay	[PMID: 29519737]
A2780	IC₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human A2780 cells after 48 to 72 hrs by WAT-1 assay Cytotoxicity against human A2780 cells after 48 to 72 hrs by WAT-1 assay	[PMID: 21126027]
A2780	IC₅₀	0.012 μM Compound: Taxol	Cytotoxicity against human A2780 cells after 2 days by alamar Blue assay Cytotoxicity against human A2780 cells after 2 days by alamar Blue assay	[PMID: 23623678]
A2780	IC₅₀	0.013 μM Compound: Paclitaxel	Cytotoxicity against human A2780 cells after 2 days by Alamar blue assay Cytotoxicity against human A2780 cells after 2 days by Alamar blue assay	[PMID: 29048892]
A2780	IC₅₀	0.013 μM Compound: Paclitaxel	Cytotoxicity against human A2780 cells assessed as inhibition of cell growth after 2 days by Alamar blue assay Cytotoxicity against human A2780 cells assessed as inhibition of cell growth after 2 days by Alamar blue assay	[PMID: 29738243]
A2780	IC₅₀	0.013 μM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by Alamar blue assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by Alamar blue assay	[PMID: 30354100]
A2780	IC₅₀	0.013 μM Compound: Paclitaxel	Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 2 days by AlamarBlue assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 2 days by AlamarBlue assay	[PMID: 31577436]
A2780	IC₅₀	0.013 μM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 2 days hrs by AlamarBlue assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 2 days hrs by AlamarBlue assay	[PMID: 32227943]
A2780	IC₅₀	0.014 μM Compound: Paclitaxel	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 19282186]
A2780	IC₅₀	0.015 μM Compound: 1a, Taxol	Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay	[PMID: 22071526]
A2780	IC₅₀	0.015 μM Compound: TAX, Taxol	Antiproliferative activity against human A2780 cells after 48 hrs by SRB method Antiproliferative activity against human A2780 cells after 48 hrs by SRB method	[PMID: 25061803]
A2780	IC₅₀	0.017 μM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells Antiproliferative activity against human A2780 cells	[PMID: 21995542]
A2780	IC₅₀	0.018 μM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells measured after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A2780 cells measured after 72 hrs by sulforhodamine B assay	[PMID: 31465222]
A2780	IC₅₀	0.019 μM Compound: Taxol	Anticancer activity against human A2780 cells by MTT assay Anticancer activity against human A2780 cells by MTT assay	[PMID: 33316408]
A2780	IC₅₀	0.02 μM Compound: Paclitaxel	Cytotoxicity against human A2780 cells after 72 hrs by SRB assay Cytotoxicity against human A2780 cells after 72 hrs by SRB assay	[PMID: 20800500]
A2780	IC₅₀	0.02 μM Compound: TAX	Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
A2780	IC₅₀	0.02 μM Compound: Taxol	Cytotoxicity against human A2780S cells by MTT assay Cytotoxicity against human A2780S cells by MTT assay	[PMID: 23425970]
A2780	IC₅₀	0.02 μM Compound: paclitaxel	Antiproliferative activity against human A2780 cells after 2 days by Alamar blue assay Antiproliferative activity against human A2780 cells after 2 days by Alamar blue assay	[PMID: 22136523]
A2780	IC₅₀	0.0204 μM Compound: Taxol	Growth inhibition of human A2780 cells after 96 hrs by MTT assay Growth inhibition of human A2780 cells after 96 hrs by MTT assay	[PMID: 28737396]
A2780	IC₅₀	0.021 μM Compound: TAX	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34649064]
A2780	IC₅₀	0.024 μM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells after 2 days by Alamar Blue assay Antiproliferative activity against human A2780 cells after 2 days by Alamar Blue assay	[PMID: 24239390]
A2780	IC₅₀	0.028 μM Compound: 2	Antiproliferative activity against human A2780 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 37856840]
A2780	IC₅₀	0.028 μM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay	[PMID: 23149304]
A2780	IC₅₀	0.028 μM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay	[PMID: 28463001]
A2780	IC₅₀	0.028 μM Compound: Taxol	Cytotoxicity against human A2780 cells assessed as growth inhibition Cytotoxicity against human A2780 cells assessed as growth inhibition	[PMID: 23659371]
A2780	IC₅₀	0.028 μM Compound: taxol, Paclitaxel	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 2 days by alamar blue assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 2 days by alamar blue assay	[PMID: 26042470]
A2780	IC₅₀	0.03 μM Compound: Taxol	Growth inhibition of human A2780 cells incubated for 3 days by SRB assay Growth inhibition of human A2780 cells incubated for 3 days by SRB assay	[PMID: 28625363]
A2780	IC₅₀	0.05 μM Compound: Paclitaxel	Growth inhibition of human A2780 cells after 48 hrs by MTT assay Growth inhibition of human A2780 cells after 48 hrs by MTT assay	[PMID: 29519737]
A2780	IC₅₀	0.136 μg/mL Compound: 1	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 12193017]
A2780	IC₅₀	0.13 ng/mL Compound: paclitaxel	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 19136258]
A2780	IC₅₀	0.27 μM Compound: TAX	Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
A2780	IC₅₀	0.4 nM Compound: Paclitaxel, Taxol	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 25047938]
A2780	IC₅₀	0.41 μM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780 cells incubated for 48 hrs by MTT assay	[PMID: 31279299]
A2780	IC₅₀	0.59 μM Compound: Taxol	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 24467317]
A2780	IC₅₀	0.62 nM Compound: 1a	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 21764308]
A2780	IC₅₀	0.65 μM Compound: paclitaxel	Cytotoxicity against human A2780 cells after 3 days by MTT assay Cytotoxicity against human A2780 cells after 3 days by MTT assay	[PMID: 20593839]
A2780	IC₅₀	0.7 nM Compound: taxol	Cytotoxicity againt human A2780 cells Cytotoxicity againt human A2780 cells	[PMID: 17239597]
A2780	IC₅₀	0.9 μM Compound: paclitaxel	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 20560647]
A2780	IC₅₀	1 nM Compound: 6	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 17206139]
A2780	IC₅₀	1.07 nM Compound: 1	Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28624703]
A2780	IC₅₀	1.1 nM Compound: Paclitaxel	Inhibitory concentration of compound required for exhibiting cytotoxic effect on human A2780 cells; no. of experiment=4 Inhibitory concentration of compound required for exhibiting cytotoxic effect on human A2780 cells; no. of experiment=4	[PMID: 15837302]
A2780	IC₅₀	1.1 μM Compound: Paclitaxel	Cytotoxicity against human A2780 cells assessed as growth inhibition Cytotoxicity against human A2780 cells assessed as growth inhibition	[PMID: 23103097]
A2780	IC₅₀	1.3 nM Compound: 1a	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 19128972]
A2780	IC₅₀	1.31 nM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A2780 cells incubated for 48 hrs by CCK8 assay	[PMID: 38972078]
A2780	IC₅₀	1.38 nM Compound: Taxol	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 24680057]
A2780	IC₅₀	1.38 nM Compound: paclitaxel	Cytotoxicity against human A2780 cells after 72 hrs Cytotoxicity against human A2780 cells after 72 hrs	[PMID: 18465846]
A2780	IC₅₀	1.38 nM Compound: paclitaxel	Cytotoxicity against human A2780 cells after 72 hrs Cytotoxicity against human A2780 cells after 72 hrs	[PMID: 19239240]
A2780	IC₅₀	1.7 nM Compound: Paclitaxel	Growth inhibition of human wild type A2780 cells after 72 hrs Growth inhibition of human wild type A2780 cells after 72 hrs	[PMID: 19423340]
A2780	IC₅₀	1.7 nM Compound: paclitaxel	Cytotoxicity against human wild type A2780 cells after 72 hrs Cytotoxicity against human wild type A2780 cells after 72 hrs	[PMID: 19239240]
A2780	IC₅₀	107 nM Compound: taxol	Antiproliferative activity against taxol resistant human A2780S cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against taxol resistant human A2780S cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
A2780	IC₅₀	1239 nM Compound: Paclitaxel	Growth inhibition of human adriamycin and doxorubicin-resistant A2780 cells after 72 hrs Growth inhibition of human adriamycin and doxorubicin-resistant A2780 cells after 72 hrs	[PMID: 19423340]
A2780	IC₅₀	13.4 nM Compound: 1a	Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 29359935]
A2780	IC₅₀	13.7 nM Compound: Taxol	Antiproliferative activity against human A2780 cells after 2 days by Alamar blue assay Antiproliferative activity against human A2780 cells after 2 days by Alamar blue assay	[PMID: 28648491]
A2780	IC₅₀	14 nM Compound: 2	Cytotoxicity against human A2780 cells after 2 days by Alamar blue assay Cytotoxicity against human A2780 cells after 2 days by Alamar blue assay	[PMID: 21802957]
A2780	IC₅₀	14.9 nM Compound: 1,PTX	Cytotoxicity against human A2780 cells after 4 days by sulforhodamine B assay Cytotoxicity against human A2780 cells after 4 days by sulforhodamine B assay	[PMID: 19359169]
A2780	IC₅₀	15 nM Compound: 1a, PTX	Cytotoxicity against A2780 cell line Cytotoxicity against A2780 cell line	[PMID: 17263521]
A2780	IC₅₀	15.2 nM Compound: PTX	Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33280896]
A2780	IC₅₀	164.2 nM Compound: Paclitaxel	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 28719204]
A2780	IC₅₀	2 nM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32339854]
A2780	IC₅₀	2.2 nM Compound: Paclitaxel	Growth inhibition of human cisplatin-resistant A2780 cells after 72 hrs Growth inhibition of human cisplatin-resistant A2780 cells after 72 hrs	[PMID: 19423340]
A2780	IC₅₀	2.2 nM Compound: paclitaxel	Cytotoxicity against human cisplatin-resistant A2780 cells after 72 hrs Cytotoxicity against human cisplatin-resistant A2780 cells after 72 hrs	[PMID: 19239240]
A2780	IC₅₀	2.3 nM Compound: 1a; PTX	Antiproliferative activity against human A2780 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell viability by MTT assay	[PMID: 37490800]
A2780	IC₅₀	2.7 nM Compound: paclitaxel	Cytotoxicity against A2780-WT, human ovarian carcinoma cell line Cytotoxicity against A2780-WT, human ovarian carcinoma cell line	[PMID: 8831755]
A2780	IC₅₀	2.8 nM Compound: Paclitaxel	Growth inhibition of human A2780 cells Growth inhibition of human A2780 cells	[PMID: 17490878]
A2780	IC₅₀	2.8 nM Compound: Paclitaxel	Cytotoxicity against human A2780 cells by MTT cell proliferation assay Cytotoxicity against human A2780 cells by MTT cell proliferation assay	[PMID: 19877653]
A2780	IC₅₀	2.8 nM Compound: Paclitaxel	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 30455148]
A2780	IC₅₀	2.85 μM Compound: PTX	Cytotoxicity against human A2780 cells incubated for 48 hrs by MTT assay Cytotoxicity against human A2780 cells incubated for 48 hrs by MTT assay	[PMID: 30913525]
A2780	IC₅₀	2.9 μM Compound: TAX, Taxol	Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method	[PMID: 25061803]
A2780	IC₅₀	23.4 nM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay	[PMID: 19028102]
A2780	IC₅₀	23.4 nM Compound: paclitaxel	Antiproliferative activity against human A2780 cells after 96 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human A2780 cells after 96 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 18177014]
A2780	IC₅₀	25 nM Compound: 1	Cytotoxicity against human A2780 cells after 48 hrs by MTS method Cytotoxicity against human A2780 cells after 48 hrs by MTS method	[PMID: 14987051]
A2780	IC₅₀	25 nM Compound: 1	Cytotoxicity against ERbeta negative human A2780 cells Cytotoxicity against ERbeta negative human A2780 cells	[PMID: 17419065]
A2780	IC₅₀	2688 nM Compound: Taxol	In vitro cytotoxicity against A2780ADR cell line In vitro cytotoxicity against A2780ADR cell line	[PMID: 14584931]
A2780	IC₅₀	3.3 nM Compound: 1	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 30448418]
A2780	IC₅₀	3.4 nM Compound: Paclitaxel	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38294341]
A2780	IC₅₀	3.4 nM Compound: paclitaxel	Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line	[PMID: 8831755]
A2780	IC₅₀	3.4 nM Compound: taxol	Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro) Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro)	[PMID: 9288161]
A2780	IC₅₀	3.8 x 10^-2 μM Compound: Paclitaxel	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 27441892]
A2780	IC₅₀	386 nM Compound: paclitaxel	Resistance factor, ratio of IC50 for human A2780 cells to IC50 for paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin Resistance factor, ratio of IC50 for human A2780 cells to IC50 for paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin	[PMID: 19239240]
A2780	IC₅₀	4 nM Compound: taxol	Antiproliferative activity against human A2780S cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human A2780S cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
A2780	IC₅₀	4.1 nM Compound: paclitaxel	Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line	[PMID: 8831755]
A2780	IC₅₀	4.6 nM Compound: Taxol	In vitro cytotoxicity against A2780CIS cell line In vitro cytotoxicity against A2780CIS cell line	[PMID: 14584931]
A2780	IC₅₀	4498 nM Compound: Taxol	In vitro cytotoxicity against A2780TAX cell line In vitro cytotoxicity against A2780TAX cell line	[PMID: 14584931]
A2780	IC₅₀	5.3 nM Compound: Taxol	In vitro cytotoxicity against A2780 cell line In vitro cytotoxicity against A2780 cell line	[PMID: 14584931]
A2780	IC₅₀	5.87 x 10^-7 mg/mL Compound: Taxol	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 26920798]
A2780	IC₅₀	547 nM Compound: paclitaxel	Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line	[PMID: 8831755]
A2780	IC₅₀	5898 nM Compound: Paclitaxel	Resistant factor, IC50 for human paclitaxel-resistant A2780TC1 cells overexpressing class 3 beta-tubulin to IC50 for human wild type A2780 cells Resistant factor, IC50 for human paclitaxel-resistant A2780TC1 cells overexpressing class 3 beta-tubulin to IC50 for human wild type A2780 cells	[PMID: 19423340]
A2780	IC₅₀	7.2 nM Compound: Paclitaxel	Growth inhibition of human topotecan-resistant A2780 cells after 72 hrs Growth inhibition of human topotecan-resistant A2780 cells after 72 hrs	[PMID: 19423340]
A2780	IC₅₀	7.2 nM Compound: paclitaxel	Cytotoxicity against human topotecan-resistant A2780 cells after 72 hrs Cytotoxicity against human topotecan-resistant A2780 cells after 72 hrs	[PMID: 19239240]
A2780	IC₅₀	7.9 nM Compound: paclitaxel	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 19708679]
A2780	IC₅₀	8.25 μM Compound: Taxol	Cytotoxicity against taxol-resistant human A2780 cells by MTT assay Cytotoxicity against taxol-resistant human A2780 cells by MTT assay	[PMID: 23425970]
A2780	IC₅₀	980 nM Compound: 1a	Cytotoxicity against p-glycoprotein expressing drug-resistant human A2780 cells after 48 hrs by MTT assay Cytotoxicity against p-glycoprotein expressing drug-resistant human A2780 cells after 48 hrs by MTT assay	[PMID: 19128972]
A2780	IC₅₀	< 0.001 μM Compound: Paclitaxel	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 23547884]
A2780	IC₅₀	< 0.001 μM Compound: paclitaxel	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 22583079]
A2780	IC₅₀	< 1 x 10^-9 M Compound: Taxol	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 20719510]
A2780	IC₅₀	< 1 x 10^-9 M Compound: Taxol	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 21530251]
A2780 ADR	IC₅₀	0.92 μM Compound: 1	Cytotoxicity against A2780/AD cells by MTT assay Cytotoxicity against A2780/AD cells by MTT assay	[PMID: 17395465]
A2780 ADR	IC₅₀	0.949 μM Compound: Taxol	Cytotoxicity against compound-resistant human A2780AD cells after 24 hrs by MTT assay Cytotoxicity against compound-resistant human A2780AD cells after 24 hrs by MTT assay	[PMID: 21396747]
A2780 ADR	IC₅₀	1239 nM Compound: paclitaxel	Cytotoxicity against human A2780/ADR cells after 72 hrs Cytotoxicity against human A2780/ADR cells after 72 hrs	[PMID: 19239240]
A2780 ADR	IC₅₀	1244 nM Compound: Paclitaxel, Taxol	Cytotoxicity against human A2780AD cells by MTT assay Cytotoxicity against human A2780AD cells by MTT assay	[PMID: 25047938]
A2780 ADR	IC₅₀	1500 nM Compound: Paclitaxel	Inhibitory concentration measured in term of cytotoxicity against human A2780/AD10 cells Inhibitory concentration measured in term of cytotoxicity against human A2780/AD10 cells	[PMID: 15837302]
A2780 ADR	IC₅₀	183 nM Compound: Paclitaxel	Growth inhibition of multidrug-resistant human 2780AD cells Growth inhibition of multidrug-resistant human 2780AD cells	[PMID: 17490878]
A2780 ADR	IC₅₀	1900 nM Compound: 1a	Cytotoxicity against multidrug-resistant human A2780AD cells overexpressing p-gp after 48 hrs by MTT assay Cytotoxicity against multidrug-resistant human A2780AD cells overexpressing p-gp after 48 hrs by MTT assay	[PMID: 21764308]
A2780 ADR	IC₅₀	415 nM Compound: Paclitaxel	Cytotoxicity against p-glycoprotein overexpressing human A2780AD cells by MTT cell proliferation assay Cytotoxicity against p-glycoprotein overexpressing human A2780AD cells by MTT cell proliferation assay	[PMID: 19877653]
A2780 ADR	IC₅₀	535 nM Compound: taxol	Cytotoxicity againt multidrug-resistant human 2780AD cells Cytotoxicity againt multidrug-resistant human 2780AD cells	[PMID: 17239597]
A2780 ADR	IC₅₀	900 nM Compound: 6	Cytotoxicity against human A2780AD cells Cytotoxicity against human A2780AD cells	[PMID: 17206139]
A2780 ADR	IC₅₀	> 1000 nM Compound: paclitaxel	Cytotoxicity against human A2780AD cells expressing p-gp after 96 hrs by MTT assay Cytotoxicity against human A2780AD cells expressing p-gp after 96 hrs by MTT assay	[PMID: 23176628]
A2780 ADR	IC₅₀	> 1000 μM Compound: Paclitaxel	Cytotoxicity against multidrug-resistant human A2780AD cells overexpressing p-gp assessed as growth inhibition Cytotoxicity against multidrug-resistant human A2780AD cells overexpressing p-gp assessed as growth inhibition	[PMID: 23103097]
A2780/Taxol	IC₅₀	0.319 μM Compound: 2	Antiproliferative activity against human A2780T cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780T cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 37856840]
A2780/Taxol	IC₅₀	17.938 μM Compound: Paclitaxel	Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36621138]
A2780/Taxol	IC₅₀	2015.6 nM Compound: Paclitaxel	Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 37145846]
A2780/Taxol	IC₅₀	25120 nM Compound: Paclitaxel	Antiproliferative activity against human A2780T cells after 48 hrs by MTT assay Antiproliferative activity against human A2780T cells after 48 hrs by MTT assay	[PMID: 28763646]
A2780/Taxol	IC₅₀	3164 nM Compound: Paclitaxel	Antiproliferative activity against human A2780T cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A2780T cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33788562]
A2780/Taxol	IC₅₀	3422 nM Compound: PTX	Antiproliferative activity against human A2780T cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A2780T cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
A2780/Taxol	IC₅₀	4.42 μM Compound: PTX	Reversal of multi-drug resistance in human A2780/Taxol cells incubated for 48 hrs by MTT assay Reversal of multi-drug resistance in human A2780/Taxol cells incubated for 48 hrs by MTT assay	[PMID: 36871374]
A2780/Taxol	IC₅₀	55857 nM Compound: PTX	Antiproliferative activity against human A2780T cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against human A2780T cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 38430854]
A2780/Taxol	IC₅₀	56600 nM Compound: Paclitaxel	Cytotoxicity against beta-tubulin 3 overexpressing human A2780T cells assessed as reduction in cell growth after 24 hrs by MTT assay Cytotoxicity against beta-tubulin 3 overexpressing human A2780T cells assessed as reduction in cell growth after 24 hrs by MTT assay	[PMID: 27213819]
A2780/Taxol	IC₅₀	58855 nM Compound: PTX	Cytotoxicity in human A2780T assessed as inhibition in cell growth measured after 24 hrs by MTT assay Cytotoxicity in human A2780T assessed as inhibition in cell growth measured after 24 hrs by MTT assay	[PMID: 35084853]
A2780/Taxol	IC₅₀	72967.4 nM Compound: Taxol	Antiproliferative activity against human A2780T cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human A2780T cells after 48 to 72 hrs by MTT assay	[PMID: 29754076]
A2780/Taxol	IC₅₀	> 500 nM Compound: PTX	Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38996194]
A2780/Taxol	IC₅₀	> 500 nM Compound: Paclitaxel	Antiproliferative activity against paclitaxel-resistant human A2780T cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against paclitaxel-resistant human A2780T cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32339854]
A2780S	IC₅₀	12.3 nM Compound: Paclitaxel	Antiproliferative activity against human A2780S cells after 48 hrs by MTT assay Antiproliferative activity against human A2780S cells after 48 hrs by MTT assay	[PMID: 28763646]
A2780S	IC₅₀	18.94 nM Compound: Taxol	Antiproliferative activity against human A2780S cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human A2780S cells after 48 to 72 hrs by MTT assay	[PMID: 29754076]
A2780S	IC₅₀	2.7 nM Compound: Paclitaxel	Antiproliferative activity against parental human A2780S cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against parental human A2780S cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 37145846]
A2780S	IC₅₀	5.62 nM Compound: PTX	Antiproliferative activity against human A2780S cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A2780S cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
A2780S	IC₅₀	58.1 nM Compound: Paclitaxel	Antiproliferative activity against human A2780S cells after 24 hrs by MTT assay Antiproliferative activity against human A2780S cells after 24 hrs by MTT assay	[PMID: 27213819]
A2780S	IC₅₀	58.3 nM Compound: PTX	Antiproliferative activity against human A2780S cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against human A2780S cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 38430854]
A2780S	IC₅₀	60.4 nM Compound: PTX	Cytotoxicity in human A2780S assessed as inhibition in cell growth measured after 24 hrs by MTT assay Cytotoxicity in human A2780S assessed as inhibition in cell growth measured after 24 hrs by MTT assay	[PMID: 35084853]
A2780S	IC₅₀	7.5 nM Compound: Paclitaxel	Antiproliferative activity against human A2780S cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A2780S cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33788562]
A2780cis	IC₅₀	0.003 μM Compound: Paclitaxel	Growth inhibition of human A2780cis cells after 72 hrs by MTT assay Growth inhibition of human A2780cis cells after 72 hrs by MTT assay	[PMID: 29519737]
A375/TxR	IC₅₀	103.8 nM Compound: Paclitaxel	Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A375/TxR	IC₅₀	112.1 nM Compound: Paclitaxel	Cytotoxicity against paclitaxel resistant human A-375/TxR cells measured after 72 hrs by western blot Cytotoxicity against paclitaxel resistant human A-375/TxR cells measured after 72 hrs by western blot	[PMID: 34378386]
A498	GI₅₀	3.5 μM Compound: Paclitaxel	Compound was tested for growth inhibition of multidrug resistant tumor A498 cell line Compound was tested for growth inhibition of multidrug resistant tumor A498 cell line	[PMID: 15546733]
A498	GI₅₀	7.9 nM Compound: Paclitaxel	Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
A498	GI₅₀	7.9 nM Compound: Paclitaxel	Cytotoxicity against human A498 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human A498 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
A498	IC₅₀	0.017 μM Compound: paclitaxel	Antitumor activity against human A498 cell line Antitumor activity against human A498 cell line	[PMID: 16884301]
A498	IC₅₀	0.02 μM Compound: PTX	Cytotoxicity against human A498 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A498 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
A498	IC₅₀	0.061 μM Compound: paclitaxel	Cytotoxicity against human A498 cells Cytotoxicity against human A498 cells	[PMID: 17113288]
A498	IC₅₀	30 ng/mL Compound: Paclitaxel	Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 3 days by MTS assay Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 3 days by MTS assay	[PMID: 20068177]
A498	IC₅₀	7.53 μg/mL Compound: Paclitaxel	Anticancer activity against human A498 cells after 24 hrs by MTT assay Anticancer activity against human A498 cells after 24 hrs by MTT assay	[PMID: 25305717]
A498	IC₅₀	8.81 μM Compound: paclitaxel	Cytotoxicity against human A498 cells after 72 hrs by MTT assay Cytotoxicity against human A498 cells after 72 hrs by MTT assay	[PMID: 19053781]
A498	IC₅₀	< 3 ng/mL Compound: 1 (paclitaxel)	Cytotoxicity against A498 Tumor cell line in SRB Cell viability test Cytotoxicity against A498 Tumor cell line in SRB Cell viability test	[PMID: 10956217]
A498	IC₅₀	< 3 ng/mL Compound: 1	Cytotoxicity against human A498 cells Cytotoxicity against human A498 cells	[PMID: 17419065]
A498	IC₅₀	> 150 ng/mL Compound: Paclitaxel	Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 1 days by MTS assay Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 1 days by MTS assay	[PMID: 20068177]
A498	IC₅₀	> 150 ng/mL Compound: Paclitaxel	Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 2 days by MTS assay Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 2 days by MTS assay	[PMID: 20068177]
A549	CC₅₀	< 20 nM Compound: Ptxl; PTX	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31248772]
A549	EC₅₀	0.0064 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 22142543]
A549	EC₅₀	4.6 nM Compound: Taxol	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 21873068]
A549	EC₅₀	< 0.005 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 18640035]
A549	EC₅₀	< 0.005 μg/mL Compound: Palitaxel	Cytotoxicity against human A549 cells after 3 days by sulforhodamine B assay Cytotoxicity against human A549 cells after 3 days by sulforhodamine B assay	[PMID: 19193043]
A549	ED₅₀	0.005 μg/mL Compound: Paclitaxel	Effective dose required for inhibitory activity against A549 human tumor cell line. Effective dose required for inhibitory activity against A549 human tumor cell line.	[PMID: 12852747]
A549	ED₅₀	0.005 μg/mL Compound: paclitaxel	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 14640511]
A549	ED₅₀	0.008 μM Compound: paclitaxel	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 20738103]
A549	ED₅₀	0.02 μg/mL Compound: 1	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 17419065]
A549	ED₅₀	0.02 μg/mL Compound: 1	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 17643301]
A549	ED₅₀	2.3 nM Compound: 1	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 17350834]
A549	ED₅₀	2.56 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay	[PMID: 21296579]
A549	GI₅₀	0.0035 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human A549 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
A549	GI₅₀	0.0035 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26299346]
A549	GI₅₀	0.0035 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay	[PMID: 28103537]
A549	GI₅₀	0.0035 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28110868]
A549	GI₅₀	0.0035 μg/mL Compound: Paclitaxel	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 28411559]
A549	GI₅₀	0.0035 μg/mL Compound: Paclitaxel	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 30910461]
A549	GI₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 21839640]
A549	GI₅₀	0.004 μM Compound: paclitaxel	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 17696332]
A549	GI₅₀	0.00489 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 22932313]
A549	GI₅₀	0.00558 μM Compound: Paclitaxel	Cytotoxicity activity against human A549 cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay Cytotoxicity activity against human A549 cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay	[PMID: 21316977]
A549	GI₅₀	0.0071 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells by sulforhodamine B assay Antiproliferative activity against human A549 cells by sulforhodamine B assay	[PMID: 25770782]
A549	GI₅₀	0.0076 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells by SRB method Cytotoxicity against human A549 cells by SRB method	[PMID: 23867604]
A549	GI₅₀	0.0076 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 24315191]
A549	GI₅₀	0.0076 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition by SRB assay	[PMID: 26242242]
A549	GI₅₀	0.0076 μM Compound: paclitaxel	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 24502232]
A549	GI₅₀	0.01 μM Compound: Paclitaxel	Inhibition of human non-small cell lung cancer A549 cell proliferation Inhibition of human non-small cell lung cancer A549 cell proliferation	[PMID: 15546733]
A549	GI₅₀	0.039 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 and 72 hrs by MTT assay Cytotoxicity against human A549 cells after 48 and 72 hrs by MTT assay	[PMID: 26927426]
A549	GI₅₀	0.04 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 27688192]
A549	GI₅₀	0.06 μM Compound: paclitaxel	Growth inhibition of human A549 cells Growth inhibition of human A549 cells	[PMID: 23167614]
A549	GI₅₀	0.08 mM Compound: Paclitaxel	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	10.1039/C6MD00278A
A549	GI₅₀	0.12 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26920799]
A549	GI₅₀	0.13 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C5MD00057B
A549	GI₅₀	0.6 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 34917259]
A549	GI₅₀	18.73 nM Compound: 1, Taxol	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 24405702]
A549	GI₅₀	2.4 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31938468]
A549	GI₅₀	2.6 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells after 48 hrs by SRB method Antiproliferative activity against human A549 cells after 48 hrs by SRB method	[PMID: 27238842]
A549	GI₅₀	3.7 nM Compound: Paclitaxel	Growth inhibition of human A549 cells after 4 days by SRB assay Growth inhibition of human A549 cells after 4 days by SRB assay	[PMID: 28740601]
A549	GI₅₀	5.46 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 22265685]
A549	GI₅₀	6 nM Compound: Taxol	Induction of microtubule stabilization in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter reagent-based assay Induction of microtubule stabilization in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter reagent-based assay	[PMID: 31191870]
A549	GI₅₀	6.3 nM Compound: Paclitaxel	Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
A549	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
A549	GI₅₀	7.03 nM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28653846]
A549	GI₅₀	7.6 nM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 3 days Cytotoxicity against human A549 cells after 3 days	[PMID: 21377368]
A549	GI₅₀	8.18 nM Compound: Paclitaxel	Growth inhibition of human A549 cells by SRB assay Growth inhibition of human A549 cells by SRB assay	[PMID: 23274123]
A549	GI₅₀	< 0.0023 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26642768]
A549	GI₅₀	< 0.004 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 27013391]
A549	GI₅₀	< 0.01 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 25827522]
A549	GI₅₀	< 0.01 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 26994690]
A549	IC₅₀	0.001 μM Compound: taxol	Cytotoxicity against human A549 after 48 hrs by SRB assay Cytotoxicity against human A549 after 48 hrs by SRB assay	[PMID: 21044847]
A549	IC₅₀	0.0019 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22595179]
A549	IC₅₀	0.002 μM Compound: 1a	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 18715782]
A549	IC₅₀	0.0021 μM Compound: taxol	Antiproliferative activity against human A549 cell line Antiproliferative activity against human A549 cell line	[PMID: 16759114]
A549	IC₅₀	0.0029 μM Compound: Taxol	Concentration required for growth inhibition of human lung carcinoma cell line (CCRF-CEM) was determined Concentration required for growth inhibition of human lung carcinoma cell line (CCRF-CEM) was determined	[PMID: 15324894]
A549	IC₅₀	0.002 μg/mL Compound: Paclitaxel	Inhibitory concentration required to inhibit A549 Cell line growth on continuous exposure time of 72 h Inhibitory concentration required to inhibit A549 Cell line growth on continuous exposure time of 72 h	[PMID: 15664868]
A549	IC₅₀	0.002 μg/mL Compound: paclitaxel	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 20232858]
A549	IC₅₀	0.003 μM Compound: 6	Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25682561]
A549	IC₅₀	0.003 μM Compound: Paclitaxel	Anticancer activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34303874]
A549	IC₅₀	0.003 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
A549	IC₅₀	0.0033 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 68 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 68 hrs by MTT assay	[PMID: 31404864]
A549	IC₅₀	0.0034 μM Compound: PTX	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 30633861]
A549	IC₅₀	0.0034 μg/mL Compound: 3	In vitro cytotoxicity against A549-human lung carcinoma cells. In vitro cytotoxicity against A549-human lung carcinoma cells.	10.1016/S0960-894X(01)80507-2
A549	IC₅₀	0.0038 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay	[PMID: 20732809]
A549	IC₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A549	IC₅₀	0.0049 μM Compound: Taxol	Antiproliferative activity against human A549 cells after 96 hrs by MTT assay Antiproliferative activity against human A549 cells after 96 hrs by MTT assay	[PMID: 20974505]
A549	IC₅₀	0.0049 μM Compound: paclitaxel	Antitumor activity against human A549 cell line Antitumor activity against human A549 cell line	[PMID: 16884301]
A549	IC₅₀	0.005 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32633512]
A549	IC₅₀	0.005 μM Compound: TAX, Taxol	Antiproliferative activity against human A549 cells after 48 hrs by SRB method Antiproliferative activity against human A549 cells after 48 hrs by SRB method	[PMID: 25061803]
A549	IC₅₀	0.0052 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 19245261]
A549	IC₅₀	0.0052 μg/mL Compound: Paclitaxel	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 22204911]
A549	IC₅₀	0.0057 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 72 hrs sulforhodamine B colorimetric assay Cytotoxicity against human A549 cells after 72 hrs sulforhodamine B colorimetric assay	[PMID: 25008456]
A549	IC₅₀	0.0057 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
A549	IC₅₀	0.006 μM Compound: 6	Antiproliferative activity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25682561]
A549	IC₅₀	0.006 μM Compound: PTX	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 35065411]
A549	IC₅₀	0.006 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25462279]
A549	IC₅₀	0.006 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 34403728]
A549	IC₅₀	0.006 μM Compound: Taxol	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 16539377]
A549	IC₅₀	0.006 μM Compound: taxol	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 17915851]
A549	IC₅₀	0.0063 μM Compound: 1	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 26448037]
A549	IC₅₀	0.007 μM Compound: Taxol	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29501947]
A549	IC₅₀	0.0072 μM Compound: Taxol	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 22027100]
A549	IC₅₀	0.009 μM Compound: TAX	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27149641]
A549	IC₅₀	0.009 μM Compound: TAX, Taxol	Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method	[PMID: 25061803]
A549	IC₅₀	0.01 μM Compound: Taxol	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 23937981]
A549	IC₅₀	0.01 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 21973054]
A549	IC₅₀	0.012 μM Compound: 1a (Paclitaxel)	Inhibitory activity against A549 lung cancer cell line Inhibitory activity against A549 lung cancer cell line	[PMID: 12031338]
A549	IC₅₀	0.012 μM Compound: PTX	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 32650183]
A549	IC₅₀	0.013 μM Compound: 1; PTX	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 33065439]
A549	IC₅₀	0.013 μM Compound: Taxol	Antiproliferative activity against A549 cell line by MTS assay Antiproliferative activity against A549 cell line by MTS assay	[PMID: 16257201]
A549	IC₅₀	0.014 μM Compound: 2	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 37856840]
A549	IC₅₀	0.014 μM Compound: Taxol	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
A549	IC₅₀	0.015 μM Compound: Paclitaxel	Antiproliferative activity against human A549 assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A549 assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34175541]
A549	IC₅₀	0.016 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23547884]
A549	IC₅₀	0.016 μM Compound: paclitaxel	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22506620]
A549	IC₅₀	0.016 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 22583079]
A549	IC₅₀	0.018 μM Compound: PTX	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30530194]
A549	IC₅₀	0.019 μM Compound: paclitaxel	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 18001087]
A549	IC₅₀	0.02 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 23738539]
A549	IC₅₀	0.02 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24063582]
A549	IC₅₀	0.02 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27704822]
A549	IC₅₀	0.02 μM Compound: Taxol	Inhibition of cell growth in human A549 cells incubated for 72 hrs by SRB method Inhibition of cell growth in human A549 cells incubated for 72 hrs by SRB method	[PMID: 38171146]
A549	IC₅₀	0.02 μM Compound: paclitaxel	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24063567]
A549	IC₅₀	0.022 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37883897]
A549	IC₅₀	0.023 μM Compound: TAX	Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 27149641]
A549	IC₅₀	0.023 μM Compound: Taxol	Antiproliferative activity against human A549 cells expressing NQO1 after 72 hrs by MTT assay Antiproliferative activity against human A549 cells expressing NQO1 after 72 hrs by MTT assay	[PMID: 28395199]
A549	IC₅₀	0.025 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25647428]
A549	IC₅₀	0.028 μM Compound: 1	Antiproliferative activity against human A549 cell line by MTT assay after 1 hr Antiproliferative activity against human A549 cell line by MTT assay after 1 hr	[PMID: 16513344]
A549	IC₅₀	0.028 μM Compound: paclitaxel	Cytotoxicity against human A549 cell line Cytotoxicity against human A549 cell line	[PMID: 16420032]
A549	IC₅₀	0.02 μg/mL Compound: Taxol	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 22989532]
A549	IC₅₀	0.03 nM Compound: PXL	Antiproliferative activity against human A549 cells after 3 days by SRB assay Antiproliferative activity against human A549 cells after 3 days by SRB assay	[PMID: 26865176]
A549	IC₅₀	0.03 μM Compound: Paclitaxel	Cytotoxicity activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 27627130]
A549	IC₅₀	0.03 μM Compound: TAX	Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
A549	IC₅₀	0.032 μM Compound: Taxol	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 24467317]
A549	IC₅₀	0.05 μM Compound: PTX	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 35213164]
A549	IC₅₀	0.051 μM Compound: Taxol	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30212198]
A549	IC₅₀	0.056 μM Compound: Taxol	Cytotoxicity against human A549 cells after 72 hrs by crystal violet staining based microplate reader analysis Cytotoxicity against human A549 cells after 72 hrs by crystal violet staining based microplate reader analysis	[PMID: 23153397]
A549	IC₅₀	0.058 μM Compound: PTX	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35447432]
A549	IC₅₀	0.058 μM Compound: Taxol	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 25771484]
A549	IC₅₀	0.06 μM Compound: taxol	Cytotoxicity againat taxol-resistant human A549T12 cells after 72 hrs by MTT assay Cytotoxicity againat taxol-resistant human A549T12 cells after 72 hrs by MTT assay	[PMID: 17915851]
A549	IC₅₀	0.07 μM Compound: TAX	Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
A549	IC₅₀	0.075 μM Compound: Taxol	Antiproliferative activity against human taxol-resistant A549-T12 cells after 72 hrs by MTT assay Antiproliferative activity against human taxol-resistant A549-T12 cells after 72 hrs by MTT assay	[PMID: 22027100]
A549	IC₅₀	0.08 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27329938]
A549	IC₅₀	0.082 μM Compound: 1, TAX	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 25084144]
A549	IC₅₀	0.1 μM Compound: PTX	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38280356]
A549	IC₅₀	0.1 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by WST-8 assay Cytotoxicity against human A549 cells after 48 hrs by WST-8 assay	[PMID: 19072209]
A549	IC₅₀	0.1 μM Compound: Paclitaxel; Taxol	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 35551039]
A549	IC₅₀	0.1 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by SRB method Cytotoxicity against human A549 cells after 48 hrs by SRB method	[PMID: 19425589]
A549	IC₅₀	0.1 μM Compound: paclitaxel	Antimicrobial activity against human A549 cells after 48 hrs by MTT assay Antimicrobial activity against human A549 cells after 48 hrs by MTT assay	[PMID: 23957453]
A549	IC₅₀	0.102 μM Compound: taxol	Cytotoxicity againat taxol-resistant human A549T24 cells after 72 hrs by MTT assay Cytotoxicity againat taxol-resistant human A549T24 cells after 72 hrs by MTT assay	[PMID: 17915851]
A549	IC₅₀	0.11 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 30798081]
A549	IC₅₀	0.131 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39163776]
A549	IC₅₀	0.19 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 22472043]
A549	IC₅₀	0.29 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34671737]
A549	IC₅₀	0.29 ng/mL Compound: paclitaxel	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19136258]
A549	IC₅₀	0.35 μM Compound: Paclitaxel	Anticancer activity against human A549 cells by MTT assay Anticancer activity against human A549 cells by MTT assay	[PMID: 31404864]
A549	IC₅₀	0.39 μM Compound: PTX	Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells	[PMID: 31200238]
A549	IC₅₀	0.39 μM Compound: Paclitaxel	Antiproliferative activity against paclitaxel-resistant human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against paclitaxel-resistant human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
A549	IC₅₀	0.4 μM Compound: Paciitaxel	Cytotoxicity against human A549 cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human A549 cells incubated for 72 hrs by CCK8 assay	[PMID: 38493728]
A549	IC₅₀	0.4 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	10.1039/C6MD00256K
A549	IC₅₀	0.5 nM Compound: PXL	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 38251859]
A549	IC₅₀	0.54 μM Compound: TAX	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30677614]
A549	IC₅₀	0.7 μM Compound: PXL	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 27707623]
A549	IC₅₀	0.7 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 33459007]
A549	IC₅₀	0.7 μM Compound: Taxol	Cytotoxicity against human A549 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30508483]
A549	IC₅₀	0.72 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
A549	IC₅₀	0.74 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay	10.1039/C4MD00573B
A549	IC₅₀	0.93 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 24 hrs by SRB assay Cytotoxicity against human A549 cells after 24 hrs by SRB assay	[PMID: 18281952]
A549	IC₅₀	0.96 μM Compound: 1a (Paclitaxel)	Inhibitory activity against Taxol-resistant A549 lung cancer cell line Inhibitory activity against Taxol-resistant A549 lung cancer cell line	[PMID: 12031338]
A549	IC₅₀	0.99 nM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27797192]
A549	IC₅₀	1 x 10^-3 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 20560647]
A549	IC₅₀	1.04 μM Compound: Taxol	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 25226363]
A549	IC₅₀	1.1 nM Compound: PTX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 35635956]
A549	IC₅₀	1.16 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 22472043]
A549	IC₅₀	1.25 μM Compound: taxol	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 15787460]
A549	IC₅₀	1.4 nM Compound: Paclitaxel	Antiproliferative potency determined as inhibitory concentration against A549 cells Antiproliferative potency determined as inhibitory concentration against A549 cells	[PMID: 12825928]
A549	IC₅₀	1.4 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 20521771]
A549	IC₅₀	1.4 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23819871]
A549	IC₅₀	1.525 μM Compound: Paclitaxel	Antiproliferative against human A549 cells after 48 hrs by MTT assay Antiproliferative against human A549 cells after 48 hrs by MTT assay	[PMID: 24996136]
A549	IC₅₀	1.6 x 10^-8 M Compound: Taxol	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20719510]
A549	IC₅₀	1.6 x 10^-8 M Compound: Taxol	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21530251]
A549	IC₅₀	1.7 μM Compound: 1	inhibitory concentration against the growth of Non-small-cell lung carcinoma A549 cell line after 72 hr of exposure inhibitory concentration against the growth of Non-small-cell lung carcinoma A549 cell line after 72 hr of exposure	[PMID: 15501062]
A549	IC₅₀	1.92 μM Compound: Taxol	Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 27623549]
A549	IC₅₀	1.93 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 20036537]
A549	IC₅₀	10 nM Compound: PXL	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 30106296]
A549	IC₅₀	10 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in viable cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in viable cells after 48 hrs by MTT assay	[PMID: 26916436]
A549	IC₅₀	1037.8 nM Compound: paclitaxel	Cytotoxicity against paclitaxel-resistant human A549 cells after 48 hrs by MTT assay Cytotoxicity against paclitaxel-resistant human A549 cells after 48 hrs by MTT assay	[PMID: 23356786]
A549	IC₅₀	12.6 nM Compound: Paclitaxel	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17764148]
A549	IC₅₀	13.05 μM Compound: Taxol	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 18701301]
A549	IC₅₀	13.2 nM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by Celltiter-Glo luminescent cell viability assay Cytotoxicity against human A549 cells after 48 hrs by Celltiter-Glo luminescent cell viability assay	[PMID: 26985296]
A549	IC₅₀	13.7 nM Compound: Taxol	Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 31050424]
A549	IC₅₀	14 nM Compound: paclitaxel	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23886686]
A549	IC₅₀	15 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay	[PMID: 36092142]
A549	IC₅₀	18 nM Compound: Paclitaxel	Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37146221]
A549	IC₅₀	19.64 ng/mL Compound: taxol	Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay	[PMID: 19138858]
A549	IC₅₀	19.64 ng/mL Compound: taxol	Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay	[PMID: 19138858]
A549	IC₅₀	2.1 nM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 28598633]
A549	IC₅₀	2.1 μM Compound: taxol	Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 26316467]
A549	IC₅₀	2.12 nM Compound: Taxol	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 26697718]
A549	IC₅₀	2.2 x 10^-3 μM Compound: Taxol	Cytotoxicity against human A549 cells assessed as reduction in cell viability Cytotoxicity against human A549 cells assessed as reduction in cell viability	[PMID: 32273216]
A549	IC₅₀	2.28 μM Compound: Taxol	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 19815316]
A549	IC₅₀	2.3 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 21480626]
A549	IC₅₀	2.3 nM Compound: paclitaxel	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 19708679]
A549	IC₅₀	2.3 nM Compound: taxol	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25937236]
A549	IC₅₀	2.3 x 10^-2 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 27441892]
A549	IC₅₀	2.4 nM Compound: PXL	Antiproliferative activity against human A549 cells after 3 days by SRB assay Antiproliferative activity against human A549 cells after 3 days by SRB assay	[PMID: 25241925]
A549	IC₅₀	2.4 μM Compound: Taxol	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
A549	IC₅₀	2.46 μM Compound: Taxol	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 19359185]
A549	IC₅₀	2.46 μM Compound: Taxol	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21067933]
A549	IC₅₀	2.46 μM Compound: Taxol	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21342735]
A549	IC₅₀	2.7 μM Compound: Paclitaxel	Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay	10.1007/s00044-012-0424-0
A549	IC₅₀	2.7 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay	10.1039/C3MD00055A
A549	IC₅₀	2.7 μM Compound: paclitaxel	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 19939522]
A549	IC₅₀	2.82 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 25959813]
A549	IC₅₀	21.02 μM Compound: Taxol	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C6MD00234J
A549	IC₅₀	23.1 nM Compound: paclitaxel	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 18606540]
A549	IC₅₀	23.18 nM Compound: Taxol	Antiproliferative activity against human A549 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 to 72 hrs by MTT assay	[PMID: 29754076]
A549	IC₅₀	23.6 nM Compound: PTX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 38430854]
A549	IC₅₀	24.2 nM Compound: PTX	Cytotoxicity in human A549 assessed as inhibition in cell growth measured after 24 hrs by MTT assay Cytotoxicity in human A549 assessed as inhibition in cell growth measured after 24 hrs by MTT assay	[PMID: 35084853]
A549	IC₅₀	29.5 x 10^-3 μM Compound: Taxol	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34883453]
A549	IC₅₀	3 nM Compound: 1a Paclitaxel	Compound was tested for its cytotoxicity by inhibiting the growth of A-549 cell line after 72 h Compound was tested for its cytotoxicity by inhibiting the growth of A-549 cell line after 72 h	[PMID: 15225730]
A549	IC₅₀	3 nM Compound: Paclitaxel	In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure	[PMID: 12477344]
A549	IC₅₀	3 x 10^-2 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 72 hrs by MTS assay Cytotoxicity against human A549 cells after 72 hrs by MTS assay	[PMID: 21812410]
A549	IC₅₀	3 x 10^-2 μM Compound: paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTS assay	[PMID: 25760674]
A549	IC₅₀	3.12 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay	[PMID: 38972078]
A549	IC₅₀	3.14 nM Compound: (+)-2, 2, taxol	Antiproliferative activity against human A549 cells after 72 hrs by SRB method Antiproliferative activity against human A549 cells after 72 hrs by SRB method	[PMID: 21870795]
A549	IC₅₀	3.2 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 29648818]
A549	IC₅₀	3.46 μM Compound: Taxol	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 22483090]
A549	IC₅₀	3.5 nM Compound: paclitaxel	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23445496]
A549	IC₅₀	3.6 nM Compound: 6	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 17206139]
A549	IC₅₀	3.6 nM Compound: Paclitaxel	Cytotoxicity against human A549 non small cell lung cell lines Cytotoxicity against human A549 non small cell lung cell lines	10.1016/S0960-894X(01)80298-5
A549	IC₅₀	3.6 nM Compound: Paclitaxel	Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines	10.1016/S0960-894X(01)80568-0
A549	IC₅₀	3.6 nM Compound: Paclitaxel	Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line	10.1016/S0960-894X(96)00595-1
A549	IC₅₀	3.6 nM Compound: Paclitaxel	In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure	[PMID: 12477344]
A549	IC₅₀	3.6 nM Compound: Paclitaxel	Growth inhibition of human non-small-lung carcinoma (A549) cell line Growth inhibition of human non-small-lung carcinoma (A549) cell line	[PMID: 9022793]
A549	IC₅₀	3.6 nM Compound: Paclitaxel	Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure	[PMID: 9022794]
A549	IC₅₀	3.6 nM Compound: Taxol	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23806112]
A549	IC₅₀	3.6 nM Compound: paclitaxel	In vitro cytotoxicity against human non-small cell lung carcinoma A549 In vitro cytotoxicity against human non-small cell lung carcinoma A549	[PMID: 8182698]
A549	IC₅₀	3.6 nM Compound: paclitaxel	Concentration required to inhibit growth of human tumor A549 (NSCL) cell line. Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.	[PMID: 8831755]
A549	IC₅₀	3.76 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells by CCK8 assay Antiproliferative activity against human A549 cells by CCK8 assay	[PMID: 34922028]
A549	IC₅₀	3.8 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36621138]
A549	IC₅₀	3.8 nM Compound: Taxol	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs	[PMID: 33038665]
A549	IC₅₀	4.1 nM Compound: PTX	Cytotoxicity against human A549 cells measured after 24 hrs Cytotoxicity against human A549 cells measured after 24 hrs	[PMID: 28835794]
A549	IC₅₀	4.4 nM Compound: Taxol	Antiproliferative activity against human A549 cells after 96 hrs by MTT assay Antiproliferative activity against human A549 cells after 96 hrs by MTT assay	[PMID: 21296467]
A549	IC₅₀	4.4 nM Compound: Taxol	Antiproliferative against human A549 cells assessed as cell viability after 96 hrs by MTT assay Antiproliferative against human A549 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 24211639]
A549	IC₅₀	4.4 nM Compound: Taxol	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 25819096]
A549	IC₅₀	4.49 x 10^-2 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21928797]
A549	IC₅₀	4.5 nM Compound: PXL	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 29319316]
A549	IC₅₀	4.7 nM Compound: Taxol	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by secondary round CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by secondary round CCK8 assay	[PMID: 34508844]
A549	IC₅₀	4.79 μg/mL Compound: 1	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	10.1021/np50078a018
A549	IC₅₀	4.9 μM Compound: Pacli	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25563891]
A549	IC₅₀	4.97 nM Compound: PTX	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
A549	IC₅₀	5 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38294341]
A549	IC₅₀	5.4 μM Compound: PTX	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
A549	IC₅₀	5.4 μM Compound: PXL	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay	[PMID: 38438305]
A549	IC₅₀	5.5 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 27748595]
A549	IC₅₀	5.82 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 29391939]
A549	IC₅₀	520 nM Compound: taxol	Antiproliferative activity against human taxol-resistant A549 cells after 48 hrs by MTT assay Antiproliferative activity against human taxol-resistant A549 cells after 48 hrs by MTT assay	[PMID: 25937236]
A549	IC₅₀	58.5 nM Compound: Taxol	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 30528697]
A549	IC₅₀	6.195 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
A549	IC₅₀	6.2 nM Compound: PXL	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 28099003]
A549	IC₅₀	6.2 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay	[PMID: 28290698]
A549	IC₅₀	6.2 nM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
A549	IC₅₀	6.2 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 31126820]
A549	IC₅₀	6.2 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay	[PMID: 31718182]
A549	IC₅₀	6.3 nM Compound: PXL	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 30010341]
A549	IC₅₀	6.3 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 31550158]
A549	IC₅₀	6.5 nM Compound: PXL	Antiproliferative activity against human A549 cells assessed as reduction in cell viability by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability by SRB assay	[PMID: 38970504]
A549	IC₅₀	6.5 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32946697]
A549	IC₅₀	6.8 nM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 29373791]
A549	IC₅₀	6.8 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay	[PMID: 30189396]
A549	IC₅₀	6.85 nM Compound: PXL	Antiproliferative activity against human A549 cells by sulforhodamine B assay Antiproliferative activity against human A549 cells by sulforhodamine B assay	[PMID: 28457756]
A549	IC₅₀	67.5 nM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35324187]
A549	IC₅₀	7 nM Compound: PTX	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23214452]
A549	IC₅₀	7 nM Compound: PTX	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by CellTiter-Fluor assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by CellTiter-Fluor assay	[PMID: 26132075]
A549	IC₅₀	7 x 10^-3 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 18419154]
A549	IC₅₀	7.1 nM Compound: Taxol	Growth inhibition of human A549 cells Growth inhibition of human A549 cells	[PMID: 29439899]
A549	IC₅₀	7.2 nM Compound: Taxol	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 23117171]
A549	IC₅₀	7.2 nM Compound: taxol	Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 21663319]
A549	IC₅₀	7.52 nM Compound: PXL	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31541869]
A549	IC₅₀	75.2 nM Compound: Taxol	Antiproliferative activity against human taxol-resistant A549-T12 cells expressing tubulin mutant gene after 72 hrs by MTT assay Antiproliferative activity against human taxol-resistant A549-T12 cells expressing tubulin mutant gene after 72 hrs by MTT assay	[PMID: 23117171]
A549	IC₅₀	75.2 nM Compound: taxol	Antiproliferative activity against human taxol-resistant A549-T12 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human taxol-resistant A549-T12 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 21663319]
A549	IC₅₀	8.2 nM Compound: paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23356786]
A549	IC₅₀	8.76 nM Compound: PXL	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 30106296]
A549	IC₅₀	854 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as cell growth inhibition by CCK8 assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition by CCK8 assay	[PMID: 32631533]
A549	IC₅₀	9.265 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 21784631]
A549	IC₅₀	9.52 nM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 28340411]
A549	IC₅₀	9.8 nM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A549	IC₅₀	92.3 nM Compound: paclitaxel	Cytotoxicity against human A549-T12 cells after 72 hrs by MTT assay Cytotoxicity against human A549-T12 cells after 72 hrs by MTT assay	[PMID: 23445496]
A549	IC₅₀	930 nM Compound: 1, Taxol	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24269481]
A549	IC₅₀	< 0.001 μM Compound: Taxol	Antiproliferative activity against human A549 cells assessed as reduction in cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth by MTT assay	[PMID: 32949719]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 23327668]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24417634]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 27704807]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells after 48 hrs by MTS assay Antiproliferative activity against human A549 cells after 48 hrs by MTS assay	[PMID: 28654256]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTS assay Cytotoxicity against human A549 cells after 48 hrs by MTS assay	[PMID: 29286250]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTS assay Cytotoxicity against human A549 cells after 48 hrs by MTS assay	[PMID: 29338226]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTS assay	[PMID: 29338260]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Growth inhibition of human A549 cells after 48 hrs by MTS assay Growth inhibition of human A549 cells after 48 hrs by MTS assay	[PMID: 29412669]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 31390200]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32628478]
A549	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34355562]
A549	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25871261]
A549	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26068802]
A549	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 4 days by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 4 days by MTT assay	[PMID: 29884535]
A549	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay	[PMID: 34781083]
A549	IC₅₀	< 0.008 μM Compound: Taxol	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36274275]
A549	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT method Cytotoxicity against human A549 cells after 48 hrs by MTT method	[PMID: 21534539]
A549	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human A549 assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 23586920]
A549	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTS assay Cytotoxicity against human A549 cells after 48 hrs by MTS assay	[PMID: 24219809]
A549	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTS assay Cytotoxicity against human A549 cells after 48 hrs by MTS assay	[PMID: 24256484]
A549	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTS assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTS assay	[PMID: 24697496]
A549	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25375202]
A549	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 25798528]
A549	IC₅₀	< 0.008 μM Compound: taxol	Antitumor activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antitumor activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 35413617]
A549	IC₅₀	< 0.015 μM Compound: 1	Antiproliferative activity against human A549 cell line by MTT assay after 72 hrs Antiproliferative activity against human A549 cell line by MTT assay after 72 hrs	[PMID: 16513344]
A549	IC₅₀	< 0.02 μg/mL Compound: 1	Cytotoxicity against human A549/VP cells Cytotoxicity against human A549/VP cells	10.1021/np50078a018
A549	IC₅₀	< 2 μg/mL Compound: paclitaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 18553923]
A549	IC₅₀	> 10 nM Compound: PXL	Antiproliferative activity against human A549 cells after 24 hrs by SRB assay Antiproliferative activity against human A549 cells after 24 hrs by SRB assay	[PMID: 30106296]
A549	IC₅₀	> 30 μM Compound: Taxol	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 29843103]
A549	IC₅₀	>= 0.0049 μM Compound: Taxol	Antiproliferative activity human A549 cells after 20 hrs by MTT assay Antiproliferative activity human A549 cells after 20 hrs by MTT assay	[PMID: 20149494]
A549/TR	EC₅₀	10.3 μM Compound: Paclitaxel	Cytotoxicity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29288939]
A549/TR	IC₅₀	0.602 μM Compound: Paclitaxel	Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37883897]
A549/TR	IC₅₀	1.029 μM Compound: Taxol	Inhibition of cell growth in human A549/Taxol cells incubated for 72 hrs by SRB method Inhibition of cell growth in human A549/Taxol cells incubated for 72 hrs by SRB method	[PMID: 38171146]
A549/TR	IC₅₀	1.51 μM Compound: Paclitaxel	Cytotoxicity against human A549/TR cells after 48 hrs by MTT assay Cytotoxicity against human A549/TR cells after 48 hrs by MTT assay	[PMID: 28340411]
A549/TR	IC₅₀	1.83 μM Compound: PTX	Antiproliferative activity against human taxol-resistant A549/TR cells after 72 hrs by MTT assay Antiproliferative activity against human taxol-resistant A549/TR cells after 72 hrs by MTT assay	[PMID: 30530194]
A549/TR	IC₅₀	24.53 μM Compound: TAX	Cytotoxicity against human A549/TAX cells after 72 hrs by MTT assay Cytotoxicity against human A549/TAX cells after 72 hrs by MTT assay	[PMID: 30677614]
A549/TR	IC₅₀	27 μM Compound: Taxol	Cytotoxicity against human A549/TR cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549/TR cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30508483]
A549/TR	IC₅₀	28 μM Compound: Taxol	Cytotoxicity against human A549/TR cells assessed as cell growth inhibition preincubated for 24 hrs followed by compound washout measured after 72 hrs by MTT assay Cytotoxicity against human A549/TR cells assessed as cell growth inhibition preincubated for 24 hrs followed by compound washout measured after 72 hrs by MTT assay	[PMID: 28710963]
A549/TR	IC₅₀	3.112 μM Compound: Taxol	Antiproliferative activity against human A549/TR cells after 72 hrs by MTT assay Antiproliferative activity against human A549/TR cells after 72 hrs by MTT assay	[PMID: 29501947]
A549/TR	IC₅₀	34.3 μM Compound: Taxol	Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by cell titer glo luminescent assay Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by cell titer glo luminescent assay	[PMID: 35640078]
A549/TR	IC₅₀	4863 nM Compound: PTX	Antiproliferative activity against human A549/T cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549/T cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
A549/TR	IC₅₀	5653 nM Compound: Paclitaxel	Antiproliferative activity against human A549/Taxol cells assessed as cell growth inhibition incubated for72 hrs by MTT assay Antiproliferative activity against human A549/Taxol cells assessed as cell growth inhibition incubated for72 hrs by MTT assay	[PMID: 37890199]
A549/TR	IC₅₀	759.39 nM Compound: Taxol	Antiproliferative activity against human A549/TR cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human A549/TR cells after 48 to 72 hrs by MTT assay	[PMID: 29754076]
A549/TR	IC₅₀	802 nM Compound: PTX	Cytotoxicity in human A549T assessed as inhibition in cell growth measured after 24 hrs by MTT assay Cytotoxicity in human A549T assessed as inhibition in cell growth measured after 24 hrs by MTT assay	[PMID: 35084853]
A549/TR	IC₅₀	834 nM Compound: PTX	Antiproliferative activity against paclitaxel resistant human A549T cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against paclitaxel resistant human A549T cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 38430854]
A549/TR	IC₅₀	> 1000 nM Compound: Paclitaxel	Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A549/TR	IC₅₀	> 500 nM Compound: PTX	Antiproliferative activity against paclitaxel resistant human A549/Taxol cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against paclitaxel resistant human A549/Taxol cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 38996194]
ACHN	GI₅₀	0.398 μM Compound: Paclitaxel	Cytotoxicity against human ACHN cells by sulforhodamine B assay Cytotoxicity against human ACHN cells by sulforhodamine B assay	[PMID: 21839640]
ACHN	GI₅₀	0.398 μM Compound: paclitaxel	Cytotoxicity against human ACHN cells Cytotoxicity against human ACHN cells	[PMID: 17696332]
ACHN	GI₅₀	158 nM Compound: Paclitaxel	Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
ACHN	GI₅₀	158 nM Compound: Paclitaxel	Cytotoxicity against human ACHN cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human ACHN cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
ACHN	IC₅₀	0.066 μM Compound: Paclitaxel	Antiproliferative activity against human ACHN cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human ACHN cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
ACHN	IC₅₀	2.33 μM Compound: 1	Cytotoxicity against human ACHN cells assessed as inhibition of cell proliferation Cytotoxicity against human ACHN cells assessed as inhibition of cell proliferation	[PMID: 25466201]
ACHN	IC₅₀	25 nM Compound: paclitaxel	Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay	[PMID: 17286393]
ACHN	IC₅₀	31.5 μM Compound: Paclitaxel	Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay	[PMID: 16562840]
ACHN	IC₅₀	31.5 μM Compound: paclitaxel	Cytotoxicity against ACHN cells Cytotoxicity against ACHN cells	[PMID: 17442577]
ACHN	IC₅₀	80 μM Compound: Paclitaxel	Antiproliferative activity against taxane-resistant human ACHN cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Antiproliferative activity against taxane-resistant human ACHN cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 29995409]
AGS	IC₅₀	1.6 μM Compound: Paclitaxel	Cytotoxicity against human AGS cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human AGS cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
AGS	IC₅₀	15.4 μM Compound: Paclitaxol	Cytotoxicity against human AGS cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human AGS cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 22901410]
AGS	IC₅₀	15.4 μM Compound: Paclitaxol	Cytotoxicity against human AGS cells after 24 hrs by MTT assay Cytotoxicity against human AGS cells after 24 hrs by MTT assay	[PMID: 22921966]
AGS	IC₅₀	53 nM Compound: Paclitaxel	Cytotoxicity against human AGS cells after 72 hrs by CCK8 assay Cytotoxicity against human AGS cells after 72 hrs by CCK8 assay	[PMID: 32489099]
AGS	IC₅₀	53 μM Compound: Paclitaxel	Cytotoxicity against human AGS cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human AGS cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 32193933]
AGS	IC₅₀	8 nM Compound: taxol	Antiproliferative activity against human AGS cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human AGS cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
AGS	IC₅₀	< 10 μM Compound: Taxol	Cytotoxicity against human AGS cells after 48 hrs by MTT assay Cytotoxicity against human AGS cells after 48 hrs by MTT assay	[PMID: 22370266]
ARO	IC₅₀	0.0002 μM Compound: Taxol	Cytotoxicity against human Aro cells by MTT assay Cytotoxicity against human Aro cells by MTT assay	[PMID: 16539377]
ARO	IC₅₀	0.0002 μM Compound: taxol	Cytotoxicity against human Aro cells after 72 hrs by MTT assay Cytotoxicity against human Aro cells after 72 hrs by MTT assay	[PMID: 17915851]
ASPC1	IC₅₀	20 nM Compound: 2	Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay	[PMID: 18081257]
ASPC1	IC₅₀	89 nM Compound: 1	Growth inhibition of human AsPC1 cells after 72 hrs by MTT assay Growth inhibition of human AsPC1 cells after 72 hrs by MTT assay	[PMID: 19022679]
ASPC1	IC₅₀	89 nM Compound: 1,paclitaxel	Cytotoxicity against taxol-sensitive human AsPC1 cells after 72 hrs by MTT assay Cytotoxicity against taxol-sensitive human AsPC1 cells after 72 hrs by MTT assay	[PMID: 18951787]
Astrocyte	ED₅₀	< 0.01 μg/mL Compound: 5	Astrocyte reversal activity in astrocytes Astrocyte reversal activity in astrocytes	[PMID: 7130988]
B16	ED₅₀	0.7 μM Compound: 1 (Taxol)	Compound was evaluated for the in vitro concentration required to produce 50% stimulation of the microtubule assembly Compound was evaluated for the in vitro concentration required to produce 50% stimulation of the microtubule assembly	10.1016/S0960-894X(00)80402-3
B16	ED₅₀	1 μM Compound: Taxol	Effective dose against B16 melanoma cells in microtubule assembly assay Effective dose against B16 melanoma cells in microtubule assembly assay	10.1016/S0960-894X(00)80346-7
B16	ED₅₀	27 nM Compound: Taxol	Effective dose against B16 melanoma cells in cytotoxicity assay Effective dose against B16 melanoma cells in cytotoxicity assay	10.1016/S0960-894X(00)80346-7
B16	ED₅₀	28 nM Compound: 1	The compound was tested for cytotoxicity against B16 melanoma cells The compound was tested for cytotoxicity against B16 melanoma cells	10.1016/S0960-894X(01)80203-1
B16	ED₅₀	28 nM Compound: 1	Cytotoxicity against B16 melanoma cell line. Cytotoxicity against B16 melanoma cell line.	[PMID: 1359143]
B16	ED₅₀	31.5 nM Compound: 1 (Taxol)	Compound was evaluated for the concentration which inhibits B16 melanoma cell proliferation by 50% Compound was evaluated for the concentration which inhibits B16 melanoma cell proliferation by 50%	10.1016/S0960-894X(00)80402-3
B16	GI₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against mouse B16 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31945642]
B16	GI₅₀	0.01 μM Compound: Taxol	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 20538462]
B16	GI₅₀	0.01 μM Compound: taxol	Cytotoxicity against mouse B16 cells after 72 hrs by MTT colorimetric assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT colorimetric assay	[PMID: 19081249]
B16	IC₅₀	0.04 μM Compound: taxol	Cytotoxicity against mouse B16 after 48 hrs by SRB assay Cytotoxicity against mouse B16 after 48 hrs by SRB assay	[PMID: 21044847]
B16	IC₅₀	0.08 μM Compound: Paclitaxel	Antiproliferative activity against mouse B16 cell line Antiproliferative activity against mouse B16 cell line	[PMID: 16793260]
B16	IC₅₀	0.63 μg/mL Compound: paclitaxel	Cytotoxicity against mouse B16 cells after 44 hrs by MTT assay Cytotoxicity against mouse B16 cells after 44 hrs by MTT assay	[PMID: 19928884]
B16	IC₅₀	19 nM Compound: 1 (taxol)	Concentration required to inhibit the proliferation of B16 melanoma cells was determined Concentration required to inhibit the proliferation of B16 melanoma cells was determined	[PMID: 1346275]
B16	IC₅₀	56 μM Compound: Paclitaxel	Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25875311]
B16	IC₅₀	8 nM Compound: Paclitaxel	In vitro antiproliferative activity against B16 cell lines In vitro antiproliferative activity against B16 cell lines	10.1016/S0960-894X(97)10152-4
B16	IC₅₀	< 0.02 μg/mL Compound: 1	Cytotoxicity against mouse B16 cells grown in PRIM medium Cytotoxicity against mouse B16 cells grown in PRIM medium	10.1021/np50078a018
B16	IC₅₀	< 0.1 μg/mL Compound: paclitaxel	Cytotoxicity against B16 cancer cell line Cytotoxicity against B16 cancer cell line	[PMID: 16384699]
B16-F0	IC₅₀	0.021 μM Compound: PTX	Antiproliferative activity against mouse B16-F0 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against mouse B16-F0 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 32650183]
B16-F1	GI₅₀	0.02 μM Compound: Taxol	Antiproliferative activity against mouse B16-F1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay Antiproliferative activity against mouse B16-F1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay	[PMID: 32199690]
B16-F10	IC₅₀	0.0041 μg/mL Compound: 3	In vitro cytotoxicity against B16F10-mouse melanoma cells. In vitro cytotoxicity against B16F10-mouse melanoma cells.	10.1016/S0960-894X(01)80507-2
B16-F10	IC₅₀	0.53 μM Compound: Paclitaxel	Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
B16-F10	IC₅₀	0.53 μM Compound: Taxol	Cytotoxicity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34704758]
B16-F10	IC₅₀	19.14 μM Compound: Taxol	Cytotoxicity against mouse B16F10 cells after 24 hrs by MTT assay Cytotoxicity against mouse B16F10 cells after 24 hrs by MTT assay	[PMID: 21964182]
B16-F10	IC₅₀	8.01 μM Compound: Paclitaxel	Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay	[PMID: 30433783]
B16-F10	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
B16-F10	IC₅₀	> 1000 nM Compound: Paclitaxel	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36621138]
BEAS-2B	IC₅₀	0.007 μM Compound: Paclitaxel	Antiproliferative activity against human BEAS2B cells after 24 hrs by CCK8 assay Antiproliferative activity against human BEAS2B cells after 24 hrs by CCK8 assay	[PMID: 30392953]
BEAS-2B	IC₅₀	0.008 μM Compound: PTX	Cytotoxicity against human BEAS-2B cells reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human BEAS-2B cells reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34600241]
BEAS-2B	IC₅₀	0.58 μM Compound: Taxol	Cytotoxicity against human BEAS2B cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human BEAS2B cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26068802]
BEAS-2B	IC₅₀	0.58 μM Compound: paclitaxel	Cytotoxicity against human BEAS2B cells after 48 hrs by MTS assay Cytotoxicity against human BEAS2B cells after 48 hrs by MTS assay	[PMID: 24256484]
BEAS-2B	IC₅₀	< 0.1 μM Compound: Paclitaxel	Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34303874]
BGC-823	GI₅₀	3.605 nM Compound: 1, Taxol	Growth inhibition of human BGC823 cells by MTT assay Growth inhibition of human BGC823 cells by MTT assay	[PMID: 24405702]
BGC-823	IC₅₀	0.0006 μM Compound: Taxol	Growth inhibition of human BGC823 cells after 96 hrs by MTT assay Growth inhibition of human BGC823 cells after 96 hrs by MTT assay	[PMID: 28737396]
BGC-823	IC₅₀	0.001 μM Compound: Taxol	Growth inhibition of human BGC823 cells incubated for 3 days by SRB assay Growth inhibition of human BGC823 cells incubated for 3 days by SRB assay	[PMID: 28625363]
BGC-823	IC₅₀	0.002 μM Compound: Paclitaxel	Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 29279273]
BGC-823	IC₅₀	0.0033 μM Compound: paclitaxel	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 22506620]
BGC-823	IC₅₀	0.004 μM Compound: Taxol	Anticancer activity against human BGC-823 cells by MTT assay Anticancer activity against human BGC-823 cells by MTT assay	[PMID: 33316408]
BGC-823	IC₅₀	0.007 μM Compound: paclitaxel	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 18001087]
BGC-823	IC₅₀	0.011 nM Compound: Paclitaxel	Cytotoxicity against human BGC-823 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 37336771]
BGC-823	IC₅₀	0.0189 μM Compound: Paclitaxol	Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 19091579]
BGC-823	IC₅₀	0.01 μg/mL Compound: Taxol	Cytotoxicity against human BGC823 cells Cytotoxicity against human BGC823 cells	[PMID: 22989532]
BGC-823	IC₅₀	0.02 μM Compound: taxol	Cytotoxicity against human BGC823 after 48 hrs by SRB assay Cytotoxicity against human BGC823 after 48 hrs by SRB assay	[PMID: 21044847]
BGC-823	IC₅₀	0.026 μM Compound: Taxol	Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 24467317]
BGC-823	IC₅₀	0.04 μM Compound: paclitaxel	Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 20560647]
BGC-823	IC₅₀	0.4 nM Compound: Taxol	Cytotoxicity against human BGC823 cells measured after 48 hrs by MTT assay Cytotoxicity against human BGC823 cells measured after 48 hrs by MTT assay	[PMID: 31050424]
BGC-823	IC₅₀	0.8 nM Compound: Paclitaxel	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 28530828]
BGC-823	IC₅₀	1.15 μM Compound: taxol	Cytotoxicity against human BGC823 cells Cytotoxicity against human BGC823 cells	[PMID: 17911017]
BGC-823	IC₅₀	1.3 nM Compound: Paclitaxel	Cytotoxicity against human BGC823 cells after 72 hrs by CCK8 assay Cytotoxicity against human BGC823 cells after 72 hrs by CCK8 assay	[PMID: 32489099]
BGC-823	IC₅₀	1.5 μM Compound: Paclitaxel	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 20716468]
BGC-823	IC₅₀	1.5 μM Compound: Paclitaxel	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 21875764]
BGC-823	IC₅₀	3.29 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 21928797]
BGC-823	IC₅₀	3.3 nM Compound: paclitaxel	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 19708679]
BGC-823	IC₅₀	3.3 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 27441892]
BGC-823	IC₅₀	3.5 nM Compound: Taxol	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 23806112]
BGC-823	IC₅₀	33.09 μM Compound: Taxol	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 21664827]
BGC-823	IC₅₀	9.24 μM Compound: Paclitaxel	Cytotoxicity against human BGC823 cells after 24 hrs by MTT assay Cytotoxicity against human BGC823 cells after 24 hrs by MTT assay	[PMID: 21514015]
BGC-823	IC₅₀	9.26 μM Compound: Paclitaxel	Cytotoxicity against human BGC823 cells measured after 24 hrs by MTT assay Cytotoxicity against human BGC823 cells measured after 24 hrs by MTT assay	[PMID: 27769031]
BGC-823	IC₅₀	< 0.001 μM Compound: Paclitaxel	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 23547884]
BGC-823	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
BGC-823	IC₅₀	< 0.001 μM Compound: paclitaxel	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 22583079]
BGC-823	IC₅₀	< 1 x 10^-9 M Compound: Taxol	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 20719510]
BGC-823	IC₅₀	< 1 x 10^-9 M Compound: Taxol	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 21530251]
BGC-823	IC₅₀	umol/L μM Compound: Taxol	Antiproliferation activity against human BGC823 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferation activity against human BGC823 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 32546298]
BNL	IC₅₀	0.2 μM Compound: Taxol	Cytotoxicity against mouse BNL cells by MTT assay Cytotoxicity against mouse BNL cells by MTT assay	[PMID: 16539377]
BT-474	IC₅₀	13.7 nM Compound: PT	Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
BT-474	IC₅₀	8.36 nM Compound: Paclitaxel	Cytotoxicity against human BT474 cells after 4 days by MTS/cell proliferation assay Cytotoxicity against human BT474 cells after 4 days by MTS/cell proliferation assay	[PMID: 25098528]
BT-549	GI₅₀	1.5 nM Compound: 1a; PTX	Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth by SRB assay Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth by SRB assay	[PMID: 37490800]
BT-549	GI₅₀	4 nM Compound: Paclitaxel	Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
BT-549	GI₅₀	4 nM Compound: Paclitaxel	Cytotoxicity against human BT-549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human BT-549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
BT-549	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
BT-549	IC₅₀	0.006 μM Compound: paclitaxel	Antiproliferative activity against human BT549 cells after 48 hrs by alamar blue assay Antiproliferative activity against human BT549 cells after 48 hrs by alamar blue assay	[PMID: 21563750]
BT-549	IC₅₀	0.02 μM Compound: paclitaxel	Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay	[PMID: 19879765]
BXPC-3	IC₅₀	0.005 μM Compound: PTX	Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
BXPC-3	IC₅₀	0.011 μM Compound: 2	Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 37856840]
BXPC-3	IC₅₀	0.09 μM Compound: Paclitaxel	Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
BeWo	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against human BeWo cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human BeWo cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27010926]
BeWo	IC₅₀	7.39 μg/mL Compound: (22) taxol	In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay	[PMID: 12620075]
Bel-7402	GI₅₀	1.792 nM Compound: 1, Taxol	Growth inhibition of human Bel7402 cells by MTT assay Growth inhibition of human Bel7402 cells by MTT assay	[PMID: 24405702]
Bel-7402	IC₅₀	0.006 μM Compound: Paclitaxel	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 23547884]
Bel-7402	IC₅₀	0.006 μM Compound: paclitaxel	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 22583079]
Bel-7402	IC₅₀	0.011 μM Compound: Taxol	Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 24467317]
Bel-7402	IC₅₀	0.013 μM Compound: Taxol	Anticancer activity against human H7402 cells by MTT assay Anticancer activity against human H7402 cells by MTT assay	[PMID: 33316408]
Bel-7402	IC₅₀	0.095 μM Compound: paclitaxel	Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay	[PMID: 19245261]
Bel-7402	IC₅₀	0.1 μM Compound: paclitaxel	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 18001087]
Bel-7402	IC₅₀	0.93 μM Compound: paclitaxel	Cytotoxicity against human BEL-7402 cells after 24 hrs by SRB assay Cytotoxicity against human BEL-7402 cells after 24 hrs by SRB assay	[PMID: 17896816]
Bel-7402	IC₅₀	0.93 μM Compound: paclitaxel	Cytotoxicity against human Bel7402 cells after 24 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 24 hrs by SRB assay	[PMID: 18281952]
Bel-7402	IC₅₀	1.07 μM Compound: taxol	Cytotoxicity against human Bel7402 after 48 hrs by SRB assay Cytotoxicity against human Bel7402 after 48 hrs by SRB assay	[PMID: 21044847]
Bel-7402	IC₅₀	1.25 μM Compound: Taxol	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 22153338]
Bel-7402	IC₅₀	1.8 μM Compound: paclitaxel	Cytotoxicity against human Bel7402 cells after 3 days by MTT assay Cytotoxicity against human Bel7402 cells after 3 days by MTT assay	[PMID: 20593839]
Bel-7402	IC₅₀	1.89 μM Compound: Taxol	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 22483090]
Bel-7402	IC₅₀	1.89 μM Compound: Taxol	Antiproliferative activity against human Bel7402 cells assessed as growth inhibition by MTT assay Antiproliferative activity against human Bel7402 cells assessed as growth inhibition by MTT assay	[PMID: 23274570]
Bel-7402	IC₅₀	1.89 μM Compound: Taxol	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 23644204]
Bel-7402	IC₅₀	1.9 μM Compound: Taxol	Cytotoxicity against human Bel7402 cells incubated for 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells incubated for 48 hrs by MTT assay	[PMID: 31042380]
Bel-7402	IC₅₀	1.95 μM Compound: PTX	Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay	[PMID: 27491707]
Bel-7402	IC₅₀	578.2 nM Compound: Taxol	Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 21296467]
Bel-7402	IC₅₀	6 x 10^-8 M Compound: Taxol	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 20719510]
Bel-7402	IC₅₀	6 x 10^-9 M Compound: Taxol	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 21530251]
Bel-7402	IC₅₀	6.3 μM Compound: paclitaxel	Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 20560647]
Bel-7402	IC₅₀	< 0.1 μM Compound: Taxol	Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
Bel-7402	IC₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against human Bel7402 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay Cytotoxicity against human Bel7402 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay	10.1039/C4MD00573B
Bel-7402	IC₅₀	> 2 μM Compound: Taxol	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 23425970]
Bel-7402	IC₅₀	> 25 μM Compound: Taxol	Cytotoxicity against human Bel7402 cells assessed as growth inhibition by MTT assay Cytotoxicity against human Bel7402 cells assessed as growth inhibition by MTT assay	[PMID: 24684840]
Bel7402/5-FU	IC₅₀	10.54 μM Compound: TAX	Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay	[PMID: 30677614]
Breast carcinoma cell	IC₅₀	7.8 μM Compound: Taxol	Cytotoxicity against patient derived inflammatory breast cancer cell spheroids assessed as increase in spheroid dissolution incubated for 24 hrs by propidium iodide/Acridine orange staining based dual-fluorescence viability assay Cytotoxicity against patient derived inflammatory breast cancer cell spheroids assessed as increase in spheroid dissolution incubated for 24 hrs by propidium iodide/Acridine orange staining based dual-fluorescence viability assay	[PMID: 30831408]
C6	IC₅₀	3.1 nM Compound: paclitaxel	Cytotoxicity against Pgp deficient human LCC6 cells after 72 hrs by sulforhodamine B test Cytotoxicity against Pgp deficient human LCC6 cells after 72 hrs by sulforhodamine B test	[PMID: 18465846]
CAKI-1	GI₅₀	158 nM Compound: Paclitaxel	Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
CAKI-1	GI₅₀	158 nM Compound: Paclitaxel	Cytotoxicity against human CAKI-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human CAKI-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
CAKI-1	IC₅₀	0.9 nM Compound: PT	Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
CAKI-2	IC₅₀	0.01 μM Compound: PTX	Cytotoxicity against human CAKI-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human CAKI-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
CAPAN-1	IC₅₀	3.3 nM Compound: Taxol	Cytotoxicity against human Capan1 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human Capan1 cells after 48 hrs by sulforhodamine B assay	[PMID: 30528697]
CCD 19Lu	IC₅₀	2 μg/mL Compound: Taxol (TAX)	Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells	10.1016/S0960-894X(97)00071-1
CCRF-CEM	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
CCRF-CEM	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human CCRF-CEM cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human CCRF-CEM cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
CCRF-CEM	IC₅₀	0.0011 μM Compound: taxol	Antiproliferative activity against human CCRF-CEM cell line Antiproliferative activity against human CCRF-CEM cell line	[PMID: 16759114]
CCRF-CEM	IC₅₀	0.0012 μM Compound: Taxol	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 19576785]
CCRF-CEM	IC₅₀	0.0012 μM Compound: Taxol	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 22507893]
CCRF-CEM	IC₅₀	0.0015 μM Compound: Taxol	Concentration required for growth inhibition of human lymphoblastic leukemic cell line (CCRF-CEM) was determined Concentration required for growth inhibition of human lymphoblastic leukemic cell line (CCRF-CEM) was determined	[PMID: 15324894]
CCRF-CEM	IC₅₀	0.001 μg/mL Compound: Taxol (TAX)	Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells	10.1016/S0960-894X(97)00071-1
CCRF-CEM	IC₅₀	0.002 μM Compound: paclitaxel	Antiproliferative activity against human CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CEM cells after 72 hrs by MTT assay	[PMID: 19743863]
CCRF-CEM	IC₅₀	0.003 μM Compound: Taxol	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 21106377]
CCRF-CEM	IC₅₀	0.003 μM Compound: Taxol	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 21144756]
CCRF-CEM	IC₅₀	0.003 μM Compound: Taxol	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 21356592]
CCRF-CEM	IC₅₀	0.0031 μM Compound: Taxol	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 20181487]
CCRF-CEM	IC₅₀	0.0031 μM Compound: taxol	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 19124250]
CCRF-CEM	IC₅₀	0.14 μM Compound: Taxol	Concentration required for growth inhibition of taxol resistant human lymphoblastic leukemic cell line (CCRF-CEM/taxol) was determined Concentration required for growth inhibition of taxol resistant human lymphoblastic leukemic cell line (CCRF-CEM/taxol) was determined	[PMID: 15324894]
CCRF-CEM	IC₅₀	0.27 nM Compound: Pac	Antiproliferative activity against human CEM cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human CEM cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
CCRF-CEM	IC₅₀	0.27 nM Compound: Pac	Antiproliferative activity against human CEM after 48 hrs by SRB assay Antiproliferative activity against human CEM after 48 hrs by SRB assay	[PMID: 21920638]
CCRF-CEM	IC₅₀	0.4 μM Compound: Taxol	Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 19576785]
CCRF-CEM	IC₅₀	0.429 μM Compound: Taxol	Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 20181487]
CCRF-CEM	IC₅₀	0.429 μM Compound: taxol	Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 19124250]
CCRF-CEM	IC₅₀	0.43 μM Compound: Taxol	Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 21106377]
CCRF-CEM	IC₅₀	0.43 μM Compound: Taxol	Cytotoxicity against Taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against Taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 21144756]
CCRF-CEM	IC₅₀	0.43 μM Compound: Taxol	Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 21356592]
CCRF-CEM	IC₅₀	0.43 μM Compound: Taxol	Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 22507893]
CCRF-CEM	IC₅₀	0.4843 μM Compound: taxol	Antiproliferative activity against human taxol resistant CCRF-CEM cell line Antiproliferative activity against human taxol resistant CCRF-CEM cell line	[PMID: 16759114]
CCRF-CEM	IC₅₀	1.1 nM Compound: Taxol	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT-tetrazolium assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT-tetrazolium assay	[PMID: 18752869]
CCRF-CEM	IC₅₀	1.2 μM Compound: Taxol	Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 19576785]
CCRF-CEM	IC₅₀	1.27 μM Compound: Taxol	Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 21106377]
CCRF-CEM	IC₅₀	1.27 μM Compound: Taxol	Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 21144756]
CCRF-CEM	IC₅₀	1.27 μM Compound: Taxol	Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 21356592]
CCRF-CEM	IC₅₀	1.27 μM Compound: Taxol	Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 22507893]
CCRF-CEM	IC₅₀	1.274 nM Compound: taxol	Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 18450456]
CCRF-CEM	IC₅₀	1.274 μM Compound: Taxol	Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 20181487]
CCRF-CEM	IC₅₀	1.274 μM Compound: taxol	Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 19124250]
CCRF-CEM	IC₅₀	1.3 nM Compound: taxol	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 18450456]
CCRF-CEM	IC₅₀	1.62 μM Compound: Taxol	Concentration required for growth inhibition of vinblastine resistant human lymphoblastic leukemic cell line (CCRF-CEM/VBL) was determined Concentration required for growth inhibition of vinblastine resistant human lymphoblastic leukemic cell line (CCRF-CEM/VBL) was determined	[PMID: 15324894]
CCRF-CEM	IC₅₀	1.731 μM Compound: taxol	Antiproliferative activity against human vinblastine resistant CCRF-CEM cell line Antiproliferative activity against human vinblastine resistant CCRF-CEM cell line	[PMID: 16759114]
CCRF-CEM	IC₅₀	4 nM Compound: Paclitaxel	Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31419740]
CCRF-CEM	IC₅₀	429 nM Compound: taxol	Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 18450456]
CEM-VLB	IC₅₀	3340 nM Compound: Pac	Antiproliferative activity against multidrug-resistant human CEM/VLB cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against multidrug-resistant human CEM/VLB cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
CEM-VLB	IC₅₀	3340 nM Compound: Pac	Antiproliferative activity against human multidrug-resistant CEM/VLB cells after 48 hrs by SRB assay Antiproliferative activity against human multidrug-resistant CEM/VLB cells after 48 hrs by SRB assay	[PMID: 21920638]
CFPAC-1	IC₅₀	0.047 μM Compound: Paclitaxel	Cytotoxicity against human CFPAC-1 cells after 72 hrs by SRB assay Cytotoxicity against human CFPAC-1 cells after 72 hrs by SRB assay	[PMID: 20800500]
CHO	ED₅₀	0.35 μM Compound: taxol	Concentration that inhibits cell division by 50% after 72 hr for CHO cells was determined Concentration that inhibits cell division by 50% after 72 hr for CHO cells was determined	[PMID: 1672157]
CHO	IC₅₀	170 nM Compound: Pac	Antiproliferative activity against CHO cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against CHO cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
CHO	IC₅₀	170 nM Compound: Pac	Antiproliferative activity against human CHO after 48 hrs by SRB assay Antiproliferative activity against human CHO after 48 hrs by SRB assay	[PMID: 21920638]
CHO-K1	GI₅₀	5.9 μM Compound: Paclitaxel	Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay	[PMID: 21513294]
CHO-K1	IC₅₀	15.99 μM Compound: paclitaxel	Cytotoxicity against CHOK1 cells after 72 hrs by MTT assay Cytotoxicity against CHOK1 cells after 72 hrs by MTT assay	[PMID: 19053781]
CHO-M19	IC₅₀	< 3 ng/mL Compound: 1	Cytotoxicity against Chinese hamster M19 cells Cytotoxicity against Chinese hamster M19 cells	[PMID: 17419065]
CHO-TAX 5-6	IC₅₀	520 nM Compound: Pac	Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
CHO-TAX 5-6	IC₅₀	520 nM Compound: Pac	Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by SRB assay Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by SRB assay	[PMID: 21920638]
CHO-VV 3-2	IC₅₀	140 nM Compound: Pac	Antiproliferative activity against paclitaxel-resistant CHO-VV 3-2 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against paclitaxel-resistant CHO-VV 3-2 cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
CHO-VV 3-2	IC₅₀	140 nM Compound: Pac	Antiproliferative activity against colchicine and vinblastine-resistant CHO-VV 3-2 cells after 48 hrs by SRB assay Antiproliferative activity against colchicine and vinblastine-resistant CHO-VV 3-2 cells after 48 hrs by SRB assay	[PMID: 21920638]
CNE-2	IC₅₀	0.003 μM Compound: TAX, Taxol	Antiproliferative activity against human CNE2 cells after 48 hrs by SRB method Antiproliferative activity against human CNE2 cells after 48 hrs by SRB method	[PMID: 25061803]
COLO 205	GI₅₀	0.003 μM Compound: Paclitaxel	Cytotoxicity against human COLO205 cells by sulforhodamine B assay Cytotoxicity against human COLO205 cells by sulforhodamine B assay	[PMID: 21839640]
COLO 205	GI₅₀	0.003 μM Compound: paclitaxel	Cytotoxicity against human COLO205 cells Cytotoxicity against human COLO205 cells	[PMID: 17696332]
COLO 205	GI₅₀	1.76 x 10^-9 M Compound: 5	Cytotoxicity against human COLO205 cells Cytotoxicity against human COLO205 cells	[PMID: 7908950]
COLO 205	GI₅₀	7.9 nM Compound: Paclitaxel	Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
COLO 205	GI₅₀	7.9 nM Compound: Paclitaxel	Cytotoxicity against human COLO 205 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human COLO 205 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
COLO 205	IC₅₀	0.003 μM Compound: Taxol	Cytotoxicity against human COLO205 cells assessed as growth inhibition by MTT assay Cytotoxicity against human COLO205 cells assessed as growth inhibition by MTT assay	[PMID: 25091926]
COLO 205	IC₅₀	0.005 μM Compound: paclitaxel	Antiproliferative activity against human COLO205 cells after 48 hrs by alamar blue assay Antiproliferative activity against human COLO205 cells after 48 hrs by alamar blue assay	[PMID: 21563750]
COLO 205	IC₅₀	0.01 μM Compound: PTX	Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
COLO 205	IC₅₀	3.3 nM Compound: Paclitaxel	Cytotoxicity against COLO205 cells Cytotoxicity against COLO205 cells	[PMID: 17228873]
COLO 205	IC₅₀	3.3 nM Compound: Paclitaxel	Antiproliferative activity against human COLO205 cells after 24 hrs by MTS assay Antiproliferative activity against human COLO205 cells after 24 hrs by MTS assay	[PMID: 19041247]
COLO 205	IC₅₀	3.3 nM Compound: paclitaxel	Cytotoxicity against COLO205 cells Cytotoxicity against COLO205 cells	[PMID: 17416524]
COLO 205	IC₅₀	3.31 nM Compound: Paclitaxel	Cytotoxicity against human COLO205 cells after 48 hrs by Alamar blue assay Cytotoxicity against human COLO205 cells after 48 hrs by Alamar blue assay	[PMID: 21779519]
COLO 320DM	IC₅₀	0.0045 μg/mL Compound: taxol	Cytotoxicity against human COLO320DM cell line by MTT assay Cytotoxicity against human COLO320DM cell line by MTT assay	[PMID: 16297622]
CT26	IC₅₀	> 10 μM Compound: Taxol	Cytotoxicity against mouse CT26 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34704758]
CWR22R	CC₅₀	3.9 nM Compound: Ptxl; PTX	Cytotoxicity against PSMA-positive human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against PSMA-positive human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31248772]
CWR22R	IC₅₀	0.08 μM Compound: Paclitaxel	Cytotoxicity against human 22Rv1 cells by MTT assay Cytotoxicity against human 22Rv1 cells by MTT assay	[PMID: 20627721]
CWR22R	IC₅₀	0.08 μM Compound: Paclitaxel	Cytotoxicity against human 22Rv1 cells by MTT assay Cytotoxicity against human 22Rv1 cells by MTT assay	[PMID: 20716468]
CWR22R	IC₅₀	0.08 μM Compound: Paclitaxel	Cytotoxicity against human 22Rv1 cells by MTT assay Cytotoxicity against human 22Rv1 cells by MTT assay	[PMID: 21875764]
Ca-Ski	IC₅₀	2.9 μM Compound: Paclitaxel	Antiproliferative activity against human CaSki cells after 24 hrs by MTT assay Antiproliferative activity against human CaSki cells after 24 hrs by MTT assay	[PMID: 24487193]
Ca-Ski	IC₅₀	2.9 μM Compound: Paclitaxel	Antiproliferative activity against human CaSki cells after 24 hrs by crystal violet staining-based assay Antiproliferative activity against human CaSki cells after 24 hrs by crystal violet staining-based assay	[PMID: 29407986]
Ca9-22	IC₅₀	> 100 μM Compound: Paclitaxel	Cytotoxicity against human Ca9-22 cells Cytotoxicity against human Ca9-22 cells	[PMID: 31945642]
Caco-2	IC₅₀	0.0078 μg/mL Compound: Paclitaxel	Cytotoxicity against human Caco-2 cells after 48 hrs by MTT assay Cytotoxicity against human Caco-2 cells after 48 hrs by MTT assay	[PMID: 17950495]
Caco-2	IC₅₀	0.007 μg/mL Compound: taxol	Cytotoxicity against human Caco-2 cell line by MTT assay Cytotoxicity against human Caco-2 cell line by MTT assay	[PMID: 16297622]
Caco-2	IC₅₀	0.008 μM Compound: Taxol	Cytotoxicity against human Caco2 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay Cytotoxicity against human Caco2 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay	[PMID: 23584542]
Caco-2	IC₅₀	0.008 μM Compound: taxol	Cytotoxicity against human CaCO2 cells after 24 hrs by MTT assay Cytotoxicity against human CaCO2 cells after 24 hrs by MTT assay	[PMID: 18586491]
Caco-2	IC₅₀	0.014 μM Compound: Paclitaxel	Cytotoxicity against human Caco2 cells assessed as cell growth inhibition Cytotoxicity against human Caco2 cells assessed as cell growth inhibition	[PMID: 26934105]
Caco-2	IC₅₀	0.014 μM Compound: Taxol	Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
Caco-2	IC₅₀	0.02 μM Compound: Taxol	Antiproliferative activity against human Caco-2 cells after 72 hrs by imaging analysis Antiproliferative activity against human Caco-2 cells after 72 hrs by imaging analysis	[PMID: 19665384]
Caco-2	IC₅₀	0.02 μM Compound: Taxol	Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
Caco-2	IC₅₀	0.31 μM Compound: Paclitaxel	Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
Caco-2	IC₅₀	2.1 μM Compound: Paclitaxel	Antiproliferative activity against human Caco-2 cells measured after 72 hrs by SRB method Antiproliferative activity against human Caco-2 cells measured after 72 hrs by SRB method	[PMID: 38340509]
Caco-2	IC₅₀	2.8 μM Compound: Paclitaxel	Antiproliferative activity against human Caco2 cells after 48 hrs by MTT assay Antiproliferative activity against human Caco2 cells after 48 hrs by MTT assay	10.1039/C6MD00256K
Calu-1	IC₅₀	1.33 μM Compound: 1	Cytotoxicity against human Calu1 cells assessed as inhibition of cell proliferation Cytotoxicity against human Calu1 cells assessed as inhibition of cell proliferation	[PMID: 25466201]
Capan-2	IC₅₀	1.7 x 10^-2 μM Compound: Paclitaxel	Cytotoxicity against human Capan2 cells by MTT assay Cytotoxicity against human Capan2 cells by MTT assay	[PMID: 27441892]
Col2	ED₅₀	46 nM Compound: paclitaxel	Cytotoxicity against human Col2 cells Cytotoxicity against human Col2 cells	[PMID: 15043407]
Col2	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human Col2 cells after 72 hrs by SRB assay Cytotoxicity against human Col2 cells after 72 hrs by SRB assay	[PMID: 12088425]
Coronary artery smooth muscle cell line	IC₅₀	~~ 1 μM Compound: paclitaxel	In vitro antiproliferative effect on cultured human coronary artery smooth muscle cells (hCASMC) In vitro antiproliferative effect on cultured human coronary artery smooth muscle cells (hCASMC)	[PMID: 15084126]
DG-75	IC₅₀	10 nM Compound: Taxol	Antiproliferative activity against human DG75 cells after 24 to 72 hrs by alamar blue assay Antiproliferative activity against human DG75 cells after 24 to 72 hrs by alamar blue assay	[PMID: 19717215]
DG-75	IC₅₀	10 nM Compound: Taxol	Cytotoxicity against human chemoresistant DG75 cells expressing SERT assessed as decrease in cell viability 10 or 50 uM after 72 hrs Alamar blue assay Cytotoxicity against human chemoresistant DG75 cells expressing SERT assessed as decrease in cell viability 10 or 50 uM after 72 hrs Alamar blue assay	[PMID: 21227702]
DLD-1	EC₅₀	0.054 μM Compound: Taxol	Induction of apoptosis in human DLD1 cells assessed as caspase activation after 48 hrs Induction of apoptosis in human DLD1 cells assessed as caspase activation after 48 hrs	[PMID: 19500976]
DLD-1	EC₅₀	0.075 μM Compound: paclitaxel	Induction of apoptosis in human DLD1 cells assessed as caspase activation after 24 hrs Induction of apoptosis in human DLD1 cells assessed as caspase activation after 24 hrs	[PMID: 15566300]
DLD-1	GI₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human DLD-1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human DLD-1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31945642]
DLD-1	GI₅₀	0.01 μM Compound: Taxol	Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay	[PMID: 20538462]
DLD-1	GI₅₀	0.01 μM Compound: taxol	Cytotoxicity against human DLD1 cells after 72 hrs by MTT colorimetric assay Cytotoxicity against human DLD1 cells after 72 hrs by MTT colorimetric assay	[PMID: 19081249]
DLD-1	GI₅₀	0.02 μM Compound: Paclitaxel	Inhibition of cell growth in human DLD-1 cells incubated for 48 hrs by SRB method Inhibition of cell growth in human DLD-1 cells incubated for 48 hrs by SRB method	[PMID: 39093920]
DLD-1	IC₅₀	0.031 μg/mL Compound: Paclitaxel	Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay	[PMID: 39052090]
DLD-1	IC₅₀	0.05 μM Compound: paclitaxel	Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay	[PMID: 21563750]
DLD-1	IC₅₀	0.09 μM Compound: Paclitaxel	Antiproliferative activity against human DLD1 cell line Antiproliferative activity against human DLD1 cell line	[PMID: 16793260]
DLD-1	IC₅₀	11 nM Compound: 2	Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay	[PMID: 18081257]
DLD-1	IC₅₀	16 nM Compound: taxol	Antiproliferative activity against human DLD1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human DLD1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
DLD-1	IC₅₀	22 nM Compound: 1	Growth inhibition of human DLD1 cells after 72 hrs by MTT assay Growth inhibition of human DLD1 cells after 72 hrs by MTT assay	[PMID: 19022679]
DLD-1	IC₅₀	22 nM Compound: 1,paclitaxel	Cytotoxicity against taxol-sensitive human DLD1 cells after 72 hrs by MTT assay Cytotoxicity against taxol-sensitive human DLD1 cells after 72 hrs by MTT assay	[PMID: 18951787]
DLD-1	IC₅₀	27 nM Compound: Paclitaxel	The compound was tested for cell growth inhibition against DLD-1 human colon cancer cells under continuous exposure conditions for 3-4 days The compound was tested for cell growth inhibition against DLD-1 human colon cancer cells under continuous exposure conditions for 3-4 days	[PMID: 10843209]
DLD-1	IC₅₀	39 μM Compound: Paclitaxel	Anticancer activity against human DLD1 cells after 72 hrs by SRB assay Anticancer activity against human DLD1 cells after 72 hrs by SRB assay	[PMID: 21707046]
DMS-114	GI₅₀	1.23 x 10^-8 M Compound: 5	Cytotoxicity against human DMS114 cells Cytotoxicity against human DMS114 cells	[PMID: 7908950]
DU-145	EC₅₀	0.0059 μM Compound: Paclitaxel	Cytotoxicity against human DU145 cells by sulforhodamine B assay Cytotoxicity against human DU145 cells by sulforhodamine B assay	[PMID: 22142543]
DU-145	EC₅₀	< 0.005 μg/mL Compound: Paclitaxel	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 18640035]
DU-145	EC₅₀	< 0.005 μg/mL Compound: Palitaxel	Cytotoxicity against human DU145 cells after 3 days by sulforhodamine B assay Cytotoxicity against human DU145 cells after 3 days by sulforhodamine B assay	[PMID: 19193043]
DU-145	ED₅₀	0.003 μM Compound: paclitaxel	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 20738103]
DU-145	ED₅₀	1.3 nM Compound: 1	Cytotoxicity against human DU145 cells by sulforhodamine B assay Cytotoxicity against human DU145 cells by sulforhodamine B assay	[PMID: 17350834]
DU-145	GI₅₀	0.00147 μM Compound: Paclitaxel	Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay	[PMID: 31059248]
DU-145	GI₅₀	0.00152 μM Compound: Paclitaxel	Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 31534659]
DU-145	GI₅₀	0.00255 μM Compound: Paclitaxel	Cytotoxicity against human DU145 cells after 72 hrs by SRB assay Cytotoxicity against human DU145 cells after 72 hrs by SRB assay	[PMID: 22932313]
DU-145	GI₅₀	0.005 μM Compound: Paclitaxel	Cytotoxicity against human DU145 cells by sulforhodamine B assay Cytotoxicity against human DU145 cells by sulforhodamine B assay	[PMID: 21839640]
DU-145	GI₅₀	0.005 μM Compound: paclitaxel	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 17696332]
DU-145	GI₅₀	0.00555 μM Compound: Paclitaxel	Cytotoxicity activity against human DU145 cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay Cytotoxicity activity against human DU145 cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay	[PMID: 21316977]
DU-145	GI₅₀	0.0057 μM Compound: Paclitaxel	Antiproliferative activity against human DU145 cells by sulforhodamine B assay Antiproliferative activity against human DU145 cells by sulforhodamine B assay	[PMID: 25770782]
DU-145	GI₅₀	0.006 μM Compound: Paclitaxel	Cytotoxicity against human DU145 cells by SRB method Cytotoxicity against human DU145 cells by SRB method	[PMID: 23867604]
DU-145	GI₅₀	0.006 μM Compound: Paclitaxel	Cytotoxicity against human DU145 cells by SRB assay Cytotoxicity against human DU145 cells by SRB assay	[PMID: 24315191]
DU-145	GI₅₀	0.006 μM Compound: Paclitaxel	Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay	[PMID: 26242242]
DU-145	GI₅₀	0.006 μM Compound: paclitaxel	Cytotoxicity against human DU145 cells by SRB assay Cytotoxicity against human DU145 cells by SRB assay	[PMID: 24502232]
DU-145	GI₅₀	0.032 μM Compound: 1a, PXL, Taxol	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 23725535]
DU-145	GI₅₀	3.86 nM Compound: Paclitaxel	Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay	[PMID: 22265685]
DU-145	GI₅₀	5.23 nM Compound: Paclitaxel	Cytotoxicity against human DU145 cells after 3 days Cytotoxicity against human DU145 cells after 3 days	[PMID: 21377368]
DU-145	GI₅₀	5.568 nM Compound: 1, Taxol	Growth inhibition of human DU145 cells by MTT assay Growth inhibition of human DU145 cells by MTT assay	[PMID: 24405702]
DU-145	GI₅₀	6.3 nM Compound: Paclitaxel	Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
DU-145	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
DU-145	GI₅₀	6.5 nM Compound: Paclitaxel	Growth inhibition of human DU145 cells by SRB assay Growth inhibition of human DU145 cells by SRB assay	[PMID: 23274123]
DU-145	GI₅₀	< 0.016 μM Compound: Paciltaxel	Antiproliferative activity against human DU145 cells by SRB assay Antiproliferative activity against human DU145 cells by SRB assay	[PMID: 31546197]
DU-145	IC₅₀	0.001 μM Compound: Paclitaxel	Antiproliferative activity against human DU145 cells measured after 72 hrs by sulforhodamine B assay Antiproliferative activity against human DU145 cells measured after 72 hrs by sulforhodamine B assay	[PMID: 31465222]
DU-145	IC₅₀	0.0024 μg/mL Compound: Paclitaxel	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 22595179]
DU-145	IC₅₀	0.002 μg/mL Compound: paclitaxel	Cytotoxicity against human DU145 cells after 3 days by SRB assay Cytotoxicity against human DU145 cells after 3 days by SRB assay	[PMID: 20232858]
DU-145	IC₅₀	0.0037 μg/mL Compound: Paclitaxel	Cytotoxicity against human DU145 cells by SRB assay Cytotoxicity against human DU145 cells by SRB assay	[PMID: 22204911]
DU-145	IC₅₀	0.0038 μM Compound: Paclitaxel	Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 26785306]
DU-145	IC₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 31120251]
DU-145	IC₅₀	0.004 μM Compound: paclitaxel	Growth inhibition of human DU145 cells by sulforhodamine B assay Growth inhibition of human DU145 cells by sulforhodamine B assay	[PMID: 25685941]
DU-145	IC₅₀	0.00489 μM Compound: paclitaxel	In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
DU-145	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human DU145 cell line by MTS assay Cytotoxicity against human DU145 cell line by MTS assay	[PMID: 16870446]
DU-145	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 18308566]
DU-145	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 23937981]
DU-145	IC₅₀	0.01 μM Compound: taxol	Cytotoxicity against human DU145 after 48 hrs by SRB assay Cytotoxicity against human DU145 after 48 hrs by SRB assay	[PMID: 21044847]
DU-145	IC₅₀	0.011 μM Compound: Taxol	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 27979593]
DU-145	IC₅₀	0.03 μM Compound: Taxol	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 23425970]
DU-145	IC₅₀	0.03 μM Compound: Taxol	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
DU-145	IC₅₀	0.04 μM Compound: paclitaxel	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 24033131]
DU-145	IC₅₀	1.1 nM Compound: Paclitaxel	Cytotoxicity against human DU145 cells after 72 hrs by MTS assay Cytotoxicity against human DU145 cells after 72 hrs by MTS assay	[PMID: 29406710]
DU-145	IC₅₀	1.15 nM Compound: Paclitaxel	Antiproliferative activity against human DU145 cells Antiproliferative activity against human DU145 cells	[PMID: 31251599]
DU-145	IC₅₀	1.3 nM Compound: Pac	Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
DU-145	IC₅₀	1.3 nM Compound: Pac	Antiproliferative activity against human DU145 after 48 hrs by SRB assay Antiproliferative activity against human DU145 after 48 hrs by SRB assay	[PMID: 21920638]
DU-145	IC₅₀	1.5 nM Compound: Paclitaxel	Cytotoxicity in human DU145 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity in human DU145 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 30122035]
DU-145	IC₅₀	1.5 nM Compound: Paclitaxel	Antiproliferative activity against human DU145 cells measured after 72 hrs by MTS assay Antiproliferative activity against human DU145 cells measured after 72 hrs by MTS assay	[PMID: 31860298]
DU-145	IC₅₀	1.5 μM Compound: Paclitaxel	Cytotoxicity against human DU145 cells assessed as reduction in cell viability Cytotoxicity against human DU145 cells assessed as reduction in cell viability	[PMID: 25105722]
DU-145	IC₅₀	1.79 μM Compound: Taxol	Cytotoxicity against human DU145 cells after 24 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 hrs by MTT assay	[PMID: 25226363]
DU-145	IC₅₀	17.2 μM Compound: PXL	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 27707623]
DU-145	IC₅₀	2.3 nM Compound: Paclitaxel	Antiproliferative activity against human DU145 cells by sulforhodamine B assay Antiproliferative activity against human DU145 cells by sulforhodamine B assay	[PMID: 21775150]
DU-145	IC₅₀	2.3 nM Compound: Paclitaxel	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 28598633]
DU-145	IC₅₀	2.3 nM Compound: Taxol	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 26697718]
DU-145	IC₅₀	2.35 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 20036537]
DU-145	IC₅₀	2.7 nM Compound: Paclitaxel	Antiproliferative activity against prostate cancer DU-145 cell line using sulforhodamine B(SRB) assay Antiproliferative activity against prostate cancer DU-145 cell line using sulforhodamine B(SRB) assay	[PMID: 15801848]
DU-145	IC₅₀	3.1 μM Compound: taxol	Cytotoxicity against human DU145 cells after 72 hrs by CCK8 assay Cytotoxicity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 26316467]
DU-145	IC₅₀	3.4 nM Compound: Taxol	Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 25819096]
DU-145	IC₅₀	4.84 μM Compound: taxol	Cytotoxicity against human DU145 cells after 72 hrs by XTT assay Cytotoxicity against human DU145 cells after 72 hrs by XTT assay	[PMID: 19754130]
DU-145	IC₅₀	4.88 nM Compound: PXL	Antiproliferative activity against human DU145 cells after 3 days by SRB assay Antiproliferative activity against human DU145 cells after 3 days by SRB assay	[PMID: 25241925]
DU-145	IC₅₀	8.626 μM Compound: Paclitaxel	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 21784631]
DU-145	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
DU-145	IC₅₀	> 3000 nM Compound: Paclitaxel	Antiproliferative activity against human paclitaxel-resistant DU145 cells by sulforhodamine B assay Antiproliferative activity against human paclitaxel-resistant DU145 cells by sulforhodamine B assay	[PMID: 21775150]
Daoy	IC₅₀	0.002 μM Compound: Paclitaxel	Cytotoxicity against human DaOY cells after 96 hrs by MTT assay Cytotoxicity against human DaOY cells after 96 hrs by MTT assay	[PMID: 29279273]
EKVX	GI₅₀	79 nM Compound: Paclitaxel	Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
EKVX	GI₅₀	79 nM Compound: Paclitaxel	Cytotoxicity against human EKVX cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human EKVX cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
EKVX	IC₅₀	150 μM Compound: Paclitaxel	Antiproliferative activity against taxane-resistant human EKVX cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Antiproliferative activity against taxane-resistant human EKVX cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 29995409]
EL4	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against mouse EL4 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against mouse EL4 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 27010926]
EL4	IC₅₀	1.34 μg/mL Compound: (22) taxol	In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay	[PMID: 12620075]
EL4	IC₅₀	1.7 μM Compound: Paclitaxel	Cytotoxicity against mouse EL4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against mouse EL4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25951057]
EMT6	IC₅₀	0.009 μM Compound: Paclitaxel	Inhibitory activity of compound against murine mammary adenocarcinoma (EMT-6) cell proliferation Inhibitory activity of compound against murine mammary adenocarcinoma (EMT-6) cell proliferation	[PMID: 9379451]
EVSA-T	IC₅₀	< 3 ng/mL Compound: 1 (paclitaxel)	Cytotoxicity against EVSA-T Tumor cell line in SRB Cell viability test Cytotoxicity against EVSA-T Tumor cell line in SRB Cell viability test	[PMID: 10956217]
EVSA-T	IC₅₀	< 3 ng/mL Compound: 1	Cytotoxicity against human EVSA-T cells Cytotoxicity against human EVSA-T cells	[PMID: 17419065]
Fibroblast	IC₅₀	0.03 μM Compound: Taxol	Antiproliferative activity against human fibroblast after 72 hrs by imaging analysis Antiproliferative activity against human fibroblast after 72 hrs by imaging analysis	[PMID: 19665384]
Fibroblast	IC₅₀	0.1 μM Compound: Taxol	Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
Fibroblast	IC₅₀	< 0.001 μM Compound: Taxol	Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
Fibroblast	IC₅₀	> 0.25 μM Compound: Paclitaxel	Cytotoxicity against human Fibroblasts assessed as cell growth inhibition Cytotoxicity against human Fibroblasts assessed as cell growth inhibition	[PMID: 26934105]
Flp-In-293	IC₅₀	< 40 μM Compound: Paclitaxel	Antiproliferative activity against human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 35751979]
GES1	IC₅₀	106.2 μM Compound: Taxol	Cytotoxicity against human GES-1 cells incubated for 48 hrs by MTT assay Cytotoxicity against human GES-1 cells incubated for 48 hrs by MTT assay	[PMID: 21664827]
GES1	IC₅₀	7.9 nM Compound: Paclitaxel	Cytotoxicity against human GES-1 cells after 72 hrs by CCK8 assay Cytotoxicity against human GES-1 cells after 72 hrs by CCK8 assay	[PMID: 32489099]
H22	IC₅₀	0.084 μM Compound: Taxol	Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32339853]
H69AR	IC₅₀	2.5 nM Compound: paclitaxel	Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay	[PMID: 17286393]
HBL-100	GI₅₀	0.017 nM Compound: Paclitaxel	Growth inhibition of human HBL100 cells Growth inhibition of human HBL100 cells	[PMID: 21986585]
HCC 2998	GI₅₀	0.003 μM Compound: Paclitaxel	Cytotoxicity against human HCC2998 cells by sulforhodamine B assay Cytotoxicity against human HCC2998 cells by sulforhodamine B assay	[PMID: 21839640]
HCC 2998	GI₅₀	0.003 μM Compound: paclitaxel	Cytotoxicity against human HCC2998 cells Cytotoxicity against human HCC2998 cells	[PMID: 17696332]
HCC 2998	GI₅₀	1 nM Compound: Paclitaxel	Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
HCC 2998	GI₅₀	1 nM Compound: Paclitaxel	Cytotoxicity against human HCC 2998 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human HCC 2998 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
HCC1806	GI₅₀	0.8 nM Compound: 1a; PTX	Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell growth by SRB assay Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell growth by SRB assay	[PMID: 37490800]
HCC1806	IC₅₀	0.001 μM Compound: Paclitaxel	Antiproliferative activity against human HCC1806 cells after 24 hrs by CCK8 assay Antiproliferative activity against human HCC1806 cells after 24 hrs by CCK8 assay	[PMID: 30392953]
HCC1806	IC₅₀	0.008 μM Compound: PTX	Cytotoxicity against human HCC1806 cells assessed as growth inhibition measured after 96 hrs by MTT assay Cytotoxicity against human HCC1806 cells assessed as growth inhibition measured after 96 hrs by MTT assay	[PMID: 34600241]
HCC1806	IC₅₀	0.009 μM Compound: PTX	Cytotoxicity against human HCC1806 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human HCC1806 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34600241]
HCC1937	GI₅₀	3.3 nM Compound: 1a; PTX	Antiproliferative activity against human HCC1937 cells assessed as inhibition of cell growth by SRB assay Antiproliferative activity against human HCC1937 cells assessed as inhibition of cell growth by SRB assay	[PMID: 37490800]
HCC1937	IC₅₀	> 10 μM Compound: Paclitaxel	Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay	[PMID: 25872984]
HCC827	IC₅₀	1.254 nM Compound: Paclitaxel	Antiproliferative activity against human HCC827 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HCC827 cells incubated for 48 hrs by CCK8 assay	[PMID: 38972078]
HCT-116	CC₅₀	1.85 μg/mL Compound: Paclitaxel	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 27301367]
HCT-116	EC₅₀	0.018 μM Compound: Paclitaxel	Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs by HTS assay Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs by HTS assay	[PMID: 20034792]
HCT-116	EC₅₀	0.018 μM Compound: paclitaxel	Induction of apoptosis in human HCT116 cells measured after 48 hrs by cell and caspase based HTS assay Induction of apoptosis in human HCT116 cells measured after 48 hrs by cell and caspase based HTS assay	[PMID: 19467598]
HCT-116	EC₅₀	0.023 μM Compound: Taxol	Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs	[PMID: 19282188]
HCT-116	EC₅₀	0.024 μM Compound: taxol	Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 18197614]
HCT-116	GI₅₀	0.01 μM Compound: 1a, PXL, Taxol	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 23725535]
HCT-116	GI₅₀	0.026 μg/mL Compound: Paclitaxel	Cytotoxicity against human HCT116 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human HCT116 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
HCT-116	GI₅₀	0.026 μg/mL Compound: Paclitaxel	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 27914801]
HCT-116	GI₅₀	0.06 μM Compound: Paclitaxel	Growth inhibition of human HCT116 cells after 48 hrs Growth inhibition of human HCT116 cells after 48 hrs	[PMID: 20034792]
HCT-116	GI₅₀	0.06 μM Compound: paclitaxel	Growth inhibition of human HCT116 cells after 48 hrs Growth inhibition of human HCT116 cells after 48 hrs	[PMID: 19467598]
HCT-116	GI₅₀	0.1279 μg/mL Compound: Paclitaxel	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28110868]
HCT-116	GI₅₀	4 nM Compound: Paclitaxel	Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
HCT-116	GI₅₀	4 nM Compound: Paclitaxel	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
HCT-116	GI₅₀	5.21 μg/mL Compound: Paclitaxel	Cytotoxicity against human HCT116 cells after 48 and 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 and 72 hrs by MTT assay	[PMID: 26927426]
HCT-116	GI₅₀	6.69 mM Compound: Paclitaxel	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	10.1039/C6MD00278A
HCT-116	GI₅₀	< 0.001 μM Compound: Paclitaxel	Compound was tested for growth inhibition of human colon carcinoma HCT116 cell line Compound was tested for growth inhibition of human colon carcinoma HCT116 cell line	[PMID: 15546733]
HCT-116	IC₅₀	0.0002 μM Compound: Taxol	Growth inhibition of human HCT116 cells after 96 hrs by MTT assay Growth inhibition of human HCT116 cells after 96 hrs by MTT assay	[PMID: 28737396]
HCT-116	IC₅₀	0.0002 μM Compound: Taxol	Antiproliferation activity against human HCT116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferation activity against human HCT116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 32546298]
HCT-116	IC₅₀	0.0006 μM Compound: paclitaxel	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 17113288]
HCT-116	IC₅₀	0.001 μM Compound: paclitaxel	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 19743863]
HCT-116	IC₅₀	0.0011 μM Compound: Taxol	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 19576785]
HCT-116	IC₅₀	0.0011 μM Compound: taxol	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 19124250]
HCT-116	IC₅₀	0.0013 μM Compound: Taxol	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 20181487]
HCT-116	IC₅₀	0.0013 μM Compound: Taxol	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 21144756]
HCT-116	IC₅₀	0.0015 μM Compound: taxol	Antiproliferative activity against human HCT116 cell line Antiproliferative activity against human HCT116 cell line	[PMID: 16759114]
HCT-116	IC₅₀	0.002 μM Compound: Taxol	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
HCT-116	IC₅₀	0.0023 μM Compound: PTX	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 30633861]
HCT-116	IC₅₀	0.0024 μM Compound: paclitaxel	Antitumor activity against human HCT116 cell line Antitumor activity against human HCT116 cell line	[PMID: 16884301]
HCT-116	IC₅₀	0.0026 μM Compound: Taxol	Concentration required for growth inhibition of human HCT116 colon tumor cell line (CCRF-CEM) was determined Concentration required for growth inhibition of human HCT116 colon tumor cell line (CCRF-CEM) was determined	[PMID: 15324894]
HCT-116	IC₅₀	0.0028 μM Compound: 1	Cytotoxicity against human HCT116 cells assessed as decrease in cell protein incubated for 48 hrs Cytotoxicity against human HCT116 cells assessed as decrease in cell protein incubated for 48 hrs	[PMID: 26448037]
HCT-116	IC₅₀	0.003 μM Compound: Paclitaxel	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition Cytotoxicity against human HCT116 cells assessed as cell growth inhibition	[PMID: 26934105]
HCT-116	IC₅₀	0.0038 μM Compound: PTX	Growth inhibition human HCT116 cells after 72 hrs by MTS assay Growth inhibition human HCT116 cells after 72 hrs by MTS assay	[PMID: 30633861]
HCT-116	IC₅₀	0.004 μM Compound: 1 (Paclitaxel)	Compound was tested for its cytotoxicity against human colon cancer cell line HCT116 Compound was tested for its cytotoxicity against human colon cancer cell line HCT116	10.1016/S0960-894X(01)80385-1
HCT-116	IC₅₀	0.004 μM Compound: 1 (Taxol)	Compound was evaluated by a cytotoxicity assay in HCT116 human colon carcinoma cell line Compound was evaluated by a cytotoxicity assay in HCT116 human colon carcinoma cell line	10.1016/S0960-894X(01)80980-X
HCT-116	IC₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25462279]
HCT-116	IC₅₀	0.0049 μM Compound: Taxol	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25771484]
HCT-116	IC₅₀	0.005 μM Compound: PTX	Antiproliferative activity against human HCT-116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells after 48 hrs by MTT assay	[PMID: 35065411]
HCT-116	IC₅₀	0.005 μM Compound: PTX	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 38430854]
HCT-116	IC₅₀	0.005 μM Compound: Paclitaxel	Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 37336771]
HCT-116	IC₅₀	0.006 μM Compound: Paclitaxel	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32633512]
HCT-116	IC₅₀	0.00613 μM Compound: Paclitaxel	Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay	[PMID: 23746477]
HCT-116	IC₅₀	0.014 μM Compound: Paclitaxel	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29223717]
HCT-116	IC₅₀	0.02 μM Compound: PTX	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 32650183]
HCT-116	IC₅₀	0.02 μM Compound: Taxol	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 29395979]
HCT-116	IC₅₀	0.02 μM Compound: Taxol	Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
HCT-116	IC₅₀	0.021 μM Compound: Paclitaxel	Antiproliferative activity against human HCT-116 assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34175541]
HCT-116	IC₅₀	0.03 μM Compound: Paclitaxel	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 33459007]
HCT-116	IC₅₀	0.03 μM Compound: Taxol	Growth inhibition of human HCT116 cells incubated for 3 days by SRB assay Growth inhibition of human HCT116 cells incubated for 3 days by SRB assay	[PMID: 28625363]
HCT-116	IC₅₀	0.038 μM Compound: Paclitaxel	Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay	[PMID: 29279273]
HCT-116	IC₅₀	0.045 μg/mL Compound: Paclitaxel	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 23755851]
HCT-116	IC₅₀	0.05 μM Compound: paclitaxel	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 22691179]
HCT-116	IC₅₀	0.061 μM Compound: paclitaxel	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 19053781]
HCT-116	IC₅₀	0.06727 μM Compound: Paclitaxel	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 27017265]
HCT-116	IC₅₀	0.11 pM Compound: Taxol	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay	[PMID: 31494469]
HCT-116	IC₅₀	0.38 μg/mL Compound: Paclitaxel	Cytotoxicity against human HCT116 cells after 48 hrs by MTT method Cytotoxicity against human HCT116 cells after 48 hrs by MTT method	[PMID: 24657569]
HCT-116	IC₅₀	0.896 nM Compound: 1	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37544183]
HCT-116	IC₅₀	0.9 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 27441892]
HCT-116	IC₅₀	1 nM Compound: 1	In vitro cytotoxicity determined against HCT116 cell line as the ratio of IC50 to that of paclitaxel In vitro cytotoxicity determined against HCT116 cell line as the ratio of IC50 to that of paclitaxel	10.1016/0960-894X(95)00453-Z
HCT-116	IC₅₀	1.1 nM Compound: paclitaxel	Cytotoxicity against human HCT116 cells after 4 days by MTT assay Cytotoxicity against human HCT116 cells after 4 days by MTT assay	[PMID: 19128156]
HCT-116	IC₅₀	1.3 nM Compound: taxol	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 18450456]
HCT-116	IC₅₀	1.37 μM Compound: Taxol	Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay	[PMID: 29172082]
HCT-116	IC₅₀	1.55 μM Compound: 1	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation	[PMID: 25466201]
HCT-116	IC₅₀	1.6 nM Compound: 1 (Paclitaxel)	In vitro cytotoxicity against human colon cancer cell lines (HCT116); Range 1.6-6.0 In vitro cytotoxicity against human colon cancer cell lines (HCT116); Range 1.6-6.0	[PMID: 10890157]
HCT-116	IC₅₀	1.8 nM Compound: Taxol	Cytotoxicity against human HCT116 cells measured after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells measured after 48 hrs by MTT assay	[PMID: 31050424]
HCT-116	IC₅₀	1.95 x 10^-8 mg/mL Compound: Taxol	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26920798]
HCT-116	IC₅₀	13.6 nM Compound: paclitaxel	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 18606540]
HCT-116	IC₅₀	18 nM Compound: taxol	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
HCT-116	IC₅₀	2 nM Compound: 1	The compound was evaluated in vitro for inhibition of human colon cancer cell line HCT116 The compound was evaluated in vitro for inhibition of human colon cancer cell line HCT116	10.1016/S0960-894X(97)10142-1
HCT-116	IC₅₀	2 nM Compound: Paclitaxel	Growth inhibition of human HCT116 cells after 96 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells after 96 hrs by sulforhodamine B assay	[PMID: 20943401]
HCT-116	IC₅₀	2 nM Compound: Taxol	Compound was tested for inhibition of proliferation of human colon cancer cell line (HCT116) Compound was tested for inhibition of proliferation of human colon cancer cell line (HCT116)	10.1016/0960-894X(94)80020-0
HCT-116	IC₅₀	2.202 μM Compound: Taxol	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34704758]
HCT-116	IC₅₀	2.4 nM Compound: 1	In vitro cytotoxicity was determined by inhibition against HCT116 cell line proliferation after 72 hours of incubation; value ranges from 2.4-4.0 nM In vitro cytotoxicity was determined by inhibition against HCT116 cell line proliferation after 72 hours of incubation; value ranges from 2.4-4.0 nM	10.1016/0960-894X(95)00453-Z
HCT-116	IC₅₀	2.4 nM Compound: 1 (Paclitaxel)	Compound is evaluated for an in vitro cytotoxicity assay against HCT116 tumor cell lines Compound is evaluated for an in vitro cytotoxicity assay against HCT116 tumor cell lines	[PMID: 7783160]
HCT-116	IC₅₀	2.61 nM Compound: PTX	Cytotoxicity against human HCT-116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT-116 cells after 72 hrs by SRB assay	[PMID: 30819618]
HCT-116	IC₅₀	2.7 nM Compound: Paclitaxel	Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay	[PMID: 25499433]
HCT-116	IC₅₀	2.9 μg/mL Compound: Taxol	Cytotoxicity against human HCT-116 cells by MTT assay Cytotoxicity against human HCT-116 cells by MTT assay	[PMID: 36325400]
HCT-116	IC₅₀	23.97 nM Compound: PTX	Antiproliferative activity against human HCT116 cells assessed as inhibition of proliferation measured after 24 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as inhibition of proliferation measured after 24 hrs by CCK-8 assay	[PMID: 37301075]
HCT-116	IC₅₀	27.9 nM Compound: Paclitaxel	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB method Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB method	[PMID: 38340509]
HCT-116	IC₅₀	3.21 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 20553003]
HCT-116	IC₅₀	3.3 μM Compound: Paclitaxel	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27748595]
HCT-116	IC₅₀	3.5 nM Compound: Paclitaxel	Cytotoxicity against human HCT116 cells after 1 hr by MTT assay Cytotoxicity against human HCT116 cells after 1 hr by MTT assay	[PMID: 19778067]
HCT-116	IC₅₀	33.8 nM Compound: Paclitaxel	Cytotoxicity against CD133 positive human HCT116 cells Cytotoxicity against CD133 positive human HCT116 cells	[PMID: 29468872]
HCT-116	IC₅₀	35 nM Compound: 1	Inhibitory activity against human colon tumor cell sensitive to paclitaxel. Inhibitory activity against human colon tumor cell sensitive to paclitaxel.	[PMID: 11741476]
HCT-116	IC₅₀	4 nM Compound: PTX	Cytotoxicity against human HCT116 assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay Cytotoxicity against human HCT116 assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay	[PMID: 23214452]
HCT-116	IC₅₀	4 nM Compound: Paclitaxel	In vitro inhibition of proliferation of human colon cancer line 116 after 72 hrs incubation. In vitro inhibition of proliferation of human colon cancer line 116 after 72 hrs incubation.	10.1016/S0960-894X(00)80075-X
HCT-116	IC₅₀	4 nM Compound: paclitaxel	Compound was tested for cytotoxicity against human colon tumor cell line (HCT116) Compound was tested for cytotoxicity against human colon tumor cell line (HCT116)	[PMID: 11277525]
HCT-116	IC₅₀	4 nM Compound: paclitaxel	Compound was tested for cytotoxicity against human colon tumor cell line (HCT116) Compound was tested for cytotoxicity against human colon tumor cell line (HCT116)	[PMID: 11277526]
HCT-116	IC₅₀	4.1 nM Compound: Taxol	Antiproliferative activity against human HCT116 cells after 72 hrs by phosphatase assay Antiproliferative activity against human HCT116 cells after 72 hrs by phosphatase assay	[PMID: 28857558]
HCT-116	IC₅₀	4.1 nM Compound: Taxol	Growth inhibition of human HCT116 cells after 72 hrs by phosphatase assay Growth inhibition of human HCT116 cells after 72 hrs by phosphatase assay	[PMID: 29439899]
HCT-116	IC₅₀	4.37 μM Compound: Taxol	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 19359185]
HCT-116	IC₅₀	4.37 μM Compound: Taxol	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 19815316]
HCT-116	IC₅₀	4.37 μM Compound: Taxol	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 21067933]
HCT-116	IC₅₀	4.37 μM Compound: Taxol	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 21342735]
HCT-116	IC₅₀	6.1 nM Compound: 28	Antiproliferative activity against human HCT116 cells after 72 hrs by WST8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by WST8 assay	[PMID: 25625617]
HCT-116	IC₅₀	6.18 μM Compound: Taxol	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 18701301]
HCT-116	IC₅₀	62.9 nM Compound: Abraxane	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 36471625]
HCT-116	IC₅₀	69 nM Compound: Paclitaxel	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24929344]
HCT-116	IC₅₀	7.48 nM Compound: PTX	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
HCT-116	IC₅₀	7.7 μM Compound: Paclitaxel	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 33529025]
HCT-116	IC₅₀	8 ng/mL Compound: Paclitaxel	Cytotoxicity against human HCT 116 cells by MTT assay Cytotoxicity against human HCT 116 cells by MTT assay	[PMID: 16872157]
HCT-116	IC₅₀	8 ng/mL Compound: paclitaxel	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 17927264]
HCT-116	IC₅₀	915 ng/mL Compound: Paclitaxel	Cytotoxicity against human HCT-116 cells by MTT assay Cytotoxicity against human HCT-116 cells by MTT assay	[PMID: 32731188]
HCT-116	IC₅₀	< 0.0008 μM Compound: Taxol	Antiproliferative activity against human HCT116 cells after 72 hrs by imaging analysis Antiproliferative activity against human HCT116 cells after 72 hrs by imaging analysis	[PMID: 19665384]
HCT-116	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
HCT-116	IC₅₀	< 0.001 μM Compound: Taxol	Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
HCT-116	IC₅₀	< 0.02 μg/mL Compound: 1	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	10.1021/np50078a018
HCT-116	IC₅₀	< 0.1 μM Compound: Taxol	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
HCT-116/VM46	IC₅₀	> 200 nM Compound: Taxol	Growth inhibition of human HCT116/VM46 cells over-expressing P-gp after 72 hrs by phosphatase assay Growth inhibition of human HCT116/VM46 cells over-expressing P-gp after 72 hrs by phosphatase assay	[PMID: 29439899]
HCT-15	ED₅₀	0.54 μM Compound: Paclitaxel	Effective dose against HCT-15 cell line. Effective dose against HCT-15 cell line.	[PMID: 11728187]
HCT-15	GI₅₀	0.011 μM Compound: Paclitaxel	Antiproliferative activity against human HCT15 cells by SRB assay Antiproliferative activity against human HCT15 cells by SRB assay	[PMID: 19394218]
HCT-15	GI₅₀	0.158 μM Compound: Paclitaxel	Cytotoxicity against human HCT15 cells by sulforhodamine B assay Cytotoxicity against human HCT15 cells by sulforhodamine B assay	[PMID: 21839640]
HCT-15	GI₅₀	0.158 μM Compound: paclitaxel	Cytotoxicity against human HCT15 cells Cytotoxicity against human HCT15 cells	[PMID: 17696332]
HCT-15	GI₅₀	0.3 μM Compound: Paclitaxel	Compound was tested for growth inhibition of multidrug resistant tumor HCT-15 cell line Compound was tested for growth inhibition of multidrug resistant tumor HCT-15 cell line	[PMID: 15546733]
HCT-15	GI₅₀	0.83 μM Compound: Paclitaxel	Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay	[PMID: 19394218]
HCT-15	GI₅₀	125 nM Compound: Paclitaxel	Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
HCT-15	GI₅₀	125 nM Compound: Paclitaxel	Cytotoxicity against human HCT-15 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human HCT-15 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
HCT-15	IC₅₀	0.12 μM Compound: Taxol	Cytotoxicity against human HCT15 cells by MTT assay Cytotoxicity against human HCT15 cells by MTT assay	[PMID: 23425970]
HCT-15	IC₅₀	140 nM Compound: Paclitaxel	Growth inhibition of human HCT15 cells after 96 hrs by sulforhodamine B assay Growth inhibition of human HCT15 cells after 96 hrs by sulforhodamine B assay	[PMID: 20943401]
HCT-15	IC₅₀	190 μM Compound: Paclitaxel	Antiproliferative activity against taxane-resistant human HCT15 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Antiproliferative activity against taxane-resistant human HCT15 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 29995409]
HCT-15	IC₅₀	24 nM Compound: taxol	Antiproliferative activity against human HCT15 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human HCT15 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
HCT-15	IC₅₀	240 nM Compound: 28	Antiproliferative activity against human HCT15 cells after 72 hrs by WST8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by WST8 assay	[PMID: 25625617]
HCT-15	IC₅₀	438 nM Compound: Placlitaxel (TAXOL)	Inhibitory concentration against HCT-15 cells was evaluated Inhibitory concentration against HCT-15 cells was evaluated	[PMID: 15341492]
HCT-15	IC₅₀	79.4 nM Compound: paclitaxel	Antiproliferative activity against drug resistant HCT15 cell line expressing MDR1 by Alamar Blue assay Antiproliferative activity against drug resistant HCT15 cell line expressing MDR1 by Alamar Blue assay	[PMID: 17286393]
HCT-15	IC₅₀	90 nM Compound: PTX	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay	[PMID: 23214452]
HCT-8	EC₅₀	0.21 μg/mL Compound: Paclitaxel	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 18640035]
HCT-8	EC₅₀	0.21 μg/mL Compound: Palitaxel	Cytotoxicity against human HCT8 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HCT8 cells after 3 days by sulforhodamine B assay	[PMID: 19193043]
HCT-8	ED₅₀	0.011 μg/mL Compound: Paclitaxel	Effective dose required for inhibitory activity against HCT-8 human tumor cell line. Effective dose required for inhibitory activity against HCT-8 human tumor cell line.	[PMID: 12852747]
HCT-8	ED₅₀	0.011 μg/mL Compound: paclitaxel	Cytotoxicity against human HCT8 cells after 3 days by SRB assay Cytotoxicity against human HCT8 cells after 3 days by SRB assay	[PMID: 14640511]
HCT-8	ED₅₀	0.06 μg/mL Compound: 1	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 17643301]
HCT-8	ED₅₀	> 100 nM Compound: Paclitaxel	Antiproliferative activity against human HCT8 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human HCT8 cells after 3 days by sulforhodamine B assay	[PMID: 21296579]
HCT-8	GI₅₀	> 100 nM Compound: Paclitaxel	Cytotoxicity against human HCT8 cells after 3 days Cytotoxicity against human HCT8 cells after 3 days	[PMID: 21377368]
HCT-8	IC₅₀	0.013 μM Compound: Paclitaxel	Cytotoxicity against human HCT8 cells after 3 days by SRB assay Cytotoxicity against human HCT8 cells after 3 days by SRB assay	[PMID: 16038545]
HCT-8	IC₅₀	0.019 μM Compound: TAX	Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27149641]
HCT-8	IC₅₀	0.02 μM Compound: TAX	Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
HCT-8	IC₅₀	0.02 μM Compound: Taxol	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 24467317]
HCT-8	IC₅₀	0.021 μM Compound: TAX, Taxol	Antiproliferative activity against human HCT8 cells after 48 hrs by SRB method Antiproliferative activity against human HCT8 cells after 48 hrs by SRB method	[PMID: 25061803]
HCT-8	IC₅₀	0.028 μM Compound: PTX	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 30530194]
HCT-8	IC₅₀	0.028 μM Compound: Taxol; PTX	Antiproliferative activity against human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33676300]
HCT-8	IC₅₀	0.037 μM Compound: paclitaxel	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 18001087]
HCT-8	IC₅₀	0.037 μM Compound: paclitaxel	Cytotoxicity against human HCT8 cells after 24 hrs by MTT assay Cytotoxicity against human HCT8 cells after 24 hrs by MTT assay	[PMID: 19245261]
HCT-8	IC₅₀	0.051 μM Compound: Paclitaxel	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 23547884]
HCT-8	IC₅₀	0.051 μM Compound: paclitaxel	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 22506620]
HCT-8	IC₅₀	0.051 μM Compound: paclitaxel	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 22583079]
HCT-8	IC₅₀	0.066 μM Compound: 6	Antiproliferative activity against human HCT8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25682561]
HCT-8	IC₅₀	0.086 μM Compound: Paclitaxel	Antiproliferative activity against human HCT-8 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-8 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
HCT-8	IC₅₀	0.13 μM Compound: TAX	Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
HCT-8	IC₅₀	0.17 μM Compound: Paclitaxel	Cytotoxicity against human HCT8 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human HCT8 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 30798081]
HCT-8	IC₅₀	0.24 μM Compound: Taxol	Anticancer activity against human HCT-8 cells by MTT assay Anticancer activity against human HCT-8 cells by MTT assay	[PMID: 33316408]
HCT-8	IC₅₀	0.67 μM Compound: paclitaxel	Cytotoxicity against human HCT8 cells after 3 days by MTT assay Cytotoxicity against human HCT8 cells after 3 days by MTT assay	[PMID: 20593839]
HCT-8	IC₅₀	13.3 μM Compound: Taxol	Cytotoxicity against taxol-resistant human HCT8 cells by MTT assay Cytotoxicity against taxol-resistant human HCT8 cells by MTT assay	[PMID: 23425970]
HCT-8	IC₅₀	17.4 nM Compound: Paclitaxel	Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay	[PMID: 28763646]
HCT-8	IC₅₀	189.4 nM Compound: Paclitaxel	Cytotoxicity against vinblastine resistant/P-gp overexpressing human HCT8 cells assessed as reduction in cell growth after 24 hrs by MTT assay Cytotoxicity against vinblastine resistant/P-gp overexpressing human HCT8 cells assessed as reduction in cell growth after 24 hrs by MTT assay	[PMID: 27213819]
HCT-8	IC₅₀	2.59 μM Compound: Taxol; PTX	Antiproliferative activity against taxol-resistant human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against taxol-resistant human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33676300]
HCT-8	IC₅₀	2.6 μM Compound: TAX, Taxol	Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method	[PMID: 25061803]
HCT-8	IC₅₀	266 nM Compound: taxol	Antiproliferative activity against taxol resistant human HCT8 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against taxol resistant human HCT8 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
HCT-8	IC₅₀	3.29 μM Compound: paclitaxel	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 18701281]
HCT-8	IC₅₀	3.6 nM Compound: paclitaxel	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 19708679]
HCT-8	IC₅₀	3.6 μM Compound: paclitaxel	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 20560647]
HCT-8	IC₅₀	36.9 nM Compound: Paclitaxel	Antiproliferative activity against human HCT8 cells after 24 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 24 hrs by MTT assay	[PMID: 27213819]
HCT-8	IC₅₀	5 nM Compound: taxol	Antiproliferative activity against human HCT8 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human HCT8 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
HCT-8	IC₅₀	5.1 x 10^-8 M Compound: Taxol	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 20719510]
HCT-8	IC₅₀	5.1 x 10^-8 M Compound: Taxol	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 21530251]
HCT-8	IC₅₀	8.7 μM Compound: PXL	Cytotoxicity against human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 27707623]
HEK-293T	CC₅₀	< 20 nM Compound: Ptxl; PTX	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31248772]
HEK-293T	IC₅₀	0.01 μM Compound: Taxol	Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 33310292]
HEK-293T	IC₅₀	1.76 nM Compound: Paclitaxel	Cytotoxicity against HEK293T cells assessed as inhibition in cell growth Cytotoxicity against HEK293T cells assessed as inhibition in cell growth	[PMID: 33974423]
HEK-293T	IC₅₀	2.3 nM Compound: Taxol	Cytotoxicity against human 293T cells assessed as reduction in cell viability after 4 days by MTS assay Cytotoxicity against human 293T cells assessed as reduction in cell viability after 4 days by MTS assay	[PMID: 29486949]
HEK-293T	IC₅₀	36.4 μM Compound: Paclitaxel	Cytotoxicity against human HEK293T cells expressing ABCB1 (unknown origin) measured after 72 hrs by MTT assay Cytotoxicity against human HEK293T cells expressing ABCB1 (unknown origin) measured after 72 hrs by MTT assay	[PMID: 34546748]
HEK-293T	IC₅₀	6.7 nM Compound: PTX	Antiproliferative activity against ACE-negative human HEK293T cells incubated for 48 hrs by MTT assay Antiproliferative activity against ACE-negative human HEK293T cells incubated for 48 hrs by MTT assay	[PMID: 34699215]
HEK293	IC₅₀	0.0039 μM Compound: Paclitaxel	Cytotoxicity against HEK cells after 72 hrs by alamar blue assay Cytotoxicity against HEK cells after 72 hrs by alamar blue assay	[PMID: 20732809]
HEK293	IC₅₀	0.008 μg/mL Compound: Paclitaxel	Cytotoxic activity against HEK293 cells after 24 hrs by MTT assay Cytotoxic activity against HEK293 cells after 24 hrs by MTT assay	[PMID: 25305717]
HEK293	IC₅₀	0.01 μM Compound: 1	Cytotoxicity against HEK293 cells Cytotoxicity against HEK293 cells	[PMID: 17485207]
HEK293	IC₅₀	0.04 μM Compound: Paclitaxel	Cytotoxicity against HEK293 cells expressing pcDNA3.1 after 72 hrs by MTT assay Cytotoxicity against HEK293 cells expressing pcDNA3.1 after 72 hrs by MTT assay	[PMID: 25842364]
HEK293	IC₅₀	0.36 μM Compound: Paclitaxel	Cytotoxicity against HEK293 cells expressing ABCB1 after 72 hrs by MTT assay Cytotoxicity against HEK293 cells expressing ABCB1 after 72 hrs by MTT assay	[PMID: 25842364]
HEK293	IC₅₀	1.5 nM Compound: Taxol	Cytotoxicity against human HEK293 cells incubated for 3 days Cytotoxicity against human HEK293 cells incubated for 3 days	[PMID: 38272190]
HEK293	IC₅₀	16.3 nM Compound: PTX	Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33280896]
HEK293	IC₅₀	26.8 nM Compound: PT	Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
HEK293	IC₅₀	43 μM Compound: taxol	Cytotoxicity against HEK293 cells after 18 hrs by MTT assay Cytotoxicity against HEK293 cells after 18 hrs by MTT assay	[PMID: 19446930]
HEK293	IC₅₀	5.8 μM Compound: Paclitaxel	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
HEL	IC₅₀	0.2 μM Compound: PTX	Cytotoxicity against human HEL cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HEL cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37201429]
HEY	IC₅₀	104.1 nM Compound: Paclitaxel	Cytotoxicity against human HEY cells after 48 hrs by MTT assay Cytotoxicity against human HEY cells after 48 hrs by MTT assay	[PMID: 28719204]
HEY	IC₅₀	2.7 μM Compound: Taxol	Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay	[PMID: 29517223]
HEp-2	IC₅₀	0.11 μM Compound: Paclitaxel	Cytotoxicity against Homo sapiens (human) Hep2 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) Hep2 cells after 48 hr by SRB assay	10.1007/s00044-011-9824-9
HFF-1	IC₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against human HFF1 after 24 hrs by MTT assay Cytotoxicity against human HFF1 after 24 hrs by MTT assay	[PMID: 30387611]
HFF-1	IC₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against human HFF1 after 48 hrs by MTT assay Cytotoxicity against human HFF1 after 48 hrs by MTT assay	[PMID: 30387611]
HGC-27	IC₅₀	0.008 μg/mL Compound: Paclitaxel	Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay	[PMID: 39052090]
HGC-27	IC₅₀	0.028 μM Compound: Taxol	Antiproliferative activity against human HGC27 cells after 72 hrs by MTT assay Antiproliferative activity against human HGC27 cells after 72 hrs by MTT assay	[PMID: 30212198]
HGC-27	IC₅₀	777.8 nM Compound: Paclitaxel	Cytotoxicity against human HGC27 cells by MTT assay Cytotoxicity against human HGC27 cells by MTT assay	[PMID: 17764148]
HGC-27	IC₅₀	8.4 nM Compound: Paclitaxel	Cytotoxicity against human HGC27 cells after 72 hrs by CCK8 assay Cytotoxicity against human HGC27 cells after 72 hrs by CCK8 assay	[PMID: 32489099]
HGC-27	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
HL-60	IC₅₀	0.0017 μM Compound: Taxol	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 25771484]
HL-60	IC₅₀	0.001 μg/mL Compound: 1 (Taxol)	Tested in vitro for the anticancer activity against HL-60 leukemia cells Tested in vitro for the anticancer activity against HL-60 leukemia cells	10.1016/S0960-894X(97)00058-9
HL-60	IC₅₀	0.002 μM Compound: Taxol	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	[PMID: 23937981]
HL-60	IC₅₀	0.0026 μM Compound: Taxol	Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay	[PMID: 29475587]
HL-60	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human HL60 cell line by MTS assay Cytotoxicity against human HL60 cell line by MTS assay	[PMID: 16870446]
HL-60	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 18308566]
HL-60	IC₅₀	0.005 μg/mL Compound: Paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 23755851]
HL-60	IC₅₀	0.007 μM Compound: Taxol, Paclitaxel	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 25462222]
HL-60	IC₅₀	0.01 μM Compound: paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTT method Cytotoxicity against human HL60 cells after 48 hrs by MTT method	[PMID: 21534539]
HL-60	IC₅₀	0.012 μM Compound: PTX	Cytotoxicity against human HL-60 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HL-60	IC₅₀	0.08 μM Compound: PTX	Cytotoxicity against human HL-60 cells by MTT assay Cytotoxicity against human HL-60 cells by MTT assay	[PMID: 33915258]
HL-60	IC₅₀	0.32 μM Compound: Paclitaxel	Antiproliferative activity against human HL60 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
HL-60	IC₅₀	0.93 μM Compound: paclitaxel	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 17896816]
HL-60	IC₅₀	0.93 μM Compound: paclitaxel	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 18281952]
HL-60	IC₅₀	1.5 μM Compound: paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method	[PMID: 25211032]
HL-60	IC₅₀	1.8 nM Compound: Taxol	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 25819096]
HL-60	IC₅₀	1.99 nM Compound: Taxol	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 26697718]
HL-60	IC₅₀	2 nM Compound: Paclitaxel	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 28598633]
HL-60	IC₅₀	2 nM Compound: Paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 29373791]
HL-60	IC₅₀	2.2 nM Compound: Paclitaxel	Cytotoxicity against human HL-60 cells assessed as growth inhibition Cytotoxicity against human HL-60 cells assessed as growth inhibition	[PMID: 34949088]
HL-60	IC₅₀	2.5 x 10^-3 μM Compound: Taxol	Cytotoxicity against human HL60 cells assessed as reduction in cell viability Cytotoxicity against human HL60 cells assessed as reduction in cell viability	[PMID: 32273216]
HL-60	IC₅₀	2.82 nM Compound: Paclitaxel	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 22959518]
HL-60	IC₅₀	3.4 nM Compound: Taxol	Cytotoxicity against human HL60 cells after 72 hrs by MTS assay Cytotoxicity against human HL60 cells after 72 hrs by MTS assay	[PMID: 21848268]
HL-60	IC₅₀	3.8 μM Compound: taxol	Cytotoxicity against human HL60 cells after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells after 72 hrs by CCK8 assay	[PMID: 26316467]
HL-60	IC₅₀	4 ng/mL Compound: Taxol	Antiproliferative activity against human HL60 cells after 24 hrs by alamar blue assay Antiproliferative activity against human HL60 cells after 24 hrs by alamar blue assay	[PMID: 19717215]
HL-60	IC₅₀	5 μM Compound: Taxol	Cytotoxicity against human HL60/TX1000 cell line by MTS assay Cytotoxicity against human HL60/TX1000 cell line by MTS assay	[PMID: 16870446]
HL-60	IC₅₀	5 μM Compound: Taxol	Cytotoxicity against multidrug-resistant human HL60 cells Cytotoxicity against multidrug-resistant human HL60 cells	[PMID: 23937981]
HL-60	IC₅₀	5.8 nM Compound: Taxol	Cytotoxicity against human HL60 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human HL60 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
HL-60	IC₅₀	7.9 nM Compound: 28	Antiproliferative activity against human HL60 cells after 72 hrs by WST8 assay Antiproliferative activity against human HL60 cells after 72 hrs by WST8 assay	[PMID: 25625617]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20521771]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human HL60 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 23327668]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 24417634]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 27704807]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Antiproliferative activity against human HL60 cells after 48 hrs by MTS assay Antiproliferative activity against human HL60 cells after 48 hrs by MTS assay	[PMID: 28654256]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTS assay Cytotoxicity against human HL60 cells after 48 hrs by MTS assay	[PMID: 29286250]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTS assay Cytotoxicity against human HL60 cells after 48 hrs by MTS assay	[PMID: 29338226]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTS assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTS assay	[PMID: 29338260]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Growth inhibition of human HL60 cells after 48 hrs by MTS assay Growth inhibition of human HL60 cells after 48 hrs by MTS assay	[PMID: 29412669]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 31310115]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32628478]
HL-60	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34355562]
HL-60	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25871261]
HL-60	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26068802]
HL-60	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 4 days by MTT assay Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 4 days by MTT assay	[PMID: 29884535]
HL-60	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay	[PMID: 34781083]
HL-60	IC₅₀	< 0.008 μM Compound: Taxol	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36274275]
HL-60	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human HL60 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 23586920]
HL-60	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 23819871]
HL-60	IC₅₀	< 0.008 μM Compound: paclitaxel	Antimicrobial activity against human HL60 cells after 48 hrs by MTT assay Antimicrobial activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 23957453]
HL-60	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTS assay Cytotoxicity against human HL60 cells after 48 hrs by MTS assay	[PMID: 24219809]
HL-60	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTS assay Cytotoxicity against human HL60 cells after 48 hrs by MTS assay	[PMID: 24256484]
HL-60	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTS assay Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTS assay	[PMID: 24697496]
HL-60	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 25375202]
HL-60	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human HL60 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HL60 cells incubated for 48 hrs by MTT assay	[PMID: 25798528]
HL-60	IC₅₀	< 2 μg/mL Compound: paclitaxel	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 18553923]
HL-60(TB)	GI₅₀	4 nM Compound: Paclitaxel	Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
HL-60(TB)	GI₅₀	4 nM Compound: Paclitaxel	Cytotoxicity against human HL-60(TB) cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human HL-60(TB) cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
HOP-62	GI₅₀	19 nM Compound: Paclitaxel	Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
HOP-62	GI₅₀	19 nM Compound: Paclitaxel	Cytotoxicity against human HOP-62 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human HOP-62 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
HOP-62	GI₅₀	6.71 x 10^-8 M Compound: 5	Cytotoxicity against human HOP62 cells Cytotoxicity against human HOP62 cells	[PMID: 7908950]
HOP-92	GI₅₀	25 nM Compound: Paclitaxel	Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
HOP-92	GI₅₀	25 nM Compound: Paclitaxel	Cytotoxicity against human HOP-92 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human HOP-92 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
HSC-2	IC₅₀	> 100 μM Compound: Paclitaxel	Cytotoxicity against human HSC-2 cells Cytotoxicity against human HSC-2 cells	[PMID: 31945642]
HSC-T6	IC₅₀	0.75 μg/mL Compound: paclitaxel	Cytotoxicity against rat HSC-T6 cells after 44 hrs by MTT assay Cytotoxicity against rat HSC-T6 cells after 44 hrs by MTT assay	[PMID: 19928884]
HT-1080	GI₅₀	3.889 nM Compound: 1, Taxol	Growth inhibition of human HT1080 cells by MTT assay Growth inhibition of human HT1080 cells by MTT assay	[PMID: 24405702]
HT-1080	IC₅₀	0.15 nM Compound: Pac	Antiproliferative activity against human HT1080 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HT1080 cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
HT-1080	IC₅₀	0.15 nM Compound: Pac	Antiproliferative activity against human HT1080 after 48 hrs by SRB assay Antiproliferative activity against human HT1080 after 48 hrs by SRB assay	[PMID: 21920638]
HT-1080	IC₅₀	1.2 nM Compound: Taxol	Antiproliferative activity against human HT1080 cells after 96 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 96 hrs by MTT assay	[PMID: 21296467]
HT-1080	IC₅₀	1.8 nM Compound: PT	Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
HT-1080	IC₅₀	6 μM Compound: paclitaxel	Cytotoxicity against human HT1080 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HT1080 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 23647462]
HT-29	EC₅₀	0.006 μM Compound: PXL	Cytotoxicity against human HT29 cells Cytotoxicity against human HT29 cells	[PMID: 16870428]
HT-29	ED₅₀	0.0006 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 20939540]
HT-29	ED₅₀	0.001 μM Compound: paclitaxel	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 23301897]
HT-29	ED₅₀	0.006 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 21973101]
HT-29	ED₅₀	0.1 nM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 21428375]
HT-29	ED₅₀	0.1 nM Compound: paclitaxel	Cytotoxicity against human HT-29 cells after 3 days by SRB assay Cytotoxicity against human HT-29 cells after 3 days by SRB assay	[PMID: 20384315]
HT-29	ED₅₀	0.1 nM Compound: paclitaxel	Anticancer activity aganist human HT-29 cells Anticancer activity aganist human HT-29 cells	[PMID: 21067206]
HT-29	GI₅₀	0.001 μM Compound: PCT	Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay	[PMID: 24727464]
HT-29	GI₅₀	0.002 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells by sulforhodamine B assay Cytotoxicity against human HT-29 cells by sulforhodamine B assay	[PMID: 21839640]
HT-29	GI₅₀	0.002 μM Compound: paclitaxel	Cytotoxicity against human HT29 cells Cytotoxicity against human HT29 cells	[PMID: 17696332]
HT-29	GI₅₀	0.003 μM Compound: Taxol	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 21115210]
HT-29	GI₅₀	0.003 μM Compound: Taxol	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 23831811]
HT-29	GI₅₀	0.012 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 21513294]
HT-29	GI₅₀	0.015 μM Compound: Pac	Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B method Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B method	[PMID: 18617414]
HT-29	GI₅₀	0.015 μM Compound: Paclitaxel	Growth inhibition of human HT29 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HT29 cells after 48 hrs by sulforhodamine B assay	[PMID: 18579387]
HT-29	GI₅₀	0.015 μM Compound: paclitaxel	Growth inhibition of human HT29 cells after 48 hrs Growth inhibition of human HT29 cells after 48 hrs	[PMID: 17498960]
HT-29	GI₅₀	0.015 μM Compound: paclitaxel	Antiproliferative activity against human HT29 cells Antiproliferative activity against human HT29 cells	[PMID: 18502639]
HT-29	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
HT-29	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
HT-29	GI₅₀	5.3 nM Compound: Taxol	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	10.1039/C2MD20089A
HT-29	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27010926]
HT-29	IC₅₀	0.00016 μM Compound: paclitaxel	In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
HT-29	IC₅₀	0.0006 μM Compound: paclitaxel	Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 23895019]
HT-29	IC₅₀	0.0008 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 3 days by sulforhodamine B assay	[PMID: 26422131]
HT-29	IC₅₀	0.0008 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay	[PMID: 27983842]
HT-29	IC₅₀	0.0008 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 29350920]
HT-29	IC₅₀	0.0008 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 31953129]
HT-29	IC₅₀	0.0008 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay Cytotoxicity against human HT-29 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay	[PMID: 32096998]
HT-29	IC₅₀	0.001 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by SRB assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by SRB assay	[PMID: 23327794]
HT-29	IC₅₀	0.001 μM Compound: Paclitaxel	Antiproliferative activity against human HT-29 cells measured after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HT-29 cells measured after 72 hrs by sulforhodamine B assay	[PMID: 31465222]
HT-29	IC₅₀	0.001 μM Compound: paclitaxel	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 24937209]
HT-29	IC₅₀	0.0014 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 28409637]
HT-29	IC₅₀	0.00198 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 23746477]
HT-29	IC₅₀	0.002 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 31120251]
HT-29	IC₅₀	0.0024 μg/mL Compound: 3	In vitro cytotoxicity against HT29-human colon adenocarcinoma cells. In vitro cytotoxicity against HT29-human colon adenocarcinoma cells.	10.1016/S0960-894X(01)80507-2
HT-29	IC₅₀	0.002 μg/mL Compound: Paclitaxel	Cytotoxicity was evaluated against HT-29 human colon adenocarcinoma cells Cytotoxicity was evaluated against HT-29 human colon adenocarcinoma cells	[PMID: 9871668]
HT-29	IC₅₀	0.006 μM Compound: paclitaxel	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 22239601]
HT-29	IC₅₀	0.008 μM Compound: Paclitaxel	Antiproliferative activity against human HT-29 cells after 24 hrs by CCK8 assay Antiproliferative activity against human HT-29 cells after 24 hrs by CCK8 assay	[PMID: 30392953]
HT-29	IC₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 after 48 hrs by MTT assay Cytotoxicity against human HT-29 after 48 hrs by MTT assay	[PMID: 30387611]
HT-29	IC₅₀	0.011 μM Compound: PTX	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35447432]
HT-29	IC₅₀	0.011 μM Compound: Taxol	Cytotoxicity against human HT-29 cells measured after 24 to 72 hrs by SRB assay Cytotoxicity against human HT-29 cells measured after 24 to 72 hrs by SRB assay	[PMID: 29656990]
HT-29	IC₅₀	0.014 μM Compound: PTX	Cytotoxicity against human HT-29 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
HT-29	IC₅₀	0.015 μM Compound: PTX	Cytotoxicity against human HT-29 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
HT-29	IC₅₀	0.01 μg/mL Compound: (22) taxol	In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay	[PMID: 12620075]
HT-29	IC₅₀	0.02 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27329938]
HT-29	IC₅₀	0.025 μM Compound: Taxol	Antiproliferative activity against human HT-29 cells expressing NQO1 after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells expressing NQO1 after 72 hrs by MTT assay	[PMID: 28395199]
HT-29	IC₅₀	0.03 μM Compound: PTX	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HT-29	IC₅₀	0.03 μg/mL Compound: 1	Cytotoxicity against human HT29 cells Cytotoxicity against human HT29 cells	[PMID: 17419065]
HT-29	IC₅₀	0.05 μM Compound: Taxol	Cytotoxicity against human HT29 cells by MTT assay Cytotoxicity against human HT29 cells by MTT assay	[PMID: 16539377]
HT-29	IC₅₀	0.05 μM Compound: taxol	Cytotoxicity against human HT29 cells after 72 hrs by MTT assay Cytotoxicity against human HT29 cells after 72 hrs by MTT assay	[PMID: 17915851]
HT-29	IC₅₀	0.07 μM Compound: PTX	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38280356]
HT-29	IC₅₀	0.07 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 after 24 hrs by MTT assay Cytotoxicity against human HT-29 after 24 hrs by MTT assay	[PMID: 30387611]
HT-29	IC₅₀	0.28 μM Compound: Paclitaxel	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34671737]
HT-29	IC₅₀	0.29 μM Compound: Paclitaxel	Antiproliferative activity against human HT-29 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
HT-29	IC₅₀	0.38 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 20627721]
HT-29	IC₅₀	0.38 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 20716468]
HT-29	IC₅₀	0.38 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 21875764]
HT-29	IC₅₀	0.45 μM Compound: Taxol	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 23425970]
HT-29	IC₅₀	0.8 nM Compound: Taxol	Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay	[PMID: 30528697]
HT-29	IC₅₀	1.4 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 20553003]
HT-29	IC₅₀	1.9 nM Compound: paclitaxel	Antiproliferative activity against human HT29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT29 cells after 48 hrs by MTT assay	[PMID: 18461997]
HT-29	IC₅₀	10.8 nM Compound: Abraxane	Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay	[PMID: 36471625]
HT-29	IC₅₀	14.56 μM Compound: Paclitaxel	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 30738663]
HT-29	IC₅₀	19.94 μM Compound: Paclitaxel	Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36481599]
HT-29	IC₅₀	3 nM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 21446699]
HT-29	IC₅₀	3 nM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 28598633]
HT-29	IC₅₀	3.04 nM Compound: Taxol	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 26697718]
HT-29	IC₅₀	3.2 nM Compound: Paclitaxel	Cytotoxicity against human colon HT-29 cell lines Cytotoxicity against human colon HT-29 cell lines	10.1016/S0960-894X(01)80298-5
HT-29	IC₅₀	3.2 nM Compound: Paclitaxel	Cytotoxicity was evaluated in vitro against HT-29 (colon carcinoma) human tumor cell lines Cytotoxicity was evaluated in vitro against HT-29 (colon carcinoma) human tumor cell lines	10.1016/S0960-894X(01)80568-0
HT-29	IC₅₀	3.2 nM Compound: Paclitaxel	Growth inhibition of human colon carcinoma (HT-29) cell line Growth inhibition of human colon carcinoma (HT-29) cell line	[PMID: 9022793]
HT-29	IC₅₀	3.2 nM Compound: Paclitaxel	Inhibition of the growth against human Colon Carcinoma (HT-29) cell line after 72 hr exposure Inhibition of the growth against human Colon Carcinoma (HT-29) cell line after 72 hr exposure	[PMID: 9022794]
HT-29	IC₅₀	3.2 nM Compound: paclitaxel	In vitro cytotoxicity against human colon carcinoma HT-29 In vitro cytotoxicity against human colon carcinoma HT-29	[PMID: 8182698]
HT-29	IC₅₀	3.4 nM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells after 1 hr by MTT assay Cytotoxicity against human HT-29 cells after 1 hr by MTT assay	[PMID: 19778067]
HT-29	IC₅₀	3.4 nM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells incubated for 72 hrs by Cell titer blue assay Cytotoxicity against human HT-29 cells incubated for 72 hrs by Cell titer blue assay	[PMID: 37216676]
HT-29	IC₅₀	3.5 μM Compound: paclitaxel	Cytotoxicity against human HT-29 cells after 48 hrs by trypan blue exclusion method Cytotoxicity against human HT-29 cells after 48 hrs by trypan blue exclusion method	[PMID: 25211032]
HT-29	IC₅₀	3.6 nM Compound: Paclitaxel	Cytotoxicity was evaluated against HT-29 colon carcinoma human cancer cell line Cytotoxicity was evaluated against HT-29 colon carcinoma human cancer cell line	10.1016/S0960-894X(96)00595-1
HT-29	IC₅₀	3.6 nM Compound: paclitaxel	Cytotoxicity against human HT-29 cells after 4 days by MTT assay Cytotoxicity against human HT-29 cells after 4 days by MTT assay	[PMID: 19128156]
HT-29	IC₅₀	3.6 nM Compound: paclitaxel	Cytotoxicity against human HT-29 cells after 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs	[PMID: 19239240]
HT-29	IC₅₀	3.6 nM Compound: paclitaxel	Concentration required to inhibit growth of human tumor HT-29 (colon) cell line. Concentration required to inhibit growth of human tumor HT-29 (colon) cell line.	[PMID: 8831755]
HT-29	IC₅₀	3.8 nM Compound: Taxol	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth by secondary round CCK8 assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth by secondary round CCK8 assay	[PMID: 34508844]
HT-29	IC₅₀	3.94 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 21928797]
HT-29	IC₅₀	5.3 ng/mL Compound: Paclitaxel	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 16872157]
HT-29	IC₅₀	5.3 ng/mL Compound: paclitaxel	Cytotoxicity against human HT29 cells by MTT assay Cytotoxicity against human HT29 cells by MTT assay	[PMID: 17927264]
HT-29	IC₅₀	5.7 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs	[PMID: 38341161]
HT-29	IC₅₀	6.1 nM Compound: Paclitaxel	Antiproliferative activity against human HT-29 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HT-29 cells after 72 hrs by sulforhodamine B assay	[PMID: 21480626]
HT-29	IC₅₀	7 nM Compound: 28	Antiproliferative activity against human HT-29 cells after 72 hrs by WST8 assay Antiproliferative activity against human HT-29 cells after 72 hrs by WST8 assay	[PMID: 25625617]
HT-29	IC₅₀	7 nM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21341718]
HT-29	IC₅₀	7.47 nM Compound: PTX	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
HT-29	IC₅₀	8 nM Compound: PTX	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23214452]
HT-29	IC₅₀	8.6 nM Compound: PTX	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33280896]
HT-29	IC₅₀	9 nM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
HT-29	IC₅₀	< 10 μM Compound: Taxol	Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 21664827]
HT-29	IC₅₀	< 10 μM Compound: Taxol	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 22370266]
HT-29	IC₅₀	< 5 nM Compound: Paclitaxel, Taxol	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by MTS assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by MTS assay	10.1039/C1MD00155H
HT-29	IC₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 24344605]
HUVEC	ED₅₀	105 nM Compound: paclitaxel	Cytotoxicity against HUVEC Cytotoxicity against HUVEC	[PMID: 15043407]
HUVEC	GI₅₀	0.00148 μM Compound: Paclitaxel	Cytotoxicity against HUVEC cells after 48 hrs by SRB assay Cytotoxicity against HUVEC cells after 48 hrs by SRB assay	[PMID: 26462052]
HUVEC	GI₅₀	> 10 μg/mL Compound: Paclitaxel	Cytotoxicity against primary HUVEC measured after 48 hrs by MTT assay Cytotoxicity against primary HUVEC measured after 48 hrs by MTT assay	[PMID: 27688192]
HUVEC	GI₅₀	> 10 μg/mL Compound: Paclitaxel	Cytotoxicity against HUVEC cells assessed as cell growth inhibition Cytotoxicity against HUVEC cells assessed as cell growth inhibition	[PMID: 33826327]
HUVEC	IC₅₀	0.0013 μM Compound: Paclitaxel	Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay	[PMID: 31901744]
HUVEC	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 33310292]
HUVEC	IC₅₀	0.007 μM Compound: Paclitaxel, IOUYT	Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay	[PMID: 24012378]
HUVEC	IC₅₀	0.05 μM Compound: Paclitaxel	Antiangiogenic activity against HUVEC assessed as inhibition of capillary-like structure formation by NCI antiangiogenesis assay Antiangiogenic activity against HUVEC assessed as inhibition of capillary-like structure formation by NCI antiangiogenesis assay	[PMID: 19084416]
HUVEC	IC₅₀	0.06 μM Compound: Paclitaxel	Antiproliferative activity against HUVEC cell line Antiproliferative activity against HUVEC cell line	[PMID: 16793260]
HUVEC	IC₅₀	0.071 μM Compound: Paclitaxel	Anti-angiogenesis activity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Anti-angiogenesis activity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
HUVEC	IC₅₀	0.1 μM Compound: Paclitaxel	Antiangiogenic activity against HUVEC assessed as inhibition of VEGF-induced cell migration by NCI antiangiogenesis assay Antiangiogenic activity against HUVEC assessed as inhibition of VEGF-induced cell migration by NCI antiangiogenesis assay	[PMID: 19084416]
HUVEC	IC₅₀	0.3 μg/mL Compound: paclitaxel	Antiangiogenic activity against HUVEC cells Antiangiogenic activity against HUVEC cells	[PMID: 16384699]
HUVEC	IC₅₀	1.65 μM Compound: Paclitaxel	Antiangiogenic activity against HUVEC assessed as growth inhibition by NCI antiangiogenesis assay Antiangiogenic activity against HUVEC assessed as growth inhibition by NCI antiangiogenesis assay	[PMID: 19084416]
HUVEC	IC₅₀	5.14 μM Compound: paclitaxel	Cytotoxicity against HUVEC cells after 72 hrs by MTT assay Cytotoxicity against HUVEC cells after 72 hrs by MTT assay	[PMID: 19053781]
HUVEC	IC₅₀	7 nM Compound: Paclitaxel	Growth inhibition of HUVEC Growth inhibition of HUVEC	[PMID: 19601594]
HUVEC	IC₅₀	9.39 μM Compound: PTX	Cytotoxicity against HUVEC incubated for 48 hrs by MTT assay Cytotoxicity against HUVEC incubated for 48 hrs by MTT assay	[PMID: 30913525]
HUVEC	IC₅₀	< 0.05 μM Compound: Paclitaxel	Antiproliferative activity against human HUVEC cells assessed as cell growth inhibition measured after 48 hrs by MTS assay Antiproliferative activity against human HUVEC cells assessed as cell growth inhibition measured after 48 hrs by MTS assay	[PMID: 35737669]
HUVEC	IC₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against HUVEC after 24 hrs by MTT assay Cytotoxicity against HUVEC after 24 hrs by MTT assay	[PMID: 30387611]
HUVEC	IC₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against HUVEC after 48 hrs by MTT assay Cytotoxicity against HUVEC after 48 hrs by MTT assay	[PMID: 30387611]
HaCaT	IC₅₀	0.002 μM Compound: Taxol	Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
HaCaT	IC₅₀	0.024 μM Compound: Paclitaxel	Cytotoxicity against human HaCaT cells after 72 hrs by MTS assay Cytotoxicity against human HaCaT cells after 72 hrs by MTS assay	[PMID: 21812410]
HaCaT	IC₅₀	0.024 μM Compound: paclitaxel	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability by MTS assay	[PMID: 25760674]
HeLa	CC₅₀	0.0048 μg/mL Compound: Paclitaxel	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 27301367]
HeLa	CC₅₀	0.01 μg/mL Compound: Paclitaxel	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 15387677]
HeLa	CC₅₀	0.01 μg/mL Compound: paclitaxel	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 17500572]
HeLa	EC₅₀	0.008 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells incubated for 48 to 72 hrs by MTT assay Cytotoxicity against human HeLa cells incubated for 48 to 72 hrs by MTT assay	[PMID: 39038808]
HeLa	GI₅₀	0.0048 μg/mL Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27013391]
HeLa	GI₅₀	0.0048 μg/mL Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay	[PMID: 28103537]
HeLa	GI₅₀	0.0048 μg/mL Compound: Paclitaxel	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 28411559]
HeLa	GI₅₀	0.0048 μg/mL Compound: Paclitaxel	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 30910461]
HeLa	GI₅₀	0.0048 μg/mL Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as cell growth inhibition Cytotoxicity against human HeLa cells assessed as cell growth inhibition	[PMID: 33826327]
HeLa	GI₅₀	0.004 μg/mL Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27563398]
HeLa	GI₅₀	0.005 μg/mL Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 26920799]
HeLa	GI₅₀	0.007 μM Compound: Paclitaxel	Cytotoxic activity against human cervical adenocarcinoma-derived HeLa cell lines Cytotoxic activity against human cervical adenocarcinoma-derived HeLa cell lines	[PMID: 10406652]
HeLa	GI₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31945642]
HeLa	GI₅₀	0.02 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 25827522]
HeLa	GI₅₀	0.02 μM Compound: Taxol	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20538462]
HeLa	GI₅₀	0.02 μM Compound: taxol	Cytotoxicity against human HeLa cells after 72 hrs by MTT colorimetric assay Cytotoxicity against human HeLa cells after 72 hrs by MTT colorimetric assay	[PMID: 19081249]
HeLa	GI₅₀	0.023 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 26994690]
HeLa	GI₅₀	0.025 μM Compound: Paclitaxel	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 25264072]
HeLa	GI₅₀	0.025 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay	[PMID: 25462234]
HeLa	GI₅₀	0.025 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27209232]
HeLa	GI₅₀	0.033 nM Compound: Paclitaxel	Growth inhibition of human HeLa cells Growth inhibition of human HeLa cells	[PMID: 21986585]
HeLa	GI₅₀	0.039 μM Compound: Paclitaxel	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 27964883]
HeLa	GI₅₀	0.08 μg/mL Compound: Paclitaxel	Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay	[PMID: 27688192]
HeLa	GI₅₀	0.14 μg/mL Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26642768]
HeLa	GI₅₀	2.34 nM Compound: Taxol	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay	[PMID: 27224875]
HeLa	GI₅₀	2.82 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by MTT assay	[PMID: 21889341]
HeLa	GI₅₀	3.2 nM Compound: Paclitaxel	Growth inhibition of human HeLa cells measured after 48 hrs by SRB assay Growth inhibition of human HeLa cells measured after 48 hrs by SRB assay	[PMID: 34110822]
HeLa	GI₅₀	3.206 nM Compound: 1, Taxol	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 24405702]
HeLa	GI₅₀	< 0.01 μM Compound: Paciltaxel	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31546197]
HeLa	GI₅₀	< 0.016 μM Compound: Paciltaxel	Antiproliferative activity against human HeLa cells by SRB assay Antiproliferative activity against human HeLa cells by SRB assay	[PMID: 31546197]
HeLa	IC₅₀	0.001 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29043798]
HeLa	IC₅₀	0.001 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells measured after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HeLa cells measured after 72 hrs by sulforhodamine B assay	[PMID: 31465222]
HeLa	IC₅₀	0.001 μM Compound: Paclitaxol	Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay	[PMID: 19091579]
HeLa	IC₅₀	0.0012 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 23855953]
HeLa	IC₅₀	0.0014 μM Compound: 18; taxol	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 dye based assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 dye based assay	[PMID: 28240909]
HeLa	IC₅₀	0.0014 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by WST-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by WST-8 assay	[PMID: 31967821]
HeLa	IC₅₀	0.0017 μM Compound: paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay	[PMID: 23855338]
HeLa	IC₅₀	0.003 μM Compound: PTX	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29306206]
HeLa	IC₅₀	0.003 μM Compound: Taxol	Anticancer activity against human HeLa cells by MTT assay Anticancer activity against human HeLa cells by MTT assay	[PMID: 33316408]
HeLa	IC₅₀	0.0033 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 68 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 68 hrs by MTT assay	[PMID: 31404864]
HeLa	IC₅₀	0.0035 μM Compound: paclitaxel	Growth inhibition of human HeLa cells by sulforhodamine B assay Growth inhibition of human HeLa cells by sulforhodamine B assay	[PMID: 25685941]
HeLa	IC₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32633512]
HeLa	IC₅₀	0.005 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 31120251]
HeLa	IC₅₀	0.006 μM Compound: PTX	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37201429]
HeLa	IC₅₀	0.006 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells Antiproliferative activity against human HeLa cells	[PMID: 33421712]
HeLa	IC₅₀	0.006 μM Compound: Taxol	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 36270090]
HeLa	IC₅₀	0.007 μM Compound: 2	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 37856840]
HeLa	IC₅₀	0.008 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25462279]
HeLa	IC₅₀	0.008 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human HeLa assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34175541]
HeLa	IC₅₀	0.008 μM Compound: Taxol	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 16539377]
HeLa	IC₅₀	0.008 μM Compound: taxol	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 17915851]
HeLa	IC₅₀	0.0089 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay	[PMID: 20732809]
HeLa	IC₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25647428]
HeLa	IC₅₀	0.018 μM Compound: PTX	Growth inhibition of human HeLa cells incubated for 72 hrs by MTT assay Growth inhibition of human HeLa cells incubated for 72 hrs by MTT assay	[PMID: 27172319]
HeLa	IC₅₀	0.02 μM Compound: PTX	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38280356]
HeLa	IC₅₀	0.02 μM Compound: PTX	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 38430854]
HeLa	IC₅₀	0.02 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 48 to 72 hrs by WAT-1 assay Cytotoxicity against human HeLa cells after 48 to 72 hrs by WAT-1 assay	[PMID: 21126027]
HeLa	IC₅₀	0.023 μM Compound: Taxol	Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay	[PMID: 29475587]
HeLa	IC₅₀	0.02 μM Compound: taxol	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 17911017]
HeLa	IC₅₀	0.034 μM Compound: Taxol	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
HeLa	IC₅₀	0.036 μM Compound: Taxol	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27979593]
HeLa	IC₅₀	0.039 μM Compound: PTX	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35447432]
HeLa	IC₅₀	0.041 μM Compound: PTX	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 32650183]
HeLa	IC₅₀	0.046 μM Compound: Taxol	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30212198]
HeLa	IC₅₀	0.05 μM Compound: PTX	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 35213164]
HeLa	IC₅₀	0.07 μM Compound: taxol	Cytotoxicity against human HeLa after 48 hrs by SRB assay Cytotoxicity against human HeLa after 48 hrs by SRB assay	[PMID: 21044847]
HeLa	IC₅₀	0.099 μM Compound: PXT	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26638041]
HeLa	IC₅₀	0.1 μg/mL Compound: Taxol	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 26351042]
HeLa	IC₅₀	0.23 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells by CCK8 assay Antiproliferative activity against human HeLa cells by CCK8 assay	[PMID: 34922028]
HeLa	IC₅₀	0.29 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
HeLa	IC₅₀	0.38 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 25959813]
HeLa	IC₅₀	0.38 μg/mL Compound: Taxol	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 22989532]
HeLa	IC₅₀	0.41 μM Compound: Taxol	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25091926]
HeLa	IC₅₀	0.47 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cell line Antiproliferative activity against human HeLa cell line	[PMID: 16793260]
HeLa	IC₅₀	0.47 μg/mL Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 48 hrs by MTT method Cytotoxicity against human HeLa cells after 48 hrs by MTT method	[PMID: 24657569]
HeLa	IC₅₀	0.6 μM Compound: paclitaxel	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 21973054]
HeLa	IC₅₀	0.61 μg/mL Compound: paclitaxel	Cytotoxicity against human HeLa cells after 44 hrs by MTT assay Cytotoxicity against human HeLa cells after 44 hrs by MTT assay	[PMID: 19928884]
HeLa	IC₅₀	0.7 nM Compound: Paclitaxel, Taxol	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 25047938]
HeLa	IC₅₀	0.89 μM Compound: Taxol	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 22483090]
HeLa	IC₅₀	0.9 nM Compound: PT	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
HeLa	IC₅₀	1 nM Compound: 1a; PTX	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability by MTT assay	[PMID: 37490800]
HeLa	IC₅₀	1 nM Compound: paclitaxel	Cytotoxicity against human HeLa cells after 96 hrs by MTT assay Cytotoxicity against human HeLa cells after 96 hrs by MTT assay	[PMID: 23176628]
HeLa	IC₅₀	1 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as growth inhibition Cytotoxicity against human HeLa cells assessed as growth inhibition	[PMID: 23103097]
HeLa	IC₅₀	1.1 nM Compound: 1	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28624703]
HeLa	IC₅₀	1.1 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38294341]
HeLa	IC₅₀	1.18 μg/mL Compound: Paclitaxel	Anticancer activity against human HeLa cells after 24 hrs by MTT assay Anticancer activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 25305717]
HeLa	IC₅₀	1.2 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 21800839]
HeLa	IC₅₀	1.21 nM Compound: Taxol	Antiproliferative activity against human HeLa cells Antiproliferative activity against human HeLa cells	[PMID: 24890652]
HeLa	IC₅₀	1.3 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation	[PMID: 25466201]
HeLa	IC₅₀	1.38 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells Antiproliferative activity against human HeLa cells	[PMID: 21786793]
HeLa	IC₅₀	1.4 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 72 hrs by MTS assay Cytotoxicity against human HeLa cells after 72 hrs by MTS assay	[PMID: 24087857]
HeLa	IC₅₀	1.5 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 28433513]
HeLa	IC₅₀	1.5 nM Compound: paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 18461997]
HeLa	IC₅₀	1.6 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells by sulforhodamine B assay Antiproliferative activity against human HeLa cells by sulforhodamine B assay	[PMID: 20973488]
HeLa	IC₅₀	1.6 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 23332369]
HeLa	IC₅₀	1.6 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells by SRB assay Antiproliferative activity against human HeLa cells by SRB assay	[PMID: 29655610]
HeLa	IC₅₀	1.6 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells assessed as decrease in cell growth measured after 48 hrs by SRB method Antiproliferative activity against human HeLa cells assessed as decrease in cell growth measured after 48 hrs by SRB method	[PMID: 33310545]
HeLa	IC₅₀	1.6 nM Compound: paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 23895532]
HeLa	IC₅₀	1.7 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 27748595]
HeLa	IC₅₀	1.9 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 25882519]
HeLa	IC₅₀	10 nM Compound: Taxol	Antiproliferative activity against human HeLa cells expressing beta3-tubulin Antiproliferative activity against human HeLa cells expressing beta3-tubulin	[PMID: 24890652]
HeLa	IC₅₀	10.9 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 24487193]
HeLa	IC₅₀	10.9 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 24 hrs by crystal violet staining-based assay Antiproliferative activity against human HeLa cells after 24 hrs by crystal violet staining-based assay	[PMID: 29407986]
HeLa	IC₅₀	100 nM Compound: Taxol	Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay	[PMID: 21296467]
HeLa	IC₅₀	11.2 nM Compound: paclitaxel	Cytotoxicity against human HeLa cells expressing class 3 tubulin after 96 hrs by MTT assay Cytotoxicity against human HeLa cells expressing class 3 tubulin after 96 hrs by MTT assay	[PMID: 23176628]
HeLa	IC₅₀	11.2 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells harboring class 3 beta tubulin mutant assessed as growth inhibition Cytotoxicity against human HeLa cells harboring class 3 beta tubulin mutant assessed as growth inhibition	[PMID: 23103097]
HeLa	IC₅₀	12 μM Compound: Paclitaxel	Cytotoxic activity against human HeLa cells Cytotoxic activity against human HeLa cells	[PMID: 24195466]
HeLa	IC₅₀	12.62 nM Compound: PTX	Cytotoxicity against human HeLa cells assessed as cell viability measured after 72 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability measured after 72 hrs by MTS assay	[PMID: 27311893]
HeLa	IC₅₀	12.95 μM Compound: Taxol	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
HeLa	IC₅₀	13.2 nM Compound: PTX	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth pre-treated with compound for 3 hrs followed by 620/25 nm red light irradiation for 30 mins measured after 72 hrs by CCK-8 assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth pre-treated with compound for 3 hrs followed by 620/25 nm red light irradiation for 30 mins measured after 72 hrs by CCK-8 assay	[PMID: 37290494]
HeLa	IC₅₀	1375 nM Compound: paclitaxel	Cytotoxicity against paclitaxel-resistant human HeLa cells after 48 hrs by MTT assay Cytotoxicity against paclitaxel-resistant human HeLa cells after 48 hrs by MTT assay	[PMID: 23356786]
HeLa	IC₅₀	16 nM Compound: paclitaxel	Growth inhibition of human HeLa cells overexpressing beta-3 after 96 hrs incubation by sulforhodamine B technique Growth inhibition of human HeLa cells overexpressing beta-3 after 96 hrs incubation by sulforhodamine B technique	[PMID: 24900865]
HeLa	IC₅₀	16 μM Compound: Paclitaxel	Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay	[PMID: 27894589]
HeLa	IC₅₀	18.9 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 48 hrs by Celltiter-Glo luminescent cell viability assay Cytotoxicity against human HeLa cells after 48 hrs by Celltiter-Glo luminescent cell viability assay	[PMID: 26985296]
HeLa	IC₅₀	19.31 μM Compound: Taxol	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C6MD00234J
HeLa	IC₅₀	19.8 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36621138]
HeLa	IC₅₀	19.87 nM Compound: Paclitaxel	Anti-cancer activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by WST-1 assay Anti-cancer activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by WST-1 assay	[PMID: 27317645]
HeLa	IC₅₀	190 nM Compound: paclitaxel	Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay	[PMID: 20180542]
HeLa	IC₅₀	2.29 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay	[PMID: 26602827]
HeLa	IC₅₀	2.5 nM Compound: paclitaxel	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 24422592]
HeLa	IC₅₀	2.6 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21446699]
HeLa	IC₅₀	2.8 nM Compound: PTX	Antiproliferative activity against wild type human HeLa cells assessed as inhibition of cell growth by SRB assay Antiproliferative activity against wild type human HeLa cells assessed as inhibition of cell growth by SRB assay	[PMID: 36889150]
HeLa	IC₅₀	2.8 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HeLa cells after 72 hrs by sulforhodamine B assay	[PMID: 30098869]
HeLa	IC₅₀	2.8 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 30297118]
HeLa	IC₅₀	2.8 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HeLa	IC₅₀	2.8 nM Compound: paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 27213719]
HeLa	IC₅₀	2.9 μM Compound: taxol	Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 26316467]
HeLa	IC₅₀	2.93 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 22959518]
HeLa	IC₅₀	20 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38294341]
HeLa	IC₅₀	21.1 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin after 48 hrs by SRB assay	[PMID: 28433513]
HeLa	IC₅₀	23.29 nM Compound: PTX	Cytotoxicity against human HeLa cells assessed as cell viability measured after 48 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability measured after 48 hrs by MTS assay	[PMID: 27311893]
HeLa	IC₅₀	24 nM Compound: PTX	Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell growth by SRB assay Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell growth by SRB assay	[PMID: 36889150]
HeLa	IC₅₀	24 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay	[PMID: 30297118]
HeLa	IC₅₀	24 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HeLa	IC₅₀	24 nM Compound: paclitaxel	Antiproliferative activity against multidrug resistant human HeLa cells expressing wild type beta3 tubulin after 48 hrs by SRB assay Antiproliferative activity against multidrug resistant human HeLa cells expressing wild type beta3 tubulin after 48 hrs by SRB assay	[PMID: 27213719]
HeLa	IC₅₀	28.45 μM Compound: Taxol	Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
HeLa	IC₅₀	28.6 nM Compound: PTX	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33280896]
HeLa	IC₅₀	28.6 nM Compound: PTX	Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
HeLa	IC₅₀	3 nM Compound: PT	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs in presence of verapamil by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs in presence of verapamil by MTT assay	[PMID: 38959729]
HeLa	IC₅₀	3 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 28598633]
HeLa	IC₅₀	3 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32339854]
HeLa	IC₅₀	3.01 nM Compound: Taxol	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 26697718]
HeLa	IC₅₀	3.11 μM Compound: paclitaxel	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 18701281]
HeLa	IC₅₀	3.2 nM Compound: Taxol	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 25819096]
HeLa	IC₅₀	30 nM Compound: paclitaxel	Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay	[PMID: 20180542]
HeLa	IC₅₀	32.9 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells overexpressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HeLa cells overexpressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay	[PMID: 25882519]
HeLa	IC₅₀	35 nM Compound: 1a; PTX	Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell viability by MTT assay	[PMID: 37490800]
HeLa	IC₅₀	4.3 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as growth inhibition Cytotoxicity against human HeLa cells assessed as growth inhibition	[PMID: 34949088]
HeLa	IC₅₀	4.6 nM Compound: 1a	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 29359935]
HeLa	IC₅₀	45.78 μM Compound: Paclitaxel	Antiproliferative activity against human HeLa after 24 hrs by MTT assay Antiproliferative activity against human HeLa after 24 hrs by MTT assay	[PMID: 30826188]
HeLa	IC₅₀	5 nM Compound: PTX	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23214452]
HeLa	IC₅₀	5 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as reduction in cell viability Cytotoxicity against human HeLa cells assessed as reduction in cell viability	[PMID: 25105722]
HeLa	IC₅₀	5.3 nM Compound: paclitaxel	Growth inhibition of wild type human HeLa cells after 96 hrs incubation by sulforhodamine B technique Growth inhibition of wild type human HeLa cells after 96 hrs incubation by sulforhodamine B technique	[PMID: 24900865]
HeLa	IC₅₀	5.3 μM Compound: Paclitaxel	Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay	[PMID: 27894589]
HeLa	IC₅₀	5.6 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 17764148]
HeLa	IC₅₀	6.2 nM Compound: PT	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs in absence of verapamil by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs in absence of verapamil by MTT assay	[PMID: 38959729]
HeLa	IC₅₀	6.3 nM Compound: paclitaxel	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 23356786]
HeLa	IC₅₀	6.4 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 27434426]
HeLa	IC₅₀	6.42 μM Compound: Taxol	Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay	[PMID: 29172082]
HeLa	IC₅₀	6.62 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 21514015]
HeLa	IC₅₀	7.7 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells expressing tubulin 3beta by sulforhodamine B assay Antiproliferative activity against human HeLa cells expressing tubulin 3beta by sulforhodamine B assay	[PMID: 20973488]
HeLa	IC₅₀	7.7 nM Compound: Paclitaxel	Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin by SRB assay Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin by SRB assay	[PMID: 29655610]
HeLa	IC₅₀	7.7 nM Compound: Paclitaxel, Taxol	Cytotoxicity against human HeLa cells transfected with wild-type tubulin beta3 by MTT assay Cytotoxicity against human HeLa cells transfected with wild-type tubulin beta3 by MTT assay	[PMID: 25047938]
HeLa	IC₅₀	7.7 nM Compound: paclitaxel	Inhibition of beta3 tubulin overexpressed in human HeLa cells after 48 hrs by SRB assay Inhibition of beta3 tubulin overexpressed in human HeLa cells after 48 hrs by SRB assay	[PMID: 23895532]
HeLa	IC₅₀	8.21 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28340411]
HeLa	IC₅₀	8 ng/mL Compound: Paclitaxel	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24387243]
HeLa	IC₅₀	9.05 nM Compound: Paclitaxel	Antiproliferative activity against beta3-tubulin overexpressing human HeLa cells Antiproliferative activity against beta3-tubulin overexpressing human HeLa cells	[PMID: 21786793]
HeLa	IC₅₀	9.1 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells expressing beta3-tubulin containing alanine residue at 227 after 72 hrs by MTS assay Cytotoxicity against human HeLa cells expressing beta3-tubulin containing alanine residue at 227 after 72 hrs by MTS assay	[PMID: 24087857]
HeLa	IC₅₀	9.2 nM Compound: Paclitaxel	Inhibition of beta-3 tubulin (unknown origin) transfected in human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay Inhibition of beta-3 tubulin (unknown origin) transfected in human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 23332369]
HeLa	IC₅₀	96 nM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24929344]
HeLa	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 27704807]
HeLa	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 31390200]
HeLa	IC₅₀	< 0.01 μM Compound: Taxol	Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
HeLa	IC₅₀	< 6.25 x 10^-3 μM Compound: Taxol	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34883453]
HeLa	IC₅₀	> 3 μg/mL Compound: paclitaxel	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 18553923]
HeLa	IC₅₀	> 400 μg/mL Compound: Paclitaxel	Antitumour activity against human HeLa cells assessed as reduction in cell viability by MTT assay Antitumour activity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 31607609]
HeLa S3	IC₅₀	0.013 μM Compound: Paclitaxel	Antiproliferative activity against human HeLaS3 cells after 72 hrs by MTT assay Antiproliferative activity against human HeLaS3 cells after 72 hrs by MTT assay	[PMID: 29803003]
HeLa S3	IC₅₀	< 40 μM Compound: Paclitaxel	Antiproliferative activity against drug-sensitive human HeLaS3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against drug-sensitive human HeLaS3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 35751979]
Hep 3B2	GI₅₀	0.0004 μM Compound: Paclitaxel	Anticancer activity against human Hep3B cells after 3 days by SRB assay Anticancer activity against human Hep3B cells after 3 days by SRB assay	[PMID: 20735140]
Hep 3B2	GI₅₀	16.17 μM Compound: Paclitaxel	Anticancer activity against vincristine-resistant human Hep3B cells after 3 days by SRB assay Anticancer activity against vincristine-resistant human Hep3B cells after 3 days by SRB assay	[PMID: 20735140]
Hep 3B2	IC₅₀	0.0054 μM Compound: paclitaxel	Cytotoxicity against human Hep3B cells Cytotoxicity against human Hep3B cells	[PMID: 17113288]
Hep 3B2	IC₅₀	0.02 μM Compound: Paclitaxel	Cytotoxicity activity against human Hep3B cells assessed as growth inhibition measured after 48 hrs by MTT assay Cytotoxicity activity against human Hep3B cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 27627130]
Hep 3B2	IC₅₀	0.031 μM Compound: Paclitaxel	Cytotoxicity against human Hep3B cells after 48 hrs by SRB assay Cytotoxicity against human Hep3B cells after 48 hrs by SRB assay	[PMID: 15043402]
Hep 3B2	IC₅₀	0.08 μg/mL Compound: Taxol	Cytotoxicity against human Hep3B cells Cytotoxicity against human Hep3B cells	[PMID: 16038548]
Hep 3B2	IC₅₀	0.13 μM Compound: paclitaxel	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 18419154]
Hep 3B2	IC₅₀	0.73 μM Compound: Pac	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 28262527]
Hep 3B2	IC₅₀	1.6 x 10^-5 μM Compound: Paclitaxel	Cytotoxicity against human Hep3B2 cells after 72 hrs by MTS assay Cytotoxicity against human Hep3B2 cells after 72 hrs by MTS assay	[PMID: 21812410]
Hep 3B2	IC₅₀	1.6 x 10^-5 μM Compound: paclitaxel	Cytotoxicity against human Hep3B2 cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human Hep3B2 cells assessed as reduction in cell viability by MTS assay	[PMID: 25760674]
Hep 3B2	IC₅₀	16 μg/mL Compound: Paclitaxel	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay	[PMID: 39052090]
Hep 3B2	IC₅₀	7.26 μM Compound: paclitaxel	Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay	[PMID: 19053781]
HepG2	CC₅₀	0.12 μM Compound: PTX	Cytotoxicity against human HepG2 cells by MTS assay Cytotoxicity against human HepG2 cells by MTS assay	[PMID: 29269214]
HepG2	ED₅₀	> 100 nM Compound: Paclitaxel	Antiproliferative activity against human HepG2 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human HepG2 cells after 3 days by sulforhodamine B assay	[PMID: 21296579]
HepG2	GI₅₀	0.059 μM Compound: taxol	Cytotoxicity against human HepG2 cells by SRB assay Cytotoxicity against human HepG2 cells by SRB assay	[PMID: 19476336]
HepG2	GI₅₀	0.18 μM Compound: paclitaxel	Growth inhibition of human HepG2 cells Growth inhibition of human HepG2 cells	[PMID: 23167614]
HepG2	GI₅₀	1 nM Compound: paclitaxel	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 19195901]
HepG2	GI₅₀	< 0.01 μM Compound: Paciltaxel	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31546197]
HepG2	GI₅₀	< 0.016 μM Compound: Paciltaxel	Antiproliferative activity against human HepG2 cells by SRB assay Antiproliferative activity against human HepG2 cells by SRB assay	[PMID: 31546197]
HepG2	IC₅₀	0.00076 μM Compound: Taxol	Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 32546298]
HepG2	IC₅₀	0.002 μM Compound: Paclitaxel	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39163776]
HepG2	IC₅₀	0.0044 μM Compound: paclitaxel	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 22506620]
HepG2	IC₅₀	0.006 μM Compound: Paclitaxel	Cytotoxicity activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay Cytotoxicity activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 27627130]
HepG2	IC₅₀	0.006 μM Compound: Taxol	Cytotoxicity against human HepG2 cells after 72 hrs by spectrophotometry Cytotoxicity against human HepG2 cells after 72 hrs by spectrophotometry	[PMID: 23708235]
HepG2	IC₅₀	0.0064 μM Compound: Taxol	Cytotoxicity against human HepG2 cells assessed as growth inhibition by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition by MTT assay	[PMID: 24684840]
HepG2	IC₅₀	0.007 μM Compound: Taxol	Cytotoxicity against human HepG2 cells after 24 to 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 to 48 hrs by MTT assay	[PMID: 22222040]
HepG2	IC₅₀	0.007 μM Compound: paclitaxel	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 18313307]
HepG2	IC₅₀	0.0076 μM Compound: Taxol	Growth inhibition of human HepG2 cells after 96 hrs by MTT assay Growth inhibition of human HepG2 cells after 96 hrs by MTT assay	[PMID: 28737396]
HepG2	IC₅₀	0.008 μg/mL Compound: Paclitaxel	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 17950495]
HepG2	IC₅₀	0.009 μM Compound: 6	Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25682561]
HepG2	IC₅₀	0.009 μM Compound: Paclitaxel	Antiproliferative activity against human HepG2 cells after 24 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells after 24 hrs by CCK8 assay	[PMID: 30392953]
HepG2	IC₅₀	0.009 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay	[PMID: 31901744]
HepG2	IC₅₀	0.009 μM Compound: taxol	Cytotoxicity against human HEPG2 cells after 24 hrs by MTT assay Cytotoxicity against human HEPG2 cells after 24 hrs by MTT assay	[PMID: 18586491]
HepG2	IC₅₀	0.0101 μM Compound: PTX	Growth inhibition of human HepG2 cells incubated for 72 hrs by MTT assay Growth inhibition of human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 27172319]
HepG2	IC₅₀	0.0102 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 29279273]
HepG2	IC₅₀	0.013 μM Compound: Taxol	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay	[PMID: 35255412]
HepG2	IC₅₀	0.016 μg/mL Compound: Paclitaxel	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay	[PMID: 39052090]
HepG2	IC₅₀	0.02 μM Compound: Taxol	Growth inhibition of human HepG2 cells incubated for 3 days by SRB assay Growth inhibition of human HepG2 cells incubated for 3 days by SRB assay	[PMID: 28625363]
HepG2	IC₅₀	0.02171 μM Compound: Paclitaxel	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 27017265]
HepG2	IC₅₀	0.028 μM Compound: TAX, Taxol	Antiproliferative activity against human HepG2 cells after 48 hrs by SRB method Antiproliferative activity against human HepG2 cells after 48 hrs by SRB method	[PMID: 25061803]
HepG2	IC₅₀	0.045 μM Compound: Taxol	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25728023]
HepG2	IC₅₀	0.05 μM Compound: Taxol	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22153338]
HepG2	IC₅₀	0.054 μM Compound: Taxol	Cytotoxicity against human HepG2 cells after 72 hrs by crystal violet staining based microplate reader analysis Cytotoxicity against human HepG2 cells after 72 hrs by crystal violet staining based microplate reader analysis	[PMID: 23153397]
HepG2	IC₅₀	0.05 μg/mL Compound: taxol	Growth inhibition of human HepG2 cells Growth inhibition of human HepG2 cells	[PMID: 17358082]
HepG2	IC₅₀	0.06 μM Compound: PTX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 35213164]
HepG2	IC₅₀	0.06 μM Compound: PTX	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HepG2	IC₅₀	0.06 μM Compound: Paciitaxel	Cytotoxicity against human HepG2 cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by CCK8 assay	[PMID: 38493728]
HepG2	IC₅₀	0.064 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 37336771]
HepG2	IC₅₀	0.06727 μM Compound: Paclitaxel	Antiproliferative against human HepG2 cells after 48 hrs by MTT assay Antiproliferative against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24996136]
HepG2	IC₅₀	0.11 μM Compound: taxol	Cytotoxicity against human HepG2 after 48 hrs by SRB assay Cytotoxicity against human HepG2 after 48 hrs by SRB assay	[PMID: 21044847]
HepG2	IC₅₀	0.18 μM Compound: PTX	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells	[PMID: 31200238]
HepG2	IC₅₀	0.18 μg/mL Compound: Taxol	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 16038548]
HepG2	IC₅₀	0.19 nM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay	[PMID: 24745968]
HepG2	IC₅₀	0.19 nM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 3 days by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 3 days by MTT assay	[PMID: 25442315]
HepG2	IC₅₀	0.19 μM Compound: Paclitaxel	Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34303874]
HepG2	IC₅₀	0.2 nM Compound: PTX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 10 uM chloramphenicol by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 10 uM chloramphenicol by MTT assay	[PMID: 34097831]
HepG2	IC₅₀	0.2 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27329938]
HepG2	IC₅₀	0.22 μM Compound: Paclitaxel; Taxol	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 35551039]
HepG2	IC₅₀	0.3 μM Compound: Pac	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 28262527]
HepG2	IC₅₀	0.3 μM Compound: Taxol	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 16539377]
HepG2	IC₅₀	0.3 μM Compound: taxol	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 17915851]
HepG2	IC₅₀	0.55 μM Compound: Taxol	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
HepG2	IC₅₀	0.59 μg/mL Compound: Paclitaxel	Cytotoxicity against human HepG2 cells after 48 hrs by MTT method Cytotoxicity against human HepG2 cells after 48 hrs by MTT method	[PMID: 24657569]
HepG2	IC₅₀	0.62 μM Compound: Taxol	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 18701301]
HepG2	IC₅₀	0.69 μg/mL Compound: paclitaxel	Growth inhibition of HepG2 cells Growth inhibition of HepG2 cells	[PMID: 17547458]
HepG2	IC₅₀	0.82 μM Compound: taxol	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 17911017]
HepG2	IC₅₀	0.99 μM Compound: Taxol	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25091926]
HepG2	IC₅₀	1 nM Compound: PTX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 1 uM chloramphenicol by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 1 uM chloramphenicol by MTT assay	[PMID: 34097831]
HepG2	IC₅₀	1.06 x 10^-8 mg/mL Compound: Taxol	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 26920798]
HepG2	IC₅₀	1.2 x 10^-2 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 27441892]
HepG2	IC₅₀	1.217 μM Compound: 1	Cytotoxicity against human HepG2 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells incubated for 48 hrs by CCK-8 assay	[PMID: 26448037]
HepG2	IC₅₀	1.9 nM Compound: Taxol	Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 31050424]
HepG2	IC₅₀	10 μM Compound: PXL	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 27707623]
HepG2	IC₅₀	10.1 nM Compound: Taxol	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth by secondary round CCK8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth by secondary round CCK8 assay	[PMID: 34508844]
HepG2	IC₅₀	10.3 μM Compound: Taxol	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30579802]
HepG2	IC₅₀	10.32 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 21514015]
HepG2	IC₅₀	10.32 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay	[PMID: 27769031]
HepG2	IC₅₀	10.32 μM Compound: Paclitaxol	Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 22901410]
HepG2	IC₅₀	10.32 μM Compound: Paclitaxol	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 22921966]
HepG2	IC₅₀	101.65 μg/mL Compound: Paclitaxel	Antitumour activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antitumour activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31607609]
HepG2	IC₅₀	12.6 nM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells assessed as growth inhibition Cytotoxicity against human HepG2 cells assessed as growth inhibition	[PMID: 33279291]
HepG2	IC₅₀	15.6 μM Compound: Taxol	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25408835]
HepG2	IC₅₀	15.6 μM Compound: Taxol	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 28197320]
HepG2	IC₅₀	16.6 nM Compound: PTX	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
HepG2	IC₅₀	2.5 nM Compound: Paclitaxel	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36621138]
HepG2	IC₅₀	2.7 μM Compound: paclitaxel	Cytotoxicity against human HepG2 cells after 48 hrs by trypan blue exclusion method Cytotoxicity against human HepG2 cells after 48 hrs by trypan blue exclusion method	[PMID: 25211032]
HepG2	IC₅₀	2037 nM Compound: PTX	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT method Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT method	[PMID: 25025991]
HepG2	IC₅₀	220 nM Compound: PTX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34097831]
HepG2	IC₅₀	2600 nM Compound: PTX	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26132075]
HepG2	IC₅₀	2600 nM Compound: Paclitaxel	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 38107170]
HepG2	IC₅₀	2660 nM Compound: PTX	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	[PMID: 29730191]
HepG2	IC₅₀	3.9 μM Compound: Paclitaxel	Antiproliferative activity against human HepG2 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay	[PMID: 32631535]
HepG2	IC₅₀	30.7 μM Compound: Taxol	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22370266]
HepG2	IC₅₀	30.74 μM Compound: Taxol	Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 21664827]
HepG2	IC₅₀	38 nM Compound: taxol	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
HepG2	IC₅₀	4.15 μM Compound: paclitaxel	Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay	[PMID: 18313307]
HepG2	IC₅₀	4.3 μg/mL Compound: Taxol	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 36325400]
HepG2	IC₅₀	4.4 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21928797]
HepG2	IC₅₀	4.4 x 10^-4 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
HepG2	IC₅₀	4.6 x 10^-3 μM Compound: paclitaxel	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 24960143]
HepG2	IC₅₀	4.68 x 10^-2 μM Compound: paclitaxel	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 18419154]
HepG2	IC₅₀	5.9 x 10^-3 μM Compound: paclitaxel	Growth inhibition of human HepG2 cells after 72 hrs by SRB assay Growth inhibition of human HepG2 cells after 72 hrs by SRB assay	[PMID: 18512984]
HepG2	IC₅₀	592 μM Compound: paclitaxel	Resistant ratio, IC50 for multidrug resistant human HepG2 cells to IC50 for human HepG2 cells Resistant ratio, IC50 for multidrug resistant human HepG2 cells to IC50 for human HepG2 cells	[PMID: 18313307]
HepG2	IC₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 28530828]
HepG2	IC₅₀	6.7 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27748595]
HepG2	IC₅₀	6.9 μM Compound: Taxol	Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay	[PMID: 16499322]
HepG2	IC₅₀	6.9 μg/mL Compound: 2	Cytotoxicity againt human HepG2 cells Cytotoxicity againt human HepG2 cells	[PMID: 17239597]
HepG2	IC₅₀	61.8 μM Compound: Taxol	Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
HepG2	IC₅₀	660 ng/mL Compound: Paclitaxel	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 32731188]
HepG2	IC₅₀	7.87 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric based assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric based assay	[PMID: 38107170]
HepG2	IC₅₀	8.1 mM Compound: taxol	Growth inhibition of human HepG2 cells Growth inhibition of human HepG2 cells	[PMID: 17595134]
HepG2	IC₅₀	8.1 μM Compound: Paclitaxel	Growth inhibition of human HepG2 cells Growth inhibition of human HepG2 cells	[PMID: 17490878]
HepG2	IC₅₀	8.1 μM Compound: Taxol	Cytotoxicity against human Hep G2 cells Cytotoxicity against human Hep G2 cells	[PMID: 17067155]
HepG2	IC₅₀	8.1 μM Compound: taxol	Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
HepG2	IC₅₀	8.1 μM Compound: taxol	Cytotoxicity against human Hep G2 by WST-8 assay Cytotoxicity against human Hep G2 by WST-8 assay	[PMID: 16933868]
HepG2	IC₅₀	8.4 μM Compound: PTX	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
HepG2	IC₅₀	84 nM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24929344]
HepG2	IC₅₀	9.49 μM Compound: Taxol	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 16724842]
HepG2	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
HepG2	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 31390200]
HepG2	IC₅₀	< 0.08 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 20627721]
HepG2	IC₅₀	< 0.08 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 20716468]
HepG2	IC₅₀	< 0.08 μM Compound: Paclitaxel	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21875764]
HepG2	IC₅₀	> 100 μM Compound: Paclitaxel	Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
Hs-578T	GI₅₀	0.003 μM Compound: Paclitaxel	Cytotoxicity against human Hs578T cells by sulforhodamine B assay Cytotoxicity against human Hs578T cells by sulforhodamine B assay	[PMID: 21839640]
Hs-578T	GI₅₀	0.003 μM Compound: paclitaxel	Cytotoxicity against human HS578T cells Cytotoxicity against human HS578T cells	[PMID: 17696332]
Hs-578T	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
Hs-578T	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human Hs-578T cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human Hs-578T cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
Hs-578T	IC₅₀	14.8 nM Compound: Pac	Inhibition of human Hs-578T cell spheroids incubated for 7 days by luciferase based assay Inhibition of human Hs-578T cell spheroids incubated for 7 days by luciferase based assay	[PMID: 36780832]
Huh-7	GI₅₀	206.7 nM Compound: 1, Taxol	Growth inhibition of human HuH7 cells by MTT assay Growth inhibition of human HuH7 cells by MTT assay	[PMID: 24405702]
Huh-7	GI₅₀	7.41 nM Compound: Taxol	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay	[PMID: 33239261]
Huh-7	IC₅₀	0.005 μM Compound: Paclitaxel	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32633512]
Huh-7	IC₅₀	0.008 μM Compound: Taxol	Antiproliferative activity against human HuH7 cells after 72 hrs by imaging analysis Antiproliferative activity against human HuH7 cells after 72 hrs by imaging analysis	[PMID: 19665384]
Huh-7	IC₅₀	0.012 μM Compound: Taxol	Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
Huh-7	IC₅₀	0.013 μM Compound: Taxol	Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
Huh-7	IC₅₀	2 nM Compound: Paclitaxel	Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32339854]
Huh-7	IC₅₀	6.75 μM Compound: Taxol	Cytotoxicity against human HuH7 cells after 72 hrs by CCK8 assay Cytotoxicity against human HuH7 cells after 72 hrs by CCK8 assay	[PMID: 27623549]
Huh-7	IC₅₀	7.35 nM Compound: PTX	Antiproliferative activity against human Huh-7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
IEC-6	EC₅₀	0.0001 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against rat IEC-6 cells incubated for 48 to 72 hrs by MTT assay Cytotoxicity against rat IEC-6 cells incubated for 48 to 72 hrs by MTT assay	[PMID: 39038808]
IGROV-1	GI₅₀	6.3 nM Compound: Paclitaxel	Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
IGROV-1	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
IGROV-1	IC₅₀	0.06 μM Compound: 3	Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs by Coulter counting analysis Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs by Coulter counting analysis	[PMID: 19833515]
IGROV-1	IC₅₀	10 ng/mL Compound: 1 (paclitaxel)	Cytotoxicity against IGROV Tumor cell line in SRB Cell viability test Cytotoxicity against IGROV Tumor cell line in SRB Cell viability test	[PMID: 10956217]
IGROV-1	IC₅₀	2.2 nM Compound: PTX	Cytotoxicity against cisplatin-resistant human IGROV1/Pt1 cells after 72 hrs by coulter counter analysis Cytotoxicity against cisplatin-resistant human IGROV1/Pt1 cells after 72 hrs by coulter counter analysis	[PMID: 23140358]
IGROV-1	IC₅₀	23 nM Compound: PTX	Cytotoxicity against human IGROV1 cells after 72 hrs by coulter counter analysis Cytotoxicity against human IGROV1 cells after 72 hrs by coulter counter analysis	[PMID: 23140358]
IMR-32	GI₅₀	0.075 μM Compound: Paclitaxel	Growth inhibition of human IMR32 cells after 48 hrs by SRB assay Growth inhibition of human IMR32 cells after 48 hrs by SRB assay	[PMID: 25264072]
IMR-32	GI₅₀	0.075 μM Compound: Paclitaxel	Antiproliferative activity against human IMR32 cells assessed as reduction in net protein increase after 48 hrs by SRB assay Antiproliferative activity against human IMR32 cells assessed as reduction in net protein increase after 48 hrs by SRB assay	[PMID: 25462234]
IMR-32	GI₅₀	0.075 μM Compound: Paclitaxel	Antiproliferative activity against human IMR32 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human IMR32 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27209232]
IMR-32	GI₅₀	0.086 μM Compound: Paclitaxel	Growth inhibition of human IMR32 cells after 48 hrs by SRB assay Growth inhibition of human IMR32 cells after 48 hrs by SRB assay	[PMID: 27964883]
IMR-32	GI₅₀	< 0.01 μM Compound: Paciltaxel	Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31546197]
IMR-32	IC₅₀	0.03 μM Compound: Paclitaxel	Cytotoxicity against Homo sapiens (human) IMR32 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) IMR32 cells after 48 hr by SRB assay	10.1007/s00044-011-9824-9
Ishikawa	IC₅₀	0.5 nM Compound: Paclitaxel	Antiproliferative activity against human Ishikawa cells assessed as reduction in cell viability Antiproliferative activity against human Ishikawa cells assessed as reduction in cell viability	[PMID: 38911148]
J774	ED₅₀	0.09 μM Compound: 2a (Taxol)	In vitro cytotoxicity against J774.2 cells after 72 hr incubation. In vitro cytotoxicity against J774.2 cells after 72 hr incubation.	10.1016/S0960-894X(01)80527-8
J774	ED₅₀	0.09 μM Compound: Taxol	Concentration that inhibits the cell division by 50% after 72 h Concentration that inhibits the cell division by 50% after 72 h	[PMID: 7910216]
J774	IC₅₀	0.015 μM Compound: Paclitaxel	Inhibitory activity of compound against murine macrophage-like (J774.2) cell proliferation Inhibitory activity of compound against murine macrophage-like (J774.2) cell proliferation	[PMID: 9379451]
J774	IC₅₀	65.6 nM Compound: Taxol	Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells	10.1016/0960-894X(95)00300-I
J774.2	ED₅₀	0.016 μM Compound: taxol	Cytotoxicity tested against J774.2 cells. Cytotoxicity tested against J774.2 cells.	10.1016/S0960-894X(97)00337-5
J774.2	ED₅₀	0.09 μM Compound: taxol	Concentration that inhibits cell division by 50% after 72 hr for J774.2 cells was determined Concentration that inhibits cell division by 50% after 72 hr for J774.2 cells was determined	[PMID: 1672157]
J774.2	IC₅₀	30.9 nM Compound: Taxol	Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells	10.1016/0960-894X(95)00300-I
J774.2	IC₅₀	332.3 nM Compound: Taxol	Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells	10.1016/0960-894X(95)00300-I
Jurkat	GI₅₀	< 0.01 μM Compound: paclitaxel	Growth inhibition of Jurkat cell Growth inhibition of Jurkat cell	[PMID: 17181155]
Jurkat	GI₅₀	> 10 μM Compound: paclitaxel	Growth inhibition of Jurkat cell overexpressing Bcl2 Growth inhibition of Jurkat cell overexpressing Bcl2	[PMID: 17181155]
Jurkat	GI₅₀	> 10 μM Compound: paclitaxel	Growth inhibition of Jurkat cell overexpressing BclXL Growth inhibition of Jurkat cell overexpressing BclXL	[PMID: 17181155]
Jurkat	IC₅₀	0.0005 μM Compound: PXT	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26638041]
Jurkat	IC₅₀	0.0045 μM Compound: Paclitaxel	Antiproliferative activity against human Jurkat cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay Antiproliferative activity against human Jurkat cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay	[PMID: 24852281]
Jurkat	IC₅₀	0.01 μM Compound: Paclitaxel	Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis	[PMID: 21126027]
Jurkat	IC₅₀	0.69 μM Compound: Paclitaxel	Cytotoxicity against human Jurkat cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay	10.1039/C4MD00573B
Jurkat	IC₅₀	< 0.01 μM Compound: Taxol	Anticancer activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
K562	EC₅₀	0.014 μM Compound: PXL	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 16870428]
K562	EC₅₀	0.054 μM Compound: Paclitaxel ; Taxol	Effective concentration required to arrest propidium iodide stained K562 cells in G2/M phase Effective concentration required to arrest propidium iodide stained K562 cells in G2/M phase	[PMID: 12852768]
K562	GI₅₀	0.004 μM Compound: Taxol	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 21115210]
K562	GI₅₀	0.01 μg/mL Compound: Paclitaxel	Growth inhibition of human K562 cells Growth inhibition of human K562 cells	[PMID: 15387677]
K562	GI₅₀	0.01 μg/mL Compound: paclitaxel	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 17500572]
K562	GI₅₀	0.1 μM Compound: PCT	Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay	[PMID: 24727464]
K562	GI₅₀	4.85 nM Compound: Taxol	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay	[PMID: 33239261]
K562	GI₅₀	6.3 nM Compound: Paclitaxel	Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
K562	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human K562 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
K562	GI₅₀	7.014 nM Compound: 1, Taxol	Growth inhibition of human K562 cells by MTT assay Growth inhibition of human K562 cells by MTT assay	[PMID: 24405702]
K562	IC₅₀	0.0033 μM Compound: Paclitaxel	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 68 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 68 hrs by MTT assay	[PMID: 31404864]
K562	IC₅₀	0.004 μM Compound: Taxol	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25091926]
K562	IC₅₀	0.0055 μM Compound: Paclitaxel	Antiproliferative activity against human K562 cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay Antiproliferative activity against human K562 cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay	[PMID: 24852281]
K562	IC₅₀	0.013 μM Compound: PTX	Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
K562	IC₅₀	0.015 μM Compound: PTX	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 38430854]
K562	IC₅₀	0.018 μg/mL Compound: Paclitaxel	Anticancer activity against human K562 cells after 24 hrs by MTT assay Anticancer activity against human K562 cells after 24 hrs by MTT assay	[PMID: 25305717]
K562	IC₅₀	0.29 μM Compound: Paclitaxel	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34671737]
K562	IC₅₀	0.35 μM Compound: Paclitaxel	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36481599]
K562	IC₅₀	0.38 μM Compound: PTX	Antiproliferative activity against human K562 cells after 24 hrs by MTT assay Antiproliferative activity against human K562 cells after 24 hrs by MTT assay	[PMID: 27491707]
K562	IC₅₀	0.41 μM Compound: Taxol	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 22483090]
K562	IC₅₀	0.41 μM Compound: Taxol	Antiproliferative activity against human K562 cells assessed as growth inhibition by MTT assay Antiproliferative activity against human K562 cells assessed as growth inhibition by MTT assay	[PMID: 23274570]
K562	IC₅₀	0.41 μM Compound: Taxol	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 23644204]
K562	IC₅₀	0.6 nM Compound: paclitaxel	Growth inhibition of human K562 cells after 72 hrs by SRB assay Growth inhibition of human K562 cells after 72 hrs by SRB assay	[PMID: 18313307]
K562	IC₅₀	0.71 nM Compound: Pac	Antiproliferative activity against human K562 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human K562 cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
K562	IC₅₀	0.71 nM Compound: Pac	Antiproliferative activity against human K562 after 48 hrs by SRB assay Antiproliferative activity against human K562 after 48 hrs by SRB assay	[PMID: 21920638]
K562	IC₅₀	0.874 μM Compound: PTX	Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37201429]
K562	IC₅₀	0.9 μM Compound: paclitaxel	Cytotoxicity against human K562 cells by MTT method Cytotoxicity against human K562 cells by MTT method	[PMID: 26287401]
K562	IC₅₀	1.16 μM Compound: Taxol	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 19359185]
K562	IC₅₀	1.16 μM Compound: Taxol	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 19815316]
K562	IC₅₀	1.16 μM Compound: Taxol	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 21067933]
K562	IC₅₀	1.16 μM Compound: Taxol	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 21342735]
K562	IC₅₀	1.26 μM Compound: Paclitaxel	Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay	10.1039/C4MD00573B
K562	IC₅₀	15.7 nM Compound: paclitaxel	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 23356786]
K562	IC₅₀	17.2 nM Compound: 1	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37544183]
K562	IC₅₀	2.4 μM Compound: paclitaxel	Cytotoxicity against human K562 cells after 48 hrs by trypan blue exclusion method Cytotoxicity against human K562 cells after 48 hrs by trypan blue exclusion method	[PMID: 25211032]
K562	IC₅₀	2.7 μM Compound: Paclitaxel	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 27748595]
K562	IC₅₀	29.6 nM Compound: Abraxane	Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay	[PMID: 36471625]
K562	IC₅₀	3 x 10^-3 μM Compound: Taxol	Cytotoxicity against human K562 cells assessed as reduction in cell viability Cytotoxicity against human K562 cells assessed as reduction in cell viability	[PMID: 32273216]
K562	IC₅₀	3.21 μM Compound: Taxol	Cytotoxicity against human K562 cells after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells after 72 hrs by CCK8 assay	[PMID: 27623549]
K562	IC₅₀	3.65 μM Compound: paclitaxel	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 18701281]
K562	IC₅₀	3.8 μM Compound: taxol	Cytotoxicity against human K562 cells after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells after 72 hrs by CCK8 assay	[PMID: 26316467]
K562	IC₅₀	4.14 μM Compound: paclitaxel	Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay	[PMID: 18313307]
K562	IC₅₀	4.9 nM Compound: Taxol	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 23806112]
K562	IC₅₀	5.1 nM Compound: Taxol	Cytotoxicity against human K562 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human K562 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
K562	IC₅₀	5.2 nM Compound: Taxol	Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 25819096]
K562	IC₅₀	5.63 μM Compound: Taxol	Cytotoxicity against multidrug-resistant human K562 cells after 48 hrs by MTT assay Cytotoxicity against multidrug-resistant human K562 cells after 48 hrs by MTT assay	[PMID: 19359185]
K562	IC₅₀	5.63 μM Compound: Taxol	Cytotoxicity against human multidrug-resistant K562 cells after 48 hrs by MTT assay Cytotoxicity against human multidrug-resistant K562 cells after 48 hrs by MTT assay	[PMID: 21342735]
K562	IC₅₀	5.8 μM Compound: PTX	Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay	[PMID: 30913525]
K562	IC₅₀	6900 μM Compound: paclitaxel	Resistant ratio, IC50 for multidrug resistant human K562 cells to IC50 for human K562 cells Resistant ratio, IC50 for multidrug resistant human K562 cells to IC50 for human K562 cells	[PMID: 18313307]
K562	IC₅₀	7 nM Compound: Taxol	Cytotoxicity against imatinib-resistant human K562 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against imatinib-resistant human K562 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
K562	IC₅₀	7.17 nM Compound: Taxol	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 26697718]
K562	IC₅₀	7.2 nM Compound: Paclitaxel	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 28598633]
K562	IC₅₀	> 100 μM Compound: Paclitaxel	Cytotoxicity against Homo sapiens (human) K562 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay	10.1007/s00044-012-0436-9
KB	EC₅₀	0.006 μM Compound: Paclitaxel	Cytotoxicity against human KB cells by sulforhodamine B assay Cytotoxicity against human KB cells by sulforhodamine B assay	[PMID: 22142543]
KB	EC₅₀	0.76 μM Compound: Paclitaxel	Cytotoxicity against multi-drug resistant variant vincristine resistant human KB cells expressing P-glycoprotein by sulforhodamine B assay Cytotoxicity against multi-drug resistant variant vincristine resistant human KB cells expressing P-glycoprotein by sulforhodamine B assay	[PMID: 22142543]
KB	EC₅₀	2 nM Compound: Paclitaxel	Cell cycle arrest in human KB cells assessed as accumulation of cells at G2/M phase after 24 hrs by propidium iodide-based FACScan Cell cycle arrest in human KB cells assessed as accumulation of cells at G2/M phase after 24 hrs by propidium iodide-based FACScan	[PMID: 21480626]
KB	EC₅₀	49 nM Compound: Paclitaxel	Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry	[PMID: 21705223]
KB	EC₅₀	49 nM Compound: paclitaxel	Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase	[PMID: 17181164]
KB	EC₅₀	49 nM Compound: paclitaxel	Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis	[PMID: 17973361]
KB	EC₅₀	49 nM Compound: paclitaxel	Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis	[PMID: 19220018]
KB	EC₅₀	49 nM Compound: paclitaxel	Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis	[PMID: 20537765]
KB	EC₅₀	< 0.005 μg/mL Compound: Paclitaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 18640035]
KB	EC₅₀	< 0.005 μg/mL Compound: Palitaxel	Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay	[PMID: 19193043]
KB	ED₅₀	0.001 μg/mL Compound: Paclitaxel	Effective dose required for inhibitory activity against KB human tumor cell line. Effective dose required for inhibitory activity against KB human tumor cell line.	[PMID: 12852747]
KB	ED₅₀	0.001 μg/mL Compound: paclitaxel	Cytotoxicity against human KB cells after 3 days by SRB assay Cytotoxicity against human KB cells after 3 days by SRB assay	[PMID: 14640511]
KB	ED₅₀	0.002 μg/mL Compound: 1	Cytotoxicity against human KB cells by sulforhodamine B assay Cytotoxicity against human KB cells by sulforhodamine B assay	[PMID: 17643301]
KB	ED₅₀	0.007 μM Compound: paclitaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 20738103]
KB	ED₅₀	0.023 μM Compound: 1	Growth inhibition of human KB cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test Growth inhibition of human KB cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test	[PMID: 19161316]
KB	ED₅₀	0.4 nM Compound: paclitaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 15043407]
KB	ED₅₀	1.2 x 10^-3 μg/mL Compound: 1	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 7264680]
KB	ED₅₀	1.8 nM Compound: 1	Cytotoxicity against human KB cells by sulforhodamine B assay Cytotoxicity against human KB cells by sulforhodamine B assay	[PMID: 17350834]
KB	ED₅₀	1 x 10^-5 μg/mL Compound: 1	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 2898009]
KB	ED₅₀	1 x 10^-5 μg/mL Compound: 2	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 2878063]
KB	ED₅₀	2.87 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells after 3 days by sulforhodamine B assay Antiproliferative activity against human KB cells after 3 days by sulforhodamine B assay	[PMID: 21296579]
KB	ED₅₀	2 x 10^-2 μg/mL Compound: paclitaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 8778244]
KB	ED₅₀	2 x 10^-2 μg/mL Compound: palitaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	10.1021/np9606660
KB	ED₅₀	8.9 μg/mL Compound: Taxol	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 7130986]
KB	GI₅₀	0.00265 μM Compound: Paclitaxel	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 22932313]
KB	GI₅₀	0.00487 μM Compound: Paclitaxel	Cytotoxicity activity against human KB cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay Cytotoxicity activity against human KB cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay	[PMID: 21316977]
KB	GI₅₀	0.0064 μM Compound: Paclitaxel	Cytotoxicity against human KB cells by SRB method Cytotoxicity against human KB cells by SRB method	[PMID: 23867604]
KB	GI₅₀	0.0064 μM Compound: Paclitaxel	Antiproliferative activity against human KB cells by sulforhodamine B assay Antiproliferative activity against human KB cells by sulforhodamine B assay	[PMID: 25770782]
KB	GI₅₀	0.0064 μM Compound: Paclitaxel	Antiproliferative activity against human KB cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human KB cells assessed as cell growth inhibition by SRB assay	[PMID: 26242242]
KB	GI₅₀	0.0064 μM Compound: paclitaxel	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 24502232]
KB	GI₅₀	0.008 μM Compound: Paclitaxel	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 24315191]
KB	GI₅₀	1 nM Compound: Paclitaxel	Growth inhibition of human KB cells after 72 hrs by MTS assay Growth inhibition of human KB cells after 72 hrs by MTS assay	[PMID: 26778612]
KB	GI₅₀	4.1 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31938468]
KB	GI₅₀	4.12 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells after 72 hrs by SRB assay Antiproliferative activity against human KB cells after 72 hrs by SRB assay	[PMID: 22265685]
KB	GI₅₀	4.6 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 34917259]
KB	GI₅₀	5.12 nM Compound: Paclitaxel	Cytotoxicity against human KB cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human KB cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28653846]
KB	GI₅₀	5.16 nM Compound: Paclitaxel	Cytotoxicity against human KB cells after 3 days Cytotoxicity against human KB cells after 3 days	[PMID: 21377368]
KB	GI₅₀	7.77 nM Compound: Paclitaxel	Growth inhibition of human KB cells by SRB assay Growth inhibition of human KB cells by SRB assay	[PMID: 23274123]
KB	GI₅₀	948 μM Compound: Paclitaxel	Antiproliferative activity against human KB cells after 48 hrs by SRB method Antiproliferative activity against human KB cells after 48 hrs by SRB method	[PMID: 27238842]
KB	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
KB	IC₅₀	0.001 μM Compound: Paclitaxel	Cytotoxicity against human KB cells after 3 days by SRB assay Cytotoxicity against human KB cells after 3 days by SRB assay	[PMID: 16038545]
KB	IC₅₀	0.0013 μg/mL Compound: Paclitaxel	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 17950495]
KB	IC₅₀	0.0015 μg/mL Compound: 44 (C7 epimer)	Cytotoxicity against human epidermoid carcinoma KB cells Cytotoxicity against human epidermoid carcinoma KB cells	10.1016/S0960-894X(97)00029-2
KB	IC₅₀	0.0015 μg/mL Compound: 53	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 14987066]
KB	IC₅₀	0.0016 μg/mL Compound: Paclitaxel	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 22595179]
KB	IC₅₀	0.001 μg/mL Compound: paclitaxel	Cytotoxicity against human KB cells after 72 hrs by methylene blue assay Cytotoxicity against human KB cells after 72 hrs by methylene blue assay	[PMID: 12502326]
KB	IC₅₀	0.001 μg/mL Compound: taxol	Cytotoxicity against human KB403 cell line by MTT assay Cytotoxicity against human KB403 cell line by MTT assay	[PMID: 16297622]
KB	IC₅₀	0.002 μg/mL Compound: paclitaxel	Cytotoxicity against human KB cells after 3 days by SRB assay Cytotoxicity against human KB cells after 3 days by SRB assay	[PMID: 20232858]
KB	IC₅₀	0.0036 μM Compound: Paclitaxel	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28590124]
KB	IC₅₀	0.0039 μM Compound: Paclitaxel	Cytotoxicity against human KB cells after 72 hrs sulforhodamine B colorimetric assay Cytotoxicity against human KB cells after 72 hrs sulforhodamine B colorimetric assay	[PMID: 25008456]
KB	IC₅₀	0.0048 μg/mL Compound: Paclitaxel	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 22204911]
KB	IC₅₀	0.00579 μM Compound: Paclitaxel	Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
KB	IC₅₀	0.006 μM Compound: paclitaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 10978200]
KB	IC₅₀	0.008 μM Compound: Paclitaxel	Antiproliferative activity against human KB cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 34403728]
KB	IC₅₀	0.0088 μg/mL Compound: 13	Cytotoxic activity was evaluated against Epidermoid Carcinoma KB cells Cytotoxic activity was evaluated against Epidermoid Carcinoma KB cells	[PMID: 9873389]
KB	IC₅₀	0.0088 μg/mL Compound: 36 (taxol)	Cytotoxicity against human epidermoid carcinoma KB cells Cytotoxicity against human epidermoid carcinoma KB cells	10.1016/S0960-894X(97)00029-2
KB	IC₅₀	0.0091 μM Compound: 1a (Paclitaxel)	Inhibitory activity against KB nasopharynx cancer cell line Inhibitory activity against KB nasopharynx cancer cell line	[PMID: 12031338]
KB	IC₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay	[PMID: 21705223]
KB	IC₅₀	0.01 μM Compound: Paclitaxel ; Taxol	Cytotoxic activity against cellular metabolic activity of Cervix KB/HeLa tumor cell line using XTT proliferation assay after incubation with the compound for 48 h Cytotoxic activity against cellular metabolic activity of Cervix KB/HeLa tumor cell line using XTT proliferation assay after incubation with the compound for 48 h	[PMID: 12852768]
KB	IC₅₀	0.01 μM Compound: paclitaxel	Antiproliferative activity against KB/HeLa cells by XTT assay after 48 hrs Antiproliferative activity against KB/HeLa cells by XTT assay after 48 hrs	[PMID: 17181164]
KB	IC₅₀	0.01 μM Compound: paclitaxel	Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay	[PMID: 17973361]
KB	IC₅₀	0.01 μM Compound: paclitaxel	Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay	[PMID: 20537765]
KB	IC₅₀	0.015 μM Compound: Taxol	Antiproliferative activity against human KB cells after 72 hrs by MTT assay Antiproliferative activity against human KB cells after 72 hrs by MTT assay	[PMID: 25771484]
KB	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 12088425]
KB	IC₅₀	0.02 μM Compound: paclitaxel	Cytotoxicity against human KB cells after 48 hrs by neutral red assay Cytotoxicity against human KB cells after 48 hrs by neutral red assay	[PMID: 19879765]
KB	IC₅₀	0.03 μM Compound: paclitaxel	Antiproliferative activity against human KB/HeLa cells by XTT assay Antiproliferative activity against human KB/HeLa cells by XTT assay	[PMID: 19220018]
KB	IC₅₀	0.04 nM Compound: PXL	Antiproliferative activity against human KB cells after 3 days by SRB assay Antiproliferative activity against human KB cells after 3 days by SRB assay	[PMID: 26865176]
KB	IC₅₀	0.08 μM Compound: Paclitaxel	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 20122764]
KB	IC₅₀	0.08 μM Compound: Paclitaxel	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 20627721]
KB	IC₅₀	0.08 μM Compound: Paclitaxel	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 20716468]
KB	IC₅₀	0.08 μM Compound: Paclitaxel	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 21875764]
KB	IC₅₀	0.8 nM Compound: Paclitaxel	Cytotoxicity against human KB cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human KB cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27797192]
KB	IC₅₀	1.55 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 20036537]
KB	IC₅₀	1.7 μM Compound: 1a (Paclitaxel)	Inhibitory activity against Vincristine-resistant KB nasopharynx cancer cell line Inhibitory activity against Vincristine-resistant KB nasopharynx cancer cell line	[PMID: 12031338]
KB	IC₅₀	1.9 nM Compound: 1	Cytotoxicity against human KB cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human KB cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28624703]
KB	IC₅₀	10 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31419740]
KB	IC₅₀	10.3 nM Compound: Paclitaxol	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
KB	IC₅₀	16500 nM Compound: paclitaxel	Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay	[PMID: 19053773]
KB	IC₅₀	2.45 nM Compound: Paclitaxel	Antiproliferative activity against KB cells expressing MDR1 Antiproliferative activity against KB cells expressing MDR1	[PMID: 17228873]
KB	IC₅₀	2.45 nM Compound: paclitaxel	Antiproliferative activity against KB cells Antiproliferative activity against KB cells	[PMID: 17416524]
KB	IC₅₀	2.5 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells after 3 days by SRB assay Antiproliferative activity against human KB cells after 3 days by SRB assay	[PMID: 19041247]
KB	IC₅₀	2.54 μM Compound: paclitaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 18701281]
KB	IC₅₀	273 nM Compound: paclitaxel	Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-TAX50 cells after 72 hrs by methylene blue dye assay Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-TAX50 cells after 72 hrs by methylene blue dye assay	[PMID: 19053773]
KB	IC₅₀	3.3 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells Antiproliferative activity against human KB cells	[PMID: 25059503]
KB	IC₅₀	3.3 nM Compound: paclitaxel	Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay	[PMID: 19053773]
KB	IC₅₀	3.3 nM Compound: paclitaxel	Growth inhibition of human KB cells after 72 hrs by methylene blue assay Growth inhibition of human KB cells after 72 hrs by methylene blue assay	[PMID: 22060033]
KB	IC₅₀	3.6 nM Compound: PXL	Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 29319316]
KB	IC₅₀	3.7 nM Compound: PXL	Antiproliferative activity against human KB cells after 3 days by SRB assay Antiproliferative activity against human KB cells after 3 days by SRB assay	[PMID: 25241925]
KB	IC₅₀	3.8 μM Compound: PXL	Cytotoxicity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 27707623]
KB	IC₅₀	3.8 μM Compound: paclitaxel	Cytotoxicity against human KB cells after 48 hrs by trypan blue exclusion method Cytotoxicity against human KB cells after 48 hrs by trypan blue exclusion method	[PMID: 25211032]
KB	IC₅₀	3.9 nM Compound: Paclitaxel	Cytotoxicity against human KB cells assessed as inhibition of cell growth after 3 days by MTT assay Cytotoxicity against human KB cells assessed as inhibition of cell growth after 3 days by MTT assay	[PMID: 24745968]
KB	IC₅₀	3.9 nM Compound: Paclitaxel	Cytotoxicity against human KB cells assessed as reduction in cell growth after 3 days by MTT assay Cytotoxicity against human KB cells assessed as reduction in cell growth after 3 days by MTT assay	[PMID: 25442315]
KB	IC₅₀	4.1 nM Compound: Paclitaxel	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay	[PMID: 24106982]
KB	IC₅₀	4.2 nM Compound: paclitaxel	Cytotoxicity against human KB cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human KB cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 18295490]
KB	IC₅₀	4.5 nM Compound: paclitaxel	Cytotoxicity against human KB cells incubated for 48 hrs at 37 degC Cytotoxicity against human KB cells incubated for 48 hrs at 37 degC	[PMID: 22074257]
KB	IC₅₀	5.1 nM Compound: Paclitaxel	Cytotoxicity against human KB cells after 72 hrs by methylene blue assay Cytotoxicity against human KB cells after 72 hrs by methylene blue assay	[PMID: 24657567]
KB	IC₅₀	5.1 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay	[PMID: 26160020]
KB	IC₅₀	5.71 nM Compound: PXL	Antiproliferative activity against human KB cells after 72 hrs by SRB assay Antiproliferative activity against human KB cells after 72 hrs by SRB assay	[PMID: 30106296]
KB	IC₅₀	5.9 nM Compound: PXL	Antiproliferative activity against human KB cells by sulforhodamine B assay Antiproliferative activity against human KB cells by sulforhodamine B assay	[PMID: 28457756]
KB	IC₅₀	5.9 μM Compound: Paclitaxel	Antiproliferative activity against human KB cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay Antiproliferative activity against human KB cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay	[PMID: 30189396]
KB	IC₅₀	6.1 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay Antiproliferative activity against human KB cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 31126820]
KB	IC₅₀	6.27 nM Compound: PXL	Antiproliferative activity against human KB cells after 72 hrs by SRB assay Antiproliferative activity against human KB cells after 72 hrs by SRB assay	[PMID: 28099003]
KB	IC₅₀	6.3 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay	[PMID: 28290698]
KB	IC₅₀	6.3 μM Compound: PXL	Antiproliferative activity against human KB cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay Antiproliferative activity against human KB cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay	[PMID: 38438305]
KB	IC₅₀	6.587 μM Compound: Paclitaxel	Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
KB	IC₅₀	6.6 nM Compound: Paclitaxel	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
KB	IC₅₀	6.6 μM Compound: Paclitaxel	Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
KB	IC₅₀	6.684 μM Compound: Paclitaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 21784631]
KB	IC₅₀	6.69 nM Compound: PXL	Antiproliferative activity against human KB cells after 48 hrs by SRB assay Antiproliferative activity against human KB cells after 48 hrs by SRB assay	[PMID: 30106296]
KB	IC₅₀	6.72 nM Compound: PXL	Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31541869]
KB	IC₅₀	6.8 nM Compound: PXL	Antiproliferative activity against human KB cells after 72 hrs by SRB assay Antiproliferative activity against human KB cells after 72 hrs by SRB assay	[PMID: 30010341]
KB	IC₅₀	626 nM Compound: Paclitaxel	Concentration required to inhibit the growth of paclitaxel-resistant human epidermoid carcinoma cells KB-8511 by 50 percent (72 hr exposure) Concentration required to inhibit the growth of paclitaxel-resistant human epidermoid carcinoma cells KB-8511 by 50 percent (72 hr exposure)	[PMID: 11133086]
KB	IC₅₀	7.1 nM Compound: PXL	Antiproliferative activity against human KB cells assessed as reduction in cell viability by SRB assay Antiproliferative activity against human KB cells assessed as reduction in cell viability by SRB assay	[PMID: 38970504]
KB	IC₅₀	7.4 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 31550158]
KB	IC₅₀	7.52 μM Compound: Paclitaxel	Antiproliferative activity against human KB cells after 72 hrs by SRB assay Antiproliferative activity against human KB cells after 72 hrs by SRB assay	[PMID: 29391939]
KB	IC₅₀	7.7 nM Compound: Paclitaxel	Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32946697]
KB	IC₅₀	7.9 nM Compound: paclitaxel	Growth inhibition of human KB-7D cells overexpressing multidrug resistant associated protein after 72 hrs by methylene blue dye assay Growth inhibition of human KB-7D cells overexpressing multidrug resistant associated protein after 72 hrs by methylene blue dye assay	[PMID: 19053773]
KB	IC₅₀	8.21 nM Compound: PXL	Antiproliferative activity against human KB cells after 24 hrs by SRB assay Antiproliferative activity against human KB cells after 24 hrs by SRB assay	[PMID: 30106296]
KB	IC₅₀	80 nM Compound: Paclitaxel (Taxol)	Compound was tested for the cytotoxicity against KB-8-5 cell line expressing P-glycoprotein; value ranges from 30-80 nM Compound was tested for the cytotoxicity against KB-8-5 cell line expressing P-glycoprotein; value ranges from 30-80 nM	[PMID: 15261296]
KB	IC₅₀	< 0.1 nM Compound: PXL	Antiproliferative activity against human KB cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 38251859]
KB	IC₅₀	< 0.1 μg/mL Compound: paclitaxel	Cytotoxicity against human KB cells after 72 hrs by methylene blue assay Cytotoxicity against human KB cells after 72 hrs by methylene blue assay	[PMID: 11473432]
KB	IC₅₀	> 0.085 μg/mL Compound: paclitaxel	Cytotoxicity against human vincristine-resistant KB cells overexpressing p-glycoprotein after 3 days by SRB assay Cytotoxicity against human vincristine-resistant KB cells overexpressing p-glycoprotein after 3 days by SRB assay	[PMID: 20232858]
KB 3-1	GI₅₀	2.23 nM Compound: Paclitaxel	Cytotoxicity against human KB-3-1 cells assessed as inhibition of cell proliferation Cytotoxicity against human KB-3-1 cells assessed as inhibition of cell proliferation	[PMID: 37849542]
KB 3-1	IC₅₀	0.0005 μM Compound: Paclitaxel	Cytotoxicity against human KB-3-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human KB-3-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29501942]
KB 3-1	IC₅₀	0.002 μM Compound: paclitaxel	Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay	[PMID: 18313307]
KB 3-1	IC₅₀	0.029 μM Compound: Paclitaxel	Antiproliferative activity against human KB-3-1 cells assessed as cell growth inhibition Antiproliferative activity against human KB-3-1 cells assessed as cell growth inhibition	[PMID: 38733884]
KB 3-1	IC₅₀	1.2 nM Compound: PTX	Cytotoxicity against paclitaxel-sensitive human KB3-1 cells assessed as decrease in cell viability after 72 hrs by neutral red dye assay Cytotoxicity against paclitaxel-sensitive human KB3-1 cells assessed as decrease in cell viability after 72 hrs by neutral red dye assay	[PMID: 20302303]
KB 3-1	IC₅₀	2.92 nM Compound: Paclitaxel	Concentration required to inhibit the growth of paclitaxel-sensitive human epidermoid carcinoma cells KB-31 by 50 percent (72 hr exposure) Concentration required to inhibit the growth of paclitaxel-sensitive human epidermoid carcinoma cells KB-31 by 50 percent (72 hr exposure)	[PMID: 11133086]
KB 3-1	IC₅₀	23.3 nM Compound: Paclitaxel	Cytotoxicity against KB-3-1 cell line Cytotoxicity against KB-3-1 cell line	[PMID: 17249649]
KB 3-1	IC₅₀	3.9 nM Compound: Placlitaxel (TAXOL)	Inhibitory concentration against KB-3-1 cells was evaluated Inhibitory concentration against KB-3-1 cells was evaluated	[PMID: 15341492]
KB 3-1	IC₅₀	400 μM Compound: paclitaxel	Resistant ratio, IC50 for multidrug resistant human KB3-1 cells to IC50 for human KB3-1 cells Resistant ratio, IC50 for multidrug resistant human KB3-1 cells to IC50 for human KB3-1 cells	[PMID: 18313307]
KB 3-1	IC₅₀	6 nM Compound: Paclitaxel (Taxol)	Compound was tested for the cytotoxicity against KB-3-1 cell line; value ranges from 2-6 nM Compound was tested for the cytotoxicity against KB-3-1 cell line; value ranges from 2-6 nM	[PMID: 15261296]
KB 3-1	IC₅₀	> 0.0021 μM Compound: Paclitaxel	Inhibitory concentration against human KB-3-1 cells Inhibitory concentration against human KB-3-1 cells	[PMID: 15863325]
KB 3-1	IC₅₀	> 0.6 μM Compound: Paclitaxel	Inhibitory concentration against KB-G2 cells Inhibitory concentration against KB-G2 cells	[PMID: 15863325]
KB 3-1	IC₅₀	> 3000 nM Compound: Paclitaxel (Taxol)	Compound was tested for the cytotoxicity against KB-V1 cell line expressing P-glycoprotein Compound was tested for the cytotoxicity against KB-V1 cell line expressing P-glycoprotein	[PMID: 15261296]
KB-V1	GI₅₀	431.55 nM Compound: Paclitaxel	Cytotoxicity against multidrug resistant human KB-V1 cells assessed as inhibition of cell proliferation Cytotoxicity against multidrug resistant human KB-V1 cells assessed as inhibition of cell proliferation	[PMID: 37849542]
KB-V1	IC₅₀	2013 nM Compound: Paclitaxel	Antiproliferative activity against KBV1 cells expressing MDR1 Antiproliferative activity against KBV1 cells expressing MDR1	[PMID: 17228873]
KB-V1	IC₅₀	2013 nM Compound: Paclitaxel	Antiproliferative activity against human KBV1 cells after 3 days by SRB assay Antiproliferative activity against human KBV1 cells after 3 days by SRB assay	[PMID: 19041247]
KB-V1	IC₅₀	2013 nM Compound: paclitaxel	Antiproliferative activity against KBV1cells Antiproliferative activity against KBV1cells	[PMID: 17416524]
KB-V1	IC₅₀	8 μM Compound: paclitaxel	Growth inhibition of human KB V1 cells after 72 hrs by MTT assay Growth inhibition of human KB V1 cells after 72 hrs by MTT assay	[PMID: 18313307]
KB-V1	IC₅₀	9800 nM Compound: 1	Cytotoxicity against human KBV1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human KBV1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28624703]
KB-V1	IC₅₀	> 10000 nM Compound: Paclitaxel	Cytotoxicity against P-glycoprotein-overexpressing KB-V1 cell line Cytotoxicity against P-glycoprotein-overexpressing KB-V1 cell line	[PMID: 17249649]
KB-V1	IC₅₀	> 2.3 μM Compound: 1	Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay	[PMID: 12088425]
KETR3	IC₅₀	0.05 μM Compound: Taxol	Anticancer activity against human KETR3 cells by MTT assay Anticancer activity against human KETR3 cells by MTT assay	[PMID: 33316408]
KG-1	IC₅₀	0.068 μM Compound: PTX	Cytotoxicity against human KG-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human KG-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
KM12	GI₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human KM12 cells by sulforhodamine B assay Cytotoxicity against human KM12 cells by sulforhodamine B assay	[PMID: 21839640]
KM12	GI₅₀	0.004 μM Compound: paclitaxel	Cytotoxicity against human KM12 cells Cytotoxicity against human KM12 cells	[PMID: 17696332]
KM12	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
KM12	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human KM12 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human KM12 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
KP-4	IC₅₀	0.007 μM Compound: 2	Antiproliferative activity against human KP-4 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human KP-4 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 37856840]
Kasumi 1	IC₅₀	0.004 μM Compound: Taxol	Cytotoxicity against human Kasumi 1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human Kasumi 1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34704758]
Kasumi 1	IC₅₀	0.01 μM Compound: Taxol	Anticancer activity against human Kasumi 1 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human Kasumi 1 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
L02	GI₅₀	30.8 nM Compound: Paclitaxel	Cytotoxicity against human L02 cells assessed as assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33201714]
L02	IC₅₀	0.002 μM Compound: Taxol	Cytotoxicity against human LO2 cells after 72 hrs by MTT assay Cytotoxicity against human LO2 cells after 72 hrs by MTT assay	[PMID: 28395199]
L02	IC₅₀	0.0518 μM Compound: Taxol	Cytotoxicity against human HL-7702 cells assessed as growth inhibition by MTT assay Cytotoxicity against human HL-7702 cells assessed as growth inhibition by MTT assay	[PMID: 24684840]
L02	IC₅₀	0.06 μM Compound: Paclitaxel	Cytotoxicity against human HL-7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL-7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27329938]
L02	IC₅₀	0.13 μM Compound: Taxol	Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
L02	IC₅₀	0.54 μM Compound: Paclitaxel; Taxol	Antiproliferative activity against human L02 cells measured after 48 hrs by MTT assay Antiproliferative activity against human L02 cells measured after 48 hrs by MTT assay	[PMID: 35551039]
L02	IC₅₀	1.1 μM Compound: paclitaxel	Cytotoxicity against human HL7702 cells by MTT assay Cytotoxicity against human HL7702 cells by MTT assay	[PMID: 24960143]
L02	IC₅₀	1.73 μM Compound: PTX	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38280356]
L02	IC₅₀	5.6 μM Compound: Taxol	Cytotoxicity against NQO1 deficient human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against NQO1 deficient human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30508483]
L02	IC₅₀	6.1 μM Compound: Taxol	Antiproliferative activity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by cell titer glo luminescent assay Antiproliferative activity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by cell titer glo luminescent assay	[PMID: 35640078]
L02	IC₅₀	79.67 μM Compound: Paclitaxel	Cytotoxicity against human L02 cells by CCK8 assay Cytotoxicity against human L02 cells by CCK8 assay	[PMID: 34922028]
L02	IC₅₀	< 0.1 μM Compound: Paclitaxel	Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34303874]
L02	IC₅₀	> 100 μM Compound: PTX	Cytotoxicity against human L02 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
L02	IC₅₀	> 100 μM Compound: Taxol	Cytotoxicity against human L02 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
L1210	IC₅₀	0.024 mM Compound: 1	Tested for cytotoxicity against murine L-1210 cell line Tested for cytotoxicity against murine L-1210 cell line	[PMID: 7650695]
L1210	IC₅₀	0.026 μg/mL Compound: 44 (C7 epimer)	Cytotoxicity against murine leukemia L1210 cells Cytotoxicity against murine leukemia L1210 cells	10.1016/S0960-894X(97)00029-2
L1210	IC₅₀	0.06 μM Compound: Paclitaxel	Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay	[PMID: 21705223]
L1210	IC₅₀	0.06 μM Compound: Paclitaxel ; Taxol	Antiproliferative activity against L1210 tumor cell line Antiproliferative activity against L1210 tumor cell line	[PMID: 12852768]
L1210	IC₅₀	0.06 μM Compound: paclitaxel	Antiproliferative activity against L1210 cells by XTT assay after 48 hrs Antiproliferative activity against L1210 cells by XTT assay after 48 hrs	[PMID: 17181164]
L1210	IC₅₀	0.06 μM Compound: paclitaxel	Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay	[PMID: 17973361]
L1210	IC₅₀	0.06 μM Compound: paclitaxel	Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay	[PMID: 19220018]
L1210	IC₅₀	0.06 μM Compound: paclitaxel	Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay	[PMID: 20537765]
L1210	IC₅₀	0.07 μM Compound: paclitaxel	Antiproliferative activity against vincristine-resistance MRP1 negative mouse L1210 cells expressing human MDR1 after 48 hrs by XTT assay Antiproliferative activity against vincristine-resistance MRP1 negative mouse L1210 cells expressing human MDR1 after 48 hrs by XTT assay	[PMID: 19220018]
L1210	IC₅₀	0.09 nM Compound: Paclitaxel	Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in L1210 cell line by MTT assay. Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in L1210 cell line by MTT assay.	[PMID: 12392737]
L1210	IC₅₀	0.33 μg/mL Compound: 13	Cytotoxic activity was evaluated against murine Leukemia L1210 cells Cytotoxic activity was evaluated against murine Leukemia L1210 cells	[PMID: 9873389]
L1210	IC₅₀	0.33 μg/mL Compound: 36 (taxol)	Cytotoxicity against murine leukemia L1210 cells Cytotoxicity against murine leukemia L1210 cells	10.1016/S0960-894X(97)00029-2
L1210	IC₅₀	0.4 nM Compound: Pac	Antiproliferative activity against mouse L1210 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against mouse L1210 cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
L1210	IC₅₀	0.4 nM Compound: Pac	Antiproliferative activity against mouse L1210 after 48 hrs by SRB assay Antiproliferative activity against mouse L1210 after 48 hrs by SRB assay	[PMID: 21920638]
L1210	IC₅₀	0.58 nM Compound: Paclitaxel	Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 72 hr in L1210 cell line by MTT assay. Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 72 hr in L1210 cell line by MTT assay.	[PMID: 12392737]
L1210	IC₅₀	120 nM Compound: paclitaxel	Cytotoxicity against mouse L1210 cells incubated for 48 hrs at 37 degC Cytotoxicity against mouse L1210 cells incubated for 48 hrs at 37 degC	[PMID: 22074257]
L1210	IC₅₀	27.6 nM Compound: Paclitaxel	Cytotoxicity against folate receptor over-expressing mouse L1210 cells after 72 hrs by MTT assay Cytotoxicity against folate receptor over-expressing mouse L1210 cells after 72 hrs by MTT assay	[PMID: 25819334]
L1210	IC₅₀	6 μM Compound: Taxol	In vitro inhibitory activity of compound against L1210/O murine leukemia cell line In vitro inhibitory activity of compound against L1210/O murine leukemia cell line	10.1016/S0960-894X(01)80411-X
L1210	IC₅₀	> 5 μM Compound: Paclitaxel	Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay	[PMID: 21705223]
L1210	IC₅₀	> 5 μM Compound: Paclitaxel ; Taxol	Antiproliferative activity against L1210 phenotype L1210 VCR tumor cell line Antiproliferative activity against L1210 phenotype L1210 VCR tumor cell line	[PMID: 12852768]
L1210	IC₅₀	> 5 μM Compound: paclitaxel	Antiproliferative activity against L1210 VCR cells by XTT assay after 48 hrs Antiproliferative activity against L1210 VCR cells by XTT assay after 48 hrs	[PMID: 17181164]
L1210	IC₅₀	> 5 μM Compound: paclitaxel	Antiproliferative activity against mouse vincristine-resistant L1210 cells after 48 hrs by XTT assay Antiproliferative activity against mouse vincristine-resistant L1210 cells after 48 hrs by XTT assay	[PMID: 17973361]
L1210	IC₅₀	> 5 μM Compound: paclitaxel	Antiproliferative activity against vincristine-resistant mouse L1210 cells after 48 hrs by XTT assay Antiproliferative activity against vincristine-resistant mouse L1210 cells after 48 hrs by XTT assay	[PMID: 20537765]
L2987	IC₅₀	0.2 μM Compound: 1	Compound was evaluated for its cytotoxicity against L2987 lung carcinoma cells Compound was evaluated for its cytotoxicity against L2987 lung carcinoma cells	[PMID: 12443783]
L2987	IC₅₀	0.2 μM Compound: 1	Cytotoxicity against human L2987 cells Cytotoxicity against human L2987 cells	[PMID: 17419065]
L929	GI₅₀	0.1 μg/mL Compound: Paclitaxel	Growth inhibition of mouse L929 cells Growth inhibition of mouse L929 cells	[PMID: 15387677]
L929	GI₅₀	0.1 μg/mL Compound: paclitaxel	Antiproliferative activity against mouse L929 cells Antiproliferative activity against mouse L929 cells	[PMID: 17500572]
L929	IC₅₀	32.95 μg/mL Compound: Paclitaxel	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 48 hrs Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 48 hrs	[PMID: 31607609]
L929	IC₅₀	62.5 nM Compound: Paclitaxel	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 38283229]
LC-2-ad	IC₅₀	2.5 nM Compound: 28	Antiproliferative activity against human LC2/ad cells after 72 hrs by WST8 assay Antiproliferative activity against human LC2/ad cells after 72 hrs by WST8 assay	[PMID: 25625617]
LNCaP	CC₅₀	1.4 nM Compound: Ptxl; PTX	Cytotoxicity against PSMA-positive human LNCAP cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against PSMA-positive human LNCAP cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31248772]
LNCaP	ED₅₀	2.6 nM Compound: 1	Cytotoxicity against human LNCAP cells by sulforhodamine B assay Cytotoxicity against human LNCAP cells by sulforhodamine B assay	[PMID: 17350834]
LNCaP	ED₅₀	5 nM Compound: paclitaxel	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 15043407]
LNCaP	ED₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay	[PMID: 19026551]
LNCaP	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay	[PMID: 12088425]
LNCaP	IC₅₀	0.058 μM Compound: PTX	Cytotoxicity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37201429]
LNCaP	IC₅₀	1.7 μg/mL Compound: PTX	Cytotoxicity against human LNCAP cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24794748]
LNCaP	IC₅₀	1.9 nM Compound: Taxol	Antiproliferative activity against human LNCAP cells after 72 hrs by phosphatase assay Antiproliferative activity against human LNCAP cells after 72 hrs by phosphatase assay	[PMID: 28857558]
LNCaP	IC₅₀	2 nM Compound: Paclitaxel	Antiproliferative activity against prostate cancer LNCaP Cell line using sulforhodamine B(SRB) assay Antiproliferative activity against prostate cancer LNCaP Cell line using sulforhodamine B(SRB) assay	[PMID: 15801848]
LNCaP	IC₅₀	20.96 μM Compound: Paclitaxel	Cytotoxicity against human LNCAP cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human LNCAP cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 30798081]
LNCaP	IC₅₀	22.3 nM Compound: PTax	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 20936874]
LNCaP	IC₅₀	6.32 μM Compound: taxol	Cytotoxicity against human LNCAP cells after 72 hrs by XTT assay Cytotoxicity against human LNCAP cells after 72 hrs by XTT assay	[PMID: 19754130]
LOX IMVI	GI₅₀	0.016 μM Compound: 1a, PXL, Taxol	Cytotoxicity against human LOXIMVI cells Cytotoxicity against human LOXIMVI cells	[PMID: 23725535]
LOX IMVI	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
LOX IMVI	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human LOX IMVI cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human LOX IMVI cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
LOX IMVI	IC₅₀	17.3 nM Compound: Placlitaxel (TAXOL)	Inhibitory concentration against Lox melanoma cells Inhibitory concentration against Lox melanoma cells	[PMID: 15341492]
LS174T	IC₅₀	9.5 nM Compound: Taxol	Antiproliferative activity against human LS174T cells after 72 hrs by phosphatase assay Antiproliferative activity against human LS174T cells after 72 hrs by phosphatase assay	[PMID: 28857558]
LS180	IC₅₀	2.8 nM Compound: Paclitaxel	Cytotoxicity against human LS180 cells after 48 hrs by MTT assay Cytotoxicity against human LS180 cells after 48 hrs by MTT assay	[PMID: 29373791]
LU-99A	IC₅₀	5.2 nM Compound: 28	Antiproliferative activity against human LU99A cells after 72 hrs by WST8 assay Antiproliferative activity against human LU99A cells after 72 hrs by WST8 assay	[PMID: 25625617]
LoVo	IC₅₀	90 nM Compound: 1	Cytotoxicity against human LoVo cells in presence of beta-glucuronidase Cytotoxicity against human LoVo cells in presence of beta-glucuronidase	[PMID: 17419065]
Lu1	ED₅₀	2 nM Compound: paclitaxel	Cytotoxicity against human Lu1 cells Cytotoxicity against human Lu1 cells	[PMID: 15043407]
Lu1	ED₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay	[PMID: 19026551]
Lu1	IC₅₀	0.01 μM Compound: 1	Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay	[PMID: 12088425]
M14	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
M14	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human M14 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human M14 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
M14	IC₅₀	0.007 μM Compound: Paclitaxel	Antiproliferative activity against human M14 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human M14 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
M14	IC₅₀	0.5 nM Compound: Paclitaxel	Cytotoxicity against human M14 cells measured after 72 hrs by western blot Cytotoxicity against human M14 cells measured after 72 hrs by western blot	[PMID: 34378386]
M14	IC₅₀	1.3 nM Compound: Paclitaxel	Antiproliferative activity against human M14 cells measured after 72 hrs by MTS assay Antiproliferative activity against human M14 cells measured after 72 hrs by MTS assay	[PMID: 31860298]
M14	IC₅₀	1.3 nM Compound: Paclitaxel	Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
M14	IC₅₀	186.3 nM Compound: Paclitaxel	Cytotoxicity against paclitaxel resistant human M14 cells measured after 72 hrs by western blot Cytotoxicity against paclitaxel resistant human M14 cells measured after 72 hrs by western blot	[PMID: 34378386]
M19-MEL	IC₅₀	< 3 ng/mL Compound: 1 (paclitaxel)	Cytotoxicity against M19 Tumor cell line in SRB Cell viability test Cytotoxicity against M19 Tumor cell line in SRB Cell viability test	[PMID: 10956217]
M21	GI₅₀	0.037 μM Compound: Pac	Antiproliferative activity against human M21 cells after 48 hrs by sulforhodamine B method Antiproliferative activity against human M21 cells after 48 hrs by sulforhodamine B method	[PMID: 18617414]
M21	GI₅₀	0.037 μM Compound: Paclitaxel	Growth inhibition of human M21 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human M21 cells after 48 hrs by sulforhodamine B assay	[PMID: 18579387]
M21	GI₅₀	0.037 μM Compound: paclitaxel	Growth inhibition of human M21 cells after 48 hrs Growth inhibition of human M21 cells after 48 hrs	[PMID: 17498960]
M21	GI₅₀	0.037 μM Compound: paclitaxel	Antiproliferative activity against human M21 cells Antiproliferative activity against human M21 cells	[PMID: 18502639]
MCF-10A	IC₅₀	0.0058 μM Compound: Paclitaxel	Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	[PMID: 28926237]
MCF-10A	IC₅₀	14.3 μM Compound: 1	Cytotoxicity against human MCF10A cells assessed as inhibition of cell proliferation Cytotoxicity against human MCF10A cells assessed as inhibition of cell proliferation	[PMID: 25466201]
MCF-10A	IC₅₀	38 μM Compound: Pacli	Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay	[PMID: 25563891]
MCF-10A	IC₅₀	427 μM Compound: Paclitaxel	Cytotoxicity against human MCF10A cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24044895]
MCF-10A	IC₅₀	7.82 μM Compound: Taxol	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 39044437]
MCF-10A	IC₅₀	> 10 μM Compound: Paclitaxel	Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition measured after 48 hrs by MTS assay Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition measured after 48 hrs by MTS assay	[PMID: 35737669]
MCF7	CC₅₀	< 20 nM Compound: Ptxl; PTX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31248772]
MCF7	EC₅₀	0.005 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells incubated for 48 to 72 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 48 to 72 hrs by MTT assay	[PMID: 39038808]
MCF7	EC₅₀	0.0072 μg/mL Compound: Paclitaxel	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 18640035]
MCF7	EC₅₀	0.0072 μg/mL Compound: Palitaxel	Cytotoxicity against human MCF7 cells after 3 days by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 3 days by sulforhodamine B assay	[PMID: 19193043]
MCF7	EC₅₀	0.036 μM Compound: PXL	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 16870428]
MCF7	EC₅₀	194.2 nM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 33705908]
MCF7	EC₅₀	2065.8 nM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells expressing TUBB3 Antiproliferative activity against human MCF7 cells expressing TUBB3	[PMID: 33705908]
MCF7	EC₅₀	44.72 μM Compound: Taxol	Antiproliferative activity against cisplatin-resistant human MCF7-CR cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against cisplatin-resistant human MCF7-CR cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35421577]
MCF7	ED₅₀	0.05 μg/mL Compound: 1	Cytotoxicity against ERalpha positive human MCF7 cells Cytotoxicity against ERalpha positive human MCF7 cells	[PMID: 17419065]
MCF7	ED₅₀	1.1 nM Compound: 1	Cytotoxicity against human MCF7 cells by sulforhodamine B assay Cytotoxicity against human MCF7 cells by sulforhodamine B assay	[PMID: 17350834]
MCF7	ED₅₀	2.1 nM Compound: paclitaxel	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 18977659]
MCF7	ED₅₀	3.2 nM Compound: 1	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 18926701]
MCF7	ED₅₀	3.23 nM Compound: 1	Cytotoxicity against human breast cancer MCF7 cell line Cytotoxicity against human breast cancer MCF7 cell line	[PMID: 16289636]
MCF7	ED₅₀	4 nM Compound: 1a (Taxol)	Cytotoxicity against MCF-7 cells with reference to taxol Cytotoxicity against MCF-7 cells with reference to taxol	[PMID: 11334567]
MCF7	ED₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay	[PMID: 19026551]
MCF7	ED₅₀	> 100 nM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 3 days by sulforhodamine B assay	[PMID: 21296579]
MCF7	GI₅₀	0.0011 μM Compound: Paclitaxel	Cytotoxic activity against human breast tumor-derived MCF-7 cell lines Cytotoxic activity against human breast tumor-derived MCF-7 cell lines	[PMID: 10406652]
MCF7	GI₅₀	0.0021 μg/mL Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition Cytotoxicity against human MCF7 cells assessed as cell growth inhibition	[PMID: 33826327]
MCF7	GI₅₀	0.003 μM Compound: Taxol	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 21115210]
MCF7	GI₅₀	0.003 μM Compound: Taxol	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23831811]
MCF7	GI₅₀	0.0048 μg/mL Compound: Paclitaxel	Cytotoxicity against human MCF7 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human MCF7 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
MCF7	GI₅₀	0.0048 μg/mL Compound: Paclitaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 27914801]
MCF7	GI₅₀	0.0048 μg/mL Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28110868]
MCF7	GI₅₀	0.005 μM Compound: PCT	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 24727464]
MCF7	GI₅₀	0.01 μM Compound: Paclitaxel	Compound was tested for growth inhibition of MCF-7 cell line (non multidrug resistant) Compound was tested for growth inhibition of MCF-7 cell line (non multidrug resistant)	[PMID: 15546733]
MCF7	GI₅₀	0.012 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 21513294]
MCF7	GI₅₀	0.03 μM Compound: paclitaxel	Growth inhibition of human MCF7 cells Growth inhibition of human MCF7 cells	[PMID: 23167614]
MCF7	GI₅₀	0.054 μM Compound: Pac	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B method Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B method	[PMID: 18617414]
MCF7	GI₅₀	0.054 μM Compound: Paclitaxel	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 18579387]
MCF7	GI₅₀	0.054 μM Compound: paclitaxel	Growth inhibition of human MCF7 cells after 48 hrs Growth inhibition of human MCF7 cells after 48 hrs	[PMID: 17498960]
MCF7	GI₅₀	0.054 μM Compound: paclitaxel	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 18502639]
MCF7	GI₅₀	0.075 μg/mL Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 and 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 and 72 hrs by MTT assay	[PMID: 26927426]
MCF7	GI₅₀	0.087 mM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	10.1039/C6MD00278A
MCF7	GI₅₀	1.07 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 3 days by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 3 days by MTT assay	[PMID: 21889341]
MCF7	GI₅₀	1.1 nM Compound: Paclitaxel	Compound was tested in vitro for growth inhibition of MCF-7 cells derived from human breast tumor. Compound was tested in vitro for growth inhibition of MCF-7 cells derived from human breast tumor.	[PMID: 9873597]
MCF7	GI₅₀	1.29 nM Compound: 1, Taxol	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 24405702]
MCF7	GI₅₀	11.9 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28653846]
MCF7	GI₅₀	2.76 nM Compound: Taxol	Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay	[PMID: 33239261]
MCF7	GI₅₀	4 nM Compound: Paclitaxel	Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
MCF7	GI₅₀	4 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
MCF7	GI₅₀	4.38 nM Compound: Taxol	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay	[PMID: 27224875]
MCF7	GI₅₀	7.1 nM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 34917259]
MCF7	GI₅₀	8.3 nM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31938468]
MCF7	GI₅₀	< 0.01 μM Compound: Paciltaxel	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31546197]
MCF7	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 27010926]
MCF7	IC₅₀	0.0001 μg/mL Compound: (22) taxol	In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay	[PMID: 12620075]
MCF7	IC₅₀	0.0005 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 17113288]
MCF7	IC₅₀	0.00125 μg/mL Compound: Paclitaxel	Inhibitory concentration required to inhibit MCF-7 Cell line growth on continuous exposure time of 72 h Inhibitory concentration required to inhibit MCF-7 Cell line growth on continuous exposure time of 72 h	[PMID: 15664868]
MCF7	IC₅₀	0.0018 μM Compound: Paclitaxel	Inhibition of serum-induced proliferation of human MCF7 cells Inhibition of serum-induced proliferation of human MCF7 cells	[PMID: 17601739]
MCF7	IC₅₀	0.0019 μM Compound: paclitaxel	Antitumor activity against human MCF7 cell line Antitumor activity against human MCF7 cell line	[PMID: 16884301]
MCF7	IC₅₀	0.002 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 20800500]
MCF7	IC₅₀	0.002 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 72 hrs by WST-1 assay Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 72 hrs by WST-1 assay	[PMID: 21440449]
MCF7	IC₅₀	0.002 μM Compound: Taxol	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 36162214]
MCF7	IC₅₀	0.002 μM Compound: Taxol	Inhibition of cell growth in human MCF7 cells incubated for 72 hrs by SRB method Inhibition of cell growth in human MCF7 cells incubated for 72 hrs by SRB method	[PMID: 38171146]
MCF7	IC₅₀	0.002 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19860383]
MCF7	IC₅₀	0.0025 μM Compound: Paclitaxel	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32731188]
MCF7	IC₅₀	0.0025 μM Compound: paclitaxel, Taxol	Cytotoxic activity against drug-sensitive Pgp-, MRP1-deficient human MCF7 cells after 48 hrs by sulforhodamine B assay in presence of 50 nM vinblastin Cytotoxic activity against drug-sensitive Pgp-, MRP1-deficient human MCF7 cells after 48 hrs by sulforhodamine B assay in presence of 50 nM vinblastin	[PMID: 21680190]
MCF7	IC₅₀	0.003 μM Compound: 6	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25682561]
MCF7	IC₅₀	0.003 μM Compound: Paclitaxel, IOUYT	Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
MCF7	IC₅₀	0.003 μM Compound: Taxol	Cytotoxicity against human MCF7 cells after 24 to 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 to 48 hrs by MTT assay	[PMID: 22222040]
MCF7	IC₅₀	0.003 μM Compound: Taxol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
MCF7	IC₅₀	0.003 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19743863]
MCF7	IC₅₀	0.0033 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 68 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 68 hrs by MTT assay	[PMID: 31404864]
MCF7	IC₅₀	0.004 μM Compound: 1, TAX	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 25084144]
MCF7	IC₅₀	0.004 μM Compound: PTX	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 32650183]
MCF7	IC₅₀	0.0044 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay	[PMID: 20732809]
MCF7	IC₅₀	0.005 μM Compound: 1, TAX	Cytotoxicity against human MCF7 cells in presence of 10 mM DTT after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells in presence of 10 mM DTT after 48 hrs by SRB assay	[PMID: 25084144]
MCF7	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human MCF7 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay Cytotoxicity against human MCF7 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay	[PMID: 23584542]
MCF7	IC₅₀	0.0055 μM Compound: 1a (Paclitaxel)	Inhibitory activity against MCF-7 breast cancer cell line Inhibitory activity against MCF-7 breast cancer cell line	[PMID: 12031338]
MCF7	IC₅₀	0.005 μg/mL Compound: taxol	Cytotoxicity against MCF7 cell line by MTT assay Cytotoxicity against MCF7 cell line by MTT assay	[PMID: 16297622]
MCF7	IC₅₀	0.006 μM Compound: taxol	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 18586491]
MCF7	IC₅₀	0.006 μM Compound: taxol	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 22472045]
MCF7	IC₅₀	0.007 μM Compound: 2	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 37856840]
MCF7	IC₅₀	0.007 μM Compound: Taxol	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 16539377]
MCF7	IC₅₀	0.007 μM Compound: taxol	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 17915851]
MCF7	IC₅₀	0.008 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34175541]
MCF7	IC₅₀	0.0088 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	[PMID: 28926237]
MCF7	IC₅₀	0.008 μg/mL Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 17950495]
MCF7	IC₅₀	0.01 μM Compound: PTX	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 37395092]
MCF7	IC₅₀	0.012 μM Compound: PTX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35447432]
MCF7	IC₅₀	0.012 μM Compound: TAX	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27149641]
MCF7	IC₅₀	0.0124 μM Compound: PTX	Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 27172319]
MCF7	IC₅₀	0.015 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 34403728]
MCF7	IC₅₀	0.015 μg/mL Compound: Taxol	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition by MTT assay	[PMID: 34000484]
MCF7	IC₅₀	0.019 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cell line Cytotoxicity against human MCF7 cell line	[PMID: 16420032]
MCF7	IC₅₀	0.01 μg/mL Compound: Paclitaxel	Anticancer activity against human MCF7 cells after 24 hrs by MTT assay Anticancer activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 25305717]
MCF7	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 12088425]
MCF7	IC₅₀	0.02 μM Compound: PTX	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MCF7	IC₅₀	0.021 μM Compound: Taxol	Antiproliferative activity human MCF7 cells after 20 hrs by MTT assay Antiproliferative activity human MCF7 cells after 20 hrs by MTT assay	[PMID: 20149494]
MCF7	IC₅₀	0.021 μM Compound: Taxol	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 20974505]
MCF7	IC₅₀	0.023 μM Compound: TAX, Taxol	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB method Antiproliferative activity against human MCF7 cells after 48 hrs by SRB method	[PMID: 25061803]
MCF7	IC₅₀	0.02581 μM Compound: Paclitaxel	Antiproliferative against human MCF7 cells after 48 hrs by MTT assay Antiproliferative against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24996136]
MCF7	IC₅₀	0.02581 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27017265]
MCF7	IC₅₀	0.03 μM Compound: PTX	Cytotoxicity against human MCF7 cells expressing TLR4 assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing TLR4 assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34600241]
MCF7	IC₅₀	0.032 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells by CCK8 assay Antiproliferative activity against human MCF7 cells by CCK8 assay	[PMID: 34922028]
MCF7	IC₅₀	0.032 μM Compound: Taxol	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25728023]
MCF7	IC₅₀	0.04 μM Compound: Paclitaxel	In vitro inhibitory concentration of compound against human cancer MACL MCF-7 cell line was determined In vitro inhibitory concentration of compound against human cancer MACL MCF-7 cell line was determined	[PMID: 12882225]
MCF7	IC₅₀	0.043 μM Compound: 1	Antiproliferative activity against human MCF7 cell line by MTT assay after 1 hr Antiproliferative activity against human MCF7 cell line by MTT assay after 1 hr	[PMID: 16513344]
MCF7	IC₅₀	0.05 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay	[PMID: 30920216]
MCF7	IC₅₀	0.06 μM Compound: Paclitaxel	Cytotoxicity activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay Cytotoxicity activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 27627130]
MCF7	IC₅₀	0.0633 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
MCF7	IC₅₀	0.08 μM Compound: Taxol	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 19467877]
MCF7	IC₅₀	0.09 μM Compound: Taxol	Anticancer activity against human MCF7 cells by MTT assay Anticancer activity against human MCF7 cells by MTT assay	[PMID: 33316408]
MCF7	IC₅₀	0.1 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by WST-8 assay Cytotoxicity against human MCF7 cells after 48 hrs by WST-8 assay	[PMID: 19072209]
MCF7	IC₅₀	0.1 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 23738539]
MCF7	IC₅₀	0.1 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24063582]
MCF7	IC₅₀	0.1 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 27449957]
MCF7	IC₅₀	0.1 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27704822]
MCF7	IC₅₀	0.1 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by SRB method Cytotoxicity against human MCF7 cells after 48 hrs by SRB method	[PMID: 19425589]
MCF7	IC₅₀	0.1 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 22360613]
MCF7	IC₅₀	0.1 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24063567]
MCF7	IC₅₀	0.14 μg/mL Compound: Taxol	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 16038548]
MCF7	IC₅₀	0.2 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 27434426]
MCF7	IC₅₀	0.2 nM Compound: Taxol	Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay	[PMID: 31050424]
MCF7	IC₅₀	0.2 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 25176329]
MCF7	IC₅₀	0.22 μM Compound: PTX	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38280356]
MCF7	IC₅₀	0.33 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
MCF7	IC₅₀	0.35 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34671737]
MCF7	IC₅₀	0.42 μM Compound: PTX	Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 100 uM photoCORM delivered CO by MTT assay Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 100 uM photoCORM delivered CO by MTT assay	[PMID: 34097831]
MCF7	IC₅₀	0.47 μM Compound: TAX	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30677614]
MCF7	IC₅₀	0.48 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
MCF7	IC₅₀	0.48 μM Compound: Paclitaxel	Antitumor activity against human MCF7 cells assessed as cell viability incubated for 48 hrs by CCK8 assay Antitumor activity against human MCF7 cells assessed as cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36753987]
MCF7	IC₅₀	0.5 nM Compound: Paclitaxel	Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in MCF-7 cell line by MTT assay. Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in MCF-7 cell line by MTT assay.	[PMID: 12392737]
MCF7	IC₅₀	0.5 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24056146]
MCF7	IC₅₀	0.55 μM Compound: Paclitaxel	Antitumor activity against human MCF7 cells incubated for 48 hrs by CCK8 assay Antitumor activity against human MCF7 cells incubated for 48 hrs by CCK8 assay	[PMID: 37229830]
MCF7	IC₅₀	0.56 μM Compound: PTX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 20 uM chloramphenicol by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 20 uM chloramphenicol by MTT assay	[PMID: 34097831]
MCF7	IC₅₀	0.57 μM Compound: PTX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 10 uM chloramphenicol by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 10 uM chloramphenicol by MTT assay	[PMID: 34097831]
MCF7	IC₅₀	0.6 nM Compound: 1	Cytotoxic potency in MCF7 human mammary carcinoma cell line after 72 hr exposure by SRB test Cytotoxic potency in MCF7 human mammary carcinoma cell line after 72 hr exposure by SRB test	[PMID: 16183281]
MCF7	IC₅₀	0.6 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 27441892]
MCF7	IC₅₀	0.61 μg/mL Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTT method Cytotoxicity against human MCF7 cells after 48 hrs by MTT method	[PMID: 24657569]
MCF7	IC₅₀	0.63 μM Compound: PTX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 50 uM photoCORM delivered CO by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 50 uM photoCORM delivered CO by MTT assay	[PMID: 34097831]
MCF7	IC₅₀	0.63 μM Compound: Taxol	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 21115212]
MCF7	IC₅₀	0.63 μM Compound: Taxol	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27979593]
MCF7	IC₅₀	0.64 μM Compound: Paclitaxel; Taxol	Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay	[PMID: 35551039]
MCF7	IC₅₀	0.66 μM Compound: Taxol	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 23425970]
MCF7	IC₅₀	0.8 μM Compound: 1	inhibitory concentration against the growth of breast cancer MCF-7 cell line after 72 hr of exposure inhibitory concentration against the growth of breast cancer MCF-7 cell line after 72 hr of exposure	[PMID: 15501062]
MCF7	IC₅₀	0.9 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 22691179]
MCF7	IC₅₀	0.91 nM Compound: (+)-2, 2, taxol	Antiproliferative activity against human MCF7 cells after 96 hrs by SRB method Antiproliferative activity against human MCF7 cells after 96 hrs by SRB method	[PMID: 21870795]
MCF7	IC₅₀	1.17 x 10^-2 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 18419154]
MCF7	IC₅₀	1.17 μM Compound: PTX	Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 30913525]
MCF7	IC₅₀	1.2 nM Compound: paclitaxel	Cytotoxicity against P-glycoprotein deficient wild type human MCF7 cells after 72 hrs Cytotoxicity against P-glycoprotein deficient wild type human MCF7 cells after 72 hrs	[PMID: 19239240]
MCF7	IC₅₀	1.25 nM Compound: PTX	Cytotoxicity against human MCF7 cells assessed as cell viability measured after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as cell viability measured after 72 hrs by MTS assay	[PMID: 27311893]
MCF7	IC₅₀	1.3 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 20627721]
MCF7	IC₅₀	1.3 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 20716468]
MCF7	IC₅₀	1.3 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21875764]
MCF7	IC₅₀	1.4 nM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 14987056]
MCF7	IC₅₀	1.4 x 10^-2 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 21812410]
MCF7	IC₅₀	1.4 x 10^-2 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTS assay	[PMID: 25760674]
MCF7	IC₅₀	1.428 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29223717]
MCF7	IC₅₀	1.5 x 10^-3 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 24960143]
MCF7	IC₅₀	1.62 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by Alamar blue assay Cytotoxicity against human MCF7 cells after 48 hrs by Alamar blue assay	[PMID: 21779519]
MCF7	IC₅₀	1.7 nM Compound: 1a Paclitaxel	Compound was tested for its cytotoxicity by inhibiting the growth of MCF-7 cell line after 72 h Compound was tested for its cytotoxicity by inhibiting the growth of MCF-7 cell line after 72 h	[PMID: 15225730]
MCF7	IC₅₀	1.7 nM Compound: 59	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 39068862]
MCF7	IC₅₀	1.7 nM Compound: Paclitaxel	Cytotoxicity against human breast MCF-7 cancer cell lines Cytotoxicity against human breast MCF-7 cancer cell lines	10.1016/S0960-894X(01)80298-5
MCF7	IC₅₀	1.7 nM Compound: Paclitaxel	Cytotoxicity was evaluated in vitro against MCF-7 (mammary carcinoma) human tumor cell lines Cytotoxicity was evaluated in vitro against MCF-7 (mammary carcinoma) human tumor cell lines	10.1016/S0960-894X(01)80568-0
MCF7	IC₅₀	1.7 nM Compound: Paclitaxel	Cytotoxicity was evaluated against MCF-7 mammary carcinoma human breast cancer cell line Cytotoxicity was evaluated against MCF-7 mammary carcinoma human breast cancer cell line	10.1016/S0960-894X(96)00595-1
MCF7	IC₅₀	1.7 nM Compound: Paclitaxel	Inhibitory activity against the growth of MCF-7 (human breast carcinoma) cell line after 72 hours of drug exposure Inhibitory activity against the growth of MCF-7 (human breast carcinoma) cell line after 72 hours of drug exposure	[PMID: 10617084]
MCF7	IC₅₀	1.7 nM Compound: Paclitaxel	In vitro cytotoxicity of compound against human MCF-7 (breast) cancer cell line after 72 hr of drug exposure In vitro cytotoxicity of compound against human MCF-7 (breast) cancer cell line after 72 hr of drug exposure	[PMID: 12477344]
MCF7	IC₅₀	1.7 nM Compound: Paclitaxel	Growth inhibition of human mammary carcinoma (MCF-7) cell line Growth inhibition of human mammary carcinoma (MCF-7) cell line	[PMID: 9022793]
MCF7	IC₅₀	1.7 nM Compound: Paclitaxel	Inhibition of the growth against human mammary carcinoma (MCF-7) cell line after 72 hr exposure Inhibition of the growth against human mammary carcinoma (MCF-7) cell line after 72 hr exposure	[PMID: 9022794]
MCF7	IC₅₀	1.7 nM Compound: Paclitaxel, Taxol	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 25047938]
MCF7	IC₅₀	1.7 nM Compound: Taxol	In vitro cytotoxicity against MCF-7 cell line In vitro cytotoxicity against MCF-7 cell line	[PMID: 14584931]
MCF7	IC₅₀	1.7 nM Compound: paclitaxel	Cytotoxicity against Pgp deficient human MCF7 cells after 72 hrs by sulforhodamine B test Cytotoxicity against Pgp deficient human MCF7 cells after 72 hrs by sulforhodamine B test	[PMID: 18465846]
MCF7	IC₅₀	1.7 nM Compound: paclitaxel	In vitro cytotoxicity against human mammary carcinoma MCF-7 In vitro cytotoxicity against human mammary carcinoma MCF-7	[PMID: 8182698]
MCF7	IC₅₀	1.7 nM Compound: paclitaxel	Concentration required to inhibit growth of human tumor MCF-7 (breast) cell line. Concentration required to inhibit growth of human tumor MCF-7 (breast) cell line.	[PMID: 8831755]
MCF7	IC₅₀	1.8 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability Cytotoxicity against human MCF7 cells assessed as reduction in cell viability	[PMID: 25105722]
MCF7	IC₅₀	1.86 μM Compound: Paclitaxel	Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay	10.1007/s00044-012-0436-9
MCF7	IC₅₀	10.4 nM Compound: PXL	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 28099003]
MCF7	IC₅₀	10.4 nM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay	[PMID: 28290698]
MCF7	IC₅₀	11 μM Compound: PXL	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay	[PMID: 38438305]
MCF7	IC₅₀	11.2 nM Compound: PXL	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 30010341]
MCF7	IC₅₀	11.2 nM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 31126820]
MCF7	IC₅₀	11.2 nM Compound: Taxol	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 14695798]
MCF7	IC₅₀	11.2 nM Compound: taxol	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 15043404]
MCF7	IC₅₀	11.4 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
MCF7	IC₅₀	11.4 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
MCF7	IC₅₀	11.46 nM Compound: PXL	Antiproliferative activity against human MCF7 cells by sulforhodamine B assay Antiproliferative activity against human MCF7 cells by sulforhodamine B assay	[PMID: 28457756]
MCF7	IC₅₀	11.5 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay	[PMID: 30189396]
MCF7	IC₅₀	12.06 nM Compound: PXL	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31541869]
MCF7	IC₅₀	12.1 nM Compound: PXL	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by SRB assay	[PMID: 38970504]
MCF7	IC₅₀	12.4 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 17764148]
MCF7	IC₅₀	13.4 nM Compound: PXL	Antiproliferative activity against HER2-negative human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against HER2-negative human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 38251859]
MCF7	IC₅₀	13.5 nM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32946697]
MCF7	IC₅₀	13.99 μM Compound: Taxol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C6MD00234J
MCF7	IC₅₀	132 nM Compound: taxol	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
MCF7	IC₅₀	15 nM Compound: Paclitaxel	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37146221]
MCF7	IC₅₀	15 nM Compound: Taxol	Cytotoxicity against estrogen receptor-positive human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay Cytotoxicity against estrogen receptor-positive human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay	[PMID: 22818081]
MCF7	IC₅₀	19.7 nM Compound: Abraxane	Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay	[PMID: 36471625]
MCF7	IC₅₀	2 nM Compound: Taxol	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 11325226]
MCF7	IC₅₀	2.1 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33587631]
MCF7	IC₅₀	2.11 μM Compound: Taxol	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19359185]
MCF7	IC₅₀	2.11 μM Compound: Taxol	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21067933]
MCF7	IC₅₀	2.11 μM Compound: Taxol	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21342735]
MCF7	IC₅₀	2.2 nM Compound: PT	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
MCF7	IC₅₀	2.3 μM Compound: taxol	Cytotoxicity against human MCF7 cells after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 26316467]
MCF7	IC₅₀	2.4 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 29648818]
MCF7	IC₅₀	2.5 nM Compound: paclitaxel	Growth inhibition of Pgp deficient MCF7 cells expressing MRP1 Growth inhibition of Pgp deficient MCF7 cells expressing MRP1	[PMID: 17567121]
MCF7	IC₅₀	2.58 μM Compound: Pacli	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25563891]
MCF7	IC₅₀	2.87 nM Compound: Paclitaxel	Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 72 hr in MCF-7 cell line by MTT assay. Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 72 hr in MCF-7 cell line by MTT assay.	[PMID: 12392737]
MCF7	IC₅₀	2.98 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 18701281]
MCF7	IC₅₀	20.5 nM Compound: Taxol	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 21296467]
MCF7	IC₅₀	20.5 nM Compound: Taxol	Antiproliferative against human MCF7 cells assessed as cell viability after 96 hrs by MTT assay Antiproliferative against human MCF7 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 24211639]
MCF7	IC₅₀	22.75 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27797192]
MCF7	IC₅₀	2290.87 nM Compound: Paclitaxel	Cytotoxicity against human paclitaxel-resistant MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human paclitaxel-resistant MCF7 cells after 72 hrs by MTT assay	[PMID: 29468872]
MCF7	IC₅₀	28.74 nM Compound: TAX; PTX	Antiproliferation activity against human MCF7 cells measured after 72 hrs incubation by MTT assay Antiproliferation activity against human MCF7 cells measured after 72 hrs incubation by MTT assay	[PMID: 38781920]
MCF7	IC₅₀	29 μM Compound: 1, paclitaxel	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 20302348]
MCF7	IC₅₀	299 nM Compound: paclitaxel	In vitro cytotoxicity against human mammary carcinoma cells 180 fold resistant to adriamycin MCF7-R In vitro cytotoxicity against human mammary carcinoma cells 180 fold resistant to adriamycin MCF7-R	[PMID: 8182698]
MCF7	IC₅₀	299 nM Compound: paclitaxel	Concentration required to inhibit growth of human tumor MFC7-R (breast) cell line. Concentration required to inhibit growth of human tumor MFC7-R (breast) cell line.	[PMID: 8831755]
MCF7	IC₅₀	3 nM Compound: Paclitaxel	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 19601594]
MCF7	IC₅₀	3 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
MCF7	IC₅₀	3 x 10^-3 μM Compound: Taxol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability Cytotoxicity against human MCF7 cells assessed as reduction in cell viability	[PMID: 32273216]
MCF7	IC₅₀	3.1 nM Compound: PTX	Cytotoxicity against human MCF7 cells assessed as cell viability measured after 48 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as cell viability measured after 48 hrs by MTS assay	[PMID: 27311893]
MCF7	IC₅₀	3.1 μM Compound: Paclitaxel	Cytotoxic activity against human MCF7 cells Cytotoxic activity against human MCF7 cells	[PMID: 24195466]
MCF7	IC₅₀	3.2 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by trypan blue exclusion method Cytotoxicity against human MCF7 cells after 48 hrs by trypan blue exclusion method	[PMID: 25211032]
MCF7	IC₅₀	3.9 nM Compound: PXL	Antiproliferative activity against human MCF7 cells after 3 days by SRB assay Antiproliferative activity against human MCF7 cells after 3 days by SRB assay	[PMID: 26865176]
MCF7	IC₅₀	3.99 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 26602827]
MCF7	IC₅₀	300 nM Compound: Paclitaxel	Cytotoxicity against adriamycin resistant human breast MCF-7 cancer cell lines Cytotoxicity against adriamycin resistant human breast MCF-7 cancer cell lines	10.1016/S0960-894X(01)80298-5
MCF7	IC₅₀	300 nM Compound: Paclitaxel	Inhibitory activity against the growth of MCF-7R ( multi drug resistant human breast carcinoma) cell line after 72 hours of drug exposure Inhibitory activity against the growth of MCF-7R ( multi drug resistant human breast carcinoma) cell line after 72 hours of drug exposure	[PMID: 10617084]
MCF7	IC₅₀	300 nM Compound: paclitaxel	Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs	[PMID: 19239240]
MCF7	IC₅₀	31.5 nM Compound: PTX	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 38430854]
MCF7	IC₅₀	32.3 nM Compound: PTX	Cytotoxicity in human MCF7 assessed as inhibition in cell growth measured after 24 hrs by MTT assay Cytotoxicity in human MCF7 assessed as inhibition in cell growth measured after 24 hrs by MTT assay	[PMID: 35084853]
MCF7	IC₅₀	32.3 nM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 27213819]
MCF7	IC₅₀	35.7 nM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay	[PMID: 35737669]
MCF7	IC₅₀	354 nM Compound: 1	Cytotoxicity against human multidrug-resistant MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human multidrug-resistant MCF7 cells after 72 hrs by SRB assay	[PMID: 14987056]
MCF7	IC₅₀	39 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 72 hrs by SRB method Cytotoxicity against human MCF7 cells after 72 hrs by SRB method	[PMID: 18990574]
MCF7	IC₅₀	4.42 mM Compound: paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB colorimetric assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB colorimetric assay	[PMID: 25856545]
MCF7	IC₅₀	4.77 μM Compound: Taxol	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 22483090]
MCF7	IC₅₀	4.7 μg/mL Compound: Taxol	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 36325400]
MCF7	IC₅₀	4.9 nM Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by MTS method Cytotoxicity against human MCF7 cells after 48 hrs by MTS method	[PMID: 14987051]
MCF7	IC₅₀	4.9 nM Compound: 1	Cytotoxicity against ERalpha positive human MCF7 cells Cytotoxicity against ERalpha positive human MCF7 cells	[PMID: 17419065]
MCF7	IC₅₀	4.9 nM Compound: Paclitaxel	Evaluated in vitro for antiproliferative activity against MCF-7 cell lines model of hormone dependent breast cancer Evaluated in vitro for antiproliferative activity against MCF-7 cell lines model of hormone dependent breast cancer	10.1016/S0960-894X(97)10152-4
MCF7	IC₅₀	40.37 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 after 24 hrs by MTT assay Antiproliferative activity against human MCF7 after 24 hrs by MTT assay	[PMID: 30826188]
MCF7	IC₅₀	45 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24929344]
MCF7	IC₅₀	47.25 μM Compound: Paclitaxel	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36481599]
MCF7	IC₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29759727]
MCF7	IC₅₀	5 nM Compound: Taxol	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 23806112]
MCF7	IC₅₀	5.1 μM Compound: PTX	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
MCF7	IC₅₀	5.5 nM Compound: PTX	Growth inhibition of human MCF7 cells after 96 hrs by trypan blue exclusion assay Growth inhibition of human MCF7 cells after 96 hrs by trypan blue exclusion assay	[PMID: 29730191]
MCF7	IC₅₀	6 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21341718]
MCF7	IC₅₀	6.1 nM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay	[PMID: 36092142]
MCF7	IC₅₀	6.2 nM Compound: Taxol	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 25819096]
MCF7	IC₅₀	6.5 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells expressing Oct4-GFP assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells expressing Oct4-GFP assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 29648818]
MCF7	IC₅₀	6.6 nM Compound: PTX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33280896]
MCF7	IC₅₀	7.05 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24332858]
MCF7	IC₅₀	7.3 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 28598633]
MCF7	IC₅₀	7.32 nM Compound: Taxol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 26697718]
MCF7	IC₅₀	7.4 nM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26690274]
MCF7	IC₅₀	7.52 nM Compound: PXL	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 30106296]
MCF7	IC₅₀	7.6 μM Compound: TAX, Taxol	Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method	[PMID: 25061803]
MCF7	IC₅₀	71 μM Compound: PTX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of chloramphenicol by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of chloramphenicol by MTT assay	[PMID: 34097831]
MCF7	IC₅₀	75.2 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24044895]
MCF7	IC₅₀	77.2 μM Compound: Taxol	Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
MCF7	IC₅₀	8.2 μM Compound: Paclitaxel	Inhibition of serum-induced proliferation of human adriamycin-resistant MCF7 cells Inhibition of serum-induced proliferation of human adriamycin-resistant MCF7 cells	[PMID: 17601739]
MCF7	IC₅₀	8.37 nM Compound: PXL	Antiproliferative activity against human MCF7 cells after 24 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 24 hrs by SRB assay	[PMID: 30106296]
MCF7	IC₅₀	8.54 nM Compound: PXL	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 30106296]
MCF7	IC₅₀	8.8 nM Compound: PXL	Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 29319316]
MCF7	IC₅₀	9.6 nM Compound: Paclitaxol	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
MCF7	IC₅₀	9.66 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay	10.1039/C4MD00573B
MCF7	IC₅₀	90 μM Compound: PTX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of photoCORM delivered CO by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of photoCORM delivered CO by MTT assay	[PMID: 34097831]
MCF7	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 23327668]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24417634]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 27704807]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 28654256]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 29286250]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 29338226]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTS assay	[PMID: 29338260]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Growth inhibition of human MCF7 cells after 48 hrs by MTS assay Growth inhibition of human MCF7 cells after 48 hrs by MTS assay	[PMID: 29412669]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 31310115]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 31390200]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32628478]
MCF7	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34355562]
MCF7	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25871261]
MCF7	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26068802]
MCF7	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 4 days by MTT assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 4 days by MTT assay	[PMID: 29884535]
MCF7	IC₅₀	< 0.008 μM Compound: Taxol	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36274275]
MCF7	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTT method Cytotoxicity against human MCF7 cells after 48 hrs by MTT method	[PMID: 21534539]
MCF7	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human MCF7 assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 23586920]
MCF7	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23819871]
MCF7	IC₅₀	< 0.008 μM Compound: paclitaxel	Antimicrobial activity against human MCF7 cells after 48 hrs by MTT assay Antimicrobial activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23957453]
MCF7	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 24219809]
MCF7	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 24256484]
MCF7	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTS assay	[PMID: 24697496]
MCF7	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25375202]
MCF7	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 25798528]
MCF7	IC₅₀	< 0.01 μM Compound: Taxol	Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
MCF7	IC₅₀	< 0.015 μM Compound: 1	Antiproliferative activity against human MCF7 cell line by MTT assay after 72 hrs Antiproliferative activity against human MCF7 cell line by MTT assay after 72 hrs	[PMID: 16513344]
MCF7	IC₅₀	< 15 nM Compound: PTX	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 30819618]
MCF7	IC₅₀	< 3 ng/mL Compound: 1 (paclitaxel)	Cytotoxicity against MCF-7 Tumor cell line in SRB Cell viability test Cytotoxicity against MCF-7 Tumor cell line in SRB Cell viability test	[PMID: 10956217]
MCF7	IC₅₀	< 3 ng/mL Compound: 1	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 17419065]
MCF7	IC₅₀	> 10 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
MCF7	IC₅₀	> 100 nM Compound: PXL	Antiproliferative activity against human MCF7 cells after 3 days by SRB assay Antiproliferative activity against human MCF7 cells after 3 days by SRB assay	[PMID: 25241925]
MCF7	IC₅₀	> 40 μM Compound: Paclitaxel	Anticancer activity against human MCF7 cells Anticancer activity against human MCF7 cells	[PMID: 31945642]
MCF7	IC₅₀	> 6 μM Compound: 1a (Paclitaxel)	Inhibitory activity against Adriamycin-resistant MCF-7 breast cancer cell line Inhibitory activity against Adriamycin-resistant MCF-7 breast cancer cell line	[PMID: 12031338]
MCF7	IC₅₀	> 81.1 x 10^-3 μM Compound: Taxol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34883453]
MCF7-DOX	IC₅₀	585 nM Compound: 1	Cytotoxic potency in doxorubicin resistant MCF7 cell line after 72 hr exposure by SRB test Cytotoxic potency in doxorubicin resistant MCF7 cell line after 72 hr exposure by SRB test	[PMID: 16183281]
MCF7-VP	IC₅₀	0.0028 μM Compound: paclitaxel, Taxol	Cytotoxic activity against Pgp-deficient human MCF7/VP cells expressing MRP1 after 48 hrs by sulforhodamine B assay Cytotoxic activity against Pgp-deficient human MCF7/VP cells expressing MRP1 after 48 hrs by sulforhodamine B assay	[PMID: 21680190]
MCF7-VP	IC₅₀	2.8 nM Compound: paclitaxel	Growth inhibition of Pgp deficient MCF7/VP cells expressing MRP1 Growth inhibition of Pgp deficient MCF7/VP cells expressing MRP1	[PMID: 17567121]
MCF7/PTX	IC₅₀	54.8 μM Compound: PTX	Cytotoxicity against human MCF7/PTX cells incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7/PTX cells incubated for 48 hrs by MTT assay	[PMID: 30913525]
MCF7R	IC₅₀	0.19 μM Compound: Paclitaxel	Antiproliferative activity against paclitaxel-resistant human MCF7R cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against paclitaxel-resistant human MCF7R cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
MCF7R	IC₅₀	1.185 μM Compound: Paclitaxel	In vitro cytotoxic activity against growth of MDR phenotype human breast carcinoma cell line (MCF-7-R) after 72 hr In vitro cytotoxic activity against growth of MDR phenotype human breast carcinoma cell line (MCF-7-R) after 72 hr	[PMID: 15177459]
MCF7R	IC₅₀	299 nM Compound: Paclitaxel	Cytotoxicity was evaluated against MCF7-R (mammary carcinoma 180-fold resistant to doxorubicin, expressing MDR phenotype) human breast cancer cell line Cytotoxicity was evaluated against MCF7-R (mammary carcinoma 180-fold resistant to doxorubicin, expressing MDR phenotype) human breast cancer cell line	10.1016/S0960-894X(96)00595-1
MCF7R	IC₅₀	299 nM Compound: Paclitaxel	Growth inhibition of human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line Growth inhibition of human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line	[PMID: 9022793]
MCF7R	IC₅₀	299 nM Compound: Paclitaxel	Inhibition of the growth against human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line after 72 hr exposure Inhibition of the growth against human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line after 72 hr exposure	[PMID: 9022794]
MCF7R	IC₅₀	299 nM Compound: Paclitaxel, Taxol	Cytotoxicity against human MCF7/R cells by MTT assay Cytotoxicity against human MCF7/R cells by MTT assay	[PMID: 25047938]
MCF7R	IC₅₀	299 nM Compound: Taxol	In vitro cytotoxicity against MCF7-R cell line In vitro cytotoxicity against MCF7-R cell line	[PMID: 14584931]
MCF7R	IC₅₀	550 nM Compound: Paclitaxel	Cytotoxicity against human mammary tumor cell line MCF7-R Cytotoxicity against human mammary tumor cell line MCF7-R	[PMID: 16298526]
MCF7R	IC₅₀	860 nM Compound: Paclitaxel	Cytotoxicity was evaluated in MCF7-R cell line Cytotoxicity was evaluated in MCF7-R cell line	[PMID: 9871652]
MCF7S	IC₅₀	0.002 μM Compound: Paclitaxel	In vitro cytotoxic activity against growth of human breast carcinoma cell line (MCF-7-S) after 72 hr In vitro cytotoxic activity against growth of human breast carcinoma cell line (MCF-7-S) after 72 hr	[PMID: 15177459]
MCF7S	IC₅₀	1.7 nM Compound: Paclitaxel	Cytotoxicity against human mammary tumor cell line MCF7-S Cytotoxicity against human mammary tumor cell line MCF7-S	[PMID: 16298526]
MDA-MB-231	GI₅₀	0.091 μM Compound: Paclitaxel	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 25264072]
MDA-MB-231	GI₅₀	0.091 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in net protein increase after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in net protein increase after 48 hrs by SRB assay	[PMID: 25462234]
MDA-MB-231	GI₅₀	0.091 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27209232]
MDA-MB-231	GI₅₀	0.092 μM Compound: Paclitaxel	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 27964883]
MDA-MB-231	GI₅₀	0.22 μM Compound: PTX	Antiproliferative activity against human MDA-MB-231 cells measured after 6 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 6 days by MTT assay	[PMID: 35617854]
MDA-MB-231	GI₅₀	0.3 μM Compound: PTX	Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay	[PMID: 35617854]
MDA-MB-231	GI₅₀	1.6 nM Compound: 1a; PTX	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay	[PMID: 37490800]
MDA-MB-231	GI₅₀	10 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28653846]
MDA-MB-231	GI₅₀	12.5 nM Compound: Paclitaxel	Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
MDA-MB-231	GI₅₀	12.5 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
MDA-MB-231	GI₅₀	5.2 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31938468]
MDA-MB-231	GI₅₀	7.4 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 34917259]
MDA-MB-231	GI₅₀	8.67 nM Compound: Taxol	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay	[PMID: 27224875]
MDA-MB-231	GI₅₀	< 0.01 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 25827522]
MDA-MB-231	GI₅₀	< 0.01 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 26994690]
MDA-MB-231	GI₅₀	< 0.016 μM Compound: Paciltaxel	Antiproliferative activity against human MDA-MB-231 cells by SRB assay Antiproliferative activity against human MDA-MB-231 cells by SRB assay	[PMID: 31546197]
MDA-MB-231	IC₅₀	0.001 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 after 48 hrs by MTT assay	[PMID: 30387611]
MDA-MB-231	IC₅₀	0.0026 μM Compound: Paclitaxel	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay	[PMID: 28252962]
MDA-MB-231	IC₅₀	0.0027 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay	[PMID: 32096998]
MDA-MB-231	IC₅₀	0.003 μM Compound: PTX	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29306206]
MDA-MB-231	IC₅₀	0.003 μM Compound: PTX	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 35065411]
MDA-MB-231	IC₅₀	0.003 μM Compound: PTX	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MDA-MB-231	IC₅₀	0.003 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32633512]
MDA-MB-231	IC₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
MDA-MB-231	IC₅₀	0.0066 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells after 72 hrs sulforhodamine B colorimetric assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs sulforhodamine B colorimetric assay	[PMID: 25008456]
MDA-MB-231	IC₅₀	0.007 μM Compound: PTX	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35447432]
MDA-MB-231	IC₅₀	0.008 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 34403728]
MDA-MB-231	IC₅₀	0.009 μM Compound: taxol	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 28594169]
MDA-MB-231	IC₅₀	0.00917 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
MDA-MB-231	IC₅₀	0.02 μM Compound: 1; PTX	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 33065439]
MDA-MB-231	IC₅₀	0.021 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 26934105]
MDA-MB-231	IC₅₀	0.027 μM Compound: PTX	Cytotoxicity against human MDA-MB-231 cells expressing TLR4 assessed as growth inhibition measured after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells expressing TLR4 assessed as growth inhibition measured after 96 hrs by MTT assay	[PMID: 34600241]
MDA-MB-231	IC₅₀	0.03 μM Compound: Taxol	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
MDA-MB-231	IC₅₀	0.04 μM Compound: PTX	Cytotoxicity against human MDA-MB-231 cells expressing TLR4 assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells expressing TLR4 assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34600241]
MDA-MB-231	IC₅₀	0.05 μM Compound: Taxol	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 36270090]
MDA-MB-231	IC₅₀	0.052 μM Compound: Taxol	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by crystal violet staining based microplate reader analysis Cytotoxicity against human MDA-MB-231 cells after 72 hrs by crystal violet staining based microplate reader analysis	[PMID: 23153397]
MDA-MB-231	IC₅₀	0.059 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	[PMID: 28926237]
MDA-MB-231	IC₅₀	0.06 μM Compound: Taxol	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
MDA-MB-231	IC₅₀	0.07 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36786551]
MDA-MB-231	IC₅₀	0.08 μM Compound: Taxol	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay	[PMID: 28262526]
MDA-MB-231	IC₅₀	0.1 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 27449957]
MDA-MB-231	IC₅₀	0.1 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 31120251]
MDA-MB-231	IC₅₀	0.1 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 33421712]
MDA-MB-231	IC₅₀	0.11 μM Compound: Paciitaxel	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by CCK8 assay	[PMID: 38493728]
MDA-MB-231	IC₅₀	0.12 μg/mL Compound: Taxol	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 16038548]
MDA-MB-231	IC₅₀	0.19 μM Compound: PTX	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38280356]
MDA-MB-231	IC₅₀	0.2 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Cell Titer-Blue cell viability assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Cell Titer-Blue cell viability assay	[PMID: 33006889]
MDA-MB-231	IC₅₀	0.2 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 after 24 hrs by MTT assay	[PMID: 30387611]
MDA-MB-231	IC₅₀	0.33 μM Compound: Taxol	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
MDA-MB-231	IC₅₀	0.457 μM Compound: Taxol, Paclitaxel	Cytotoxicity against paclitaxel-resistant human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against paclitaxel-resistant human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 25462222]
MDA-MB-231	IC₅₀	0.6 nM Compound: Taxol	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay	[PMID: 33859802]
MDA-MB-231	IC₅₀	0.6 x 10^-3 μM Compound: Taxol	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36884371]
MDA-MB-231	IC₅₀	0.7 nM Compound: Pac	Inhibition of human MDA-MB-231 cell spheroids incubated for 7 days by luciferase based assay Inhibition of human MDA-MB-231 cell spheroids incubated for 7 days by luciferase based assay	[PMID: 36780832]
MDA-MB-231	IC₅₀	0.8 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells measured after 72 hrs by western blot Cytotoxicity against human MDA-MB-231 cells measured after 72 hrs by western blot	[PMID: 34378386]
MDA-MB-231	IC₅₀	0.9 nM Compound: PXL	Antiproliferative activity against triple negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against triple negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 38251859]
MDA-MB-231	IC₅₀	0.9 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	1.1 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36621138]
MDA-MB-231	IC₅₀	1.6 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
MDA-MB-231	IC₅₀	10.7 nM Compound: Paclitaxel	Antiproliferative activity against triple-negative human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against triple-negative human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 31550158]
MDA-MB-231	IC₅₀	12.1 nM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 30106296]
MDA-MB-231	IC₅₀	13.23 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 30738663]
MDA-MB-231	IC₅₀	17 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
MDA-MB-231	IC₅₀	170 nM Compound: Taxol	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 31633350]
MDA-MB-231	IC₅₀	18 nM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay	[PMID: 26865176]
MDA-MB-231	IC₅₀	19.3 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay	[PMID: 36092142]
MDA-MB-231	IC₅₀	2.01 μM Compound: Paclitaxel	Antimigratory activity in human MDA-MB-231 cells assessed as inhibition of cell motility after 24 hrs by microscopic analysis Antimigratory activity in human MDA-MB-231 cells assessed as inhibition of cell motility after 24 hrs by microscopic analysis	[PMID: 31838326]
MDA-MB-231	IC₅₀	2.56 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 26602827]
MDA-MB-231	IC₅₀	2.6 nM Compound: Taxol	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay	[PMID: 30192537]
MDA-MB-231	IC₅₀	2.7 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay	[PMID: 27983842]
MDA-MB-231	IC₅₀	2.8 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
MDA-MB-231	IC₅₀	25 μM Compound: 1, paclitaxel	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 20302348]
MDA-MB-231	IC₅₀	3 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29373791]
MDA-MB-231	IC₅₀	3 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32339854]
MDA-MB-231	IC₅₀	3.05 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27797192]
MDA-MB-231	IC₅₀	3.1 nM Compound: PTX	Antiproliferative activity against ACE-positive human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against ACE-positive human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 34699215]
MDA-MB-231	IC₅₀	3.388 nM Compound: Paclitaxel	Anti-cancer activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by WST-1 assay Anti-cancer activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by WST-1 assay	[PMID: 27317645]
MDA-MB-231	IC₅₀	3.42 nM Compound: PTX	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
MDA-MB-231	IC₅₀	3.77 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 34726897]
MDA-MB-231	IC₅₀	3.8 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Cell titer blue assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Cell titer blue assay	[PMID: 37216676]
MDA-MB-231	IC₅₀	3.9 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26690274]
MDA-MB-231	IC₅₀	3.9 μg/mL Compound: PTX	Anticancer activity against human MDA-MB-231 cells by MTT assay Anticancer activity against human MDA-MB-231 cells by MTT assay	[PMID: 18826299]
MDA-MB-231	IC₅₀	30 nM Compound: Paclitaxel	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37146221]
MDA-MB-231	IC₅₀	38.31 nM Compound: PTX	Antitumor activity against human MDA-MB-231 cells assessed as inhibition of cell viability by measuring inhibition rate measured after 72 hrs by CCK-8 assay relative to control Antitumor activity against human MDA-MB-231 cells assessed as inhibition of cell viability by measuring inhibition rate measured after 72 hrs by CCK-8 assay relative to control	[PMID: 39208364]
MDA-MB-231	IC₅₀	4.5 nM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS method Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS method	[PMID: 14987051]
MDA-MB-231	IC₅₀	4.5 nM Compound: 1	Cytotoxicity against ERalpha negative human MDA-MB-231 cells Cytotoxicity against ERalpha negative human MDA-MB-231 cells	[PMID: 17419065]
MDA-MB-231	IC₅₀	4.55 μM Compound: Taxol	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 39044437]
MDA-MB-231	IC₅₀	40.5 nM Compound: paclitaxel	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 18606540]
MDA-MB-231	IC₅₀	47.1 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB method Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB method	[PMID: 18990574]
MDA-MB-231	IC₅₀	5 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
MDA-MB-231	IC₅₀	5.34 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 29391939]
MDA-MB-231	IC₅₀	5.6 nM Compound: PTX	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 24564494]
MDA-MB-231	IC₅₀	56.12 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay	[PMID: 34922028]
MDA-MB-231	IC₅₀	6.2 μM Compound: Taxol	Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay	[PMID: 25453798]
MDA-MB-231	IC₅₀	6.9 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs	[PMID: 38341161]
MDA-MB-231	IC₅₀	7 nM Compound: PTX	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26132075]
MDA-MB-231	IC₅₀	7 nM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 29319316]
MDA-MB-231	IC₅₀	7.03 x 10^-2 μM Compound: paclitaxel	Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 18419154]
MDA-MB-231	IC₅₀	8.1 nM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 30010341]
MDA-MB-231	IC₅₀	8.2 x 10^-3 μM Compound: paclitaxel	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 24960143]
MDA-MB-231	IC₅₀	8.4 nM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay	[PMID: 38970504]
MDA-MB-231	IC₅₀	8.51 nM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 30106296]
MDA-MB-231	IC₅₀	8.6 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32946697]
MDA-MB-231	IC₅₀	8.7 μM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay	[PMID: 38438305]
MDA-MB-231	IC₅₀	8.8 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay	[PMID: 28290698]
MDA-MB-231	IC₅₀	8.82 nM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 28099003]
MDA-MB-231	IC₅₀	87 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24044895]
MDA-MB-231	IC₅₀	9.1 nM Compound: Pac	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
MDA-MB-231	IC₅₀	9.1 nM Compound: Pac	Antiproliferative activity against human MDA-MB-231 after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 after 48 hrs by SRB assay	[PMID: 21920638]
MDA-MB-231	IC₅₀	9.1 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 31126820]
MDA-MB-231	IC₅₀	9.384 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
MDA-MB-231	IC₅₀	9.4 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
MDA-MB-231	IC₅₀	9.4 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
MDA-MB-231	IC₅₀	9.6 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay	[PMID: 30189396]
MDA-MB-231	IC₅₀	9.63 nM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 28457756]
MDA-MB-231	IC₅₀	9.74 nM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31541869]
MDA-MB-231	IC₅₀	< 0.001 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 26448037]
MDA-MB-231	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
MDA-MB-231	IC₅₀	< 0.001 μM Compound: Taxol	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 33713977]
MDA-MB-231	IC₅₀	< 0.001 μM Compound: Taxol	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 36057236]
MDA-MB-231	IC₅₀	< 0.005 μM Compound: Taxol	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37837671]
MDA-MB-231	IC₅₀	< 0.025 μM Compound: Taxol	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay	[PMID: 32949719]
MDA-MB-231	IC₅₀	< 1 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 23848163]
MDA-MB-231	IC₅₀	> 10 nM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by SRB assay	[PMID: 30106296]
MDA-MB-231	IC₅₀	> 100 μM Compound: PTX	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 37395092]
MDA-MB-231	IC₅₀	> 50 μM Compound: taxol	Cytotoxicity against human MDA-MB-231 after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 after 48 hrs by SRB assay	[PMID: 21044847]
MDA-MB-231	IC₅₀	> 7.8 nM Compound: PXL	Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay	[PMID: 25241925]
MDA-MB-361	IC₅₀	4 ng/mL Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 3 days by MTS assay Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 3 days by MTS assay	[PMID: 20068177]
MDA-MB-361	IC₅₀	> 150 ng/mL Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 1 days by MTS assay Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 1 days by MTS assay	[PMID: 20068177]
MDA-MB-361	IC₅₀	> 150 ng/mL Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 2 days by MTS assay Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 2 days by MTS assay	[PMID: 20068177]
MDA-MB-435	EC₅₀	4.5 nM Compound: paclitaxel	Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27213719]
MDA-MB-435	GI₅₀	1 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 0.1% FBS by sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 0.1% FBS by sulforhodamine B assay	[PMID: 28112516]
MDA-MB-435	GI₅₀	1.9 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 1% FBS by sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 1% FBS by sulforhodamine B assay	[PMID: 28112516]
MDA-MB-435	GI₅₀	3.4 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 10% FBS by sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 10% FBS by sulforhodamine B assay	[PMID: 28112516]
MDA-MB-435	GI₅₀	4 nM Compound: Paclitaxel	Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
MDA-MB-435	GI₅₀	4 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
MDA-MB-435	GI₅₀	4 nM Compound: paclitaxel	Antiproliferative activity against human MDA-MB-435 cells after 72 hrs Antiproliferative activity against human MDA-MB-435 cells after 72 hrs	[PMID: 18610995]
MDA-MB-435	IC₅₀	0.0002 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay	[PMID: 32096998]
MDA-MB-435	IC₅₀	0.0005 μM Compound: taxol	Cytotoxicity against human MDA-MB-435 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human MDA-MB-435 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 28594169]
MDA-MB-435	IC₅₀	0.0008 μM Compound: 1 (Paclitaxel)	Cytotoxicity against paclitaxel sensitive LCC6-WT-human breast carcinoma cell line Cytotoxicity against paclitaxel sensitive LCC6-WT-human breast carcinoma cell line	[PMID: 11549446]
MDA-MB-435	IC₅₀	0.0031 μM Compound: Paclitaxel	Cytotoxicity in human MDA-MB-435 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay Cytotoxicity in human MDA-MB-435 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay	[PMID: 28252962]
MDA-MB-435	IC₅₀	0.004 μM Compound: Paclitaxel	In vitro cytotoxic activity against growth of human breast carcinoma cell line (LCC6-WT) after 72 hr In vitro cytotoxic activity against growth of human breast carcinoma cell line (LCC6-WT) after 72 hr	[PMID: 15177459]
MDA-MB-435	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human MDA435 cell line by MTS assay Cytotoxicity against human MDA435 cell line by MTS assay	[PMID: 16870446]
MDA-MB-435	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human MDA435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA435 cells after 72 hrs by MTT assay	[PMID: 18308566]
MDA-MB-435	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human MDA435 cells Cytotoxicity against human MDA435 cells	[PMID: 23937981]
MDA-MB-435	IC₅₀	0.005 μM Compound: Taxol, Paclitaxel	Cytotoxicity against human MDA435 cells after 24 hrs by MTT assay Cytotoxicity against human MDA435 cells after 24 hrs by MTT assay	[PMID: 25462222]
MDA-MB-435	IC₅₀	0.2 nM Compound: P	Cytotoxicity against human MDA-MB-435 cells treated for 72 hrs Cytotoxicity against human MDA-MB-435 cells treated for 72 hrs	[PMID: 38964520]
MDA-MB-435	IC₅₀	0.2 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay	[PMID: 27983842]
MDA-MB-435	IC₅₀	0.3 nM Compound: Taxol	Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay	[PMID: 33859802]
MDA-MB-435	IC₅₀	0.3 x 10^-3 μM Compound: Taxol	Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36884371]
MDA-MB-435	IC₅₀	0.379 μM Compound: Paclitaxel	In vitro cytotoxic activity against growth of MDR1 transduced line (LCC6-MDR) after 72 hr In vitro cytotoxic activity against growth of MDR1 transduced line (LCC6-MDR) after 72 hr	[PMID: 15177459]
MDA-MB-435	IC₅₀	0.4 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by Cell Titer-Blue cell viability assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by Cell Titer-Blue cell viability assay	[PMID: 33006889]
MDA-MB-435	IC₅₀	0.4 nM Compound: Taxol	Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 31633350]
MDA-MB-435	IC₅₀	0.612 μM Compound: 1 (Paclitaxel)	Cytotoxicity against paclitaxel resistant LCC6-MDR-MDR1 transfected cell line Cytotoxicity against paclitaxel resistant LCC6-MDR-MDR1 transfected cell line	[PMID: 11549446]
MDA-MB-435	IC₅₀	1.9 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by Cell titer blue assay Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by Cell titer blue assay	[PMID: 37216676]
MDA-MB-435	IC₅₀	1.93 nM Compound: Taxol	Antiproliferative activity against human MDA-MB-435 cells Antiproliferative activity against human MDA-MB-435 cells	[PMID: 24890652]
MDA-MB-435	IC₅₀	105 nM Compound: paclitaxel	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	13 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
MDA-MB-435	IC₅₀	16 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-435 cells by sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells by sulforhodamine B assay	[PMID: 21775150]
MDA-MB-435	IC₅₀	2 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by SRB assay	[PMID: 28433513]
MDA-MB-435	IC₅₀	2.3 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell viability incubated for 72 hrs Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell viability incubated for 72 hrs	[PMID: 38341161]
MDA-MB-435	IC₅₀	2.6 nM Compound: Paclitaxel	Cytotoxicity against human MDAMB-435 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human MDAMB-435 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 38237151]
MDA-MB-435	IC₅₀	2.9 nM Compound: paclitaxel	Antiproliferative activity against MDA435/LCC6 cells by ELISA Antiproliferative activity against MDA435/LCC6 cells by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	277 nM Compound: paclitaxel	Cytotoxicity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay	[PMID: 20919720]
MDA-MB-435	IC₅₀	3.1 nM Compound: Taxol	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay	[PMID: 30192537]
MDA-MB-435	IC₅₀	3.3 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay	[PMID: 25882519]
MDA-MB-435	IC₅₀	4 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 23547728]
MDA-MB-435	IC₅₀	4.5 nM Compound: PTX	Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth by SRB assay Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth by SRB assay	[PMID: 36889150]
MDA-MB-435	IC₅₀	4.5 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by sulforhodamine B assay	[PMID: 30098869]
MDA-MB-435	IC₅₀	4.5 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
MDA-MB-435	IC₅₀	4.8 nM Compound: paclitaxel	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	465 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-435 cells expressing LCC6MDR1 by sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells expressing LCC6MDR1 by sulforhodamine B assay	[PMID: 21775150]
MDA-MB-435	IC₅₀	490 nM Compound: 1 (Paclitaxel)	Inhibitory concentration against LCC6-MDR human breast cancer cell line Inhibitory concentration against LCC6-MDR human breast cancer cell line	[PMID: 11549446]
MDA-MB-435	IC₅₀	5.2 nM Compound: paclitaxel	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	69.3 nM Compound: paclitaxel	Resistance index, ratio of IC50 for human multidrug-resistant MDA-MB-435/LCCMDR1 cells to IC50 for human MDA-MB-435 cells Resistance index, ratio of IC50 for human multidrug-resistant MDA-MB-435/LCCMDR1 cells to IC50 for human MDA-MB-435 cells	[PMID: 20919720]
MDA-MB-435	IC₅₀	860 nM Compound: Paclitaxel	Cytotoxicity was evaluated in MDA 435/LCC6-MDR cell line Cytotoxicity was evaluated in MDA 435/LCC6-MDR cell line	[PMID: 9871652]
MDA-MB-435S	IC₅₀	0.009 μM Compound: Taxol	Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25091926]
MDA-MB-436	IC₅₀	8 nM Compound: PTX	Cytotoxicity against human MDA-MB-436 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-436 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26132075]
MDA-MB-453	IC₅₀	0.7 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
MDA-MB-468	GI₅₀	0.1 μM Compound: PTX	Antiproliferative activity against human MDA-MB-468 cells measured after 6 days by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 6 days by MTT assay	[PMID: 35617854]
MDA-MB-468	GI₅₀	12.5 nM Compound: Paclitaxel	Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
MDA-MB-468	IC₅₀	0.0061 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-468 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay Cytotoxicity against human MDA-MB-468 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	[PMID: 28926237]
MDA-MB-468	IC₅₀	0.2 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 27449957]
MDA-MB-468	IC₅₀	0.31 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay	10.1039/C4MD00573B
MDA-MB-468	IC₅₀	1 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
MDA-MB-468	IC₅₀	3 nM Compound: PTX	Antiproliferative activity against ACE-positive human MDA-MB-468 cells incubated for 48 hrs by MTT assay Antiproliferative activity against ACE-positive human MDA-MB-468 cells incubated for 48 hrs by MTT assay	[PMID: 34699215]
MDA-MB-468	IC₅₀	3.5 nM Compound: PT	Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
MDA-MB-468	IC₅₀	3.87 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by SRB assay	[PMID: 26602827]
MDA-MB-468	IC₅₀	5 nM Compound: PTX	Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26132075]
MDA-MB-468	IC₅₀	5.4 nM Compound: Taxol	Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by phosphatase assay Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by phosphatase assay	[PMID: 28857558]
MDA-MB-468	IC₅₀	7.17 nM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-468 cells after 4 days by MTS/cell proliferation assay Cytotoxicity against human MDA-MB-468 cells after 4 days by MTS/cell proliferation assay	[PMID: 25098528]
MDR	IC₅₀	0.4 μM Compound: paclitaxel	Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs	[PMID: 17181164]
MES-SA	GI₅₀	0.007 μM Compound: Paclitaxel	Antiproliferative activity against human MES-SA cells after 48 to 96 hrs by MTT assay Antiproliferative activity against human MES-SA cells after 48 to 96 hrs by MTT assay	[PMID: 27218860]
MES-SA	GI₅₀	0.007 μM Compound: paclitaxel	Cytotoxicity against human MES-SA cells assessed as growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human MES-SA cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 26360047]
MES-SA	GI₅₀	0.007 μM Compound: taxol	Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25671501]
MES-SA	GI₅₀	4 nM Compound: PTX, Taxol	Growth inhibition of human MES-SA cells Growth inhibition of human MES-SA cells	[PMID: 23750455]
MES-SA	GI₅₀	7 nM Compound: Taxol	Growth inhibition of human MES-SA cells after 48 hrs by MTT assay Growth inhibition of human MES-SA cells after 48 hrs by MTT assay	[PMID: 23927793]
MES-SA	GI₅₀	< 0.00001 μM Compound: Paclitaxel	Antiproliferative activity against human MESSA cells by SRB assay Antiproliferative activity against human MESSA cells by SRB assay	[PMID: 19394218]
MES-SA	IC₅₀	0.0005 μM Compound: paclitaxel	Cytotoxicity against human MES-SA cells Cytotoxicity against human MES-SA cells	[PMID: 17113288]
MES-SA	IC₅₀	0.0006 μM Compound: PTX	The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay. The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay.	[PMID: 10698449]
MES-SA	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human MES-SA cell line by MTS assay Cytotoxicity against human MES-SA cell line by MTS assay	[PMID: 16870446]
MES-SA	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human MESSA cells after 72 hrs by MTT assay Cytotoxicity against human MESSA cells after 72 hrs by MTT assay	[PMID: 18308566]
MES-SA	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human MES-SA cells Cytotoxicity against human MES-SA cells	[PMID: 23937981]
MES-SA	IC₅₀	0.008 μM Compound: Taxol, Paclitaxel	Cytotoxicity against human MES-SA cells after 24 hrs by MTT assay Cytotoxicity against human MES-SA cells after 24 hrs by MTT assay	[PMID: 25462222]
MES-SA	IC₅₀	0.008 μM Compound: paclitaxel	Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay	[PMID: 19053781]
MES-SA	IC₅₀	1.1 nM Compound: PT	Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
MES-SA	IC₅₀	1.6 nM Compound: paclitaxel	Antiproliferative activity against drug sensitive Messa cell line by Alamar Blue assay Antiproliferative activity against drug sensitive Messa cell line by Alamar Blue assay	[PMID: 17286393]
MES-SA	IC₅₀	2.47 nM Compound: Paclitaxel	Cytotoxicity against human MES-SA cells assessed as inhibition in cell growth Cytotoxicity against human MES-SA cells assessed as inhibition in cell growth	[PMID: 33974423]
MES-SA	IC₅₀	2.96 nM Compound: Paclitaxel	Antiproliferative activity against human MES-SA cells Antiproliferative activity against human MES-SA cells	[PMID: 21324687]
MES-SA	IC₅₀	2.96 nM Compound: paclitaxel	Antiproliferative activity against human MES-SA cells assessed as growth inhibition Antiproliferative activity against human MES-SA cells assessed as growth inhibition	[PMID: 21324686]
MES-SA	IC₅₀	2.96 nM Compound: paclitaxel	Cytotoxicity against human MES-SA cells Cytotoxicity against human MES-SA cells	[PMID: 21324692]
MES-SA	IC₅₀	3 nM Compound: Paclitaxel	Cytotoxicity against human MES-SA cells Cytotoxicity against human MES-SA cells	[PMID: 23141916]
MES-SA	IC₅₀	4 nM Compound: A, paclitaxel, taxol	Cytotoxicity against human MES-SA cells after 96 hrs by trypan blue exclusion assay Cytotoxicity against human MES-SA cells after 96 hrs by trypan blue exclusion assay	[PMID: 22587519]
MES-SA	IC₅₀	4 nM Compound: PTX	Cytotoxicity against human MES-SA cells assessed as cell viability after 96 hrs by trypan blue exclusion Cytotoxicity against human MES-SA cells assessed as cell viability after 96 hrs by trypan blue exclusion	[PMID: 21812421]
MES-SA	IC₅₀	4 nM Compound: PTX	Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay	[PMID: 23214452]
MES-SA	IC₅₀	4 nM Compound: PTX	Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by CellTitre-Glo assay Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by CellTitre-Glo assay	[PMID: 25025991]
MES-SA	IC₅₀	4 nM Compound: PTX	Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay	[PMID: 26132075]
MES-SA	IC₅₀	5 μM Compound: Taxol	Cytotoxicity against multidrug-resistant human MES-SA cells Cytotoxicity against multidrug-resistant human MES-SA cells	[PMID: 23937981]
MES-SA	IC₅₀	< 0.001 μM Compound: paclitaxel	Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay	[PMID: 19743863]
MES-SA/Dx5	GI₅₀	0.063 μM Compound: paclitaxel	Tested for inhibition of cell proliferation activity in human uterus sarcoma MES-SA cell Tested for inhibition of cell proliferation activity in human uterus sarcoma MES-SA cell	[PMID: 12773051]
MES-SA/Dx5	GI₅₀	0.16 μM Compound: Paclitaxel	Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay	[PMID: 19394218]
MES-SA/Dx5	GI₅₀	10 μM Compound: Paclitaxel	Antiproliferative activity against human MES-SA/Dx5 cells after 48 to 96 hrs by MTT assay Antiproliferative activity against human MES-SA/Dx5 cells after 48 to 96 hrs by MTT assay	[PMID: 27218860]
MES-SA/Dx5	GI₅₀	10 μM Compound: paclitaxel	Cytotoxicity against human MES-SA/Dx5 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human MES-SA/Dx5 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 26360047]
MES-SA/Dx5	GI₅₀	1800 nM Compound: Paclitaxel	Antiproliferative activity against human MES-SA/Dx5 cells Antiproliferative activity against human MES-SA/Dx5 cells	[PMID: 29617135]
MES-SA/Dx5	GI₅₀	7.54 μM Compound: Taxol	Intrinsic cytotoxicity against human MES-SA/Dx5 cells Intrinsic cytotoxicity against human MES-SA/Dx5 cells	[PMID: 19679475]
MES-SA/Dx5	GI₅₀	750 nM Compound: PTX, Taxol	Growth inhibition of multidrug-resistant human MES-SA/Dx5 cells Growth inhibition of multidrug-resistant human MES-SA/Dx5 cells	[PMID: 23750455]
MES-SA/Dx5	GI₅₀	9.8 μM Compound: taxol	Antiproliferative activity against human MES-SA/Dx5 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MES-SA/Dx5 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25671501]
MES-SA/Dx5	GI₅₀	9800 nM Compound: Taxol	Growth inhibition of human doxorubicin-resistant MES-SA/Dx5 cells after 48 hrs by MTT assay Growth inhibition of human doxorubicin-resistant MES-SA/Dx5 cells after 48 hrs by MTT assay	[PMID: 23927793]
MES-SA/Dx5	GI₅₀	> 10 μM Compound: paclitaxel	Tested for inhibition of cell proliferation activity in doxorubicin resistant human uterus sarcoma MES-SA/DX5 cell Tested for inhibition of cell proliferation activity in doxorubicin resistant human uterus sarcoma MES-SA/DX5 cell	[PMID: 12773051]
MES-SA/Dx5	IC₅₀	0.0003 μM Compound: PTX	The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay. The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay.	[PMID: 10698449]
MES-SA/Dx5	IC₅₀	10 μM Compound: Taxol	Cytotoxicity against human MES-SA/Dx5 cells Cytotoxicity against human MES-SA/Dx5 cells	[PMID: 23937981]
MES-SA/Dx5	IC₅₀	1764 nM Compound: PTX	Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay	[PMID: 23214452]
MES-SA/Dx5	IC₅₀	1764 nM Compound: PTX	Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo assay Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo assay	[PMID: 25025991]
MES-SA/Dx5	IC₅₀	1764 nM Compound: PTX	Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay	[PMID: 26132075]
MES-SA/Dx5	IC₅₀	2.7 μM Compound: PTX	The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay. The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay.	[PMID: 10698449]
MES-SA/Dx5	IC₅₀	210 nM Compound: Paclitaxel	Growth inhibition of human MES-SA/Dx5 cells after 72 hrs by SRB assay Growth inhibition of human MES-SA/Dx5 cells after 72 hrs by SRB assay	[PMID: 29251920]
MES-SA/Dx5	IC₅₀	5 μM Compound: Taxol	Cytotoxicity against human MES-SA/DX5 cell line by MTS assay Cytotoxicity against human MES-SA/DX5 cell line by MTS assay	[PMID: 16870446]
MES-SA/Dx5	IC₅₀	5 μM Compound: Taxol	Cytotoxicity against human MESSA/DX5 cells after 72 hrs by MTT assay Cytotoxicity against human MESSA/DX5 cells after 72 hrs by MTT assay	[PMID: 18308566]
MES-SA/Dx5	IC₅₀	5.1 μM Compound: Taxol, Paclitaxel	Cytotoxicity against human MES-SA/Dx5 cells after 24 hrs by MTT assay Cytotoxicity against human MES-SA/Dx5 cells after 24 hrs by MTT assay	[PMID: 25462222]
MES-SA/Dx5	IC₅₀	750 nM Compound: A, paclitaxel, taxol	Cytotoxicity against human MESSA/DX5 cells after 96 hrs by trypan blue exclusion assay Cytotoxicity against human MESSA/DX5 cells after 96 hrs by trypan blue exclusion assay	[PMID: 22587519]
MES-SA/Dx5	IC₅₀	750 nM Compound: PTX	Cytotoxicity against multidrug-resistant human MES-SA/Dx5 cells assessed as cell viability after 96 hrs by trypan blue exclusion Cytotoxicity against multidrug-resistant human MES-SA/Dx5 cells assessed as cell viability after 96 hrs by trypan blue exclusion	[PMID: 21812421]
MES-SA/Dx5	IC₅₀	7538 nM Compound: Taxol	Cytotoxicity against human MES-SA/Dx5 cells Cytotoxicity against human MES-SA/Dx5 cells	[PMID: 19679475]
MES-SA/Dx5	IC₅₀	> 1000 nM Compound: paclitaxel	Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay	[PMID: 17286393]
MES-SA/Dx5	IC₅₀	> 400 nM Compound: Paclitaxel	Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition in cell growth Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition in cell growth	[PMID: 33974423]
MES-SA/Dx5	IC₅₀	uM μM Compound: paclitaxel	In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
MEXF514	IC₅₀	1.03 μM Compound: Paclitaxel	In vitro inhibitory concentration of compound against human cancer MEXF 514 cell line was determined In vitro inhibitory concentration of compound against human cancer MEXF 514 cell line was determined	[PMID: 12882225]
MGC-803	IC₅₀	0.83 μM Compound: PTX	Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay	[PMID: 27491707]
MGC-803	IC₅₀	0.85 μM Compound: Taxol	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 22483090]
MGC-803	IC₅₀	0.85 μM Compound: Taxol	Antiproliferative activity against human MGC803 cells assessed as growth inhibition by MTT assay Antiproliferative activity against human MGC803 cells assessed as growth inhibition by MTT assay	[PMID: 23274570]
MGC-803	IC₅₀	0.85 μM Compound: Taxol	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 23644204]
MGC-803	IC₅₀	3.8 nM Compound: Paclitaxel	Cytotoxicity against human MGC803 cells after 72 hrs by CCK8 assay Cytotoxicity against human MGC803 cells after 72 hrs by CCK8 assay	[PMID: 32489099]
MGC-803	IC₅₀	3.8 μM Compound: Paclitaxel	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against human MGC803 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 32193933]
MGC-803	IC₅₀	45.22 nM Compound: Paclitaxel	Potentiation of paclitaxel-induced cytotoxicity against PTX-resistant human MGC-803 cells assessed as paclitaxel IC50 incubated for 24 hrs by MTT assay (Rvb = 88.68 nM) Potentiation of paclitaxel-induced cytotoxicity against PTX-resistant human MGC-803 cells assessed as paclitaxel IC50 incubated for 24 hrs by MTT assay (Rvb = 88.68 nM)	[PMID: 32682200]
MIA PaCa-2	EC₅₀	0.002 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human MIA PaCa-2 cells incubated for 48 to 72 hrs by MTT assay Cytotoxicity against human MIA PaCa-2 cells incubated for 48 to 72 hrs by MTT assay	[PMID: 39038808]
MIA PaCa-2	IC₅₀	0.003 μM Compound: PTX	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MIA PaCa-2	IC₅₀	0.1 μM Compound: Paclitaxel	Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
MIA PaCa-2	IC₅₀	2.5 μM Compound: Paclitaxel	Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay	10.1039/C6MD00256K
MIA PaCa-2	IC₅₀	2.5 μM Compound: Paclitaxel	Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay	[PMID: 28667872]
MIA PaCa-2	IC₅₀	6 nM Compound: Paclitaxel	Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29759727]
MIA PaCa-2	IC₅₀	6.1 nM Compound: 28	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by WST8 assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by WST8 assay	[PMID: 25625617]
MIA PaCa-2	IC₅₀	7.2 nM Compound: PTX	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by coulter counter analysis Cytotoxicity against human MIAPaCa2 cells after 72 hrs by coulter counter analysis	[PMID: 23140358]
MKN-45	EC₅₀	0.003 μM Compound: Taxol	Antitumor activity against human MKN-45 cells assessed as inhibition of cell growth measured after 48 hrs by CCK-8 assay Antitumor activity against human MKN-45 cells assessed as inhibition of cell growth measured after 48 hrs by CCK-8 assay	[PMID: 38878517]
MKN-45	IC₅₀	0.0005 μM Compound: paclitaxel	Cytotoxicity against human MKN45 cells Cytotoxicity against human MKN45 cells	[PMID: 17113288]
MKN-45	IC₅₀	0.0026 μM Compound: paclitaxel	Antitumor activity against human MKN45 cell line Antitumor activity against human MKN45 cell line	[PMID: 16884301]
MKN-45	IC₅₀	4 nM Compound: 28	Antiproliferative activity against human MKN45 cells after 72 hrs by WST8 assay Antiproliferative activity against human MKN45 cells after 72 hrs by WST8 assay	[PMID: 25625617]
MKN-45	IC₅₀	89.06 μM Compound: paclitaxel	Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 19053781]
MM96L	IC₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against human MM96L after 24 hrs by MTT assay Cytotoxicity against human MM96L after 24 hrs by MTT assay	[PMID: 30387611]
MM96L	IC₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against human MM96L after 48 hrs by MTT assay Cytotoxicity against human MM96L after 48 hrs by MTT assay	[PMID: 30387611]
MOLM-13	IC₅₀	0.004 μM Compound: PTX	Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 38430854]
MOLM-13	IC₅₀	3.45 nM Compound: PTX	Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
MOLT-4	GI₅₀	0.032 μM Compound: 1a, PXL, Taxol	Cytotoxicity against human MOLT4 cells Cytotoxicity against human MOLT4 cells	[PMID: 23725535]
MOLT-4	GI₅₀	2.232 nM Compound: 1, Taxol	Growth inhibition of human MOLT4 cells by MTT assay Growth inhibition of human MOLT4 cells by MTT assay	[PMID: 24405702]
MOLT-4	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
MOLT-4	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
MOLT-4	IC₅₀	0.004 μM Compound: PTX	Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MOLT-4	IC₅₀	1.6 nM Compound: taxol	The compound was tested for inhibition concentration against MOLT-4 cell line The compound was tested for inhibition concentration against MOLT-4 cell line	[PMID: 7907372]
MOLT-4	IC₅₀	1.8 nM Compound: Taxol	Cytotoxicity against human MOLT4 cells by MTT assay Cytotoxicity against human MOLT4 cells by MTT assay	[PMID: 23806112]
MOLT-4	IC₅₀	2.2 nM Compound: Taxol	Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 25819096]
MOLT-4	IC₅₀	2.7 nM Compound: Taxol	Cytotoxicity against human MOLT4 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human MOLT4 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
MOLT-4	IC₅₀	2.7 μM Compound: taxol	Cytotoxicity against human MOLT4 cells after 72 hrs by CCK8 assay Cytotoxicity against human MOLT4 cells after 72 hrs by CCK8 assay	[PMID: 26316467]
MRC5	IC₅₀	0.00052 μM Compound: Paclitaxel	Cytotoxic activity against human MRC5 cells incubated for 72 hrs by resazurin dye based spectrophotometry Cytotoxic activity against human MRC5 cells incubated for 72 hrs by resazurin dye based spectrophotometry	[PMID: 28282127]
MRC5	IC₅₀	0.00052 μM Compound: Paclitaxel	Growth inhibition of human MRC5 cells after 72 hrs by resazurin dye based spectrophotometric method assay Growth inhibition of human MRC5 cells after 72 hrs by resazurin dye based spectrophotometric method assay	[PMID: 32091210]
MRC5	IC₅₀	0.00052 μM Compound: Paclitaxel	Cytotoxicity against human MRC5 cells assessed as growth inhibition measured after 72 hrs by MTS assay Cytotoxicity against human MRC5 cells assessed as growth inhibition measured after 72 hrs by MTS assay	[PMID: 33825474]
MRC5	IC₅₀	0.523 μM Compound: Paclitaxel	Cytotoxicity against human MRC-5 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MRC-5 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 35450348]
MRC5	IC₅₀	25 μM Compound: 31	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability by Almar Blue stained fluorescence-based assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability by Almar Blue stained fluorescence-based assay	[PMID: 32858470]
MRC5	IC₅₀	80 nM Compound: 28	Antiproliferative activity against human MRC5 cells after 72 hrs by WST8 assay Antiproliferative activity against human MRC5 cells after 72 hrs by WST8 assay	[PMID: 25625617]
MRC5	IC₅₀	> 200 μM Compound: Paclitaxel	Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 30798081]
MV4-11	IC₅₀	0.017 μM Compound: Taxol	Antiproliferative activity against human MV411 cells after 72 hrs by MTT assay Antiproliferative activity against human MV411 cells after 72 hrs by MTT assay	[PMID: 30212198]
MV4-11	IC₅₀	0.75 μM Compound: Paclitaxel	Cytotoxicity against human MV411 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay Cytotoxicity against human MV411 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay	10.1039/C4MD00573B
MV4-11	IC₅₀	1.62 nM Compound: PTX	Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
MV4-11	IC₅₀	3.4 nM Compound: 1	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37544183]
MV4-11	IC₅₀	3.4 nM Compound: 1	Antiproliferative activity against human MV4-11 cells transfected with FLT3-ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells transfected with FLT3-ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37544183]
MX1	IC₅₀	0.0225 μM Compound: taxol	Antiproliferative activity against human MX1 cell line Antiproliferative activity against human MX1 cell line	[PMID: 16759114]
MX1	IC₅₀	0.035 μM Compound: Taxol	Cytotoxicity against human MX1 cells after 72 hrs by SRB assay Cytotoxicity against human MX1 cells after 72 hrs by SRB assay	[PMID: 20181487]
MX1	IC₅₀	0.035 μM Compound: Taxol	Cytotoxicity against human MX1 cells after 72 hrs by SRB assay Cytotoxicity against human MX1 cells after 72 hrs by SRB assay	[PMID: 21144756]
MX1	IC₅₀	0.046 μM Compound: Taxol	Cytotoxicity against human MX1 cells after 72 hrs by SRB assay Cytotoxicity against human MX1 cells after 72 hrs by SRB assay	[PMID: 19576785]
MX1	IC₅₀	0.046 μM Compound: taxol	Cytotoxicity against human MX1 cells after 72 hrs by SRB assay Cytotoxicity against human MX1 cells after 72 hrs by SRB assay	[PMID: 19124250]
MX1	IC₅₀	35 nM Compound: taxol	Cytotoxicity against human MX1 cells after 72 hrs by SRB assay Cytotoxicity against human MX1 cells after 72 hrs by SRB assay	[PMID: 18450456]
MX1	IC₅₀	5.59 nM Compound: Paclitaxel	Cytotoxicity against folate receptor over-expressing human MX1 cells after 72 hrs by MTT assay Cytotoxicity against folate receptor over-expressing human MX1 cells after 72 hrs by MTT assay	[PMID: 25819334]
Malme-3M	GI₅₀	50 nM Compound: Paclitaxel	Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
Malme-3M	GI₅₀	50 nM Compound: Paclitaxel	Cytotoxicity against human Malme-3M cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human Malme-3M cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
NALM-6	IC₅₀	0.0041 μM Compound: Paclitaxel	Antiproliferative activity against human NALM6 cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay Antiproliferative activity against human NALM6 cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay	[PMID: 24852281]
NB-4	IC₅₀	0.03 μM Compound: Paclitaxel	Cytotoxicity against human NB4 cells after 3 days by MTT assay Cytotoxicity against human NB4 cells after 3 days by MTT assay	[PMID: 23738539]
NB-4	IC₅₀	0.03 μM Compound: Paclitaxel	Cytotoxicity against human NB4 cells after 48 hrs by MTT assay Cytotoxicity against human NB4 cells after 48 hrs by MTT assay	[PMID: 24063582]
NB-4	IC₅₀	0.03 μM Compound: paclitaxel	Cytotoxicity against human NB4 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NB4 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24063567]
NB-4	IC₅₀	0.1 μM Compound: Paclitaxel	Cytotoxicity against human NB4 cells after 48 hrs by WST-8 assay Cytotoxicity against human NB4 cells after 48 hrs by WST-8 assay	[PMID: 19072209]
NB-4	IC₅₀	0.1 μM Compound: paclitaxel	Cytotoxicity against human NB4 cells after 48 hrs by SRB method Cytotoxicity against human NB4 cells after 48 hrs by SRB method	[PMID: 19425589]
NB-4	IC₅₀	2.3 nM Compound: PTX	Cytotoxicity against human NB4 cells assessed as growth inhibition after 48 hrs by CellTiter-Fluor assay Cytotoxicity against human NB4 cells assessed as growth inhibition after 48 hrs by CellTiter-Fluor assay	[PMID: 26132075]
NCI-H1299	EC₅₀	0.098 μM Compound: Taxol	Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs	[PMID: 19500976]
NCI-H1299	EC₅₀	0.163 μM Compound: paclitaxel	Induction of apoptosis in human H1299 cells assessed as caspase activation after 24 hrs Induction of apoptosis in human H1299 cells assessed as caspase activation after 24 hrs	[PMID: 15566300]
NCI-H1299	GI₅₀	0.023 μM Compound: Taxol	Growth inhibition of human H1299 cells after 48 hrs Growth inhibition of human H1299 cells after 48 hrs	[PMID: 19500976]
NCI-H1299	IC₅₀	0.005 μM Compound: Taxol	Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth by MTT assay	[PMID: 32949719]
NCI-H1299	IC₅₀	0.009 μM Compound: Paclitaxel	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
NCI-H1299	IC₅₀	15 nM Compound: 1	Cytotoxicity against human NCI-H1299 cells after 96 hrs Cytotoxicity against human NCI-H1299 cells after 96 hrs	[PMID: 17419065]
NCI-H1299	IC₅₀	15 nM Compound: PTX	Inhibitory concentration against NCI-H1299 Human Nonsmall cell lung cancer cells after 96h exposure to the compound. Inhibitory concentration against NCI-H1299 Human Nonsmall cell lung cancer cells after 96h exposure to the compound.	[PMID: 10579854]
NCI-H1299	IC₅₀	1500 nM Compound: Paclitaxel	Cytotoxicity against human H1299 cells incubated for 24 hrs by MTT assay Cytotoxicity against human H1299 cells incubated for 24 hrs by MTT assay	[PMID: 27983842]
NCI-H1299	IC₅₀	35 nM Compound: 1	Cytotoxicity against human NCI-H1299 cells after 12 hrs Cytotoxicity against human NCI-H1299 cells after 12 hrs	[PMID: 17419065]
NCI-H1299	IC₅₀	35 nM Compound: PTX	Inhibitory concentration against NCI-H1299 Human Nonsmall cell lung cancer cells after 24 hr exposure to the compound. Inhibitory concentration against NCI-H1299 Human Nonsmall cell lung cancer cells after 24 hr exposure to the compound.	[PMID: 10579854]
NCI-H1299	IC₅₀	37.7 nM Compound: Placlitaxel (TAXOL)	Inhibitory concentration against NCI-H1299 cells was evaluated Inhibitory concentration against NCI-H1299 cells was evaluated	[PMID: 15341492]
NCI-H1299	IC₅₀	7.83 μM Compound: Taxol	Antiproliferative activity against human H1299 cells after 48 hrs by MTS assay Antiproliferative activity against human H1299 cells after 48 hrs by MTS assay	[PMID: 29172082]
NCI-H1437	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human NCI-H1437 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1437 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
NCI-H1650	IC₅₀	0.07 μM Compound: Taxol	Growth inhibition of human NCI-H1650 cells incubated for 3 days by SRB assay Growth inhibition of human NCI-H1650 cells incubated for 3 days by SRB assay	[PMID: 28625363]
NCI-H1650	IC₅₀	3.17 x 10^-8 mg/mL Compound: Taxol	Cytotoxicity against human NCI-H1650 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells after 72 hrs by MTT assay	[PMID: 26920798]
NCI-H1650	IC₅₀	6.8 x 10^-2 μM Compound: Paclitaxel	Cytotoxicity against human NCI-H1650 cells by MTT assay Cytotoxicity against human NCI-H1650 cells by MTT assay	[PMID: 27441892]
NCI-H1650	IC₅₀	> 1 μM Compound: Taxol	Growth inhibition of human NCI-H1650 cells after 96 hrs by MTT assay Growth inhibition of human NCI-H1650 cells after 96 hrs by MTT assay	[PMID: 28737396]
NCI-H1975	GI₅₀	5.77 nM Compound: Taxol	Cytotoxicity against human NCI-H1975 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human NCI-H1975 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay	[PMID: 27224875]
NCI-H1975	IC₅₀	2.5 nM Compound: PTX	Cytotoxicity against human NCI-H1975 cells assessed as growth inhibition after 72 hrs by CellTiter-Fluor assay Cytotoxicity against human NCI-H1975 cells assessed as growth inhibition after 72 hrs by CellTiter-Fluor assay	[PMID: 26132075]
NCI-H1975	IC₅₀	2.8 μM Compound: taxol	Cytotoxicity against human NCI-H1975 cells after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H1975 cells after 72 hrs by CCK8 assay	[PMID: 26316467]
NCI-H1975	IC₅₀	28 nM Compound: Paclitaxel	Anticancer activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37146221]
NCI-H1975	IC₅₀	3.9 μM Compound: Taxol	Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 30579802]
NCI-H1975	IC₅₀	7.7 nM Compound: Taxol	Cytotoxicity against human NCI-H1975 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H1975 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 25819096]
NCI-H1975	IC₅₀	7.94 nM Compound: Paclitaxel	Cytotoxicity against human NCI-H1975 cells after 4 days by MTS/cell proliferation assay Cytotoxicity against human NCI-H1975 cells after 4 days by MTS/cell proliferation assay	[PMID: 25098528]
NCI-H1975	IC₅₀	75 μM Compound: PTX	Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
NCI-H1993	GI₅₀	0.004 μM Compound: Paclitaxel	Antiproliferative activity against patient-derived paclitaxel-sensitive NCI-H1993 cells after 48 to 96 hrs by MTT assay Antiproliferative activity against patient-derived paclitaxel-sensitive NCI-H1993 cells after 48 to 96 hrs by MTT assay	[PMID: 27218860]
NCI-H2126	IC₅₀	2.5 μM Compound: Paclitaxel	Cytotoxicity against human NCI-H2126 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H2126 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
NCI-H226	GI₅₀	20 μM Compound: Paclitaxel	Compound was tested for growth inhibition of multidrug resistant tumor NCI-H226 cell line Compound was tested for growth inhibition of multidrug resistant tumor NCI-H226 cell line	[PMID: 15546733]
NCI-H226	GI₅₀	3.9 nM Compound: Paclitaxel	Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
NCI-H226	GI₅₀	3.9 nM Compound: Paclitaxel	Cytotoxicity against human NCI-H226 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H226 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
NCI-H226	IC₅₀	0.0068 μM Compound: paclitaxel	Cytotoxicity against human NCI-H226 cells Cytotoxicity against human NCI-H226 cells	[PMID: 17113288]
NCI-H226	IC₅₀	< 3 ng/mL Compound: 1 (paclitaxel)	Cytotoxicity against H226 Tumor cell line in SRB Cell viability test Cytotoxicity against H226 Tumor cell line in SRB Cell viability test	[PMID: 10956217]
NCI-H23	GI₅₀	6.3 nM Compound: Paclitaxel	Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
NCI-H23	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
NCI-H292	IC₅₀	0.006 μM Compound: Taxol	Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay	[PMID: 26712098]
NCI-H295R	IC₅₀	0.08 μM Compound: Taxol	Cytotoxicity against human H295R cells by MTT assay Cytotoxicity against human H295R cells by MTT assay	[PMID: 16539377]
NCI-H322M	GI₅₀	0.013 μM Compound: Paclitaxel	Cytotoxicity against human NCI-H322M cells by sulforhodamine B assay Cytotoxicity against human NCI-H322M cells by sulforhodamine B assay	[PMID: 21839640]
NCI-H322M	GI₅₀	0.013 μM Compound: paclitaxel	Cytotoxicity against human NCI-H322M cells Cytotoxicity against human NCI-H322M cells	[PMID: 17696332]
NCI-H322M	GI₅₀	0.05 μM Compound: 1a, PXL, Taxol	Cytotoxicity against human NCI-H322M cells Cytotoxicity against human NCI-H322M cells	[PMID: 23725535]
NCI-H322M	GI₅₀	12.5 nM Compound: Paclitaxel	Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
NCI-H322M	GI₅₀	12.5 nM Compound: Paclitaxel	Cytotoxicity against human NCI-H322M cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H322M cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
NCI-H358	IC₅₀	0.01 μM Compound: Taxol	Cytotoxicity against human NCI-H358 cells by MTT assay Cytotoxicity against human NCI-H358 cells by MTT assay	[PMID: 23425970]
NCI-H358	IC₅₀	2 nM Compound: taxol	Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
NCI-H358	IC₅₀	3.8 μg/mL Compound: PTX	Anticancer activity against human NCI-H358 cells by MTT assay Anticancer activity against human NCI-H358 cells by MTT assay	[PMID: 18826299]
NCI-H358	IC₅₀	7.9 nM Compound: 28	Antiproliferative activity against human NCI-H358 cells after 72 hrs by WST8 assay Antiproliferative activity against human NCI-H358 cells after 72 hrs by WST8 assay	[PMID: 25625617]
NCI-H441	IC₅₀	0.15 μM Compound: Taxol	Anticancer activity against human NCI-H441 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human NCI-H441 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
NCI-H460	ED₅₀	0.015 μM Compound: Paclitaxel	Effective dose against NCI-H460 cell line. Effective dose against NCI-H460 cell line.	[PMID: 11728187]
NCI-H460	GI₅₀	0.00165 μM Compound: Paclitaxel	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 31534659]
NCI-H460	GI₅₀	0.00176 μM Compound: Paclitaxel	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay	[PMID: 31059248]
NCI-H460	GI₅₀	0.007 μM Compound: Paclitaxel	Compound was tested for growth inhibition of human non-small cell lung cancer NCI-H460 cell line Compound was tested for growth inhibition of human non-small cell lung cancer NCI-H460 cell line	[PMID: 15546733]
NCI-H460	GI₅₀	0.024 μM Compound: Paclitaxel	Cytotoxicity against human H460 cells after 48 hrs by SRB assay Cytotoxicity against human H460 cells after 48 hrs by SRB assay	[PMID: 21513294]
NCI-H460	GI₅₀	0.03 μM Compound: paclitaxel	Growth inhibition of human NCI-H460 cells Growth inhibition of human NCI-H460 cells	[PMID: 23167614]
NCI-H460	GI₅₀	0.1 μM Compound: PCT	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 24727464]
NCI-H460	GI₅₀	2.19 x 10^-8 M Compound: 5	Cytotoxicity against human NCI-H460 cells Cytotoxicity against human NCI-H460 cells	[PMID: 7908950]
NCI-H460	GI₅₀	6.3 nM Compound: Paclitaxel	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
NCI-H460	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
NCI-H460	IC₅₀	0.00014 μM Compound: paclitaxel	In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
NCI-H460	IC₅₀	0.0006 μM Compound: Paclitaxel	Anticancer activity against human NCI-H460 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Anticancer activity against human NCI-H460 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 35450348]
NCI-H460	IC₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human NCI-H460 cells after 96 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 96 hrs by MTT assay	[PMID: 29279273]
NCI-H460	IC₅₀	0.004 μM Compound: paclitaxel	Antiproliferative activity against human NCI-H460 cells after 48 hrs by alamar blue assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by alamar blue assay	[PMID: 21563750]
NCI-H460	IC₅₀	0.005 μM Compound: Taxol	Anticancer activity against human H460 cells by MTT assay Anticancer activity against human H460 cells by MTT assay	[PMID: 33316408]
NCI-H460	IC₅₀	0.005 μM Compound: Taxol	Antiproliferative activity against human H460 cells assessed as reduction in cell viability after 96 hrs by MTT assay Antiproliferative activity against human H460 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 36270090]
NCI-H460	IC₅₀	0.006 μM Compound: PTX	Cytotoxicity against human NCI-H460 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
NCI-H460	IC₅₀	0.007 μM Compound: PTX	Cytotoxicity against human NCI-H460 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
NCI-H460	IC₅₀	0.008 μM Compound: Taxol	Cytotoxicity against human H460 cells after 24 to 48 hrs by MTT assay Cytotoxicity against human H460 cells after 24 to 48 hrs by MTT assay	[PMID: 22222040]
NCI-H460	IC₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay	[PMID: 21705223]
NCI-H460	IC₅₀	0.01 μM Compound: Paclitaxel	Antiproliferative activity against human NCI-H460 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
NCI-H460	IC₅₀	0.01 μM Compound: Paclitaxel ; Taxol	Cytotoxic activity against cellular metabolic activity of Lung NCI-H460 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h Cytotoxic activity against cellular metabolic activity of Lung NCI-H460 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h	[PMID: 12852768]
NCI-H460	IC₅₀	0.01 μM Compound: Taxol	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition by MTT assay Cytotoxicity against human NCI-H460 cells assessed as growth inhibition by MTT assay	[PMID: 25091926]
NCI-H460	IC₅₀	0.01 μM Compound: paclitaxel	Antiproliferative activity against NCI-H460 cells by XTT assay after 48 hrs Antiproliferative activity against NCI-H460 cells by XTT assay after 48 hrs	[PMID: 17181164]
NCI-H460	IC₅₀	0.01 μM Compound: paclitaxel	Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay	[PMID: 17973361]
NCI-H460	IC₅₀	0.01 μM Compound: paclitaxel	Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay	[PMID: 20537765]
NCI-H460	IC₅₀	0.012 μM Compound: Taxol	Antiproliferative activity against NCI-H460 cell line by MTS assay Antiproliferative activity against NCI-H460 cell line by MTS assay	[PMID: 16257201]
NCI-H460	IC₅₀	0.07 μM Compound: paclitaxel	Antiproliferative activity against human NCI-H460 cells by XTT assay Antiproliferative activity against human NCI-H460 cells by XTT assay	[PMID: 19220018]
NCI-H460	IC₅₀	0.08 μM Compound: Paclitaxel	Cytotoxicity against human H460 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human H460 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 30798081]
NCI-H460	IC₅₀	0.117 μM Compound: Paclitaxel	Anticancer activity against against human multi-drug resistant NCI-H460/R cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Anticancer activity against against human multi-drug resistant NCI-H460/R cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 35450348]
NCI-H460	IC₅₀	1 nM Compound: Paclitaxel	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 28530828]
NCI-H460	IC₅₀	1.43 μM Compound: 1	Cytotoxicity against human H460 cells assessed as inhibition of cell proliferation Cytotoxicity against human H460 cells assessed as inhibition of cell proliferation	[PMID: 25466201]
NCI-H460	IC₅₀	10 nM Compound: 28	Antiproliferative activity against human NCI-H460 cells after 72 hrs by WST8 assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by WST8 assay	[PMID: 25625617]
NCI-H460	IC₅₀	14.6 nM Compound: Paclitaxel	Antiproliferative activity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay	[PMID: 21480626]
NCI-H460	IC₅₀	2078 μM Compound: Paclitaxel	Anticancer activity against multidrug resistant human NCI-H460 cells after 72 hrs by SRB assay Anticancer activity against multidrug resistant human NCI-H460 cells after 72 hrs by SRB assay	[PMID: 21707046]
NCI-H460	IC₅₀	24 μM Compound: Taxol	Cytotoxicity against human H460 cells by MTT assay Cytotoxicity against human H460 cells by MTT assay	[PMID: 23425970]
NCI-H460	IC₅₀	4.287 μM Compound: 1	Cytotoxicity against human H460 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human H460 cells incubated for 48 hrs by CCK-8 assay	[PMID: 26448037]
NCI-H460	IC₅₀	4.9 nM Compound: paclitaxel	Cytotoxicity against human H460 cells after 72 hrs Cytotoxicity against human H460 cells after 72 hrs	[PMID: 19239240]
NCI-H460	IC₅₀	6.01 nM Compound: PTX	Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
NCI-H460	IC₅₀	632.6 nM Compound: Paclitaxel	Anti-cancer activity of human PTX-resistant NCI-H460 cells incubated for 48 hrs by CCK8 assay Anti-cancer activity of human PTX-resistant NCI-H460 cells incubated for 48 hrs by CCK8 assay	[PMID: 38692523]
NCI-H460	IC₅₀	7 nM Compound: Paclitaxel	Evaluated in vitro for antiproliferative activity against NIC-H460 cell lines derived from large cell carcinoma of the lung Evaluated in vitro for antiproliferative activity against NIC-H460 cell lines derived from large cell carcinoma of the lung	10.1016/S0960-894X(97)10152-4
NCI-H460	IC₅₀	8 μM Compound: Taxol	Cytotoxicity against human NCI-H460 cells after overnight incubation by MTT assay Cytotoxicity against human NCI-H460 cells after overnight incubation by MTT assay	[PMID: 21942765]
NCI-H460	IC₅₀	9.4 μM Compound: Paclitaxel	Anticancer activity against human NCI-H460 cells after 72 hrs by SRB assay Anticancer activity against human NCI-H460 cells after 72 hrs by SRB assay	[PMID: 21707046]
NCI-H460	IC₅₀	9.5 nM Compound: Taxol	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 14695798]
NCI-H460	IC₅₀	9.5 nM Compound: taxol	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 15043404]
NCI-H460	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
NCI-H460	IC₅₀	< 0.001 μM Compound: Taxol	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth by MTT assay	[PMID: 32949719]
NCI-H460	IC₅₀	> 10 nM Compound: Paclitaxel	Antiproliferative activity against the human non small cell lung carcinoma cell line NCI-H460 Antiproliferative activity against the human non small cell lung carcinoma cell line NCI-H460	[PMID: 11814821]
NCI-H520	IC₅₀	8.2 nM Compound: Taxol	Antiproliferative activity against human NCI-H520 cells after 72 hrs by phosphatase assay Antiproliferative activity against human NCI-H520 cells after 72 hrs by phosphatase assay	[PMID: 28857558]
NCI-H522	GI₅₀	15.8 nM Compound: Paclitaxel	Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
NCI-H522	GI₅₀	15.8 nM Compound: Paclitaxel	Cytotoxicity against human NCI-H522 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H522 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
NCI-H596	IC₅₀	0.035 μM Compound: Taxol	Antiproliferative activity against NQO1 deficient human NCI-H596 cells after 72 hrs by MTT assay Antiproliferative activity against NQO1 deficient human NCI-H596 cells after 72 hrs by MTT assay	[PMID: 28395199]
NCI-H630	IC₅₀	0.024 μM Compound: paclitaxel	Antitumor activity against human NCI-H630 cell line Antitumor activity against human NCI-H630 cell line	[PMID: 16884301]
NCI-H69	IC₅₀	1.9 nM Compound: paclitaxel	Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay	[PMID: 17286393]
NCI-H727	IC₅₀	0.01 μM Compound: Taxol	Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
NCI-H838	IC₅₀	0.026 μM Compound: paclitaxel	Cytotoxicity against human NCI-H838 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H838 cells after 72 hrs by MTT assay	[PMID: 19053781]
NCI-N87	IC₅₀	5.9 nM Compound: Taxol	Antiproliferative activity against human NCI-N87 cells after 96 hrs by MTT assay Antiproliferative activity against human NCI-N87 cells after 96 hrs by MTT assay	[PMID: 21296467]
NCI-N87	IC₅₀	7.53 nM Compound: Paclitaxel	Cytotoxicity against human NCI-N87 cells after 4 days by MTS/cell proliferation assay Cytotoxicity against human NCI-N87 cells after 4 days by MTS/cell proliferation assay	[PMID: 25098528]
NCI/ADR-RES	EC₅₀	13 nM Compound: paclitaxel	Cytotoxicity against human NCI-ADR-RES cells assessed as inhibition of cell proliferation by SRB assay Cytotoxicity against human NCI-ADR-RES cells assessed as inhibition of cell proliferation by SRB assay	[PMID: 24801610]
NCI/ADR-RES	EC₅₀	> 10 μM Compound: Taxol	Cell cycle arrest in NCI/ADR (MDR) cells by accumulation at G2/M phase Cell cycle arrest in NCI/ADR (MDR) cells by accumulation at G2/M phase	[PMID: 16377187]
NCI/ADR-RES	ED₅₀	1.5 μM Compound: 1	Cytotoxicity against human NCI/ADR-RES cells Cytotoxicity against human NCI/ADR-RES cells	[PMID: 18926701]
NCI/ADR-RES	ED₅₀	1.53 nM Compound: 1	Cytotoxicity against multidrug resistant breast cancer MCF7/ADR cell line Cytotoxicity against multidrug resistant breast cancer MCF7/ADR cell line	[PMID: 16289636]
NCI/ADR-RES	ED₅₀	2 μM Compound: paclitaxel	Cytotoxicity against human NCI/ADR-RES cells Cytotoxicity against human NCI/ADR-RES cells	[PMID: 18977659]
NCI/ADR-RES	GI₅₀	0.04 μM Compound: PCT	Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay	[PMID: 24727464]
NCI/ADR-RES	GI₅₀	5943 nM Compound: Paclitaxel	Antiproliferative activity against human NCI/ADR-RES cells Antiproliferative activity against human NCI/ADR-RES cells	[PMID: 29617135]
NCI/ADR-RES	GI₅₀	630 nM Compound: Paclitaxel	Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
NCI/ADR-RES	GI₅₀	630 nM Compound: Paclitaxel	Cytotoxicity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
NCI/ADR-RES	GI₅₀	8 μM Compound: Paclitaxel	Compound was tested for growth inhibition of multidrug resistant tumor MCF-7/ADR cell line Compound was tested for growth inhibition of multidrug resistant tumor MCF-7/ADR cell line	[PMID: 15546733]
NCI/ADR-RES	GI₅₀	> 15000 nM Compound: Paclitaxel	Compound was tested in vitro for growth inhibition of MCF-7/ADR cells that exhibit MDR phenotype. Compound was tested in vitro for growth inhibition of MCF-7/ADR cells that exhibit MDR phenotype.	[PMID: 9873597]
NCI/ADR-RES	GI₅₀	> 50 μM Compound: Paclitaxel	Cytotoxic activity against MCF-7/ADR cell lines Cytotoxic activity against MCF-7/ADR cell lines	[PMID: 10406652]
NCI/ADR-RES	IC₅₀	0.181 μM Compound: Paclitaxel	Anticancer activity against Multi drug resistant human NCI-ADR-RES cells assessed as inhibition of cell growth Anticancer activity against Multi drug resistant human NCI-ADR-RES cells assessed as inhibition of cell growth	[PMID: 33328099]
NCI/ADR-RES	IC₅₀	1.5 μM Compound: Paclitaxel	Antiproliferative activity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by sulforhodamine B assay	[PMID: 37902628]
NCI/ADR-RES	IC₅₀	13 μM Compound: Paclitaxel	Cytotoxicity against human NCI-ADR-RES expressing MDR1 cells after 48 to 72 hrs by WAT-1 assay Cytotoxicity against human NCI-ADR-RES expressing MDR1 cells after 48 to 72 hrs by WAT-1 assay	[PMID: 21126027]
NCI/ADR-RES	IC₅₀	1300 nM Compound: 1,paclitaxel	Cytotoxicity against taxol-resistant human NCI/ADR-RES cells after 72 hrs by MTT assay Cytotoxicity against taxol-resistant human NCI/ADR-RES cells after 72 hrs by MTT assay	[PMID: 18951787]
NCI/ADR-RES	IC₅₀	1500 nM Compound: PTX	Growth inhibition of doxorubicin-resistant human NCI-ADR-RES cells overexpressing P-glycoprotein after 96 hrs Growth inhibition of doxorubicin-resistant human NCI-ADR-RES cells overexpressing P-glycoprotein after 96 hrs	[PMID: 22044164]
NCI/ADR-RES	IC₅₀	17.68 μM Compound: TAX	Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay	[PMID: 30677614]
NCI/ADR-RES	IC₅₀	2500 μM Compound: Paclitaxel	Growth inhibition of human NCI/ADR-RES cells over expressing Pgp measured after 96 hrs by sulforhodamine B assay Growth inhibition of human NCI/ADR-RES cells over expressing Pgp measured after 96 hrs by sulforhodamine B assay	[PMID: 27894589]
NCI/ADR-RES	IC₅₀	299 nM Compound: Paclitaxel	In vitro cytotoxicity of compound against human MCF-7-MDR (breast) cancer cell line after 72 hr of drug exposure In vitro cytotoxicity of compound against human MCF-7-MDR (breast) cancer cell line after 72 hr of drug exposure	[PMID: 12477344]
NCI/ADR-RES	IC₅₀	3100 nM Compound: PTX	Growth inhibition of human NCI/ADR-RES cells after 96 hrs by trypan blue exclusion assay Growth inhibition of human NCI/ADR-RES cells after 96 hrs by trypan blue exclusion assay	[PMID: 29730191]
NCI/ADR-RES	IC₅₀	3300 nM Compound: PTX	Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition by trypan blue exclusion assay Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition by trypan blue exclusion assay	[PMID: 23214452]
NCI/ADR-RES	IC₅₀	3300 nM Compound: PTX	Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy	[PMID: 25025991]
NCI/ADR-RES	IC₅₀	4.36 x 10^-2 M Compound: paclitaxel	Cytotoxicity against human MCF7/ADR cells assessed as reduction in cell viability after 48 hrs by SRB colorimetric assay Cytotoxicity against human MCF7/ADR cells assessed as reduction in cell viability after 48 hrs by SRB colorimetric assay	[PMID: 25856545]
NCI/ADR-RES	IC₅₀	463.86 nM Compound: TAX; PTX	Antiproliferation activity against human MCF7/ADR cells measured after 72 hrs incubation by MTT assay Antiproliferation activity against human MCF7/ADR cells measured after 72 hrs incubation by MTT assay	[PMID: 38781920]
NCI/ADR-RES	IC₅₀	5000 nM Compound: paclitaxel	Growth inhibition of human NCI/ADR-RES cells overexpressing P-gp after 96 hrs incubation by sulforhodamine B technique Growth inhibition of human NCI/ADR-RES cells overexpressing P-gp after 96 hrs incubation by sulforhodamine B technique	[PMID: 24900865]
NCI/ADR-RES	IC₅₀	58.7 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay	[PMID: 33725657]
NCI/ADR-RES	IC₅₀	58.7 μM Compound: Paclitaxel	Antitumor activity against human MCF7ADR cells incubated for 48 hrs by CCK8 assay Antitumor activity against human MCF7ADR cells incubated for 48 hrs by CCK8 assay	[PMID: 37229830]
NCI/ADR-RES	IC₅₀	6.9 μM Compound: Taxol	Cytotoxicity against human MCF7/ADR cells by MTT assay Cytotoxicity against human MCF7/ADR cells by MTT assay	[PMID: 23425970]
NCI/ADR-RES	IC₅₀	6000 nM Compound: PTX	Cytotoxicity against Pgp overexpressing human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against Pgp overexpressing human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26132075]
NCI/ADR-RES	IC₅₀	6263 nM Compound: Paclitaxel	Anticancer activity against P-gp overexpressing human NCI/ADR-RES cells after 96 hrs by SRB assay Anticancer activity against P-gp overexpressing human NCI/ADR-RES cells after 96 hrs by SRB assay	[PMID: 21557538]
NCI/ADR-RES	IC₅₀	800 nM Compound: Paclitaxel	Antiproliferative activity against human NCI/ADR-RES cells overexpressing Pgp Antiproliferative activity against human NCI/ADR-RES cells overexpressing Pgp	[PMID: 33705908]
NCI/ADR-RES	IC₅₀	9100 nM Compound: PTX	Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	[PMID: 38502936]
NCI/ADR-RES	IC₅₀	9153 nM Compound: Paclitaxel	Cytotoxicity against P-gp overexpressing human MCF7/ADR cells assessed as reduction in cell growth after 24 hrs by MTT assay Cytotoxicity against P-gp overexpressing human MCF7/ADR cells assessed as reduction in cell growth after 24 hrs by MTT assay	[PMID: 27213819]
NCI/ADR-RES	IC₅₀	9326 nM Compound: PTX	Antiproliferative activity against human MCF7ADR cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against human MCF7ADR cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 38430854]
NCI/ADR-RES	IC₅₀	9335 nM Compound: PTX	Cytotoxicity in human NCI-ADR-RES assessed as inhibition in cell growth measured after 24 hrs by MTT assay Cytotoxicity in human NCI-ADR-RES assessed as inhibition in cell growth measured after 24 hrs by MTT assay	[PMID: 35084853]
NCI/ADR-RES	IC₅₀	> 10 μM Compound: Paclitaxel	Antiproliferative activity against human NCI-ADR-RES cells after 48 hrs by SRB assay Antiproliferative activity against human NCI-ADR-RES cells after 48 hrs by SRB assay	[PMID: 28335606]
NCI/ADR-RES	IC₅₀	> 10000 nM Compound: PTX	Cytotoxicity against human MCF7/ADR cells after 72 hrs by SRB assay Cytotoxicity against human MCF7/ADR cells after 72 hrs by SRB assay	[PMID: 30819618]
NCI/ADR-RES	IC₅₀	> 100000 nM Compound: Paclitaxol	Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
NCI/ADR-RES	IC₅₀	> 6400 nM Compound: Paclitaxel	Cytotoxicity against human NCI-ADR-RES cells after 48 hrs by Alamar blue assay Cytotoxicity against human NCI-ADR-RES cells after 48 hrs by Alamar blue assay	[PMID: 21779519]
NCI/ADR-RES	IC₅₀	> 9000 μM Compound: Paclitaxel	Antiproliferative activity against taxane-resistant human NCI/ADR-RES cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Antiproliferative activity against taxane-resistant human NCI/ADR-RES cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 29995409]
NCM460	IC₅₀	9.2 nM Compound: PTX	Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33280896]
NCM460	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity in human NCM460 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human NCM460 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 31390200]
NCM460	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human NCM460 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCM460 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32628478]
NFF	IC₅₀	0.0047 μM Compound: Paclitaxel	Cytotoxicity against human NFF after 72 hrs by alamar blue assay Cytotoxicity against human NFF after 72 hrs by alamar blue assay	[PMID: 20732809]
NIH-3T3-G185	IC₅₀	53.9 μM Compound: Taxol (Paclitaxel)	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	54 μM Compound: Taxol (Paclitaxel)	TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	70.2 μM Compound: Taxol (Paclitaxel)	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH3T3	IC₅₀	0.58 μM Compound: 6	Antiproliferative activity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25682561]
NIH3T3	IC₅₀	1.29 μM Compound: Paclitaxel	Antiproliferative activity against mouse NIH3T3 cell line Antiproliferative activity against mouse NIH3T3 cell line	[PMID: 16793260]
NIH3T3	IC₅₀	20.01 μM Compound: Paclitaxel	Antiproliferative activity against mouse NIH/3T3 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against mouse NIH/3T3 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 25959813]
NIH3T3	IC₅₀	25 nM Compound: 1	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay	[PMID: 30448418]
NIH3T3	IC₅₀	4.2 μM Compound: paclitaxel	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability by MTS assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability by MTS assay	[PMID: 25760674]
NIH3T3	IC₅₀	4875 nM Compound: 1	Cytotoxicity against mouse NIH/3T3 cells harboring MDR G185 after 48 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells harboring MDR G185 after 48 hrs by MTT assay	[PMID: 30448418]
NSCLC	IC₅₀	4.3 nM Compound: Paclitaxel	Evaluated in vitro for antiproliferative activity against NYH cell lines derived from small cell lung cancer Evaluated in vitro for antiproliferative activity against NYH cell lines derived from small cell lung cancer	10.1016/S0960-894X(97)10152-4
NUGC-3	GI₅₀	0.02 μM Compound: paclitaxel	Growth inhibition of human NUGC3 cells Growth inhibition of human NUGC3 cells	[PMID: 23167614]
OCI-Ly1	IC₅₀	0.18 μM Compound: Paclitaxel	Cytotoxicity against human OCI-LY1 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay Cytotoxicity against human OCI-LY1 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay	10.1039/C4MD00573B
OE19	IC₅₀	0.4 μM Compound: taxol	Cytotoxicity against human OE19 cells after 72 hrs by MTT assay Cytotoxicity against human OE19 cells after 72 hrs by MTT assay	[PMID: 17915851]
OE33	IC₅₀	0.2 μM Compound: taxol	Cytotoxicity against human OE33 cells after 72 hrs by MTT assay Cytotoxicity against human OE33 cells after 72 hrs by MTT assay	[PMID: 17915851]
OS-RC-2	IC₅₀	< 0.08 μM Compound: Paclitaxel	Cytotoxicity against human OS-RC2 cells by MTT assay Cytotoxicity against human OS-RC2 cells by MTT assay	[PMID: 20627721]
OS-RC-2	IC₅₀	< 0.08 μM Compound: Paclitaxel	Cytotoxicity against human OS-RC2 cells by MTT assay Cytotoxicity against human OS-RC2 cells by MTT assay	[PMID: 20716468]
OS-RC-2	IC₅₀	< 0.08 μM Compound: Paclitaxel	Cytotoxicity against human OS-RC2 cells by MTT assay Cytotoxicity against human OS-RC2 cells by MTT assay	[PMID: 21875764]
OV-1063	IC₅₀	0.015 μM Compound: Paclitaxel	Inhibitory activity of compound against human ovarian carcinoma (OV-1063) Cell proliferation Inhibitory activity of compound against human ovarian carcinoma (OV-1063) Cell proliferation	[PMID: 9379451]
OV-90	IC₅₀	5.19 μM Compound: Taxol	Anticancer activity against human OV-90 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human OV-90 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
OVCAR	IC₅₀	0.06 μM Compound: Paclitaxel	Cytotoxicity against Homo sapiens (human) OVCAR cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) OVCAR cells after 48 hr by SRB assay	10.1007/s00044-011-9824-9
OVCAR-3	GI₅₀	0.02 μM Compound: 1a, PXL, Taxol	Cytotoxicity against human OVCAR3 cells Cytotoxicity against human OVCAR3 cells	[PMID: 23725535]
OVCAR-3	GI₅₀	0.2 μM Compound: PCT	Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay	[PMID: 24727464]
OVCAR-3	GI₅₀	1.97 x 10^-8 M Compound: 5	Cytotoxicity against human OVCAR-3 cells Cytotoxicity against human OVCAR-3 cells	[PMID: 7908950]
OVCAR-3	GI₅₀	4 nM Compound: Paclitaxel	Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
OVCAR-3	GI₅₀	4 nM Compound: Paclitaxel	Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
OVCAR-3	IC₅₀	0.0015 μM Compound: Paclitaxel	Cytotoxicity against human OVCAR3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human OVCAR3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 31953129]
OVCAR-3	IC₅₀	0.002 μM Compound: taxol	Cytotoxicity against human OVCAR3 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human OVCAR3 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 28594169]
OVCAR-3	IC₅₀	0.0033 μM Compound: Paclitaxel	Cytotoxicity against human OVCAR3 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay Cytotoxicity against human OVCAR3 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay	[PMID: 32096998]
OVCAR-3	IC₅₀	0.004 μM Compound: PTX	Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
OVCAR-3	IC₅₀	0.0075 μM Compound: Paclitaxel	Cytotoxicity in human OVCAR3 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay Cytotoxicity in human OVCAR3 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay	[PMID: 28252962]
OVCAR-3	IC₅₀	0.01 μM Compound: Taxol	Cytotoxicity against human Ovcar3 cells by MTT assay Cytotoxicity against human Ovcar3 cells by MTT assay	[PMID: 16539377]
OVCAR-3	IC₅₀	0.01 μM Compound: taxol	Cytotoxicity against human Ovcar3 cells after 72 hrs by MTT assay Cytotoxicity against human Ovcar3 cells after 72 hrs by MTT assay	[PMID: 17915851]
OVCAR-3	IC₅₀	0.011 μM Compound: Taxol	Cytotoxicity against human OVCAR3 cells measured after 24 to 72 hrs by SRB assay Cytotoxicity against human OVCAR3 cells measured after 24 to 72 hrs by SRB assay	[PMID: 29656990]
OVCAR-3	IC₅₀	0.1 nM Compound: P	Cytotoxicity against human OVCAR-3 cells treated for 72 hrs Cytotoxicity against human OVCAR-3 cells treated for 72 hrs	[PMID: 38964520]
OVCAR-3	IC₅₀	0.2 nM Compound: 1	Cytotoxicity against human OVCAR-3 cells Cytotoxicity against human OVCAR-3 cells	[PMID: 17419065]
OVCAR-3	IC₅₀	0.38 μM Compound: Paclitaxel	Antiproliferative activity against human OVCAR3 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human OVCAR3 cells incubated for 48 hrs by MTT assay	[PMID: 31279299]
OVCAR-3	IC₅₀	1.8 nM Compound: Taxol	Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay	[PMID: 33859802]
OVCAR-3	IC₅₀	1.8 x 10^-3 μM Compound: Taxol	Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36884371]
OVCAR-3	IC₅₀	13 nM Compound: Paclitaxel	Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
OVCAR-3	IC₅₀	2.6 nM Compound: Taxol	Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay	[PMID: 37643353]
OVCAR-3	IC₅₀	2.7 μM Compound: paclitaxel	Growth inhibition of human OVCAR-3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19939522]
OVCAR-3	IC₅₀	3.3 nM Compound: Paclitaxel	Cytotoxicity against human OVCAR3 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay Cytotoxicity against human OVCAR3 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay	[PMID: 27983842]
OVCAR-3	IC₅₀	4.9 nM Compound: Paclitaxel	Cytotoxicity against human OVCAR-3 cells incubated for 72 hrs by Cell titer blue assay Cytotoxicity against human OVCAR-3 cells incubated for 72 hrs by Cell titer blue assay	[PMID: 37216676]
OVCAR-3	IC₅₀	5 nM Compound: Taxol	Antiproliferative activity against human OVCAR3 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against human OVCAR3 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 31633350]
OVCAR-3	IC₅₀	5.1 nM Compound: Paclitaxel	Cytotoxicity against human OVCAR-3 cells after 72 hrs by Cell Titer-Blue cell viability assay Cytotoxicity against human OVCAR-3 cells after 72 hrs by Cell Titer-Blue cell viability assay	[PMID: 33006889]
OVCAR-3	IC₅₀	5.6 nM Compound: Paclitaxel	Cytotoxicity against human OVCAR-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human OVCAR-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 38237151]
OVCAR-3	IC₅₀	5.9 μM Compound: Paclitaxel	Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs	[PMID: 38341161]
OVCAR-3	IC₅₀	6.201 x 10^-10 M Compound: 150 (Taxol)	Cytotoxicity by measuring inhibitory concentration against ovcar-3 tumor cell line Cytotoxicity by measuring inhibitory concentration against ovcar-3 tumor cell line	[PMID: 16134928]
OVCAR-3	IC₅₀	7.5 nM Compound: Taxol	Cytotoxicity against human OVCAR3 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay Cytotoxicity against human OVCAR3 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay	[PMID: 30192537]
OVCAR-3	IC₅₀	6.2 x 10^-10 M Compound: 150 (Taxol)	Cytotoxicity by measuring inhibitory concentration against ovcar-3 tumor cell line Cytotoxicity by measuring inhibitory concentration against ovcar-3 tumor cell line	[PMID: 16134928]
OVCAR-4	GI₅₀	630 nM Compound: Paclitaxel	Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
OVCAR-4	GI₅₀	630 nM Compound: Paclitaxel	Cytotoxicity against human OVCAR-4 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human OVCAR-4 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
OVCAR-4	IC₅₀	> 600 μM Compound: Paclitaxel	Antiproliferative activity against taxane-resistant human OVCAR4 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Antiproliferative activity against taxane-resistant human OVCAR4 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 29995409]
OVCAR-5	GI₅₀	7.9 nM Compound: Paclitaxel	Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
OVCAR-5	GI₅₀	7.9 nM Compound: Paclitaxel	Cytotoxicity against human OVCAR-5 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human OVCAR-5 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
OVCAR-5	IC₅₀	3.6 nM Compound: Taxol	Cytotoxicity against human OVCAR-5 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay Cytotoxicity against human OVCAR-5 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay	[PMID: 37643353]
OVCAR-5	IC₅₀	7.3 nM Compound: Paclitaxel	Cytotoxicity against human OVCAR-5 cells incubated for 72 hrs by Cell titer blue assay Cytotoxicity against human OVCAR-5 cells incubated for 72 hrs by Cell titer blue assay	[PMID: 37216676]
OVCAR-8	EC₅₀	18 nM Compound: paclitaxel	Cytotoxicity against human OVCAR8 cells assessed as inhibition of cell proliferation by SRB assay Cytotoxicity against human OVCAR8 cells assessed as inhibition of cell proliferation by SRB assay	[PMID: 24801610]
OVCAR-8	GI₅₀	7.9 nM Compound: Paclitaxel	Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
OVCAR-8	GI₅₀	7.9 nM Compound: Paclitaxel	Cytotoxicity against human OVCAR-8 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human OVCAR-8 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
OVCAR-8	IC₅₀	0.01 μM Compound: Paclitaxel	Growth inhibition of human OVCAR8 cells after 72 hrs by SRB assay Growth inhibition of human OVCAR8 cells after 72 hrs by SRB assay	[PMID: 29519737]
OVCAR-8	IC₅₀	10 nM Compound: paclitaxel	Growth inhibition of human OVCAR8 cells after 96 hrs incubation by sulforhodamine B technique Growth inhibition of human OVCAR8 cells after 96 hrs incubation by sulforhodamine B technique	[PMID: 24900865]
OVCAR-8	IC₅₀	2 nM Compound: PTX	Growth inhibition of human OVCAR8 cells overexpressing P-glycoprotein after 96 hrs Growth inhibition of human OVCAR8 cells overexpressing P-glycoprotein after 96 hrs	[PMID: 22044164]
OVCAR-8	IC₅₀	3.7 nM Compound: PTX	Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26132075]
OVCAR-8	IC₅₀	4 nM Compound: PTX	Growth inhibition of human OVCAR8 cells after 96 hrs by trypan blue exclusion assay Growth inhibition of human OVCAR8 cells after 96 hrs by trypan blue exclusion assay	[PMID: 29730191]
OVCAR-8	IC₅₀	4.7 nM Compound: Paclitaxel	Anticancer activity against human OVCAR8 cells after 96 hrs by SRB assay Anticancer activity against human OVCAR8 cells after 96 hrs by SRB assay	[PMID: 21557538]
OVCAR-8	IC₅₀	5 nM Compound: PTX	Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by trypan blue exclusion assay Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by trypan blue exclusion assay	[PMID: 23214452]
OVCAR-8	IC₅₀	5 nM Compound: PTX	Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy	[PMID: 25025991]
OVCAR-8	IC₅₀	5 μM Compound: Paclitaxel	Growth inhibition of human OVCAR8 cells measured after 96 hrs by sulforhodamine B assay Growth inhibition of human OVCAR8 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 27894589]
OVCAR-8	IC₅₀	5.3 nM Compound: Paclitaxel	Antiproliferative activity against human OVCAR-8 cells Antiproliferative activity against human OVCAR-8 cells	[PMID: 33705908]
OVCAR-8	IC₅₀	6.5 nM Compound: Taxol	Cytotoxicity against human OVCAR-8 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay Cytotoxicity against human OVCAR-8 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay	[PMID: 37643353]
P388	GI₅₀	16 nM Compound: Paclitaxel	Compound was tested in vitro for growth inhibition of murine leukemic P388 cells Compound was tested in vitro for growth inhibition of murine leukemic P388 cells	[PMID: 9873597]
P388	GI₅₀	2.93 ng/mL Compound: Paclitaxel	Cytotoxic activity against mouse leukemia P388 cell line Cytotoxic activity against mouse leukemia P388 cell line	[PMID: 12482420]
P388	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 27010926]
P388	IC₅₀	0.01 μM Compound: Taxol	Cytotoxicity against murine P388 cell line by MTS assay Cytotoxicity against murine P388 cell line by MTS assay	[PMID: 16870446]
P388	IC₅₀	0.01 μM Compound: Taxol	Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay	[PMID: 18308566]
P388	IC₅₀	0.01 μg/mL Compound: Taxol (TAX)	Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells	10.1016/S0960-894X(97)00071-1
P388	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against mouse P388 cells after 72 hrs by SRB assay Cytotoxicity against mouse P388 cells after 72 hrs by SRB assay	[PMID: 12088425]
P388	IC₅₀	0.03 μg/mL Compound: paclitaxel	Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 9134747]
P388	IC₅₀	0.04 μM Compound: Paclitaxel	Antiproliferative activity against mouse P388 cells after 48 hrs by XTT proliferation assay Antiproliferative activity against mouse P388 cells after 48 hrs by XTT proliferation assay	[PMID: 21705223]
P388	IC₅₀	0.04 μM Compound: paclitaxel	Antiproliferative activity against P388 cells by XTT assay after 48 hrs Antiproliferative activity against P388 cells by XTT assay after 48 hrs	[PMID: 17181164]
P388	IC₅₀	0.04 μM Compound: paclitaxel	Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay	[PMID: 17973361]
P388	IC₅₀	0.04 μM Compound: paclitaxel	Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay	[PMID: 20537765]
P388	IC₅₀	0.046 μg/mL Compound: 3	In vitro cytotoxicity against P388-mouse leukemia cells. In vitro cytotoxicity against P388-mouse leukemia cells.	10.1016/S0960-894X(01)80507-2
P388	IC₅₀	0.05 μM Compound: paclitaxel	Antiproliferative activity against doxorubicin-resistant mouse P388 cells expressing MDR1 protein after 48 hrs by XTT assay Antiproliferative activity against doxorubicin-resistant mouse P388 cells expressing MDR1 protein after 48 hrs by XTT assay	[PMID: 19220018]
P388	IC₅₀	0.05 μg/mL Compound: 2	Antiproliferative activity against mouse P388 cells by MTT assay Antiproliferative activity against mouse P388 cells by MTT assay	10.1021/np50089a022
P388	IC₅₀	0.07 μM Compound: paclitaxel	Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay	[PMID: 19220018]
P388	IC₅₀	0.27 μg/mL Compound: Taxol	The concentration required to 50% inhibition of the P388 leukemic cell proliferation The concentration required to 50% inhibition of the P388 leukemic cell proliferation	[PMID: 1672159]
P388	IC₅₀	0.2 μg/mL Compound: Paclitaxel	Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 23755851]
P388	IC₅₀	0.2 μg/mL Compound: Paclitaxel	Cytotoxicity was evaluated against P388 mouse lymphoma cells Cytotoxicity was evaluated against P388 mouse lymphoma cells	[PMID: 9871668]
P388	IC₅₀	0.93 μM Compound: paclitaxel	Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay	[PMID: 17896816]
P388	IC₅₀	0.93 μM Compound: paclitaxel	Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay	[PMID: 18281952]
P388	IC₅₀	16 nM Compound: Paclitaxel	The compound was tested for susceptibility to a multidrug resistant(MDR) subline of murine P388/S leukemia cells under continuous exposure conditions for 3-4 days The compound was tested for susceptibility to a multidrug resistant(MDR) subline of murine P388/S leukemia cells under continuous exposure conditions for 3-4 days	[PMID: 10843209]
P388	IC₅₀	170 nM Compound: Paclitaxel	The compound was tested for susceptibility to P-glycoprotein (PgP) mediated drug efflux using murine P388/VMDRC.04 cells under continuous exposure conditions for 3-4 days The compound was tested for susceptibility to P-glycoprotein (PgP) mediated drug efflux using murine P388/VMDRC.04 cells under continuous exposure conditions for 3-4 days	[PMID: 10843209]
P388	IC₅₀	2.27 μg/mL Compound: (22) taxol	In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay	[PMID: 12620075]
P388	IC₅₀	22 nM Compound: paclitaxel	Antiproliferative activity against P388 cells by ELISA Antiproliferative activity against P388 cells by ELISA	[PMID: 17154505]
P388	IC₅₀	45 μg/mL Compound: 1	Cytotoxicity against mouse P388 cells by MTT assay Cytotoxicity against mouse P388 cells by MTT assay	[PMID: 7561894]
P388	IC₅₀	6 μM Compound: Taxol	In vitro inhibitory activity of compound against P388/O murine leukemia cell line In vitro inhibitory activity of compound against P388/O murine leukemia cell line	10.1016/S0960-894X(01)80411-X
P388	IC₅₀	> 5 μM Compound: Paclitaxel	Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay	[PMID: 21705223]
P388	IC₅₀	> 5 μM Compound: paclitaxel	Antiproliferative activity against P388 ADR cells by XTT assay after 48 hrs Antiproliferative activity against P388 ADR cells by XTT assay after 48 hrs	[PMID: 17181164]
P388	IC₅₀	> 5 μM Compound: paclitaxel	Antiproliferative activity against mouse adriamycin-resistant P388 cells after 48 hrs by XTT assay Antiproliferative activity against mouse adriamycin-resistant P388 cells after 48 hrs by XTT assay	[PMID: 17973361]
P388	IC₅₀	> 5 μM Compound: paclitaxel	Antiproliferative activity against adriamycin-resistant mouse P388 cells after 48 hrs by XTT assay Antiproliferative activity against adriamycin-resistant mouse P388 cells after 48 hrs by XTT assay	[PMID: 20537765]
P388/ADR	GI₅₀	> 15000 nM Compound: Paclitaxel	Compound was tested in vitro for growth inhibition of murine leukemic P388/ADR cells that exhibit MDR phenotype. Compound was tested in vitro for growth inhibition of murine leukemic P388/ADR cells that exhibit MDR phenotype.	[PMID: 9873597]
P388/ADR	IC₅₀	0.04 μM Compound: Paclitaxel ; Taxol	Antiproliferative activity against P388 tumor cell line Antiproliferative activity against P388 tumor cell line	[PMID: 12852768]
P388/ADR	IC₅₀	1636 nM Compound: paclitaxel	Antiproliferative activity against adriamycin resistant P388 cells by ELISA Antiproliferative activity against adriamycin resistant P388 cells by ELISA	[PMID: 17154505]
P388/ADR	IC₅₀	30 nM Compound: paclitaxel	Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	[PMID: 17154505]
P388/ADR	IC₅₀	> 5 μM Compound: Paclitaxel ; Taxol	Antiproliferative activity against P388 phenotype P388 ADR tumor cell line Antiproliferative activity against P388 phenotype P388 ADR tumor cell line	[PMID: 12852768]
P388D1	IC₅₀	35 nM Compound: Pac	Antiproliferative activity against mouse P388D1 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against mouse P388D1 cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
P388D1	IC₅₀	35 nM Compound: Pac	Antiproliferative activity against human P388D1 after 48 hrs by SRB assay Antiproliferative activity against human P388D1 after 48 hrs by SRB assay	[PMID: 21920638]
PA-1	IC₅₀	0.006 μg/mL Compound: taxol	Cytotoxicity against human PA1 cell line by MTT assay Cytotoxicity against human PA1 cell line by MTT assay	[PMID: 16297622]
PA-1	IC₅₀	0.008 μM Compound: Taxol	Cytotoxicity against human PA1 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay Cytotoxicity against human PA1 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay	[PMID: 23584542]
PA-1	IC₅₀	3 nM Compound: Taxol	Antiproliferative activity against human PA1 cells after 72 hrs by phosphatase assay Antiproliferative activity against human PA1 cells after 72 hrs by phosphatase assay	[PMID: 28857558]
PANC-1	CC₅₀	0.1279 μg/mL Compound: Paclitaxel	Cytotoxicity against human PANC1 cells by MTT assay Cytotoxicity against human PANC1 cells by MTT assay	[PMID: 27301367]
PANC-1	GI₅₀	0.0038 μg/mL Compound: Paclitaxel	Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 26920799]
PANC-1	GI₅₀	0.004 μg/mL Compound: Paclitaxel	Cytotoxicity against human PANC1 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C5MD00057B
PANC-1	GI₅₀	0.012 μM Compound: Paclitaxel	Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay	[PMID: 25827522]
PANC-1	GI₅₀	0.1279 μg/mL Compound: Paclitaxel	Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 26299346]
PANC-1	GI₅₀	0.1279 μg/mL Compound: Paclitaxel	Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 27013391]
PANC-1	GI₅₀	0.1279 μg/mL Compound: Paclitaxel	Cytotoxicity against human PANC1 cells assessed as growth inhibition by MTT assay Cytotoxicity against human PANC1 cells assessed as growth inhibition by MTT assay	[PMID: 28103537]
PANC-1	GI₅₀	0.1279 μg/mL Compound: Paclitaxel	Growth inhibition of human PANC1 cells by MTT assay Growth inhibition of human PANC1 cells by MTT assay	[PMID: 28411559]
PANC-1	GI₅₀	0.1279 μg/mL Compound: Paclitaxel	Growth inhibition of human PANC1 cells by MTT assay Growth inhibition of human PANC1 cells by MTT assay	[PMID: 30910461]
PANC-1	GI₅₀	0.127 μg/mL Compound: Paclitaxel	Cytotoxicity against human PANC1 cells assessed as growth inhibition after 90 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as growth inhibition after 90 hrs by MTT assay	[PMID: 27563398]
PANC-1	GI₅₀	2.409 nM Compound: 1, Taxol	Growth inhibition of human PANC1 cells by MTT assay Growth inhibition of human PANC1 cells by MTT assay	[PMID: 24405702]
PANC-1	GI₅₀	5.8 μg/mL Compound: Paclitaxel	Cytotoxicity against human PANC1 cells measured after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells measured after 48 hrs by MTT assay	[PMID: 27688192]
PANC-1	IC₅₀	0.003 μM Compound: PTX	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
PANC-1	IC₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human PANC-1 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 37336771]
PANC-1	IC₅₀	0.021 μM Compound: Paclitaxel	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39163776]
PANC-1	IC₅₀	0.04 μM Compound: Paclitaxel	Antiproliferative activity against human PANC1 cells after 24 hrs by CCK8 assay Antiproliferative activity against human PANC1 cells after 24 hrs by CCK8 assay	[PMID: 30392953]
PANC-1	IC₅₀	0.06 μM Compound: Paclitaxel	Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
PANC-1	IC₅₀	0.26 μM Compound: Paclitaxel	Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
PANC-1	IC₅₀	1.1 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay	[PMID: 21812410]
PANC-1	IC₅₀	1.1 x 10^-3 μM Compound: paclitaxel	Cytotoxicity against human PANC1 cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human PANC1 cells assessed as reduction in cell viability by MTS assay	[PMID: 25760674]
PANC-1	IC₅₀	1.18 μM Compound: 1	Cytotoxicity against human PANC1 cells assessed as inhibition of cell proliferation Cytotoxicity against human PANC1 cells assessed as inhibition of cell proliferation	[PMID: 25466201]
PANC-1	IC₅₀	25.7 nM Compound: paclitaxel	Cytotoxicity against human PANC1 cells expressing mdr1, mrp1, mrp2, lrp genes after 72 hrs Cytotoxicity against human PANC1 cells expressing mdr1, mrp1, mrp2, lrp genes after 72 hrs	[PMID: 19239240]
PANC-1	IC₅₀	3.5 μM Compound: Taxol	Cytotoxicity against human PANC1 cells incubated for 48 hrs by MTT assay Cytotoxicity against human PANC1 cells incubated for 48 hrs by MTT assay	[PMID: 31042380]
PANC-1	IC₅₀	384.1 nM Compound: Taxol	Antiproliferative activity against human PANC1 cells after 96 hrs by MTT assay Antiproliferative activity against human PANC1 cells after 96 hrs by MTT assay	[PMID: 21296467]
PANC-1	IC₅₀	5.2 nM Compound: PTX	Cytotoxicity against human PANC1 cells after 72 hrs by coulter counter analysis Cytotoxicity against human PANC1 cells after 72 hrs by coulter counter analysis	[PMID: 23140358]
PANC-1	IC₅₀	7 nM Compound: 2	Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay	[PMID: 18081257]
PANC-1	IC₅₀	9.9 nM Compound: 1	Growth inhibition of human PANC1 cells after 72 hrs by MTT assay Growth inhibition of human PANC1 cells after 72 hrs by MTT assay	[PMID: 19022679]
PANC-1	IC₅₀	9.9 nM Compound: 1,paclitaxel	Cytotoxicity against taxol-sensitive human PANC1 cells after 72 hrs by MTT assay Cytotoxicity against taxol-sensitive human PANC1 cells after 72 hrs by MTT assay	[PMID: 18951787]
PANC-1	IC₅₀	< 0.008 μM Compound: Paclitaxel	Growth inhibition of human PANC1 cells after 48 hrs by SRB assay Growth inhibition of human PANC1 cells after 48 hrs by SRB assay	[PMID: 20521771]
PANC-1	IC₅₀	< 1 μM Compound: Paclitaxel	Cytotoxicity against human PANC1 cells after 72 hrs by SRB assay Cytotoxicity against human PANC1 cells after 72 hrs by SRB assay	[PMID: 23848163]
PBMC	IC₅₀	5 μM Compound: Taxol	Cytotoxicity against human PBMC cells Cytotoxicity against human PBMC cells	[PMID: 23937981]
PC-12	GI₅₀	539 ng/mL Compound: Paclitaxel	Cytotoxic activity against human lung cancer PC-12 cell line Cytotoxic activity against human lung cancer PC-12 cell line	[PMID: 12482420]
PC-14	IC₅₀	4.4 nM Compound: 28	Antiproliferative activity against human PC14 cells after 72 hrs by WST8 assay Antiproliferative activity against human PC14 cells after 72 hrs by WST8 assay	[PMID: 25625617]
PC-3	CC₅₀	2.7 nM Compound: Ptxl; PTX	Cytotoxicity against PSMA-deficient human PC3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against PSMA-deficient human PC3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31248772]
PC-3	EC₅₀	0.0097 μg/mL Compound: Paclitaxel	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 18640035]
PC-3	EC₅₀	0.0097 μg/mL Compound: Palitaxel	Cytotoxicity against human PC3 cells after 3 days by sulforhodamine B assay Cytotoxicity against human PC3 cells after 3 days by sulforhodamine B assay	[PMID: 19193043]
PC-3	ED₅₀	55.5 nM Compound: 1	Cytotoxicity against human PC3 cells by sulforhodamine B assay Cytotoxicity against human PC3 cells by sulforhodamine B assay	[PMID: 17350834]
PC-3	ED₅₀	8.87 nM Compound: Paclitaxel	Antiproliferative activity against human PC3 cells after 3 days by sulforhodamine B assay Antiproliferative activity against human PC3 cells after 3 days by sulforhodamine B assay	[PMID: 21296579]
PC-3	GI₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells by sulforhodamine B assay Cytotoxicity against human PC3 cells by sulforhodamine B assay	[PMID: 21839640]
PC-3	GI₅₀	0.004 μM Compound: Taxol	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21115210]
PC-3	GI₅₀	0.004 μM Compound: paclitaxel	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 17696332]
PC-3	GI₅₀	0.013 μM Compound: Paclitaxel	Growth inhibition of human PC3 cells after 48 hrs by SRB assay Growth inhibition of human PC3 cells after 48 hrs by SRB assay	[PMID: 29655982]
PC-3	GI₅₀	0.015 nM Compound: Paclitaxel	Inhibitory concentration against PC3 (prostate) cells Inhibitory concentration against PC3 (prostate) cells	[PMID: 12825928]
PC-3	GI₅₀	0.03 μM Compound: Taxol	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 32199690]
PC-3	GI₅₀	1.46 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells assessed as growth inhibition after 3 days by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 3 days by MTT assay	[PMID: 21889341]
PC-3	GI₅₀	5.8 nM Compound: Paclitaxel	Growth inhibition of human PC3 cells after 4 days by SRB assay Growth inhibition of human PC3 cells after 4 days by SRB assay	[PMID: 28740601]
PC-3	GI₅₀	6.3 nM Compound: Paclitaxel	Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
PC-3	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
PC-3	GI₅₀	7.2 nM Compound: Taxol	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	10.1039/C2MD20089A
PC-3	GI₅₀	< 0.1 μM Compound: PCT	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 24727464]
PC-3	IC₅₀	0.002 μM Compound: Taxol	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by Alamar blue assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by Alamar blue assay	[PMID: 26904921]
PC-3	IC₅₀	0.002 μM Compound: Taxol	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
PC-3	IC₅₀	0.002 μM Compound: taxol	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 27214307]
PC-3	IC₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells assessed as cell growth inhibition Cytotoxicity against human PC3 cells assessed as cell growth inhibition	[PMID: 26934105]
PC-3	IC₅₀	0.004 μM Compound: Paclitaxel	Antiproliferative activity against human PC3 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human PC3 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
PC-3	IC₅₀	0.01 μM Compound: PTX	Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
PC-3	IC₅₀	0.012 μM Compound: Paclitaxel	Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
PC-3	IC₅₀	0.012 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25647428]
PC-3	IC₅₀	0.016 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 15043402]
PC-3	IC₅₀	0.017 μM Compound: paclitaxel	Antitumor activity against human PC3 cell line Antitumor activity against human PC3 cell line	[PMID: 16884301]
PC-3	IC₅₀	0.02 μM Compound: Paclitaxel	Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 26785306]
PC-3	IC₅₀	0.02 μM Compound: paclitaxel	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 24033131]
PC-3	IC₅₀	0.021 μM Compound: PTX	Growth inhibition of human PC3 cells incubated for 72 hrs by MTT assay Growth inhibition of human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 27172319]
PC-3	IC₅₀	0.03 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27329938]
PC-3	IC₅₀	0.04 μM Compound: Paclitaxel	Cytotoxicity against human PC-3 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 33459007]
PC-3	IC₅₀	0.04 μM Compound: paclitaxel	Growth inhibition of human PC3 cells by sulforhodamine B assay Growth inhibition of human PC3 cells by sulforhodamine B assay	[PMID: 25685941]
PC-3	IC₅₀	0.12 μM Compound: Paclitaxel	Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay	10.1007/s00044-011-9824-9
PC-3	IC₅₀	0.14 μM Compound: Taxol	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 23425970]
PC-3	IC₅₀	0.15 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells measured after 72 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells measured after 72 hrs by sulforhodamine B assay	[PMID: 30920216]
PC-3	IC₅₀	0.17 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 31120251]
PC-3	IC₅₀	0.2 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells after 48 hrs by WST-8 assay Cytotoxicity against human PC3 cells after 48 hrs by WST-8 assay	[PMID: 19072209]
PC-3	IC₅₀	0.2 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells after 3 days by MTT assay Cytotoxicity against human PC3 cells after 3 days by MTT assay	[PMID: 23738539]
PC-3	IC₅₀	0.2 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 24063582]
PC-3	IC₅₀	0.2 μM Compound: paclitaxel	Cytotoxicity against human PC3 cells after 48 hrs by SRB method Cytotoxicity against human PC3 cells after 48 hrs by SRB method	[PMID: 19425589]
PC-3	IC₅₀	0.2 μM Compound: paclitaxel	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24063567]
PC-3	IC₅₀	0.4 nM Compound: paclitaxel	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	[PMID: 22783954]
PC-3	IC₅₀	0.43 nM Compound: Paclitaxel	Antiproliferative activity against human PC3 cells by sulforhodamine B assay Antiproliferative activity against human PC3 cells by sulforhodamine B assay	[PMID: 21775150]
PC-3	IC₅₀	0.67 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 30798081]
PC-3	IC₅₀	0.94 μM Compound: Taxol	Cytotoxicity against human PC3 cells after 24 hrs by MTT assay Cytotoxicity against human PC3 cells after 24 hrs by MTT assay	[PMID: 25226363]
PC-3	IC₅₀	1.1 nM Compound: Paclitaxel	Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 30122035]
PC-3	IC₅₀	1.1 nM Compound: Paclitaxel	Antiproliferative activity against human PC3 cells Antiproliferative activity against human PC3 cells	[PMID: 31251599]
PC-3	IC₅₀	1.4 nM Compound: 1,PTX	Cytotoxicity against human PC3 cells after 4 days by sulforhodamine B assay Cytotoxicity against human PC3 cells after 4 days by sulforhodamine B assay	[PMID: 19359169]
PC-3	IC₅₀	1.5 μM Compound: Paclitaxel	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 24056146]
PC-3	IC₅₀	1.9 nM Compound: Paclitaxel	Antiproliferative activity against human PC3 cells measured after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells measured after 72 hrs by MTS assay	[PMID: 31860298]
PC-3	IC₅₀	1.9 μM Compound: Paclitaxel	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	10.1039/C6MD00256K
PC-3	IC₅₀	14.5 μM Compound: PXL	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 27707623]
PC-3	IC₅₀	188 nM Compound: Paclitaxel	Antiproliferative activity against human paclitaxel-resistant PC3 cells by sulforhodamine B assay Antiproliferative activity against human paclitaxel-resistant PC3 cells by sulforhodamine B assay	[PMID: 21775150]
PC-3	IC₅₀	2.5 nM Compound: paclitaxel	Cytotoxicity against human PC3 cells assessed as viability after 96 hrs Cytotoxicity against human PC3 cells assessed as viability after 96 hrs	[PMID: 24900437]
PC-3	IC₅₀	2.6 μM Compound: Paclitaxel	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
PC-3	IC₅₀	2.73 μM Compound: Taxol	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 18701301]
PC-3	IC₅₀	2.85 μM Compound: paclitaxel	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 18701281]
PC-3	IC₅₀	2.9 μg/mL Compound: PTX	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24794748]
PC-3	IC₅₀	3.4 nM Compound: Paclitaxel	Antiproliferative activity against prostate cancer PC-3 cell line using sulforhodamine B(SRB) assay Antiproliferative activity against prostate cancer PC-3 cell line using sulforhodamine B(SRB) assay	[PMID: 15801848]
PC-3	IC₅₀	3.7 nM Compound: Paclitaxel	Cytotoxicity against human PC3 cells after 72 hrs by MTS assay Cytotoxicity against human PC3 cells after 72 hrs by MTS assay	[PMID: 29406710]
PC-3	IC₅₀	3990 nM Compound: PTX	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT method Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT method	[PMID: 25025991]
PC-3	IC₅₀	4.57 μM Compound: Taxol	Antiproliferative activity against human PC3 cells after 48 hrs by MTS assay Antiproliferative activity against human PC3 cells after 48 hrs by MTS assay	[PMID: 29172082]
PC-3	IC₅₀	4900 nM Compound: PTX	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26132075]
PC-3	IC₅₀	4900 μM Compound: Paclitaxel	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability Cytotoxicity against human PC-3 cells assessed as reduction in cell viability	[PMID: 38107170]
PC-3	IC₅₀	5 nM Compound: 1a, PTX	Cytotoxicity against PC3 cell line by MTT assay Cytotoxicity against PC3 cell line by MTT assay	[PMID: 17263521]
PC-3	IC₅₀	57.2 μM Compound: Taxol	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 22370266]
PC-3	IC₅₀	7 nM Compound: Paclitaxel	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29759727]
PC-3	IC₅₀	7 μM Compound: Taxol	Growth inhibition of human PC3 cells after 48 hrs by MTT assay Growth inhibition of human PC3 cells after 48 hrs by MTT assay	[PMID: 30108837]
PC-3	IC₅₀	77 nM Compound: 1	Cytotoxicity against human PC3 cells after 48 hrs by MTS method Cytotoxicity against human PC3 cells after 48 hrs by MTS method	[PMID: 14987051]
PC-3	IC₅₀	77 nM Compound: 1	Cytotoxicity against ERbeta positive human PC3 cells Cytotoxicity against ERbeta positive human PC3 cells	[PMID: 17419065]
PC-3	IC₅₀	< 0.0008 μM Compound: Taxol	Antiproliferative activity against human PC3 cells after 72 hrs by imaging analysis Antiproliferative activity against human PC3 cells after 72 hrs by imaging analysis	[PMID: 19665384]
PC-3	IC₅₀	< 0.001 μM Compound: 1	Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 26448037]
PC-3	IC₅₀	< 0.001 μM Compound: Taxol	Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
PC-3	IC₅₀	< 0.01 μM Compound: Taxol	Anticancer activity against human PC-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human PC-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
PC-3	IC₅₀	< 0.025 μM Compound: Taxol	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 33713977]
PC-3	IC₅₀	< 0.025 μM Compound: Taxol	Cytotoxicity against human PC-3 cells by MTT assay Cytotoxicity against human PC-3 cells by MTT assay	[PMID: 36057236]
PC-3	IC₅₀	> 50 μM Compound: taxol	Cytotoxicity against human PC3 after 48 hrs by SRB assay Cytotoxicity against human PC3 after 48 hrs by SRB assay	[PMID: 21044847]
PC-3M	IC₅₀	0.027 μM Compound: paclitaxel	Cytotoxicity against human PC3M cells after 24 hrs by MTT assay Cytotoxicity against human PC3M cells after 24 hrs by MTT assay	[PMID: 19245261]
PC-6	GI₅₀	1.27 ng/mL Compound: Paclitaxel	Cytotoxic activity against human lung cancer PC-6 cell line Cytotoxic activity against human lung cancer PC-6 cell line	[PMID: 12482420]
PC-6	GI₅₀	1.27 ng/mL Compound: 161	Growth inhibition of human PC-6 cells Growth inhibition of human PC-6 cells	[PMID: 34213340]
PC-9	IC₅₀	2.7 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human PC9 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human PC9 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 29648818]
PC-9	IC₅₀	3.7 μM Compound: Taxol	Cytotoxicity against human PC9 cells after 72 hrs by MTT assay Cytotoxicity against human PC9 cells after 72 hrs by MTT assay	[PMID: 30579802]
PC-9	IC₅₀	umol/L μM Compound: Taxol	Antiproliferation activity against human PC9 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferation activity against human PC9 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 32546298]
PPC-1	IC₅₀	3.4 nM Compound: Paclitaxel	Antiproliferative activity against prostate cancer PPC-1 cell line using sulforhodamine B(SRB) assay Antiproliferative activity against prostate cancer PPC-1 cell line using sulforhodamine B(SRB) assay	[PMID: 15801848]
PT-45	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human PT45 cells by MTT assay Cytotoxicity against human PT45 cells by MTT assay	[PMID: 16539377]
PT-45	IC₅₀	0.005 μM Compound: taxol	Cytotoxicity against human PT45 cells after 72 hrs by MTT assay Cytotoxicity against human PT45 cells after 72 hrs by MTT assay	[PMID: 17915851]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	0.1 nM Compound: Taxol	Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program	[PMID: 15743190]
RAW264.7	IC₅₀	> 5 μM Compound: Paclitaxel	Antiproliferative activity against mouse RAW264.7 cells after 18 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against mouse RAW264.7 cells after 18 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
RCC4	IC₅₀	0.1 μM Compound: Taxol	Anticancer activity against human RCC4 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human RCC4 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
RCC4/VHL	IC₅₀	0.06 μM Compound: Taxol	Anticancer activity against human RCC4/VHL cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human RCC4/VHL cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
RD	IC₅₀	14200 nM Compound: PTX	Cytotoxicity against human RD cells assessed as growth inhibition after 48 hrs by MTT method Cytotoxicity against human RD cells assessed as growth inhibition after 48 hrs by MTT method	[PMID: 25025991]
RD	IC₅₀	> 10000 nM Compound: PTX	Cytotoxicity against human RD cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human RD cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26132075]
RD	IC₅₀	> 10000 nM Compound: Paclitaxel	Antiproliferative activity against human RD cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human RD cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 38107170]
RKO	IC₅₀	0.01 μM Compound: Paclitaxel ; Taxol	Cytotoxic activity against human colon adenocarcinoma RKO cells without ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1 Cytotoxic activity against human colon adenocarcinoma RKO cells without ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1	[PMID: 12852768]
RKO	IC₅₀	0.01 μM Compound: paclitaxel	Antiproliferative activity against RKO cells by XTT assay after 48 hrs Antiproliferative activity against RKO cells by XTT assay after 48 hrs	[PMID: 17181164]
RKO	IC₅₀	0.01 μM Compound: paclitaxel	Cytotoxicity against human RKO cells after 48 hrs by XTT assay Cytotoxicity against human RKO cells after 48 hrs by XTT assay	[PMID: 17973361]
RKO	IC₅₀	0.01 μM Compound: paclitaxel	Antiproliferative activity against human RKO cells after 48 hrs by XTT assay Antiproliferative activity against human RKO cells after 48 hrs by XTT assay	[PMID: 20537765]
RKO	IC₅₀	0.02 μM Compound: paclitaxel	Antiproliferative activity against human RKO cells by XTT assay Antiproliferative activity against human RKO cells by XTT assay	[PMID: 19220018]
RKO	IC₅₀	> 10 μM Compound: paclitaxel	Antiproliferative activity against human RKO cells containing ecdysone-inducible expression vector of p27kipl by XTT assay Antiproliferative activity against human RKO cells containing ecdysone-inducible expression vector of p27kipl by XTT assay	[PMID: 19220018]
RKO	IC₅₀	> 3 μM Compound: Paclitaxel ; Taxol	Cytotoxic activity against human colon adenocarcinoma RKO cells with ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1 Cytotoxic activity against human colon adenocarcinoma RKO cells with ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1	[PMID: 12852768]
RKO	IC₅₀	> 3 μM Compound: paclitaxel	Antiproliferative activity against RKO cells with ectopic-induced p27kip1-expression by XTT assay after 48 hrs Antiproliferative activity against RKO cells with ectopic-induced p27kip1-expression by XTT assay after 48 hrs	[PMID: 17181164]
RKO	IC₅₀	> 3 μM Compound: paclitaxel	Cytotoxicity against human RKO cells with ectopic-inducible expression of p27kip1 after 48 hrs by XTT assay Cytotoxicity against human RKO cells with ectopic-inducible expression of p27kip1 after 48 hrs by XTT assay	[PMID: 17973361]
RKO	IC₅₀	> 3 μM Compound: paclitaxel	Antiproliferative activity against human RKO cells expressing p27Kip1 after 48 hrs by XTT assay Antiproliferative activity against human RKO cells expressing p27Kip1 after 48 hrs by XTT assay	[PMID: 20537765]
RL	IC₅₀	0.003 μM Compound: paclitaxel	Antiproliferative activity against human RL cells after 72 hrs by MTT assay Antiproliferative activity against human RL cells after 72 hrs by MTT assay	[PMID: 19743863]
RL	IC₅₀	0.007 μM Compound: PTX	Cytotoxicity against human RL cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human RL cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
RPMI-7951	IC₅₀	0.013 μM Compound: Paclitaxel	Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32435422]
RPMI-8226	GI₅₀	0.002 μM Compound: Paclitaxel	Cytotoxicity against human RPMI8226 cells by sulforhodamine B assay Cytotoxicity against human RPMI8226 cells by sulforhodamine B assay	[PMID: 21839640]
RPMI-8226	GI₅₀	0.002 μM Compound: paclitaxel	Cytotoxicity against human RPMI8226 cells Cytotoxicity against human RPMI8226 cells	[PMID: 17696332]
RPMI-8226	GI₅₀	19.9 nM Compound: Paclitaxel	Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
RPMI-8226	GI₅₀	19.9 nM Compound: Paclitaxel	Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
RPMI-8226	IC₅₀	0.002 μM Compound: PTX	Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
RPMI-8226	IC₅₀	1.53 μM Compound: PTX	Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells	[PMID: 31200238]
RPTEC	IC₅₀	0.0009 μM Compound: paclitaxel	Cytotoxicity against human RPTEC cells Cytotoxicity against human RPTEC cells	[PMID: 17113288]
RT-112	IC₅₀	0.07 μM Compound: Paclitaxel	Cytotoxicity against human RT-112 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human RT-112 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 33459007]
RWPE-1	IC₅₀	0.7 μg/mL Compound: PTX	Cytotoxicity against human RWPE1 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human RWPE1 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24794748]
RXF 393	GI₅₀	0.05 μM Compound: 1a, PXL, Taxol	Cytotoxicity against human RXF393 cells Cytotoxicity against human RXF393 cells	[PMID: 23725535]
RXF 393	GI₅₀	15.8 nM Compound: Paclitaxel	Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
RXF 393	GI₅₀	15.8 nM Compound: Paclitaxel	Cytotoxicity against human RXF 393 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human RXF 393 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
RXF 944	IC₅₀	0.05 μM Compound: Paclitaxel	In vitro inhibitory concentration of compound against human cancer RXF 944 cell line was determined In vitro inhibitory concentration of compound against human cancer RXF 944 cell line was determined	[PMID: 12882225]
Raji	EC₅₀	0.008 x 10^-3 μM Compound: Paclitaxel	Cytotoxicity against human Raji cells incubated for 48 to 72 hrs by MTT assay Cytotoxicity against human Raji cells incubated for 48 to 72 hrs by MTT assay	[PMID: 39038808]
Ramos	IC₅₀	3.35 nM Compound: PTX	Antiproliferative activity against human Ramos cells incubated for 72 hrs by MTT assay Antiproliferative activity against human Ramos cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
Rhabdomyosarcoma cell	IC₅₀	8.4 nM Compound: Paclitaxel	Antiproliferative activity against human Rhabdomyosarcoma cells after 96 hrs by MTS assay Antiproliferative activity against human Rhabdomyosarcoma cells after 96 hrs by MTS assay	[PMID: 26386818]
SAOS-2	IC₅₀	0.35 μM Compound: Paclitaxel	Antiproliferative activity against human Saos2 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human Saos2 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
SF-268	GI₅₀	0.012 μM Compound: Paclitaxel	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 21513294]
SF-268	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SF-268	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human SF-268 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SF-268 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SF-268	IC₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human SF268 cells after 48 hrs by XTT assay Cytotoxicity against human SF268 cells after 48 hrs by XTT assay	[PMID: 21705223]
SF-268	IC₅₀	0.01 μM Compound: Paclitaxel ; Taxol	Cytotoxic activity against cellular metabolic activity of Glioma SF-268 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h Cytotoxic activity against cellular metabolic activity of Glioma SF-268 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h	[PMID: 12852768]
SF-268	IC₅₀	0.01 μM Compound: paclitaxel	Antiproliferative activity against SF268 cells by XTT assay after 48 hrs Antiproliferative activity against SF268 cells by XTT assay after 48 hrs	[PMID: 17181164]
SF-268	IC₅₀	0.01 μM Compound: paclitaxel	Cytotoxicity against human SF268 cells after 48 hrs by XTT assay Cytotoxicity against human SF268 cells after 48 hrs by XTT assay	[PMID: 17973361]
SF-268	IC₅₀	0.01 μM Compound: paclitaxel	Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay	[PMID: 20537765]
SF-268	IC₅₀	0.05 μM Compound: paclitaxel	Antiproliferative activity against human SF268 cells by XTT assay Antiproliferative activity against human SF268 cells by XTT assay	[PMID: 19220018]
SF-268	IC₅₀	15.3 nM Compound: paclitaxel	Cytotoxicity against human SF268 cells Cytotoxicity against human SF268 cells	[PMID: 18606540]
SF-268	IC₅₀	21.7 nM Compound: Taxol	Cytotoxicity against human SF268 cells after 48 hrs by MTT assay Cytotoxicity against human SF268 cells after 48 hrs by MTT assay	[PMID: 14695798]
SF-268	IC₅₀	21.7 nM Compound: taxol	Cytotoxicity against human SF268 cells after 48 hrs by MTT assay Cytotoxicity against human SF268 cells after 48 hrs by MTT assay	[PMID: 15043404]
SF-295	GI₅₀	25 nM Compound: Paclitaxel	Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SF-295	GI₅₀	25 nM Compound: Paclitaxel	Cytotoxicity against human SF-295 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SF-295 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SF-295	IC₅₀	0.056 μM Compound: Paclitaxel	Antiproliferative activity against human SF295 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human SF295 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
SF-295	IC₅₀	24.55 nM Compound: Paclitaxel	Antiproliferative activity against human SF295 cells Antiproliferative activity against human SF295 cells	[PMID: 21324687]
SF-295	IC₅₀	290 nM Compound: paclitaxel	Cytotoxicity against human SF295 cells Cytotoxicity against human SF295 cells	[PMID: 18606540]
SF-295	IC₅₀	56 μM Compound: Paclitaxel	Antiproliferative activity against taxane-resistant human SF295 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Antiproliferative activity against taxane-resistant human SF295 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 29995409]
SF-539	GI₅₀	3.66 x 10^-9 M Compound: 5	Cytotoxicity against human SF539 cells Cytotoxicity against human SF539 cells	[PMID: 7908950]
SF-539	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SF-539	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human SF-539 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SF-539 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SGC-7901	GI₅₀	3.088 nM Compound: 1, Taxol	Growth inhibition of human SGC7901 cells by MTT assay Growth inhibition of human SGC7901 cells by MTT assay	[PMID: 24405702]
SGC-7901	IC₅₀	0.15 μM Compound: Taxol	Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 37856864]
SGC-7901	IC₅₀	0.2 μg/mL Compound: Taxol	Cytotoxicity against human SGC7901 cells after 48 hrs by SRB assay Cytotoxicity against human SGC7901 cells after 48 hrs by SRB assay	[PMID: 26351042]
SGC-7901	IC₅₀	14.35 μM Compound: Paclitaxel	Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric assay Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric assay	[PMID: 38107170]
SGC-7901	IC₅₀	3.34 μM Compound: Taxol	Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 19815316]
SGC-7901	IC₅₀	5.1 nM Compound: Taxol	Cytotoxicity against human SGC7901 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human SGC7901 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 25819096]
SGC-7901	IC₅₀	9.8 μM Compound: taxol	Cytotoxicity against human SGC7901 cells after 72 hrs by CCK8 assay Cytotoxicity against human SGC7901 cells after 72 hrs by CCK8 assay	[PMID: 26316467]
SH-SY5Y	IC₅₀	0.004 μM Compound: Taxol	Cytotoxicity against human SH-SY5Y cells after 24 to 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 24 to 48 hrs by MTT assay	[PMID: 22222040]
SH-SY5Y	IC₅₀	0.2 μM Compound: Paclitaxel	Cytotoxicity against human SH-SY5Y cells after 48 hrs by WST-8 assay Cytotoxicity against human SH-SY5Y cells after 48 hrs by WST-8 assay	[PMID: 19072209]
SH-SY5Y	IC₅₀	0.2 μM Compound: Paclitaxel	Cytotoxicity against human SH-SY5Y cells after 3 days by MTT assay Cytotoxicity against human SH-SY5Y cells after 3 days by MTT assay	[PMID: 23738539]
SH-SY5Y	IC₅₀	0.2 μM Compound: Paclitaxel	Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTT assay	[PMID: 24063582]
SH-SY5Y	IC₅₀	0.2 μM Compound: paclitaxel	Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method	[PMID: 19425589]
SH-SY5Y	IC₅₀	0.2 μM Compound: paclitaxel	Cytotoxicity against human SH-SY5Y cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24063567]
SH-SY5Y	IC₅₀	7.3 μg/mL Compound: Paclitaxel	Anticancer activity against human SH-SY5Y cells after 24 hrs by MTT assay Anticancer activity against human SH-SY5Y cells after 24 hrs by MTT assay	[PMID: 25305717]
SH-SY5Y	IC₅₀	8.56 μM Compound: Paclitaxel	Cytotoxicity against human SH-SY5Y cells after 24 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 24 hrs by MTT assay	[PMID: 21514015]
SJSA-1	IC₅₀	3.2 nM Compound: taxol	Cytotoxicity against human SJSA1 cells expressing GRP78 after 6 hrs by MTT assay Cytotoxicity against human SJSA1 cells expressing GRP78 after 6 hrs by MTT assay	[PMID: 18243696]
SK-BR-3	GI₅₀	6.1 μM Compound: PTX	Antiproliferative activity against human SK-BR3 cells after 96 hrs by MTS assay Antiproliferative activity against human SK-BR3 cells after 96 hrs by MTS assay	[PMID: 18164205]
SK-BR-3	IC₅₀	0.0019 μM Compound: Paclitaxel	Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay	[PMID: 22850214]
SK-BR-3	IC₅₀	0.11 μM Compound: Paclitaxel	Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay	[PMID: 20521771]
SK-BR-3	IC₅₀	0.11 μM Compound: paclitaxel	Cytotoxicity against human SKBR3 cells by MTT assay Cytotoxicity against human SKBR3 cells by MTT assay	[PMID: 22691179]
SK-BR-3	IC₅₀	12.7 μM Compound: PXL	Cytotoxicity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 27707623]
SK-BR-3	IC₅₀	> 100 nM Compound: PXL	Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay	[PMID: 25241925]
SK-HEP1	GI₅₀	0.011 μM Compound: Paclitaxel	Growth inhibition of human SKHEP1 cells after 48 hrs by SRB assay Growth inhibition of human SKHEP1 cells after 48 hrs by SRB assay	[PMID: 29655982]
SK-HEP1	IC₅₀	0.24 μM Compound: Taxol	Cytotoxicity against human SKHEP1 cells by MTT assay Cytotoxicity against human SKHEP1 cells by MTT assay	[PMID: 23425970]
SK-MEL	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against human SK-MEL cells assessed as reduction in cell growth inhibition Antiproliferative activity against human SK-MEL cells assessed as reduction in cell growth inhibition	[PMID: 27010926]
SK-MEL	IC₅₀	4.1 μM Compound: paclitaxel	Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay	[PMID: 19879765]
SK-MEL-2	GI₅₀	400 nM Compound: Paclitaxel	Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SK-MEL-2	GI₅₀	400 nM Compound: Paclitaxel	Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SK-MEL-2	IC₅₀	0.0072 μM Compound: paclitaxel	Antitumor activity against human SK-MEL-2 cell line Antitumor activity against human SK-MEL-2 cell line	[PMID: 16884301]
SK-MEL-2	IC₅₀	0.009 μM Compound: Paclitaxel	Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
SK-MEL-2	IC₅₀	0.07 μM Compound: 1	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay	[PMID: 12088425]
SK-MEL-24	IC₅₀	4.73 μM Compound: Paclitaxel	Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32435422]
SK-MEL-28	GI₅₀	400 nM Compound: Paclitaxel	Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SK-MEL-28	GI₅₀	400 nM Compound: Paclitaxel	Cytotoxicity against human SK-MEL-28 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-28 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SK-MEL-28	IC₅₀	1.07 μM Compound: PTX	Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37197457]
SK-MEL-5	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SK-MEL-5	IC₅₀	0.15 μM Compound: paclitaxel	Cytotoxicity against human SK-MEL-5 cells by MTT assay Cytotoxicity against human SK-MEL-5 cells by MTT assay	[PMID: 22691179]
SK-MEL3	IC₅₀	4.73 μM Compound: PTX	Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37197457]
SK-MES-1	IC₅₀	0.01 μM Compound: PTX	Cytotoxicity against human SK-MES-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human SK-MES-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
SK-MES-1	IC₅₀	13.5 nM Compound: Paclitaxel	Cytotoxicity against human SKMES1 cells after 48 hrs by Celltiter-Glo luminescent cell viability assay Cytotoxicity against human SKMES1 cells after 48 hrs by Celltiter-Glo luminescent cell viability assay	[PMID: 26985296]
SK-N-SH	GI₅₀	2.19 μM Compound: Paclitaxel	Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 3 days by MTT assay Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 3 days by MTT assay	[PMID: 21889341]
SK-OV-3	GI₅₀	0.00134 μM Compound: Paclitaxel	Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay	[PMID: 31059248]
SK-OV-3	GI₅₀	0.00136 μM Compound: Paclitaxel	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 31534659]
SK-OV-3	GI₅₀	0.008 μM Compound: Paclitaxel	Cytotoxicity against human SKOV3 cells by sulforhodamine B assay Cytotoxicity against human SKOV3 cells by sulforhodamine B assay	[PMID: 21839640]
SK-OV-3	GI₅₀	0.008 μM Compound: paclitaxel	Cytotoxicity against human SK-OV3 cells Cytotoxicity against human SK-OV3 cells	[PMID: 17696332]
SK-OV-3	GI₅₀	4.7 nM Compound: Paclitaxel	Cytotoxicity against human SKOV3 cells by SRB method Cytotoxicity against human SKOV3 cells by SRB method	[PMID: 24893224]
SK-OV-3	GI₅₀	6.3 nM Compound: Paclitaxel	Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SK-OV-3	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SK-OV-3	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
SK-OV-3	IC₅₀	0.00134 μM Compound: Taxol	Antitumor activity against human SKOV3 cells after 72 hrs by MTT assay Antitumor activity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 18762358]
SK-OV-3	IC₅₀	0.002 μM Compound: PTX	Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 29306206]
SK-OV-3	IC₅₀	0.002 μM Compound: Paclitaxel	Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32633512]
SK-OV-3	IC₅₀	0.005 μM Compound: paclitaxel	Antitumor activity against human SKOV3 cell line Antitumor activity against human SKOV3 cell line	[PMID: 16884301]
SK-OV-3	IC₅₀	0.006 μM Compound: paclitaxel	Antiproliferative activity against human SKOV3 cells after 48 hrs by alamar blue assay Antiproliferative activity against human SKOV3 cells after 48 hrs by alamar blue assay	[PMID: 21563750]
SK-OV-3	IC₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay	[PMID: 21705223]
SK-OV-3	IC₅₀	0.01 μM Compound: Paclitaxel ; Taxol	Cytotoxic activity against cellular metabolic activity of Ovary SKOV3 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h Cytotoxic activity against cellular metabolic activity of Ovary SKOV3 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h	[PMID: 12852768]
SK-OV-3	IC₅₀	0.01 μM Compound: paclitaxel	Antiproliferative activity against SKOV3 cells by XTT assay after 48 hrs Antiproliferative activity against SKOV3 cells by XTT assay after 48 hrs	[PMID: 17181164]
SK-OV-3	IC₅₀	0.01 μM Compound: paclitaxel	Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay	[PMID: 17973361]
SK-OV-3	IC₅₀	0.01 μM Compound: paclitaxel	Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay	[PMID: 20537765]
SK-OV-3	IC₅₀	0.012 μM Compound: Taxol	Cytotoxicity against human SKOV3 cells after 72 hrs by spectrophotometry Cytotoxicity against human SKOV3 cells after 72 hrs by spectrophotometry	[PMID: 23708235]
SK-OV-3	IC₅₀	0.016 μM Compound: Paclitaxol	Antiproliferative activity against human SKOV3 cells after 96 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 96 hrs by MTT assay	[PMID: 19091579]
SK-OV-3	IC₅₀	0.02 fmol Compound: PTX; 1	Photocytotoxicity against human SKOV3 cells assessed as reduction in cell viability per cell incubated for 24 hrs followed by 10 J/cm2 laser light irradiation and measured after 72 hrs by MTT assay Photocytotoxicity against human SKOV3 cells assessed as reduction in cell viability per cell incubated for 24 hrs followed by 10 J/cm2 laser light irradiation and measured after 72 hrs by MTT assay	[PMID: 30987891]
SK-OV-3	IC₅₀	0.05 μM Compound: paclitaxel	Antiproliferative activity against human SKOV3 cells by XTT assay Antiproliferative activity against human SKOV3 cells by XTT assay	[PMID: 19220018]
SK-OV-3	IC₅₀	0.1 μM Compound: Taxol	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 23425970]
SK-OV-3	IC₅₀	0.4 μM Compound: paclitaxel	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 22691179]
SK-OV-3	IC₅₀	0.43 μM Compound: Paclitaxel	Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by MTT assay	[PMID: 31279299]
SK-OV-3	IC₅₀	0.53 μM Compound: paclitaxel	Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay	[PMID: 19879765]
SK-OV-3	IC₅₀	1.19 nM Compound: Paclitaxel	Antiproliferative activity against human SK-OV-3 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human SK-OV-3 cells incubated for 48 hrs by CCK8 assay	[PMID: 38972078]
SK-OV-3	IC₅₀	1.35 μM Compound: taxol	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 15787460]
SK-OV-3	IC₅₀	1200 nM Compound: PTX	Antiproliferative activity against human SK-OV-3 cells overexpressing MDR-1-M6/6 assessed as inhibition of cell growth by SRB assay Antiproliferative activity against human SK-OV-3 cells overexpressing MDR-1-M6/6 assessed as inhibition of cell growth by SRB assay	[PMID: 36889150]
SK-OV-3	IC₅₀	1200 nM Compound: Paclitaxel	Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
SK-OV-3	IC₅₀	1200 nM Compound: paclitaxel	Antiproliferative activity against multidrug resistant human SKOV3 cells expressing MDR1-M6/6 after 48 hrs by SRB assay Antiproliferative activity against multidrug resistant human SKOV3 cells expressing MDR1-M6/6 after 48 hrs by SRB assay	[PMID: 27213719]
SK-OV-3	IC₅₀	14.5 nM Compound: Paclitaxel	Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay	[PMID: 21480626]
SK-OV-3	IC₅₀	2.39 nM Compound: Taxol	Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay	[PMID: 29517223]
SK-OV-3	IC₅₀	2.43 μM Compound: paclitaxel	Cytotoxicity against human SKOV3 cells Cytotoxicity against human SKOV3 cells	[PMID: 18701281]
SK-OV-3	IC₅₀	2.6 nM Compound: Pac	Antiproliferative activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay	[PMID: 21604746]
SK-OV-3	IC₅₀	2.6 nM Compound: Pac	Antiproliferative activity against human SKOV3 after 48 hrs by SRB assay Antiproliferative activity against human SKOV3 after 48 hrs by SRB assay	[PMID: 21920638]
SK-OV-3	IC₅₀	2.7 nM Compound: PTX	Cytotoxicity against human SKOV3 cells after 72 hrs by coulter counter analysis Cytotoxicity against human SKOV3 cells after 72 hrs by coulter counter analysis	[PMID: 23140358]
SK-OV-3	IC₅₀	2.95 nM Compound: Paclitaxel	Antiproliferative activity against human SKOV3 cells Antiproliferative activity against human SKOV3 cells	[PMID: 21786793]
SK-OV-3	IC₅₀	2596 nM Compound: Paclitaxel	Inhibition of MDR1 (unknown origin) transfected in human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay Inhibition of MDR1 (unknown origin) transfected in human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 23332369]
SK-OV-3	IC₅₀	2600 nM Compound: Paclitaxel	Antiproliferative activity against human SKOV3 cells expressing MDR1-6/6 by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells expressing MDR1-6/6 by sulforhodamine B assay	[PMID: 20973488]
SK-OV-3	IC₅₀	2655 nM Compound: Taxol	Antiproliferative activity against human SKOV3 cells expressing MDR1/M-6-6 Antiproliferative activity against human SKOV3 cells expressing MDR1/M-6-6	[PMID: 24890652]
SK-OV-3	IC₅₀	3 nM Compound: Paclitaxel	Antiproliferative activity against human SKOV3 cells by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells by sulforhodamine B assay	[PMID: 20973488]
SK-OV-3	IC₅₀	3 nM Compound: Paclitaxel	Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay	[PMID: 24087857]
SK-OV-3	IC₅₀	3 nM Compound: Paclitaxel	Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 28433513]
SK-OV-3	IC₅₀	3 nM Compound: Paclitaxel	Antiproliferative activity against human SKOV3 cells by SRB assay Antiproliferative activity against human SKOV3 cells by SRB assay	[PMID: 29655610]
SK-OV-3	IC₅₀	3 nM Compound: Paclitaxel	Antiproliferative activity against human SK-OV-3 cells assessed as decrease in cell growth measured after 48 hrs by SRB method Antiproliferative activity against human SK-OV-3 cells assessed as decrease in cell growth measured after 48 hrs by SRB method	[PMID: 33310545]
SK-OV-3	IC₅₀	3 nM Compound: Taxol	Antiproliferative activity against human SKOV3 cells Antiproliferative activity against human SKOV3 cells	[PMID: 24890652]
SK-OV-3	IC₅₀	3 nM Compound: paclitaxel	Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 23895532]
SK-OV-3	IC₅₀	3.99 nM Compound: Taxol	Cytotoxicity against human SKOV3 cells after 72 to 120 hrs in presence of verapamil by sulforhodamine B assay Cytotoxicity against human SKOV3 cells after 72 to 120 hrs in presence of verapamil by sulforhodamine B assay	[PMID: 29517223]
SK-OV-3	IC₅₀	31.3 nM Compound: Taxol	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured for 72 hrs Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured for 72 hrs	[PMID: 33038665]
SK-OV-3	IC₅₀	34.5 nM Compound: Paclitaxel	Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36621138]
SK-OV-3	IC₅₀	35 nM Compound: 1, Taxol	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 24269481]
SK-OV-3	IC₅₀	4.4 nM Compound: Paclitaxel	Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 23332369]
SK-OV-3	IC₅₀	4.7 nM Compound: PTX	Dark cytotoxicity against human SKOV3 cells assessed as cell viability after 72 hrs by MTT assay Dark cytotoxicity against human SKOV3 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26974508]
SK-OV-3	IC₅₀	4875 nM Compound: Paclitaxel	Antiproliferative activity against MDR-1-6/6 overexpressing human SKOV3 cells Antiproliferative activity against MDR-1-6/6 overexpressing human SKOV3 cells	[PMID: 21786793]
SK-OV-3	IC₅₀	4875 nM Compound: Paclitaxel	Cytotoxicity against human SKOV3 cells expressing MDR1 after 72 hrs by MTS assay Cytotoxicity against human SKOV3 cells expressing MDR1 after 72 hrs by MTS assay	[PMID: 24087857]
SK-OV-3	IC₅₀	4 μg/mL Compound: PTX	Anticancer activity against human SKOV3 cells by MTT assay Anticancer activity against human SKOV3 cells by MTT assay	[PMID: 18826299]
SK-OV-3	IC₅₀	5 nM Compound: PTX	Antiproliferative activity against wild type human SK-OV-3 cells assessed as inhibition of cell growth by SRB assay Antiproliferative activity against wild type human SK-OV-3 cells assessed as inhibition of cell growth by SRB assay	[PMID: 36889150]
SK-OV-3	IC₅₀	5 nM Compound: Paclitaxel	Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay	[PMID: 30098869]
SK-OV-3	IC₅₀	5 nM Compound: Paclitaxel	Antiproliferative activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay	[PMID: 30297118]
SK-OV-3	IC₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
SK-OV-3	IC₅₀	5 nM Compound: paclitaxel	Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27213719]
SK-OV-3	IC₅₀	6.2 μM Compound: paclitaxel	Growth inhibition of human SKOV3 cells by sulforhodamine B assay Growth inhibition of human SKOV3 cells by sulforhodamine B assay	[PMID: 25685941]
SK-OV-3	IC₅₀	6.29 μM Compound: PTX	Cytotoxicity against human SKOV3 cells incubated for 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells incubated for 48 hrs by MTT assay	[PMID: 30913525]
SK-OV-3	IC₅₀	6.3 nM Compound: Paclitaxel	Antiproliferative activity against human SKOV3 cells overexpressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells overexpressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay	[PMID: 25882519]
SK-OV-3	IC₅₀	65.8 nM Compound: Paclitaxel	Cytotoxicity against human SKOV3 cells after 72 hrs by SRB method Cytotoxicity against human SKOV3 cells after 72 hrs by SRB method	[PMID: 18990574]
SK-OV-3	IC₅₀	8.7 μg/mL Compound: paclitaxel	Cytotoxicity against sk-ov-3 cancer cell line Cytotoxicity against sk-ov-3 cancer cell line	[PMID: 16384699]
SK-OV-3	IC₅₀	< 0.0001 μM Compound: paclitaxel	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 22506620]
SK-OV-3	IC₅₀	< 1 nM Compound: Paclitaxel	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by sulforhodamine B colorimetric assay	[PMID: 25462285]
SK-OV-3	IC₅₀	< 1 μM Compound: Paclitaxel	Anticancer against human SKOV3 cells overexpressing P-gp assessed as cell viability after 48 hrs by SRB assay Anticancer against human SKOV3 cells overexpressing P-gp assessed as cell viability after 48 hrs by SRB assay	[PMID: 24946145]
SMMC-7721	IC₅₀	0.07 μM Compound: PTX	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 35213164]
SMMC-7721	IC₅₀	0.097 μM Compound: Taxol	Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36274275]
SMMC-7721	IC₅₀	0.12 μM Compound: Taxol	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 25771484]
SMMC-7721	IC₅₀	0.143 μM Compound: Taxol	Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay	[PMID: 34781083]
SMMC-7721	IC₅₀	0.15 μM Compound: Paclitaxel	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
SMMC-7721	IC₅₀	0.88 μM Compound: Taxol	Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 22153338]
SMMC-7721	IC₅₀	1.42 μM Compound: Taxol	Cytotoxicity against human SMMC7721 cells after 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 24 hrs by MTT assay	[PMID: 21115212]
SMMC-7721	IC₅₀	2.86 μM Compound: paclitaxel	Cytotoxicity against human SMMC7721 cells Cytotoxicity against human SMMC7721 cells	[PMID: 18701281]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 20521771]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 23327668]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 24417634]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SMMC7721 cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human SMMC7721 cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 27704807]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTS assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTS assay	[PMID: 28654256]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay	[PMID: 29286250]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay	[PMID: 29338226]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTS assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTS assay	[PMID: 29338260]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Growth inhibition of human SMMC7721 cells after 48 hrs by MTS assay Growth inhibition of human SMMC7721 cells after 48 hrs by MTS assay	[PMID: 29412669]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32628478]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25871261]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human SMMC7721 cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human SMMC7721 cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26068802]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human SMMC7721 cells assessed as decrease in cell viability after 4 days by MTT assay Cytotoxicity against human SMMC7721 cells assessed as decrease in cell viability after 4 days by MTT assay	[PMID: 29884535]
SMMC-7721	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT method Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT method	[PMID: 21534539]
SMMC-7721	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SMMC7721 assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 23586920]
SMMC-7721	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 23819871]
SMMC-7721	IC₅₀	< 0.008 μM Compound: paclitaxel	Antimicrobial activity against human SMMC7721 cells after 48 hrs by MTT assay Antimicrobial activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 23957453]
SMMC-7721	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay	[PMID: 24219809]
SMMC-7721	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay	[PMID: 24256484]
SMMC-7721	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTS assay Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTS assay	[PMID: 24697496]
SMMC-7721	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 25375202]
SMMC-7721	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SMMC7721 cells incubated for 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells incubated for 48 hrs by MTT assay	[PMID: 25798528]
SMMC-7721	IC₅₀	> 50 μM Compound: taxol	Cytotoxicity against human SMMC7721 after 48 hrs by SRB assay Cytotoxicity against human SMMC7721 after 48 hrs by SRB assay	[PMID: 21044847]
SN12C	GI₅₀	6.3 nM Compound: Paclitaxel	Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SN12C	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human SN12C cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SN12C cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SNB-19	GI₅₀	0.04 μM Compound: 1a, PXL, Taxol	Cytotoxicity against human SNB19 cells Cytotoxicity against human SNB19 cells	[PMID: 23725535]
SNB-19	GI₅₀	10 nM Compound: Paclitaxel	Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SNB-19	GI₅₀	10 nM Compound: Paclitaxel	Cytotoxicity against human SNB-19 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SNB-19 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SNB-75	GI₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human SNB75 cells by sulforhodamine B assay Cytotoxicity against human SNB75 cells by sulforhodamine B assay	[PMID: 21839640]
SNB-75	GI₅₀	0.004 μM Compound: paclitaxel	Cytotoxicity against human SNB75 cells Cytotoxicity against human SNB75 cells	[PMID: 17696332]
SNB-75	GI₅₀	7.9 nM Compound: Paclitaxel	Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SNB-75	GI₅₀	7.9 nM Compound: Paclitaxel	Cytotoxicity against human SNB-75 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SNB-75 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SNB-75	GI₅₀	8.08 x 10^-9 M Compound: 5	Cytotoxicity against human SNB75 cells Cytotoxicity against human SNB75 cells	[PMID: 7908950]
SNU-387	IC₅₀	0.27 μM Compound: Paclitaxel	Cytotoxicity against human SNU387 cells after 48 hrs by MTT assay Cytotoxicity against human SNU387 cells after 48 hrs by MTT assay	[PMID: 23701597]
SNU-398	EC₅₀	0.009 μM Compound: Paclitaxel	Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs by HTS assay Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs by HTS assay	[PMID: 20034792]
SNU-398	EC₅₀	0.009 μM Compound: paclitaxel	Induction of apoptosis in human SNU398 cells measured after 48 hrs by cell and caspase based HTS assay Induction of apoptosis in human SNU398 cells measured after 48 hrs by cell and caspase based HTS assay	[PMID: 19467598]
SNU-398	EC₅₀	0.011 μM Compound: taxol	Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 18197614]
SNU-398	GI₅₀	0.01 μM Compound: Taxol	Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs	[PMID: 19282188]
SNU-398	GI₅₀	0.061 μM Compound: Paclitaxel	Growth inhibition of human SNU398 cells after 48 hrs Growth inhibition of human SNU398 cells after 48 hrs	[PMID: 20034792]
SNU-398	GI₅₀	0.061 μM Compound: paclitaxel	Growth inhibition of human SNU398 cells after 48 hrs Growth inhibition of human SNU398 cells after 48 hrs	[PMID: 19467598]
SNU-398	IC₅₀	0.6 nM Compound: Taxol	Cytotoxicity against human SNU398 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human SNU398 cells after 48 hrs by sulforhodamine B assay	[PMID: 30528697]
SR	GI₅₀	6.3 nM Compound: Paclitaxel	Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SR	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human SR cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SR cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SU-DHL-6	GI₅₀	7.9 nM Compound: Paclitaxel	Growth inhibition of human SU-DHL6 cells incubated for 72 hrs by CellTiter-Glo assay Growth inhibition of human SU-DHL6 cells incubated for 72 hrs by CellTiter-Glo assay	[PMID: 30878826]
SUP-B15	IC₅₀	8 nM Compound: Taxol	Cytotoxicity against human SUP-B15 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human SUP-B15 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
SW-620	GI₅₀	4 nM Compound: Paclitaxel	Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
SW-620	GI₅₀	4 nM Compound: Paclitaxel	Cytotoxicity against human SW-620 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SW-620 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SW-620	IC₅₀	0.03 μM Compound: Paclitaxel	Cytotoxicity against human SW620 cells after 48 to 72 hrs by WAT-1 assay Cytotoxicity against human SW620 cells after 48 to 72 hrs by WAT-1 assay	[PMID: 21126027]
SW-620	IC₅₀	0.03 μM Compound: Paclitaxel	Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29501942]
SW1573	GI₅₀	0.3 μM Compound: PTX	Growth inhibition of human SW1573 cells overexpressing P-glycoprotein measured after 48 hrs in absence of verapamil by SRB colorimetric assay Growth inhibition of human SW1573 cells overexpressing P-glycoprotein measured after 48 hrs in absence of verapamil by SRB colorimetric assay	[PMID: 37137247]
SW1573	GI₅₀	0.31 nM Compound: PTX	Growth inhibition of human SW1573 cells overexpressing P-glycoprotein measured after 48 hrs in presence of verapamil by SRB colorimetric assay Growth inhibition of human SW1573 cells overexpressing P-glycoprotein measured after 48 hrs in presence of verapamil by SRB colorimetric assay	[PMID: 37137247]
SW1573	GI₅₀	0.46 nM Compound: PTX	Growth inhibition of human SW1573 cells measured after 48 hrs in presence of verapamil by SRB colorimetric assay Growth inhibition of human SW1573 cells measured after 48 hrs in presence of verapamil by SRB colorimetric assay	[PMID: 37137247]
SW1573	GI₅₀	0.53 nM Compound: PTX	Growth inhibition of human SW1573 cells measured after 48 hrs in absence of verapamil by SRB colorimetric assay Growth inhibition of human SW1573 cells measured after 48 hrs in absence of verapamil by SRB colorimetric assay	[PMID: 37137247]
SW1573	GI₅₀	1.5 nM Compound: PTX	Antiproliferative activity against human SW1573 cells incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay Antiproliferative activity against human SW1573 cells incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay	[PMID: 31271961]
SW1573	GI₅₀	1.5 μM Compound: PTX	Antiproliferative activity against human SW1573 cells incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay Antiproliferative activity against human SW1573 cells incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay	[PMID: 31070367]
SW1573	GI₅₀	1.6 nM Compound: PTX	Antiproliferative activity against human SW1573 cells incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay Antiproliferative activity against human SW1573 cells incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay	[PMID: 31271961]
SW1573	GI₅₀	1.6 μM Compound: PTX	Antiproliferative activity against human SW1573 cells incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay Antiproliferative activity against human SW1573 cells incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay	[PMID: 31070367]
SW1573	GI₅₀	196 nM Compound: PTX	Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay	[PMID: 31271961]
SW1573	GI₅₀	196 μM Compound: PTX	Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay	[PMID: 31070367]
SW1573	GI₅₀	4.2 nM Compound: PTX	Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay	[PMID: 31271961]
SW1573	GI₅₀	4.2 μM Compound: PTX	Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay	[PMID: 31070367]
SW1573	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human SW1573 cells Growth inhibition of human SW1573 cells	[PMID: 21986585]
SW1990	IC₅₀	0.01 μM Compound: Paclitaxel	Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
SW1990	IC₅₀	0.18 μM Compound: Taxol	Anticancer activity against human SW1990 cells by MTT assay Anticancer activity against human SW1990 cells by MTT assay	[PMID: 33316408]
SW48	IC₅₀	0.001 μM Compound: paclitaxel	Antiproliferative activity against human SW48 cells after 72 hrs by MTT assay Antiproliferative activity against human SW48 cells after 72 hrs by MTT assay	[PMID: 19743863]
SW480	IC₅₀	0.002 μM Compound: paclitaxel	Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay	[PMID: 19743863]
SW480	IC₅₀	0.007 μM Compound: TAX, Taxol	Antiproliferative activity against human SW480 cells after 48 hrs by SRB method Antiproliferative activity against human SW480 cells after 48 hrs by SRB method	[PMID: 25061803]
SW480	IC₅₀	0.011 μM Compound: paclitaxel	Antiproliferative activity against human SW480 cells after 48 hrs by alamar blue assay Antiproliferative activity against human SW480 cells after 48 hrs by alamar blue assay	[PMID: 21563750]
SW480	IC₅₀	0.021 μM Compound: 6	Antiproliferative activity against human SW480 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SW480 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25682561]
SW480	IC₅₀	0.04 μM Compound: paclitaxel	Cytotoxicity against human SW480 cells after 48 hrs by MTT assay Cytotoxicity against human SW480 cells after 48 hrs by MTT assay	[PMID: 23819871]
SW480	IC₅₀	0.04 μM Compound: paclitaxel	Antimicrobial activity against human SW480 cells after 48 hrs by MTT assay Antimicrobial activity against human SW480 cells after 48 hrs by MTT assay	[PMID: 23957453]
SW480	IC₅₀	0.15 μM Compound: Paclitaxel	Cytotoxicity against human SW480 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 23327668]
SW480	IC₅₀	0.15 μM Compound: paclitaxel	Cytotoxicity against human SW480 cells after 48 hrs by MTT assay Cytotoxicity against human SW480 cells after 48 hrs by MTT assay	[PMID: 25375202]
SW480	IC₅₀	0.19 μM Compound: Taxol	Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 29395979]
SW480	IC₅₀	0.312 μM Compound: Taxol	In vitro anti-cancer activity against the colon cancer cell line SW480 was determined In vitro anti-cancer activity against the colon cancer cell line SW480 was determined	[PMID: 12873496]
SW480	IC₅₀	12.1 nM Compound: paclitaxel	Cytotoxicity against human SW480 cells after 48 hrs by MTT assay Cytotoxicity against human SW480 cells after 48 hrs by MTT assay	[PMID: 23356786]
SW480	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SW480 cells after 48 hrs by MTT assay Cytotoxicity against human SW480 cells after 48 hrs by MTT assay	[PMID: 24417634]
SW480	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SW480 cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human SW480 cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 27704807]
SW480	IC₅₀	< 0.008 μM Compound: Paclitaxel	Antiproliferative activity against human SW480 cells after 48 hrs by MTS assay Antiproliferative activity against human SW480 cells after 48 hrs by MTS assay	[PMID: 28654256]
SW480	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SW480 cells after 48 hrs by MTS assay Cytotoxicity against human SW480 cells after 48 hrs by MTS assay	[PMID: 29286250]
SW480	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SW480 cells after 48 hrs by MTS assay Cytotoxicity against human SW480 cells after 48 hrs by MTS assay	[PMID: 29338226]
SW480	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTS assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTS assay	[PMID: 29338260]
SW480	IC₅₀	< 0.008 μM Compound: Paclitaxel	Growth inhibition of human SW480 cells after 48 hrs by MTS assay Growth inhibition of human SW480 cells after 48 hrs by MTS assay	[PMID: 29412669]
SW480	IC₅₀	< 0.008 μM Compound: Paclitaxel	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
SW480	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32628478]
SW480	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34355562]
SW480	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25871261]
SW480	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human SW480 cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human SW480 cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26068802]
SW480	IC₅₀	< 0.008 μM Compound: Taxol	Cytotoxicity against human SW480 cells assessed as decrease in cell viability after 4 days by MTT assay Cytotoxicity against human SW480 cells assessed as decrease in cell viability after 4 days by MTT assay	[PMID: 29884535]
SW480	IC₅₀	< 0.008 μM Compound: Taxol	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36274275]
SW480	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SW480 cells after 48 hrs by MTT method Cytotoxicity against human SW480 cells after 48 hrs by MTT method	[PMID: 21534539]
SW480	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SW480 assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SW480 assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 23586920]
SW480	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SW480 cells after 48 hrs by MTS assay Cytotoxicity against human SW480 cells after 48 hrs by MTS assay	[PMID: 24219809]
SW480	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SW480 cells after 48 hrs by MTS assay Cytotoxicity against human SW480 cells after 48 hrs by MTS assay	[PMID: 24256484]
SW480	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SW480 cells assessed as growth inhibition after 48 hrs by MTS assay Cytotoxicity against human SW480 cells assessed as growth inhibition after 48 hrs by MTS assay	[PMID: 24697496]
SW480	IC₅₀	< 0.008 μM Compound: paclitaxel	Cytotoxicity against human SW480 cells incubated for 48 hrs by MTT assay Cytotoxicity against human SW480 cells incubated for 48 hrs by MTT assay	[PMID: 25798528]
SW620/AD300	IC₅₀	1.97 μM Compound: Paclitaxel	Cytotoxicity against human SW620/AD300 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SW620/AD300 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29501942]
SW626	ED₅₀	12 pM Compound: 1	Growth inhibition of human SW626 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test Growth inhibition of human SW626 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test	[PMID: 19161316]
SW626	IC₅₀	uM μM Compound: 1	Cytotoxicity against human SW626 cells after 72 hrs by SRB assay Cytotoxicity against human SW626 cells after 72 hrs by SRB assay	[PMID: 12088425]
SW780	IC₅₀	1.1 nM Compound: paclitaxel	Cytotoxicity against human SW780 cells after 96 hrs by MTT assay Cytotoxicity against human SW780 cells after 96 hrs by MTT assay	[PMID: 23176628]
SiHa	GI₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human SiHa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human SiHa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31945642]
SiHa	GI₅₀	0.03 μM Compound: Taxol	Cytotoxicity against human SiHa cells after 72 hrs by MTT assay Cytotoxicity against human SiHa cells after 72 hrs by MTT assay	[PMID: 20538462]
SiHa	GI₅₀	0.03 μM Compound: taxol	Cytotoxicity against human SiHa cells after 72 hrs by MTT colorimetric assay Cytotoxicity against human SiHa cells after 72 hrs by MTT colorimetric assay	[PMID: 19081249]
SiHa	IC₅₀	1.3 μg/mL Compound: paclitaxel	Cytotoxicity against SiHa cancer cell line Cytotoxicity against SiHa cancer cell line	[PMID: 16384699]
SiHa	IC₅₀	1.4 μM Compound: Paclitaxel	Cytotoxicity against human SiHa cells measured after 72 hrs by sulforhodamine B assay Cytotoxicity against human SiHa cells measured after 72 hrs by sulforhodamine B assay	[PMID: 30920216]
SiHa	IC₅₀	3.5 μM Compound: Paclitaxel	Antiproliferative activity against human SiHa cell line Antiproliferative activity against human SiHa cell line	[PMID: 16793260]
T47D	EC₅₀	0.03 μM Compound: paclitaxel	Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs	[PMID: 15566300]
T47D	EC₅₀	0.035 μM Compound: Taxol	Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs	[PMID: 19282188]
T47D	EC₅₀	0.036 μM Compound: taxol	Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 18197614]
T47D	EC₅₀	0.037 μM Compound: Paclitaxel	Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay	[PMID: 20034792]
T47D	EC₅₀	0.037 μM Compound: Taxol	Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs	[PMID: 19500976]
T47D	EC₅₀	0.037 μM Compound: paclitaxel	Induction of apoptosis in human T47D cells measured after 48 hrs by cell and caspase based HTS assay Induction of apoptosis in human T47D cells measured after 48 hrs by cell and caspase based HTS assay	[PMID: 19467598]
T47D	GI₅₀	0.01 μM Compound: 1a, PXL, Taxol	Cytotoxicity against human T47D cells Cytotoxicity against human T47D cells	[PMID: 23725535]
T47D	GI₅₀	0.026 μM Compound: Paclitaxel	Growth inhibition of human T47D cells after 48 hrs Growth inhibition of human T47D cells after 48 hrs	[PMID: 20034792]
T47D	GI₅₀	0.026 μM Compound: Taxol	Growth inhibition of human T47D cells after 48 hrs Growth inhibition of human T47D cells after 48 hrs	[PMID: 19500976]
T47D	GI₅₀	0.026 μM Compound: paclitaxel	Growth inhibition of human T47D cells after 48 hrs Growth inhibition of human T47D cells after 48 hrs	[PMID: 19467598]
T47D	GI₅₀	0.15 nM Compound: Paclitaxel	Growth inhibition of human T47D cells Growth inhibition of human T47D cells	[PMID: 21986585]
T47D	GI₅₀	12.5 nM Compound: Paclitaxel	Cytotoxicity against human T47D cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human T47D cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
T47D	IC₅₀	0.004 μM Compound: paclitaxel	Antiproliferative activity against human T47D cells after 72 hrs by MTT assay Antiproliferative activity against human T47D cells after 72 hrs by MTT assay	[PMID: 19743863]
T47D	IC₅₀	0.2 μM Compound: Paclitaxel	Antiproliferative activity against human T47D cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human T47D cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 27449957]
T47D	IC₅₀	4 nM Compound: Paclitaxel	Cytotoxicity against human T47D cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human T47D cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 23468529]
T98G	IC₅₀	0.012 μM Compound: Taxol	Cytotoxicity against human T98G assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human T98G assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 33310292]
T98G	IC₅₀	0.74 μM Compound: Taxol	Cytotoxicity against human T98G cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Cytotoxicity against human T98G cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 29395979]
T98G	IC₅₀	8.7 μM Compound: Paclitaxel	Cytotoxicity against human T98G cells assessed as growth inhibition Cytotoxicity against human T98G cells assessed as growth inhibition	[PMID: 34949088]
TERT-RPE1	ED₅₀	23 nM Compound: paclitaxel	Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells	[PMID: 15043407]
TERT-RPE1	IC₅₀	5.1 nM Compound: PT	Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
THP-1	CC₅₀	0.1374 μg/mL Compound: Paclitaxel	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 27301367]
THP-1	GI₅₀	0.133 μg/mL Compound: Paclitaxel	Cytotoxicity against human THP1 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27563398]
THP-1	GI₅₀	0.1374 μg/mL Compound: Paclitaxel	Cytotoxicity against human THP1 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human THP1 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
THP-1	GI₅₀	0.1374 μg/mL Compound: Paclitaxel	Cytotoxicity against human THP1 cells after 48 hrs by MTT assay Cytotoxicity against human THP1 cells after 48 hrs by MTT assay	[PMID: 26299346]
THP-1	GI₅₀	0.1374 μg/mL Compound: Paclitaxel	Cytotoxicity against human THP1 cells after 48 hrs by MTT assay Cytotoxicity against human THP1 cells after 48 hrs by MTT assay	[PMID: 27013391]
THP-1	GI₅₀	0.1374 μg/mL Compound: Paclitaxel	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 27914801]
THP-1	GI₅₀	0.14 μg/mL Compound: Paclitaxel	Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C5MD00057B
THP-1	GI₅₀	5.7 μg/mL Compound: Paclitaxel	Cytotoxicity against human THP1 cells measured after 48 hrs by MTT assay Cytotoxicity against human THP1 cells measured after 48 hrs by MTT assay	[PMID: 27688192]
THP-1	GI₅₀	> 100 μg/mL Compound: Paclitaxel	Cytotoxicity against PMP-differentiated human THP1 cells measured after 48 hrs by MTT assay Cytotoxicity against PMP-differentiated human THP1 cells measured after 48 hrs by MTT assay	[PMID: 27688192]
THP-1	IC₅₀	3.01 nM Compound: PTX	Antiproliferative activity against human THP-1 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human THP-1 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
THP-1	IC₅₀	< 1.5 nM Compound: 1	Antiproliferative activity against human THP-1 cells transfected with wild type FLT3 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human THP-1 cells transfected with wild type FLT3 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37544183]
TK-10	GI₅₀	19.9 nM Compound: Paclitaxel	Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
TK-10	GI₅₀	19.9 nM Compound: Paclitaxel	Cytotoxicity against human TK-10 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human TK-10 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
TOV21G	IC₅₀	0.264 μM Compound: Paclitaxel	Anticancer activity against human TOV-21G-RT cells assessed as inhibition of cell growth Anticancer activity against human TOV-21G-RT cells assessed as inhibition of cell growth	[PMID: 33328099]
U-251	GI₅₀	0.003 μM Compound: PCT	Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay	[PMID: 24727464]
U-251	GI₅₀	6.3 nM Compound: Paclitaxel	Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
U-251	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human U-251 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human U-251 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
U-251	IC₅₀	0.03 μM Compound: taxol	Cytotoxicity against human U251 after 48 hrs by SRB assay Cytotoxicity against human U251 after 48 hrs by SRB assay	[PMID: 21044847]
U-251	IC₅₀	0.323 μM Compound: Paclitaxel	Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 39163776]
U-251	IC₅₀	128 nM Compound: Paclitaxel	Cytotoxicity against human U251 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human U251 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24929344]
U-251	IC₅₀	23 nM Compound: taxol	Antiproliferative activity against human U251 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human U251 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
U-87MG ATCC	GI₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human U87 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31945642]
U-87MG ATCC	GI₅₀	0.02 μM Compound: Taxol	Cytotoxicity against human U87 cells after 72 hrs by MTT assay Cytotoxicity against human U87 cells after 72 hrs by MTT assay	[PMID: 20538462]
U-87MG ATCC	GI₅₀	0.02 μM Compound: taxol	Cytotoxicity against human U87 cells after 72 hrs by MTT colorimetric assay Cytotoxicity against human U87 cells after 72 hrs by MTT colorimetric assay	[PMID: 19081249]
U-87MG ATCC	IC₅₀	0.00038 μM Compound: Taxol	Antiproliferation activity against human U87MG cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferation activity against human U87MG cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 32546298]
U-87MG ATCC	IC₅₀	0.008 μM Compound: Taxol	Cytotoxicity against human U-87 MG cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human U-87 MG cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 33310292]
U-87MG ATCC	IC₅₀	0.01 μM Compound: Taxol	Anticancer activity against human U-87 MG cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human U-87 MG cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
U-87MG ATCC	IC₅₀	0.08 μM Compound: Paclitaxel	Antiproliferative activity against human U87 MG cell line Antiproliferative activity against human U87 MG cell line	[PMID: 16793260]
U-87MG ATCC	IC₅₀	3.2 μg/mL Compound: paclitaxel	Cytotoxicity against U87 cancer cell line Cytotoxicity against U87 cancer cell line	[PMID: 16384699]
U-87MG ATCC	IC₅₀	4.67 μM Compound: Taxol	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 29395979]
U-87MG ATCC	IC₅₀	8.1 μM Compound: Paclitaxel	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
U-87MG ATCC	IC₅₀	90 μM Compound: Paclitaxel	Anticancer activity against human U87MG cells after 72 hrs by SRB assay Anticancer activity against human U87MG cells after 72 hrs by SRB assay	[PMID: 21707046]
U-937	GI₅₀	2.12 nM Compound: Taxol	Cytotoxicity against human U937 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human U937 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay	[PMID: 27224875]
U-937	GI₅₀	2.392 nM Compound: 1, Taxol	Growth inhibition of human U937 cells by MTT assay Growth inhibition of human U937 cells by MTT assay	[PMID: 24405702]
U-937	IC₅₀	0.006 μM Compound: PXT	Cytotoxicity against human U937 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26638041]
U-937	IC₅₀	1 nM Compound: taxol	The compound was tested for inhibition concentration against U-937 cell line The compound was tested for inhibition concentration against U-937 cell line	[PMID: 7907372]
U-937	IC₅₀	1.66 nM Compound: Taxol	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 26697718]
U-937	IC₅₀	1.7 nM Compound: Paclitaxel	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 28598633]
U-937	IC₅₀	1.9 nM Compound: Taxol	Cytotoxicity against human U937 cells by MTT assay Cytotoxicity against human U937 cells by MTT assay	[PMID: 23806112]
U-937	IC₅₀	2.1 μM Compound: taxol	Cytotoxicity against human U937 cells after 72 hrs by CCK8 assay Cytotoxicity against human U937 cells after 72 hrs by CCK8 assay	[PMID: 26316467]
U-937	IC₅₀	2.3 nM Compound: Taxol	Cytotoxicity against human U937 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human U937 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
U-937	IC₅₀	2.5 nM Compound: Taxol	Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 25819096]
U-937	IC₅₀	3.37 nM Compound: Paclitaxel	Cytotoxicity against human U937 cells after 72 hrs by MTT assay Cytotoxicity against human U937 cells after 72 hrs by MTT assay	[PMID: 22959518]
U-937/GTB	IC₅₀	0.0059 μM Compound: Paclitaxel	Cytotoxicity against human U937 GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay Cytotoxicity against human U937 GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay	[PMID: 16562840]
U-937/GTB	IC₅₀	0.0059 μM Compound: paclitaxel	Cytotoxicity against U937 GTB cells Cytotoxicity against U937 GTB cells	[PMID: 17442577]
U2OS	IC₅₀	0.03 μM Compound: Taxol	Anticancer activity against human U2OS cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human U2OS cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
U2OS	IC₅₀	24 nM Compound: paclitaxel	Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay	[PMID: 18461997]
U2OS	IC₅₀	3.4 nM Compound: PTX	Cytotoxicity against human U2OS cells after 72 hrs by coulter counter analysis Cytotoxicity against human U2OS cells after 72 hrs by coulter counter analysis	[PMID: 23140358]
UACC-257	GI₅₀	0.04 μM Compound: Paclitaxel	Cytotoxicity against human UACC257 cells by sulforhodamine B assay Cytotoxicity against human UACC257 cells by sulforhodamine B assay	[PMID: 21839640]
UACC-257	GI₅₀	0.04 μM Compound: paclitaxel	Cytotoxicity against human UACC257 cells Cytotoxicity against human UACC257 cells	[PMID: 17696332]
UACC-62	GI₅₀	0.01 μM Compound: PCT	Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay	[PMID: 24727464]
UACC-62	GI₅₀	5 nM Compound: Paclitaxel	Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
UACC-62	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human UACC-62 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human UACC-62 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
UACC-62	IC₅₀	0.006 μM Compound: Paclitaxel	Antiproliferative activity against human UACC62 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human UACC62 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
UACC-812	IC₅₀	0.7 μM Compound: paclitaxel	Antiproliferative activity against human UACC-812 cells after 72 hrs by MTT assay Antiproliferative activity against human UACC-812 cells after 72 hrs by MTT assay	[PMID: 19743863]
UO-31	GI₅₀	125 nM Compound: Paclitaxel	Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29655610]
UO-31	GI₅₀	125 nM Compound: Paclitaxel	Cytotoxicity against human UO-31 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human UO-31 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
UO-31	IC₅₀	240 μM Compound: Paclitaxel	Antiproliferative activity against taxane-resistant human UO31 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Antiproliferative activity against taxane-resistant human UO31 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 29995409]
Vero	ED₅₀	> 0.3 μg/mL Compound: paclitaxel	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 8778244]
Vero	GI₅₀	0.03 μM Compound: PCT	Growth inhibition of African green monkey Vero cells after 48 hrs by sulforhodamine B assay Growth inhibition of African green monkey Vero cells after 48 hrs by sulforhodamine B assay	[PMID: 24727464]
Vero	IC₅₀	0.65 μM Compound: PXT	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26638041]
Vero	IC₅₀	> 100 μg/mL Compound: Paclitaxel	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27105027]
WALKER	IC₅₀	150 nM Compound: Paclitaxel	In vitro antiproliferative activity against Walker cell line In vitro antiproliferative activity against Walker cell line	10.1016/S0960-894X(97)10152-4
WI-38	GI₅₀	13.7 nM Compound: paclitaxel	Cytotoxicity against human WI38 cells Cytotoxicity against human WI38 cells	[PMID: 19195901]
WI-38	IC₅₀	0.02 μg/mL Compound: taxol	Growth inhibition of human WI38 cells Growth inhibition of human WI38 cells	[PMID: 17358082]
WI-38	IC₅₀	0.034 μM Compound: Taxol	Growth inhibition of human WI38 cells after 48 hrs by WST8 assay Growth inhibition of human WI38 cells after 48 hrs by WST8 assay	[PMID: 16499322]
WI-38	IC₅₀	0.034 μg/mL Compound: 2	Cytotoxicity againt human WI38 cells Cytotoxicity againt human WI38 cells	[PMID: 17239597]
WI-38	IC₅₀	0.04 mM Compound: taxol	Growth inhibition of human WI38 cells Growth inhibition of human WI38 cells	[PMID: 17595134]
WI-38	IC₅₀	0.04 μM Compound: Paclitaxel	Growth inhibition of human WI38 cells Growth inhibition of human WI38 cells	[PMID: 17490878]
WI-38	IC₅₀	0.04 μM Compound: Taxol	Cytotoxicity against human WI38 cells Cytotoxicity against human WI38 cells	[PMID: 17067155]
WI-38	IC₅₀	0.04 μM Compound: taxol	Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
WI-38	IC₅₀	0.04 μM Compound: taxol	Cytotoxicity against human WI38 cells by WST-8 assay Cytotoxicity against human WI38 cells by WST-8 assay	[PMID: 16933868]
WI-38	IC₅₀	0.0468 μM Compound: Taxol	Cytotoxicity against human WI38 cells Cytotoxicity against human WI38 cells	[PMID: 16724842]
WI-38	IC₅₀	0.05 μM Compound: paclitaxel	Cytotoxicity against human WI38 cells after 72 hrs by MTT assay Cytotoxicity against human WI38 cells after 72 hrs by MTT assay	[PMID: 24033131]
WI-38	IC₅₀	0.05 μg/mL Compound: paclitaxel	Growth inhibition of WI38 cells Growth inhibition of WI38 cells	[PMID: 17547458]
WI-38	IC₅₀	55.7 nM Compound: Paclitaxel	Cytotoxicity against folate receptor deficient human WI38 cells after 72 hrs by MTT assay Cytotoxicity against folate receptor deficient human WI38 cells after 72 hrs by MTT assay	[PMID: 25819334]
WI-38	IC₅₀	> 10 μM Compound: Paclitaxel	Antiproliferative activity against human WI-38 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay Antiproliferative activity against human WI-38 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay	[PMID: 35737669]
WI-38 VA13	CC₅₀	< 20 nM Compound: Ptxl; PTX	Cytotoxicity against human VA13 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human VA13 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31248772]
WI-38 VA13	IC₅₀	0.0043 μM Compound: Taxol	Growth inhibition of human VA13 cells after 48 hrs by WST8 assay Growth inhibition of human VA13 cells after 48 hrs by WST8 assay	[PMID: 16499322]
WI-38 VA13	IC₅₀	0.0043 μg/mL Compound: 2	Cytotoxicity againt human VA13 cells Cytotoxicity againt human VA13 cells	[PMID: 17239597]
WI-38 VA13	IC₅₀	0.005 mM Compound: taxol	Growth inhibition of human VA13 cells Growth inhibition of human VA13 cells	[PMID: 17595134]
WI-38 VA13	IC₅₀	0.005 μM Compound: Paclitaxel	Growth inhibition of human VA13 cells Growth inhibition of human VA13 cells	[PMID: 17490878]
WI-38 VA13	IC₅₀	0.005 μM Compound: Taxol	Cytotoxicity against human VA13 cells Cytotoxicity against human VA13 cells	[PMID: 17067155]
WI-38 VA13	IC₅₀	0.005 μM Compound: taxol	Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
WI-38 VA13	IC₅₀	0.005 μM Compound: taxol	Cytotoxicity against human VA-13 cells by by WST-8 assay Cytotoxicity against human VA-13 cells by by WST-8 assay	[PMID: 16933868]
WI-38 VA13	IC₅₀	0.0059 μM Compound: Taxol	Cytotoxicity against human VA13 cells Cytotoxicity against human VA13 cells	[PMID: 16724842]
WI-38 VA13	IC₅₀	0.01 μg/mL Compound: paclitaxel	Growth inhibition of VA13 cells Growth inhibition of VA13 cells	[PMID: 17547458]
WI-38 VA13	IC₅₀	0.01 μg/mL Compound: taxol	Growth inhibition of human VA13 cells Growth inhibition of human VA13 cells	[PMID: 17358082]
WM 266-4	IC₅₀	0.32 nM Compound: Taxol	Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay	[PMID: 31494469]
WRL68	IC₅₀	0.0035 μg/mL Compound: taxol	Cytotoxicity against human WRL68 cell line by MTT assay Cytotoxicity against human WRL68 cell line by MTT assay	[PMID: 16297622]
WRL68	IC₅₀	0.004 μM Compound: Taxol	Cytotoxicity against human WRL68 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay Cytotoxicity against human WRL68 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay	[PMID: 23584542]
WRL68	IC₅₀	0.004 μM Compound: taxol	Cytotoxicity against human WRL68 cells after 24 hrs by MTT assay Cytotoxicity against human WRL68 cells after 24 hrs by MTT assay	[PMID: 18586491]
WRL68	IC₅₀	0.004 μg/mL Compound: Paclitaxel	Anticancer activity against human WRL68 cells after 24 hrs by MTT assay Anticancer activity against human WRL68 cells after 24 hrs by MTT assay	[PMID: 25305717]
WiDr	GI₅₀	0.22 nM Compound: Paclitaxel	Growth inhibition of human WiDr cells Growth inhibition of human WiDr cells	[PMID: 21986585]
WiDr	IC₅₀	< 3 ng/mL Compound: 1 (paclitaxel)	Cytotoxicity against WIDR Tumor cell line in SRB Cell viability test Cytotoxicity against WIDR Tumor cell line in SRB Cell viability test	[PMID: 10956217]
WiDr	IC₅₀	< 3 ng/mL Compound: 1	Cytotoxicity against human WIDR cells Cytotoxicity against human WIDR cells	[PMID: 17419065]
YOSHIDA	IC₅₀	7.9 nM Compound: Paclitaxel	In vitro antiproliferative activity against Yoshida cell lines In vitro antiproliferative activity against Yoshida cell lines	10.1016/S0960-894X(97)10152-4
ZR-75-1	IC₅₀	308 nM Compound: Paclitaxel	Cytotoxicity against ZR-75-1 cell line Cytotoxicity against ZR-75-1 cell line	[PMID: 17249649]
ZR-75-1	IC₅₀	6.2 nM Compound: Paclitaxel	Cytotoxicity against human ZR-75-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human ZR-75-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 23468529]
ZR-75-1	IC₅₀	> 100 nM Compound: PXL	Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay	[PMID: 25241925]

体外研究
(In Vitro)

Paclitaxel (20 nM；48 h) 诱导程序性细胞死亡，并在细胞周期的 G2/M 期存在阻滞^[1]。
Paclitaxel (20 nM；48 hours) 诱导 p53 水平的持续增加^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	MCF-7, MDA-MB-231 cells
Concentration:	20 nM
Incubation Time:	48 hours
Result:	Induced programmed cell death.

Cell Cycle Analysis^[1]

Cell Line:	MCF-7, MDA-MB-231 cells
Concentration:	20 nM
Incubation Time:	48 hours
Result:	>60% of MCF-7 cells and 50% of MDA-MB-231 cells were in the G2/M phase following 24 h treament.

Western Blot Analysis^[1]

Cell Line:	MCF-7 cells (harboring wild-type p53)
Concentration:	20 nM
Incubation Time:	48 hours
Result:	Induced a consistent increase in the level of p53.

体内研究
(In Vivo)

Paclitaxel (1 -20 mg/kg；腹腔注射；1次/2天，共5个周期) 在低 Paclitaxel 组明显诱导肝转移，对原发肿瘤生长影响不大^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MDA-231 xenograft-bearing mice^[3]
Dosage:	1, 20 mg/kg
Administration:	Intraperitoneal injection; five cycles (1 time/2 days)
Result:	Liver metastases were obviously induced in the low-PTX (1 mg/kg) group with little influence on primary tumor growth compared with high-PTX group.

Clinical Trial

分子量

853.91

Formula

C₄₇H₅₁NO₁₄

CAS 号

33069-62-4

性状

固体

颜色

White to off-white

中文名称

紫杉醇

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (117.11 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.1711 mL	5.8554 mL	11.7108 mL
5 mM	0.2342 mL	1.1711 mL	2.3422 mL
10 mM	0.1171 mL	0.5855 mL	1.1711 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.44 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (2.44 mM); 悬浊液; 超声助溶

此方案可获得 2.08 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (2.44 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： Corn Oil
Solubility: 10 mg/mL (11.71 mM); 悬浊液; 超声助溶
方案二

请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: 10 mg/mL (11.71 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.97%

选择批次：

Data Sheet (649 KB) SDS (418 KB)

COA (298 KB) HNMR (245 KB) LCMS (354 KB) 元素分析报告 (220 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Choi YH, et al. Paclitaxel-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep. 2012 Dec;28(6):2163-9. [Content Brief]

[2]. Dziadyk JM, et al. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res. 2004 Jan-Feb;24(1):27-36. [Content Brief]

[3]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Aug;283(15):2836-52. [Content Brief]

[4]. Pan Z, et al. Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calciumrelease in a dosage dependent manner. Biochem Biophys Res Commun. 2013 Feb 13. pii: S0006-291X(13)00259-3. [Content Brief]

[5]. Cadamuro M, et al. Low dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 2016 Jun 21. [Content Brief]

[6]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Jun 16. [Content Brief]

[7]. Yilmaz E, et al. Sensory neuron subpopulation-specific dysregulation of intracellular calcium in a rat model of chemotherapy-induced peripheral neuropathy. Neuroscience. 2015 Aug 6;300:210-8. [Content Brief]

[8]. Jing C, et al. E7080 enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res. 2017 Apr 1;7(4):903-912. [Content Brief]

Paclitaxel 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.1711 mL	5.8554 mL	11.7108 mL	29.2771 mL
	5 mM	0.2342 mL	1.1711 mL	2.3422 mL	5.8554 mL
	10 mM	0.1171 mL	0.5855 mL	1.1711 mL	2.9277 mL
	15 mM	0.0781 mL	0.3904 mL	0.7807 mL	1.9518 mL
	20 mM	0.0586 mL	0.2928 mL	0.5855 mL	1.4639 mL
	25 mM	0.0468 mL	0.2342 mL	0.4684 mL	1.1711 mL
	30 mM	0.0390 mL	0.1952 mL	0.3904 mL	0.9759 mL
	40 mM	0.0293 mL	0.1464 mL	0.2928 mL	0.7319 mL
	50 mM	0.0234 mL	0.1171 mL	0.2342 mL	0.5855 mL
	60 mM	0.0195 mL	0.0976 mL	0.1952 mL	0.4880 mL
	80 mM	0.0146 mL	0.0732 mL	0.1464 mL	0.3660 mL
	100 mM	0.0117 mL	0.0586 mL	0.1171 mL	0.2928 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Paclitaxel33069-62-4紫杉醇Microtubule/TubulinADC PayloadApoptosisAutophagyADC CytotoxinInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Paclitaxel (Synonyms: 紫杉醇)

Customer Review

Other Forms of Paclitaxel:

MCE 顾客使用本产品发表的 307 篇科研文献

Paclitaxel 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 ADC Payload 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Paclitaxel 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Paclitaxel (Synonyms: 紫杉醇)

Customer Review

Other Forms of Paclitaxel:

Paclitaxel 相关抗体

MCE 顾客使用本产品发表的 307 篇科研文献

Paclitaxel 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 ADC Payload 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Paclitaxel 相关抗体:

摩尔计算器

稀释计算器

Paclitaxel 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z